concept,type,df_count,df_fraction,status
analysis,SURFACE,40,1.0,STOPLISTED
case,SURFACE,40,1.0,STOPLISTED
diagnosis,SURFACE,40,1.0,STOPLISTED
differential diagnoses,SURFACE,40,1.0,STOPLISTED
differential diagnosis,SURFACE,40,1.0,STOPLISTED
findings,SURFACE,40,1.0,STOPLISTED
json,SURFACE,40,1.0,STOPLISTED
patient,SURFACE,40,1.0,STOPLISTED
patient case,SURFACE,40,1.0,STOPLISTED
recommended tests,SURFACE,40,1.0,STOPLISTED
comprehensive,SURFACE,39,0.975,STOPLISTED
consensus,SURFACE,39,0.975,STOPLISTED
discussion,SURFACE,39,0.975,STOPLISTED
examination\,SURFACE,39,0.975,STOPLISTED
patient's,SURFACE,39,0.975,STOPLISTED
presentation\,SURFACE,39,0.975,STOPLISTED
{\n,SURFACE,39,0.975,STOPLISTED
diagnostic tests,SURFACE,38,0.95,STOPLISTED
tests,SURFACE,38,0.95,STOPLISTED
collaborative,SURFACE,37,0.925,STOPLISTED
potential,SURFACE,37,0.925,STOPLISTED
condition,SURFACE,36,0.9,STOPLISTED
contributions,SURFACE,36,0.9,STOPLISTED
evaluate,SURFACE,36,0.9,STOPLISTED
testing,SURFACE,36,0.9,STOPLISTED
conditions,SURFACE,35,0.875,KEPT
evaluation,SURFACE,35,0.875,KEPT
clinical presentation,SURFACE,34,0.85,KEPT
complex,SURFACE,34,0.85,KEPT
discussions,SURFACE,34,0.85,KEPT
associated with,SURFACE,33,0.825,KEPT
considerations,SURFACE,33,0.825,KEPT
doctor0,SURFACE,33,0.825,KEPT
presentation,SURFACE,33,0.825,KEPT
imaging,SURFACE,32,0.8,KEPT
assessment,SURFACE,31,0.775,KEPT
finalize,SURFACE,31,0.775,KEPT
information,SURFACE,31,0.775,KEPT
specialists,SURFACE,31,0.775,KEPT
symptoms,SURFACE,31,0.775,KEPT
absence,SURFACE,30,0.75,KEPT
age,SURFACE,29,0.725,KEPT
collaboration,SURFACE,29,0.725,KEPT
diagnostic approach,SURFACE,29,0.725,KEPT
doctor1,SURFACE,29,0.725,KEPT
evaluations,SURFACE,29,0.725,KEPT
management,SURFACE,29,0.725,KEPT
points,SURFACE,29,0.725,KEPT
assessments,SURFACE,28,0.7,KEPT
clarity,SURFACE,28,0.7,KEPT
genetic testing,SURFACE,28,0.7,KEPT
presence,SURFACE,28,0.7,KEPT
recommendations,SURFACE,27,0.675,KEPT
diagnoses,SURFACE,26,0.65,KEPT
let's,SURFACE,26,0.65,KEPT
monitoring,SURFACE,26,0.65,KEPT
results,SURFACE,26,0.65,KEPT
cases,SURFACE,25,0.625,KEPT
disagreement,SURFACE,25,0.625,KEPT
features,SURFACE,25,0.625,KEPT
insights,SURFACE,25,0.625,KEPT
investigation,SURFACE,25,0.625,KEPT
let,SURFACE,25,0.625,KEPT
mri,SURFACE,25,0.625,KEPT
refine,SURFACE,25,0.625,KEPT
thoughts,SURFACE,25,0.625,KEPT
history,SURFACE,24,0.6,KEPT
refining,SURFACE,24,0.6,KEPT
changes,SURFACE,23,0.575,KEPT
insightful,SURFACE,23,0.575,KEPT
involvement,SURFACE,23,0.575,KEPT
plan,SURFACE,23,0.575,KEPT
suggestions,SURFACE,23,0.575,KEPT
clinical picture,SURFACE,22,0.55,KEPT
differential,SURFACE,22,0.55,KEPT
doctors,SURFACE,22,0.55,KEPT
months,SURFACE,22,0.55,KEPT
relevant,SURFACE,22,0.55,KEPT
diagnostic,SURFACE,21,0.525,KEPT
diagnostic process,SURFACE,21,0.525,KEPT
essential,SURFACE,21,0.525,KEPT
follow-up,SURFACE,21,0.525,KEPT
presentations,SURFACE,21,0.525,KEPT
test,SURFACE,21,0.525,KEPT
**differential diagnoses**,SURFACE,20,0.5,KEPT
agreement,SURFACE,20,0.5,KEPT
alignment,SURFACE,20,0.5,KEPT
exploration,SURFACE,20,0.5,KEPT
family,SURFACE,20,0.5,KEPT
necessity,SURFACE,20,0.5,KEPT
appreciate,SURFACE,19,0.475,KEPT
atypical,SURFACE,19,0.475,KEPT
bilateral,SURFACE,19,0.475,KEPT
complexities,SURFACE,19,0.475,KEPT
examination,SURFACE,19,0.475,KEPT
impact,SURFACE,19,0.475,KEPT
inclusion,SURFACE,19,0.475,KEPT
likelihood,SURFACE,19,0.475,KEPT
moving forward,SURFACE,19,0.475,KEPT
robust,SURFACE,19,0.475,KEPT
years,SURFACE,19,0.475,KEPT
clinical,SURFACE,18,0.45,KEPT
complications,SURFACE,18,0.45,KEPT
confirmation,SURFACE,18,0.45,KEPT
emphasis,SURFACE,18,0.45,KEPT
severe,SURFACE,18,0.45,KEPT
approach,SURFACE,17,0.425,KEPT
challenges,SURFACE,17,0.425,KEPT
concerns,SURFACE,17,0.425,KEPT
confirming,SURFACE,17,0.425,KEPT
diagnostics,SURFACE,17,0.425,KEPT
effort,SURFACE,17,0.425,KEPT
family history,SURFACE,17,0.425,KEPT
genetic counseling,SURFACE,17,0.425,KEPT
genetic testing**,SURFACE,17,0.425,KEPT
hearing,SURFACE,17,0.425,KEPT
levels,SURFACE,17,0.425,KEPT
medical history,SURFACE,17,0.425,KEPT
perspectives,SURFACE,17,0.425,KEPT
prioritized,SURFACE,17,0.425,KEPT
systemic,SURFACE,17,0.425,KEPT
weeks,SURFACE,17,0.425,KEPT
characterized,SURFACE,16,0.4,KEPT
comments,SURFACE,16,0.4,KEPT
commitment,SURFACE,16,0.4,KEPT
diagnostic tests**,SURFACE,16,0.4,KEPT
evaluating,SURFACE,16,0.4,KEPT
genetic,SURFACE,16,0.4,KEPT
input,SURFACE,16,0.4,KEPT
investigate,SURFACE,16,0.4,KEPT
male,SURFACE,16,0.4,KEPT
patients,SURFACE,16,0.4,KEPT
suggestion,SURFACE,16,0.4,KEPT
test results,SURFACE,16,0.4,KEPT
abnormalities,SURFACE,15,0.375,KEPT
complexity,SURFACE,15,0.375,KEPT
data,SURFACE,15,0.375,KEPT
diagnostic strategy,SURFACE,15,0.375,KEPT
evidence,SURFACE,15,0.375,KEPT
investigations,SURFACE,15,0.375,KEPT
ongoing,SURFACE,15,0.375,KEPT
outcomes,SURFACE,15,0.375,KEPT
patterns,SURFACE,15,0.375,KEPT
relevance,SURFACE,15,0.375,KEPT
risks,SURFACE,15,0.375,KEPT
suspicion,SURFACE,15,0.375,KEPT
treatment,SURFACE,15,0.375,KEPT
assessing,SURFACE,14,0.35,KEPT
collaborative approach,SURFACE,14,0.35,KEPT
confirm,SURFACE,14,0.35,KEPT
dedication,SURFACE,14,0.35,KEPT
dialogue,SURFACE,14,0.35,KEPT
identification,SURFACE,14,0.35,KEPT
influence,SURFACE,14,0.35,KEPT
long-term,SURFACE,14,0.35,KEPT
manifestations,SURFACE,14,0.35,KEPT
markers,SURFACE,14,0.35,KEPT
moving,SURFACE,14,0.35,KEPT
mutations,SURFACE,14,0.35,KEPT
parents,SURFACE,14,0.35,KEPT
patient’s condition,SURFACE,14,0.35,KEPT
review,SURFACE,14,0.35,KEPT
structural,SURFACE,14,0.35,KEPT
syndromes,SURFACE,14,0.35,KEPT
abnormal,SURFACE,13,0.325,KEPT
accurate,SURFACE,13,0.325,KEPT
adjustments,SURFACE,13,0.325,KEPT
aligns,SURFACE,13,0.325,KEPT
clinical features,SURFACE,13,0.325,KEPT
combination,SURFACE,13,0.325,KEPT
consistent with,SURFACE,13,0.325,KEPT
diagnosed,SURFACE,13,0.325,KEPT
diagnostic plan,SURFACE,13,0.325,KEPT
elevated,SURFACE,13,0.325,KEPT
engagement,SURFACE,13,0.325,KEPT
finalizing,SURFACE,13,0.325,KEPT
genetics,SURFACE,13,0.325,KEPT
immediate,SURFACE,13,0.325,KEPT
lesions,SURFACE,13,0.325,KEPT
metabolic,SURFACE,13,0.325,KEPT
overlap,SURFACE,13,0.325,KEPT
patient’s,SURFACE,13,0.325,KEPT
risk,SURFACE,13,0.325,KEPT
supervisor,SURFACE,13,0.325,KEPT
vital,SURFACE,13,0.325,KEPT
analyses,SURFACE,12,0.3,KEPT
anomalies,SURFACE,12,0.3,KEPT
clarification,SURFACE,12,0.3,KEPT
clinical findings,SURFACE,12,0.3,KEPT
consideration,SURFACE,12,0.3,KEPT
context,SURFACE,12,0.3,KEPT
identified,SURFACE,12,0.3,KEPT
imaging studies,SURFACE,12,0.3,KEPT
interventions,SURFACE,12,0.3,KEPT
issues,SURFACE,12,0.3,KEPT
lack,SURFACE,12,0.3,KEPT
mention,SURFACE,12,0.3,KEPT
nature,SURFACE,12,0.3,KEPT
outlined,SURFACE,12,0.3,KEPT
pathology,SURFACE,12,0.3,KEPT
pertinent,SURFACE,12,0.3,KEPT
physical examination,SURFACE,12,0.3,KEPT
please,SURFACE,12,0.3,KEPT
priority,SURFACE,12,0.3,KEPT
structured approach,SURFACE,12,0.3,KEPT
thoughtful contributions,SURFACE,12,0.3,KEPT
time,SURFACE,12,0.3,KEPT
care,SURFACE,11,0.275,KEPT
cause,SURFACE,11,0.275,KEPT
characteristics,SURFACE,11,0.275,KEPT
communication,SURFACE,11,0.275,KEPT
details,SURFACE,11,0.275,KEPT
developmental,SURFACE,11,0.275,KEPT
engaging,SURFACE,11,0.275,KEPT
factors,SURFACE,11,0.275,KEPT
function,SURFACE,11,0.275,KEPT
level,SURFACE,11,0.275,KEPT
modifications,SURFACE,11,0.275,KEPT
panels,SURFACE,11,0.275,KEPT
primary diagnosis,SURFACE,11,0.275,KEPT
progression,SURFACE,11,0.275,KEPT
response,SURFACE,11,0.275,KEPT
syndrome,SURFACE,11,0.275,KEPT
team,SURFACE,11,0.275,KEPT
thoroughness,SURFACE,11,0.275,KEPT
admitted,SURFACE,10,0.25,KEPT
association,SURFACE,10,0.25,KEPT
check,SURFACE,10,0.25,KEPT
conclusions,SURFACE,10,0.25,KEPT
diagnosing,SURFACE,10,0.25,KEPT
diagnostic considerations,SURFACE,10,0.25,KEPT
diagnostic pathway,SURFACE,10,0.25,KEPT
doctor2,SURFACE,10,0.25,KEPT
early,SURFACE,10,0.25,KEPT
expertise,SURFACE,10,0.25,KEPT
familial,SURFACE,10,0.25,KEPT
female,SURFACE,10,0.25,KEPT
group,SURFACE,10,0.25,KEPT
i look forward,SURFACE,10,0.25,KEPT
i'm,SURFACE,10,0.25,KEPT
inflammatory,SURFACE,10,0.25,KEPT
management plan,SURFACE,10,0.25,KEPT
nuances,SURFACE,10,0.25,KEPT
patient's case,SURFACE,10,0.25,KEPT
persistent,SURFACE,10,0.25,KEPT
perspective,SURFACE,10,0.25,KEPT
proposal,SURFACE,10,0.25,KEPT
recommendation,SURFACE,10,0.25,KEPT
recurrent,SURFACE,10,0.25,KEPT
share,SURFACE,10,0.25,KEPT
significant,SURFACE,10,0.25,KEPT
structural abnormalities,SURFACE,10,0.25,KEPT
terminate,SURFACE,10,0.25,KEPT
vigilant,SURFACE,10,0.25,KEPT
visualize,SURFACE,10,0.25,KEPT
’ve,SURFACE,10,0.25,KEPT
absent,SURFACE,9,0.225,KEPT
acknowledgment,SURFACE,9,0.225,KEPT
action,SURFACE,9,0.225,KEPT
alternative,SURFACE,9,0.225,KEPT
assessed,SURFACE,9,0.225,KEPT
child,SURFACE,9,0.225,KEPT
collaborative spirit,SURFACE,9,0.225,KEPT
colleagues,SURFACE,9,0.225,KEPT
contention,SURFACE,9,0.225,KEPT
ct scan,SURFACE,9,0.225,KEPT
days,SURFACE,9,0.225,KEPT
decisions,SURFACE,9,0.225,KEPT
detected,SURFACE,9,0.225,KEPT
diagnostic testing,SURFACE,9,0.225,KEPT
elaboration,SURFACE,9,0.225,KEPT
expand,SURFACE,9,0.225,KEPT
focus,SURFACE,9,0.225,KEPT
hear,SURFACE,9,0.225,KEPT
i welcome,SURFACE,9,0.225,KEPT
increased,SURFACE,9,0.225,KEPT
infection,SURFACE,9,0.225,KEPT
infections,SURFACE,9,0.225,KEPT
manifest,SURFACE,9,0.225,KEPT
multifaceted,SURFACE,9,0.225,KEPT
multiple,SURFACE,9,0.225,KEPT
negative,SURFACE,9,0.225,KEPT
observed,SURFACE,9,0.225,KEPT
patient care,SURFACE,9,0.225,KEPT
patient's history,SURFACE,9,0.225,KEPT
phenotypic,SURFACE,9,0.225,KEPT
primary,SURFACE,9,0.225,KEPT
prioritization,SURFACE,9,0.225,KEPT
profile,SURFACE,9,0.225,KEPT
progressive,SURFACE,9,0.225,KEPT
recommended,SURFACE,9,0.225,KEPT
screening,SURFACE,9,0.225,KEPT
skeletal,SURFACE,9,0.225,KEPT
stage,SURFACE,9,0.225,KEPT
strong,SURFACE,9,0.225,KEPT
thoughtful,SURFACE,9,0.225,KEPT
understanding,SURFACE,9,0.225,KEPT
urgency,SURFACE,9,0.225,KEPT
vigilance,SURFACE,9,0.225,KEPT
action plan,SURFACE,8,0.2,KEPT
adapt,SURFACE,8,0.2,KEPT
admission,SURFACE,8,0.2,KEPT
agreed,SURFACE,8,0.2,KEPT
aspects,SURFACE,8,0.2,KEPT
attention,SURFACE,8,0.2,KEPT
birth,SURFACE,8,0.2,KEPT
brain,SURFACE,8,0.2,KEPT
clearer,SURFACE,8,0.2,KEPT
continuous,SURFACE,8,0.2,KEPT
coupled,SURFACE,8,0.2,KEPT
development,SURFACE,8,0.2,KEPT
developments,SURFACE,8,0.2,KEPT
diagnostic accuracy,SURFACE,8,0.2,KEPT
direction,SURFACE,8,0.2,KEPT
echocardiogram,SURFACE,8,0.2,KEPT
etiology,SURFACE,8,0.2,KEPT
framework,SURFACE,8,0.2,KEPT
functional,SURFACE,8,0.2,KEPT
genetic conditions,SURFACE,8,0.2,KEPT
genetic evaluation,SURFACE,8,0.2,KEPT
guiding,SURFACE,8,0.2,KEPT
health,SURFACE,8,0.2,KEPT
i concur,SURFACE,8,0.2,KEPT
implementation,SURFACE,8,0.2,KEPT
inputs,SURFACE,8,0.2,KEPT
life,SURFACE,8,0.2,KEPT
malignancy,SURFACE,8,0.2,KEPT
multidisciplinary approach,SURFACE,8,0.2,KEPT
parameters,SURFACE,8,0.2,KEPT
pediatric,SURFACE,8,0.2,KEPT
prepare,SURFACE,8,0.2,KEPT
prioritize,SURFACE,8,0.2,KEPT
progress,SURFACE,8,0.2,KEPT
reflections,SURFACE,8,0.2,KEPT
session,SURFACE,8,0.2,KEPT
skeletal anomalies,SURFACE,8,0.2,KEPT
specialist,SURFACE,8,0.2,KEPT
steps,SURFACE,8,0.2,KEPT
summary,SURFACE,8,0.2,KEPT
suspected,SURFACE,8,0.2,KEPT
syndromic conditions,SURFACE,8,0.2,KEPT
timeline,SURFACE,8,0.2,KEPT
timing,SURFACE,8,0.2,KEPT
ultrasound,SURFACE,8,0.2,KEPT
variants,SURFACE,8,0.2,KEPT
’s condition,SURFACE,8,0.2,KEPT
"\""physical",SURFACE,7,0.175,KEPT
activity,SURFACE,7,0.175,KEPT
acute,SURFACE,7,0.175,KEPT
align,SURFACE,7,0.175,KEPT
apparent,SURFACE,7,0.175,KEPT
biopsy,SURFACE,7,0.175,KEPT
chest x-ray,SURFACE,7,0.175,KEPT
children,SURFACE,7,0.175,KEPT
clinically,SURFACE,7,0.175,KEPT
collaborative discussion,SURFACE,7,0.175,KEPT
complicate,SURFACE,7,0.175,KEPT
concluding,SURFACE,7,0.175,KEPT
conjunction,SURFACE,7,0.175,KEPT
counseling,SURFACE,7,0.175,KEPT
critical points,SURFACE,7,0.175,KEPT
day,SURFACE,7,0.175,KEPT
degree,SURFACE,7,0.175,KEPT
developmental delays,SURFACE,7,0.175,KEPT
disorders,SURFACE,7,0.175,KEPT
documented,SURFACE,7,0.175,KEPT
enhance,SURFACE,7,0.175,KEPT
enhances,SURFACE,7,0.175,KEPT
evolving,SURFACE,7,0.175,KEPT
fever,SURFACE,7,0.175,KEPT
future,SURFACE,7,0.175,KEPT
genetic disorder,SURFACE,7,0.175,KEPT
"geographic location.\"",\n\n",SURFACE,7,0.175,KEPT
healthy,SURFACE,7,0.175,KEPT
hereditary conditions,SURFACE,7,0.175,KEPT
holistic,SURFACE,7,0.175,KEPT
implement,SURFACE,7,0.175,KEPT
implementing,SURFACE,7,0.175,KEPT
infectious,SURFACE,7,0.175,KEPT
inflammation,SURFACE,7,0.175,KEPT
initially,SURFACE,7,0.175,KEPT
initiate,SURFACE,7,0.175,KEPT
location,SURFACE,7,0.175,KEPT
mind,SURFACE,7,0.175,KEPT
mmhg,SURFACE,7,0.175,KEPT
monitored,SURFACE,7,0.175,KEPT
mother,SURFACE,7,0.175,KEPT
navigate,SURFACE,7,0.175,KEPT
next steps,SURFACE,7,0.175,KEPT
non-invasive,SURFACE,7,0.175,KEPT
ocular,SURFACE,7,0.175,KEPT
plans,SURFACE,7,0.175,KEPT
positive,SURFACE,7,0.175,KEPT
possibilities,SURFACE,7,0.175,KEPT
prior,SURFACE,7,0.175,KEPT
prioritizing,SURFACE,7,0.175,KEPT
process,SURFACE,7,0.175,KEPT
prominent,SURFACE,7,0.175,KEPT
questions,SURFACE,7,0.175,KEPT
rationale,SURFACE,7,0.175,KEPT
reassess,SURFACE,7,0.175,KEPT
reflection,SURFACE,7,0.175,KEPT
resolution,SURFACE,7,0.175,KEPT
risk factors,SURFACE,7,0.175,KEPT
scenario,SURFACE,7,0.175,KEPT
scheduling,SURFACE,7,0.175,KEPT
specifics,SURFACE,7,0.175,KEPT
systemic symptoms,SURFACE,7,0.175,KEPT
variations,SURFACE,7,0.175,KEPT
x-ray,SURFACE,7,0.175,KEPT
**differential diagnosis**,SURFACE,6,0.15,KEPT
"\""physical examination",SURFACE,6,0.15,KEPT
abdomen,SURFACE,6,0.15,KEPT
abdominal pain,SURFACE,6,0.15,KEPT
acknowledged,SURFACE,6,0.15,KEPT
advanced imaging,SURFACE,6,0.15,KEPT
angles,SURFACE,6,0.15,KEPT
anyone,SURFACE,6,0.15,KEPT
areas,SURFACE,6,0.15,KEPT
assess,SURFACE,6,0.15,KEPT
await,SURFACE,6,0.15,KEPT
bilaterally,SURFACE,6,0.15,KEPT
birth weight,SURFACE,6,0.15,KEPT
born,SURFACE,6,0.15,KEPT
c-reactive protein,SURFACE,6,0.15,KEPT
cardiac,SURFACE,6,0.15,KEPT
cardiac anomalies,SURFACE,6,0.15,KEPT
cardiovascular,SURFACE,6,0.15,KEPT
case discussion,SURFACE,6,0.15,KEPT
clinical presentations,SURFACE,6,0.15,KEPT
cognitive,SURFACE,6,0.15,KEPT
comprehensive care,SURFACE,6,0.15,KEPT
congenital anomalies,SURFACE,6,0.15,KEPT
consider,SURFACE,6,0.15,KEPT
conversation,SURFACE,6,0.15,KEPT
correlate,SURFACE,6,0.15,KEPT
cough,SURFACE,6,0.15,KEPT
critical aspects,SURFACE,6,0.15,KEPT
decision-making,SURFACE,6,0.15,KEPT
deformities,SURFACE,6,0.15,KEPT
detailed,SURFACE,6,0.15,KEPT
detect,SURFACE,6,0.15,KEPT
developmental delay,SURFACE,6,0.15,KEPT
duration,SURFACE,6,0.15,KEPT
dysmorphic features,SURFACE,6,0.15,KEPT
ears,SURFACE,6,0.15,KEPT
echo,SURFACE,6,0.15,KEPT
episode,SURFACE,6,0.15,KEPT
everyone,SURFACE,6,0.15,KEPT
expansion,SURFACE,6,0.15,KEPT
eyes,SURFACE,6,0.15,KEPT
facial dysmorphism,SURFACE,6,0.15,KEPT
facial features,SURFACE,6,0.15,KEPT
family members,SURFACE,6,0.15,KEPT
follow-ups,SURFACE,6,0.15,KEPT
genetic findings,SURFACE,6,0.15,KEPT
genetic syndromes,SURFACE,6,0.15,KEPT
genetic tests,SURFACE,6,0.15,KEPT
geneticists,SURFACE,6,0.15,KEPT
growth,SURFACE,6,0.15,KEPT
hands,SURFACE,6,0.15,KEPT
hospital,SURFACE,6,0.15,KEPT
hypertension,SURFACE,6,0.15,KEPT
imperative,SURFACE,6,0.15,KEPT
improvement,SURFACE,6,0.15,KEPT
inconclusive,SURFACE,6,0.15,KEPT
indicative,SURFACE,6,0.15,KEPT
infectious causes,SURFACE,6,0.15,KEPT
inherited,SURFACE,6,0.15,KEPT
integration,SURFACE,6,0.15,KEPT
interpretation,SURFACE,6,0.15,KEPT
intervention,SURFACE,6,0.15,KEPT
investigating,SURFACE,6,0.15,KEPT
invite,SURFACE,6,0.15,KEPT
isolated,SURFACE,6,0.15,KEPT
key points,SURFACE,6,0.15,KEPT
layer,SURFACE,6,0.15,KEPT
lean,SURFACE,6,0.15,KEPT
left,SURFACE,6,0.15,KEPT
low,SURFACE,6,0.15,KEPT
mild,SURFACE,6,0.15,KEPT
month,SURFACE,6,0.15,KEPT
obesity,SURFACE,6,0.15,KEPT
opinions,SURFACE,6,0.15,KEPT
options,SURFACE,6,0.15,KEPT
organized,SURFACE,6,0.15,KEPT
overlaps,SURFACE,6,0.15,KEPT
path,SURFACE,6,0.15,KEPT
physical findings,SURFACE,6,0.15,KEPT
please share,SURFACE,6,0.15,KEPT
pregnancy,SURFACE,6,0.15,KEPT
proceeding,SURFACE,6,0.15,KEPT
rare,SURFACE,6,0.15,KEPT
recap,SURFACE,6,0.15,KEPT
refinements,SURFACE,6,0.15,KEPT
regular,SURFACE,6,0.15,KEPT
relationship,SURFACE,6,0.15,KEPT
renal,SURFACE,6,0.15,KEPT
renal function,SURFACE,6,0.15,KEPT
renal issues,SURFACE,6,0.15,KEPT
responses,SURFACE,6,0.15,KEPT
short stature,SURFACE,6,0.15,KEPT
significance,SURFACE,6,0.15,KEPT
skeletal abnormalities,SURFACE,6,0.15,KEPT
solid,SURFACE,6,0.15,KEPT
stable,SURFACE,6,0.15,KEPT
standard,SURFACE,6,0.15,KEPT
structural anomalies,SURFACE,6,0.15,KEPT
symptomatology,SURFACE,6,0.15,KEPT
unified,SURFACE,6,0.15,KEPT
visualizing,SURFACE,6,0.15,KEPT
weight,SURFACE,6,0.15,KEPT
worsening,SURFACE,6,0.15,KEPT
accurately,SURFACE,5,0.125,KEPT
actions,SURFACE,5,0.125,KEPT
additionally,SURFACE,5,0.125,KEPT
additions,SURFACE,5,0.125,KEPT
affecting,SURFACE,5,0.125,KEPT
ana,SURFACE,5,0.125,KEPT
antibodies,SURFACE,5,0.125,KEPT
appearance,SURFACE,5,0.125,KEPT
associated,SURFACE,5,0.125,KEPT
associated anomalies,SURFACE,5,0.125,KEPT
baseline,SURFACE,5,0.125,KEPT
begin,SURFACE,5,0.125,KEPT
benefit,SURFACE,5,0.125,KEPT
blood,SURFACE,5,0.125,KEPT
blood pressure,SURFACE,5,0.125,KEPT
brain**,SURFACE,5,0.125,KEPT
cardiology,SURFACE,5,0.125,KEPT
cautious,SURFACE,5,0.125,KEPT
chromosomal abnormalities,SURFACE,5,0.125,KEPT
clarifications,SURFACE,5,0.125,KEPT
clarifying,SURFACE,5,0.125,KEPT
classic,SURFACE,5,0.125,KEPT
clinical manifestations,SURFACE,5,0.125,KEPT
collaborative efforts,SURFACE,5,0.125,KEPT
combined,SURFACE,5,0.125,KEPT
connections,SURFACE,5,0.125,KEPT
connective tissue disorders,SURFACE,5,0.125,KEPT
consanguinity,SURFACE,5,0.125,KEPT
continuous monitoring,SURFACE,5,0.125,KEPT
correlation,SURFACE,5,0.125,KEPT
daily,SURFACE,5,0.125,KEPT
definitively,SURFACE,5,0.125,KEPT
delay,SURFACE,5,0.125,KEPT
diagnostic direction,SURFACE,5,0.125,KEPT
diagnostic efforts,SURFACE,5,0.125,KEPT
differential considerations,SURFACE,5,0.125,KEPT
differential list,SURFACE,5,0.125,KEPT
disagreements,SURFACE,5,0.125,KEPT
disease,SURFACE,5,0.125,KEPT
disturbances,SURFACE,5,0.125,KEPT
dysmorphic,SURFACE,5,0.125,KEPT
effective,SURFACE,5,0.125,KEPT
effectiveness,SURFACE,5,0.125,KEPT
effects,SURFACE,5,0.125,KEPT
endocrinology,SURFACE,5,0.125,KEPT
environmental,SURFACE,5,0.125,KEPT
environmental factors,SURFACE,5,0.125,KEPT
erythrocyte,SURFACE,5,0.125,KEPT
establish,SURFACE,5,0.125,KEPT
evolves,SURFACE,5,0.125,KEPT
excellent,SURFACE,5,0.125,KEPT
exclusion,SURFACE,5,0.125,KEPT
exposure,SURFACE,5,0.125,KEPT
exposure to,SURFACE,5,0.125,KEPT
facial,SURFACE,5,0.125,KEPT
finalization,SURFACE,5,0.125,KEPT
fit,SURFACE,5,0.125,KEPT
genetic panel,SURFACE,5,0.125,KEPT
genetic predispositions,SURFACE,5,0.125,KEPT
geographic,SURFACE,5,0.125,KEPT
guidance,SURFACE,5,0.125,KEPT
height,SURFACE,5,0.125,KEPT
i support,SURFACE,5,0.125,KEPT
i want,SURFACE,5,0.125,KEPT
illuminate,SURFACE,5,0.125,KEPT
indicative of,SURFACE,5,0.125,KEPT
individuals,SURFACE,5,0.125,KEPT
infectious processes,SURFACE,5,0.125,KEPT
inflammatory processes,SURFACE,5,0.125,KEPT
invasive,SURFACE,5,0.125,KEPT
json format,SURFACE,5,0.125,KEPT
juncture,SURFACE,5,0.125,KEPT
leading diagnosis,SURFACE,5,0.125,KEPT
lifestyle,SURFACE,5,0.125,KEPT
limbs,SURFACE,5,0.125,KEPT
list,SURFACE,5,0.125,KEPT
malignancies,SURFACE,5,0.125,KEPT
man,SURFACE,5,0.125,KEPT
measuring,SURFACE,5,0.125,KEPT
metabolic panel,SURFACE,5,0.125,KEPT
monitoring**,SURFACE,5,0.125,KEPT
neurological,SURFACE,5,0.125,KEPT
no significant,SURFACE,5,0.125,KEPT
objections,SURFACE,5,0.125,KEPT
observation,SURFACE,5,0.125,KEPT
obstruction,SURFACE,5,0.125,KEPT
older patients,SURFACE,5,0.125,KEPT
outcome,SURFACE,5,0.125,KEPT
overt,SURFACE,5,0.125,KEPT
pathogens,SURFACE,5,0.125,KEPT
pathway,SURFACE,5,0.125,KEPT
patient management,SURFACE,5,0.125,KEPT
patient's care,SURFACE,5,0.125,KEPT
pattern,SURFACE,5,0.125,KEPT
periodic,SURFACE,5,0.125,KEPT
phenotype,SURFACE,5,0.125,KEPT
priorities,SURFACE,5,0.125,KEPT
proactive approach,SURFACE,5,0.125,KEPT
protocol,SURFACE,5,0.125,KEPT
psychological support,SURFACE,5,0.125,KEPT
recurrence,SURFACE,5,0.125,KEPT
relatives,SURFACE,5,0.125,KEPT
sarcoidosis,SURFACE,5,0.125,KEPT
scenarios,SURFACE,5,0.125,KEPT
screenings,SURFACE,5,0.125,KEPT
secondary to,SURFACE,5,0.125,KEPT
sequencing,SURFACE,5,0.125,KEPT
serum,SURFACE,5,0.125,KEPT
severity,SURFACE,5,0.125,KEPT
shortened,SURFACE,5,0.125,KEPT
situation,SURFACE,5,0.125,KEPT
skeletal dysplasias,SURFACE,5,0.125,KEPT
skeletal features,SURFACE,5,0.125,KEPT
solidifying,SURFACE,5,0.125,KEPT
specialized,SURFACE,5,0.125,KEPT
specific,SURFACE,5,0.125,KEPT
spectrum,SURFACE,5,0.125,KEPT
stand,SURFACE,5,0.125,KEPT
strategy,SURFACE,5,0.125,KEPT
support,SURFACE,5,0.125,KEPT
surveillance,SURFACE,5,0.125,KEPT
symptomatic,SURFACE,5,0.125,KEPT
syndromic,SURFACE,5,0.125,KEPT
syndromic features,SURFACE,5,0.125,KEPT
systemic conditions,SURFACE,5,0.125,KEPT
systemic features,SURFACE,5,0.125,KEPT
systemic inflammation,SURFACE,5,0.125,KEPT
testing plan,SURFACE,5,0.125,KEPT
testing strategy,SURFACE,5,0.125,KEPT
timelines,SURFACE,5,0.125,KEPT
traits,SURFACE,5,0.125,KEPT
treated,SURFACE,5,0.125,KEPT
treated with,SURFACE,5,0.125,KEPT
variability,SURFACE,5,0.125,KEPT
variant,SURFACE,5,0.125,KEPT
vascular issues,SURFACE,5,0.125,KEPT
visualization,SURFACE,5,0.125,KEPT
week,SURFACE,5,0.125,KEPT
well-prepared,SURFACE,5,0.125,KEPT
well-supported,SURFACE,5,0.125,KEPT
woman,SURFACE,5,0.125,KEPT
you,SURFACE,5,0.125,KEPT
young,SURFACE,5,0.125,KEPT
**differential diagnoses:**,SURFACE,4,0.1,KEPT
**mri,SURFACE,4,0.1,KEPT
**patient,SURFACE,4,0.1,KEPT
affirm,SURFACE,4,0.1,KEPT
affirmation,SURFACE,4,0.1,KEPT
age group,SURFACE,4,0.1,KEPT
aligned,SURFACE,4,0.1,KEPT
anatomy,SURFACE,4,0.1,KEPT
anemia,SURFACE,4,0.1,KEPT
anterior,SURFACE,4,0.1,KEPT
area,SURFACE,4,0.1,KEPT
arrive,SURFACE,4,0.1,KEPT
articulated,SURFACE,4,0.1,KEPT
autoimmune conditions,SURFACE,4,0.1,KEPT
autoimmune markers,SURFACE,4,0.1,KEPT
awareness,SURFACE,4,0.1,KEPT
background,SURFACE,4,0.1,KEPT
bases,SURFACE,4,0.1,KEPT
blood tests,SURFACE,4,0.1,KEPT
bone age,SURFACE,4,0.1,KEPT
cardiac issues,SURFACE,4,0.1,KEPT
case details,SURFACE,4,0.1,KEPT
clinical data,SURFACE,4,0.1,KEPT
clinical history,SURFACE,4,0.1,KEPT
clinical profile,SURFACE,4,0.1,KEPT
clinical signs,SURFACE,4,0.1,KEPT
clinical status,SURFACE,4,0.1,KEPT
clinical suspicion,SURFACE,4,0.1,KEPT
clinical symptoms,SURFACE,4,0.1,KEPT
cohesive approach,SURFACE,4,0.1,KEPT
collaborate,SURFACE,4,0.1,KEPT
collaborative analysis,SURFACE,4,0.1,KEPT
collaborative process,SURFACE,4,0.1,KEPT
complained,SURFACE,4,0.1,KEPT
complaints,SURFACE,4,0.1,KEPT
confidence,SURFACE,4,0.1,KEPT
considering,SURFACE,4,0.1,KEPT
considers,SURFACE,4,0.1,KEPT
constructive,SURFACE,4,0.1,KEPT
consultations,SURFACE,4,0.1,KEPT
coordination,SURFACE,4,0.1,KEPT
correlates,SURFACE,4,0.1,KEPT
critical,SURFACE,4,0.1,KEPT
crp,SURFACE,4,0.1,KEPT
ct angiography,SURFACE,4,0.1,KEPT
decline,SURFACE,4,0.1,KEPT
decreased,SURFACE,4,0.1,KEPT
defects,SURFACE,4,0.1,KEPT
deficiencies,SURFACE,4,0.1,KEPT
delays,SURFACE,4,0.1,KEPT
delivery,SURFACE,4,0.1,KEPT
derangements,SURFACE,4,0.1,KEPT
description,SURFACE,4,0.1,KEPT
detection,SURFACE,4,0.1,KEPT
deterioration,SURFACE,4,0.1,KEPT
diabetes,SURFACE,4,0.1,KEPT
diagnostic evaluations,SURFACE,4,0.1,KEPT
diagnostic focus,SURFACE,4,0.1,KEPT
diagnostic framework,SURFACE,4,0.1,KEPT
diagnostic possibilities,SURFACE,4,0.1,KEPT
diagnostic workup,SURFACE,4,0.1,KEPT
diarrhea,SURFACE,4,0.1,KEPT
discharge,SURFACE,4,0.1,KEPT
discharged,SURFACE,4,0.1,KEPT
discrepancies,SURFACE,4,0.1,KEPT
diseases,SURFACE,4,0.1,KEPT
doctor0's,SURFACE,4,0.1,KEPT
doctor1's,SURFACE,4,0.1,KEPT
dynamic,SURFACE,4,0.1,KEPT
education,SURFACE,4,0.1,KEPT
effectively,SURFACE,4,0.1,KEPT
electrolyte,SURFACE,4,0.1,KEPT
emphasize,SURFACE,4,0.1,KEPT
encapsulate,SURFACE,4,0.1,KEPT
engage,SURFACE,4,0.1,KEPT
enlarged,SURFACE,4,0.1,KEPT
episodes,SURFACE,4,0.1,KEPT
evaluated,SURFACE,4,0.1,KEPT
event,SURFACE,4,0.1,KEPT
events,SURFACE,4,0.1,KEPT
evident,SURFACE,4,0.1,KEPT
evolve,SURFACE,4,0.1,KEPT
expert,SURFACE,4,0.1,KEPT
extensive,SURFACE,4,0.1,KEPT
factor,SURFACE,4,0.1,KEPT
familial history,SURFACE,4,0.1,KEPT
families,SURFACE,4,0.1,KEPT
family history of,SURFACE,4,0.1,KEPT
females,SURFACE,4,0.1,KEPT
final thoughts,SURFACE,4,0.1,KEPT
finalized,SURFACE,4,0.1,KEPT
fits,SURFACE,4,0.1,KEPT
fitting,SURFACE,4,0.1,KEPT
flexible,SURFACE,4,0.1,KEPT
gene mutations,SURFACE,4,0.1,KEPT
genes,SURFACE,4,0.1,KEPT
genetic causes,SURFACE,4,0.1,KEPT
genetic counselor,SURFACE,4,0.1,KEPT
genetic counselors,SURFACE,4,0.1,KEPT
genetic disorders,SURFACE,4,0.1,KEPT
genetic exploration,SURFACE,4,0.1,KEPT
genetic syndrome,SURFACE,4,0.1,KEPT
geneticist,SURFACE,4,0.1,KEPT
growth patterns,SURFACE,4,0.1,KEPT
hereditary,SURFACE,4,0.1,KEPT
high-risk,SURFACE,4,0.1,KEPT
history of,SURFACE,4,0.1,KEPT
holistic approach,SURFACE,4,0.1,KEPT
hormonal,SURFACE,4,0.1,KEPT
hospitalization,SURFACE,4,0.1,KEPT
i invite,SURFACE,4,0.1,KEPT
i recommend,SURFACE,4,0.1,KEPT
i'd,SURFACE,4,0.1,KEPT
illness,SURFACE,4,0.1,KEPT
imbalances,SURFACE,4,0.1,KEPT
impacts,SURFACE,4,0.1,KEPT
impaired,SURFACE,4,0.1,KEPT
improving,SURFACE,4,0.1,KEPT
inclination,SURFACE,4,0.1,KEPT
including,SURFACE,4,0.1,KEPT
increase,SURFACE,4,0.1,KEPT
infancy,SURFACE,4,0.1,KEPT
infant,SURFACE,4,0.1,KEPT
infectious agents,SURFACE,4,0.1,KEPT
inflammatory markers,SURFACE,4,0.1,KEPT
"information.\"",\n\n",SURFACE,4,0.1,KEPT
inquiry,SURFACE,4,0.1,KEPT
intellectual disability,SURFACE,4,0.1,KEPT
intervals,SURFACE,4,0.1,KEPT
joint,SURFACE,4,0.1,KEPT
karyotype,SURFACE,4,0.1,KEPT
karyotype analysis,SURFACE,4,0.1,KEPT
keeping,SURFACE,4,0.1,KEPT
kidneys,SURFACE,4,0.1,KEPT
knees,SURFACE,4,0.1,KEPT
laboratory findings,SURFACE,4,0.1,KEPT
laboratory tests,SURFACE,4,0.1,KEPT
lacks,SURFACE,4,0.1,KEPT
last-minute thoughts,SURFACE,4,0.1,KEPT
lesion,SURFACE,4,0.1,KEPT
limb,SURFACE,4,0.1,KEPT
limb anomalies,SURFACE,4,0.1,KEPT
limb malformations,SURFACE,4,0.1,KEPT
lipid profile,SURFACE,4,0.1,KEPT
lipid profiles,SURFACE,4,0.1,KEPT
lung,SURFACE,4,0.1,KEPT
lungs,SURFACE,4,0.1,KEPT
lymphoma,SURFACE,4,0.1,KEPT
manifestation,SURFACE,4,0.1,KEPT
measured,SURFACE,4,0.1,KEPT
medical,SURFACE,4,0.1,KEPT
medications,SURFACE,4,0.1,KEPT
meeting,SURFACE,4,0.1,KEPT
mitigate,SURFACE,4,0.1,KEPT
moderate,SURFACE,4,0.1,KEPT
monitor,SURFACE,4,0.1,KEPT
multidisciplinary,SURFACE,4,0.1,KEPT
multifaceted approach,SURFACE,4,0.1,KEPT
needs,SURFACE,4,0.1,KEPT
neonatal,SURFACE,4,0.1,KEPT
neurological decline,SURFACE,4,0.1,KEPT
neurological symptoms,SURFACE,4,0.1,KEPT
neurology,SURFACE,4,0.1,KEPT
next-generation sequencing,SURFACE,4,0.1,KEPT
ngs,SURFACE,4,0.1,KEPT
no history,SURFACE,4,0.1,KEPT
"normal.\""\n",SURFACE,4,0.1,KEPT
noteworthy,SURFACE,4,0.1,KEPT
observations,SURFACE,4,0.1,KEPT
optimal,SURFACE,4,0.1,KEPT
overall,SURFACE,4,0.1,KEPT
parties,SURFACE,4,0.1,KEPT
patient’s diagnosis,SURFACE,4,0.1,KEPT
plausible,SURFACE,4,0.1,KEPT
please confirm,SURFACE,4,0.1,KEPT
position,SURFACE,4,0.1,KEPT
post-surgery,SURFACE,4,0.1,KEPT
prader-willi syndrome,SURFACE,4,0.1,KEPT
pregnancies,SURFACE,4,0.1,KEPT
presenting symptoms,SURFACE,4,0.1,KEPT
presents,SURFACE,4,0.1,KEPT
proactive,SURFACE,4,0.1,KEPT
probable,SURFACE,4,0.1,KEPT
prolonged,SURFACE,4,0.1,KEPT
psychological,SURFACE,4,0.1,KEPT
pulmonary issues,SURFACE,4,0.1,KEPT
readiness,SURFACE,4,0.1,KEPT
reaffirmation,SURFACE,4,0.1,KEPT
recommend,SURFACE,4,0.1,KEPT
reduced,SURFACE,4,0.1,KEPT
reinforcing,SURFACE,4,0.1,KEPT
renal dysfunction,SURFACE,4,0.1,KEPT
resonates,SURFACE,4,0.1,KEPT
resources,SURFACE,4,0.1,KEPT
respiratory issues,SURFACE,4,0.1,KEPT
respiratory symptoms,SURFACE,4,0.1,KEPT
reviewed,SURFACE,4,0.1,KEPT
reviewing,SURFACE,4,0.1,KEPT
right,SURFACE,4,0.1,KEPT
right side,SURFACE,4,0.1,KEPT
scans,SURFACE,4,0.1,KEPT
seizures,SURFACE,4,0.1,KEPT
sensitive,SURFACE,4,0.1,KEPT
sensitivity,SURFACE,4,0.1,KEPT
sequence,SURFACE,4,0.1,KEPT
serological tests,SURFACE,4,0.1,KEPT
short neck,SURFACE,4,0.1,KEPT
siblings,SURFACE,4,0.1,KEPT
signs of,SURFACE,4,0.1,KEPT
skeletal dysplasia,SURFACE,4,0.1,KEPT
smoking history,SURFACE,4,0.1,KEPT
solidifies,SURFACE,4,0.1,KEPT
specialties,SURFACE,4,0.1,KEPT
speech,SURFACE,4,0.1,KEPT
stance,SURFACE,4,0.1,KEPT
status,SURFACE,4,0.1,KEPT
strategies,SURFACE,4,0.1,KEPT
structure,SURFACE,4,0.1,KEPT
summarizing,SURFACE,4,0.1,KEPT
syndromic presentations,SURFACE,4,0.1,KEPT
synthesis,SURFACE,4,0.1,KEPT
systematic approach,SURFACE,4,0.1,KEPT
systematically,SURFACE,4,0.1,KEPT
systemic issues,SURFACE,4,0.1,KEPT
systemic lupus erythematosus,SURFACE,4,0.1,KEPT
tailored,SURFACE,4,0.1,KEPT
targeted,SURFACE,4,0.1,KEPT
targeted testing,SURFACE,4,0.1,KEPT
temperature,SURFACE,4,0.1,KEPT
test outcomes,SURFACE,4,0.1,KEPT
thoughtful discussion,SURFACE,4,0.1,KEPT
thoughtful response,SURFACE,4,0.1,KEPT
thoughtful summary,SURFACE,4,0.1,KEPT
toes,SURFACE,4,0.1,KEPT
trauma,SURFACE,4,0.1,KEPT
treatment plan,SURFACE,4,0.1,KEPT
treatments,SURFACE,4,0.1,KEPT
tumors,SURFACE,4,0.1,KEPT
undiagnosed,SURFACE,4,0.1,KEPT
unfolds,SURFACE,4,0.1,KEPT
unique,SURFACE,4,0.1,KEPT
upper limbs,SURFACE,4,0.1,KEPT
urine,SURFACE,4,0.1,KEPT
variable,SURFACE,4,0.1,KEPT
vascular,SURFACE,4,0.1,KEPT
vasculitis,SURFACE,4,0.1,KEPT
viral,SURFACE,4,0.1,KEPT
vision,SURFACE,4,0.1,KEPT
visual acuity,SURFACE,4,0.1,KEPT
vital signs,SURFACE,4,0.1,KEPT
walking,SURFACE,4,0.1,KEPT
weigh,SURFACE,4,0.1,KEPT
**genetic testing,SURFACE,3,0.075,KEPT
**mri**,SURFACE,3,0.075,KEPT
**next-generation sequencing,SURFACE,3,0.075,KEPT
**renal ultrasound**,SURFACE,3,0.075,KEPT
"\""laboratory tests",SURFACE,3,0.075,KEPT
abdominal ultrasound,SURFACE,3,0.075,KEPT
accumulation,SURFACE,3,0.075,KEPT
action steps,SURFACE,3,0.075,KEPT
acute symptoms,SURFACE,3,0.075,KEPT
adequate,SURFACE,3,0.075,KEPT
affirmations,SURFACE,3,0.075,KEPT
agrees,SURFACE,3,0.075,KEPT
aiding,SURFACE,3,0.075,KEPT
aligning,SURFACE,3,0.075,KEPT
analyze,SURFACE,3,0.075,KEPT
aneuploidies,SURFACE,3,0.075,KEPT
anyone else,SURFACE,3,0.075,KEPT
appreciate everyone,SURFACE,3,0.075,KEPT
appreciate everyone's,SURFACE,3,0.075,KEPT
appropriate,SURFACE,3,0.075,KEPT
array,SURFACE,3,0.075,KEPT
assisting,SURFACE,3,0.075,KEPT
associated abnormalities,SURFACE,3,0.075,KEPT
asthma,SURFACE,3,0.075,KEPT
asymptomatic,SURFACE,3,0.075,KEPT
autoimmunity,SURFACE,3,0.075,KEPT
baby,SURFACE,3,0.075,KEPT
bacterial infection,SURFACE,3,0.075,KEPT
behavioral,SURFACE,3,0.075,KEPT
behçet's disease,SURFACE,3,0.075,KEPT
best care,SURFACE,3,0.075,KEPT
biopsies,SURFACE,3,0.075,KEPT
bone,SURFACE,3,0.075,KEPT
broad spectrum,SURFACE,3,0.075,KEPT
cardiac evaluation,SURFACE,3,0.075,KEPT
cardiac function,SURFACE,3,0.075,KEPT
cardiac mri,SURFACE,3,0.075,KEPT
case analysis,SURFACE,3,0.075,KEPT
case information,SURFACE,3,0.075,KEPT
causes,SURFACE,3,0.075,KEPT
central nervous system,SURFACE,3,0.075,KEPT
cesarean section,SURFACE,3,0.075,KEPT
characteristic,SURFACE,3,0.075,KEPT
characterization,SURFACE,3,0.075,KEPT
chest,SURFACE,3,0.075,KEPT
chest ct,SURFACE,3,0.075,KEPT
child's,SURFACE,3,0.075,KEPT
childhood,SURFACE,3,0.075,KEPT
chromosomal,SURFACE,3,0.075,KEPT
chromosomal anomalies,SURFACE,3,0.075,KEPT
chromosomal microarray analysis,SURFACE,3,0.075,KEPT
chronic kidney disease,SURFACE,3,0.075,KEPT
clinical context,SURFACE,3,0.075,KEPT
clinical scenario,SURFACE,3,0.075,KEPT
cns,SURFACE,3,0.075,KEPT
cognitive decline,SURFACE,3,0.075,KEPT
cognitive function,SURFACE,3,0.075,KEPT
cognitive impairment,SURFACE,3,0.075,KEPT
compile,SURFACE,3,0.075,KEPT
complete blood count,SURFACE,3,0.075,KEPT
conclusive,SURFACE,3,0.075,KEPT
conclusive results,SURFACE,3,0.075,KEPT
concur,SURFACE,3,0.075,KEPT
concurrent,SURFACE,3,0.075,KEPT
congenital disorders,SURFACE,3,0.075,KEPT
congenital heart defects,SURFACE,3,0.075,KEPT
congenital syndromes,SURFACE,3,0.075,KEPT
conjunctival,SURFACE,3,0.075,KEPT
connective tissue,SURFACE,3,0.075,KEPT
connective tissue diseases,SURFACE,3,0.075,KEPT
consanguineous,SURFACE,3,0.075,KEPT
consensus diagnosis,SURFACE,3,0.075,KEPT
considered,SURFACE,3,0.075,KEPT
consult with,SURFACE,3,0.075,KEPT
consultation,SURFACE,3,0.075,KEPT
consulting,SURFACE,3,0.075,KEPT
contexts,SURFACE,3,0.075,KEPT
contingency,SURFACE,3,0.075,KEPT
contribution,SURFACE,3,0.075,KEPT
coordinate,SURFACE,3,0.075,KEPT
coordinated,SURFACE,3,0.075,KEPT
correlating,SURFACE,3,0.075,KEPT
cortisol,SURFACE,3,0.075,KEPT
couple,SURFACE,3,0.075,KEPT
craniofacial anomalies,SURFACE,3,0.075,KEPT
criteria,SURFACE,3,0.075,KEPT
csf,SURFACE,3,0.075,KEPT
ct imaging,SURFACE,3,0.075,KEPT
culture,SURFACE,3,0.075,KEPT
cytomegalovirus,SURFACE,3,0.075,KEPT
d-dimer,SURFACE,3,0.075,KEPT
damage,SURFACE,3,0.075,KEPT
decision,SURFACE,3,0.075,KEPT
decrease,SURFACE,3,0.075,KEPT
deletions,SURFACE,3,0.075,KEPT
deliberation,SURFACE,3,0.075,KEPT
dental anomalies,SURFACE,3,0.075,KEPT
developmental issues,SURFACE,3,0.075,KEPT
developmental regression,SURFACE,3,0.075,KEPT
diagnosis state,SURFACE,3,0.075,KEPT
diagnostic certainty,SURFACE,3,0.075,KEPT
diagnostic discussion,SURFACE,3,0.075,KEPT
diagnostic evaluation,SURFACE,3,0.075,KEPT
diagnostic state,SURFACE,3,0.075,KEPT
died,SURFACE,3,0.075,KEPT
differentials,SURFACE,3,0.075,KEPT
diligence,SURFACE,3,0.075,KEPT
diminished,SURFACE,3,0.075,KEPT
discovered,SURFACE,3,0.075,KEPT
discuss,SURFACE,3,0.075,KEPT
discussing,SURFACE,3,0.075,KEPT
disorder,SURFACE,3,0.075,KEPT
distal,SURFACE,3,0.075,KEPT
distance,SURFACE,3,0.075,KEPT
distinctions,SURFACE,3,0.075,KEPT
distribution,SURFACE,3,0.075,KEPT
diverse,SURFACE,3,0.075,KEPT
document,SURFACE,3,0.075,KEPT
documentation,SURFACE,3,0.075,KEPT
down syndrome,SURFACE,3,0.075,KEPT
drugs,SURFACE,3,0.075,KEPT
eager,SURFACE,3,0.075,KEPT
early detection,SURFACE,3,0.075,KEPT
echocardiographic,SURFACE,3,0.075,KEPT
echocardiography,SURFACE,3,0.075,KEPT
edema,SURFACE,3,0.075,KEPT
educational resources,SURFACE,3,0.075,KEPT
eeg,SURFACE,3,0.075,KEPT
electrolytes,SURFACE,3,0.075,KEPT
elevation,SURFACE,3,0.075,KEPT
emergence,SURFACE,3,0.075,KEPT
empower,SURFACE,3,0.075,KEPT
epilepsy,SURFACE,3,0.075,KEPT
epstein-barr virus,SURFACE,3,0.075,KEPT
esr,SURFACE,3,0.075,KEPT
etiologies,SURFACE,3,0.075,KEPT
exacerbating,SURFACE,3,0.075,KEPT
exceptional,SURFACE,3,0.075,KEPT
excess,SURFACE,3,0.075,KEPT
excessive,SURFACE,3,0.075,KEPT
expedite,SURFACE,3,0.075,KEPT
experts,SURFACE,3,0.075,KEPT
face,SURFACE,3,0.075,KEPT
facets,SURFACE,3,0.075,KEPT
facial characteristics,SURFACE,3,0.075,KEPT
family education**,SURFACE,3,0.075,KEPT
family history of consanguinity,SURFACE,3,0.075,KEPT
family's,SURFACE,3,0.075,KEPT
father,SURFACE,3,0.075,KEPT
fatigue,SURFACE,3,0.075,KEPT
feet,SURFACE,3,0.075,KEPT
femur,SURFACE,3,0.075,KEPT
fertility,SURFACE,3,0.075,KEPT
fetal,SURFACE,3,0.075,KEPT
fetus,SURFACE,3,0.075,KEPT
fields,SURFACE,3,0.075,KEPT
first-degree relatives,SURFACE,3,0.075,KEPT
flexion,SURFACE,3,0.075,KEPT
format,SURFACE,3,0.075,KEPT
fostering,SURFACE,3,0.075,KEPT
gender,SURFACE,3,0.075,KEPT
genetic analysis,SURFACE,3,0.075,KEPT
genetic anomalies,SURFACE,3,0.075,KEPT
genetic components,SURFACE,3,0.075,KEPT
genetic condition,SURFACE,3,0.075,KEPT
genetic etiology,SURFACE,3,0.075,KEPT
genetic evaluations,SURFACE,3,0.075,KEPT
genetic investigations,SURFACE,3,0.075,KEPT
genetic predisposition,SURFACE,3,0.075,KEPT
genetic studies,SURFACE,3,0.075,KEPT
gestation,SURFACE,3,0.075,KEPT
girl,SURFACE,3,0.075,KEPT
growth hormone,SURFACE,3,0.075,KEPT
growth issues,SURFACE,3,0.075,KEPT
head circumference,SURFACE,3,0.075,KEPT
health issues,SURFACE,3,0.075,KEPT
health status,SURFACE,3,0.075,KEPT
hearing loss,SURFACE,3,0.075,KEPT
heart,SURFACE,3,0.075,KEPT
hereditary condition,SURFACE,3,0.075,KEPT
hereditary syndromes,SURFACE,3,0.075,KEPT
high forehead,SURFACE,3,0.075,KEPT
high index,SURFACE,3,0.075,KEPT
hint,SURFACE,3,0.075,KEPT
histological,SURFACE,3,0.075,KEPT
histopathological,SURFACE,3,0.075,KEPT
holistic view,SURFACE,3,0.075,KEPT
hypertelorism,SURFACE,3,0.075,KEPT
hypoplasia,SURFACE,3,0.075,KEPT
hypothyroidism,SURFACE,3,0.075,KEPT
hypotonia,SURFACE,3,0.075,KEPT
i urge,SURFACE,3,0.075,KEPT
ideas,SURFACE,3,0.075,KEPT
imaging study,SURFACE,3,0.075,KEPT
imaging techniques,SURFACE,3,0.075,KEPT
immunology,SURFACE,3,0.075,KEPT
implications,SURFACE,3,0.075,KEPT
incidence,SURFACE,3,0.075,KEPT
inconsistencies,SURFACE,3,0.075,KEPT
incorporating,SURFACE,3,0.075,KEPT
incorporation,SURFACE,3,0.075,KEPT
indications,SURFACE,3,0.075,KEPT
indicators,SURFACE,3,0.075,KEPT
individual,SURFACE,3,0.075,KEPT
infant's,SURFACE,3,0.075,KEPT
infectious disease,SURFACE,3,0.075,KEPT
infectious etiologies,SURFACE,3,0.075,KEPT
infectious process,SURFACE,3,0.075,KEPT
inflammatory response,SURFACE,3,0.075,KEPT
influences,SURFACE,3,0.075,KEPT
informed,SURFACE,3,0.075,KEPT
intact,SURFACE,3,0.075,KEPT
integral,SURFACE,3,0.075,KEPT
integrate,SURFACE,3,0.075,KEPT
integrity,SURFACE,3,0.075,KEPT
intensive care unit,SURFACE,3,0.075,KEPT
interpreting,SURFACE,3,0.075,KEPT
intersection,SURFACE,3,0.075,KEPT
interstitial lung disease,SURFACE,3,0.075,KEPT
introduction,SURFACE,3,0.075,KEPT
items,SURFACE,3,0.075,KEPT
i’d,SURFACE,3,0.075,KEPT
justified,SURFACE,3,0.075,KEPT
karyotyping,SURFACE,3,0.075,KEPT
kidney,SURFACE,3,0.075,KEPT
kidney function,SURFACE,3,0.075,KEPT
lab findings,SURFACE,3,0.075,KEPT
laboratory,SURFACE,3,0.075,KEPT
latent,SURFACE,3,0.075,KEPT
layers,SURFACE,3,0.075,KEPT
leans,SURFACE,3,0.075,KEPT
left side,SURFACE,3,0.075,KEPT
length,SURFACE,3,0.075,KEPT
lifestyle factors,SURFACE,3,0.075,KEPT
limb defects,SURFACE,3,0.075,KEPT
limitations,SURFACE,3,0.075,KEPT
lipid levels,SURFACE,3,0.075,KEPT
liver,SURFACE,3,0.075,KEPT
liver function tests,SURFACE,3,0.075,KEPT
long bones,SURFACE,3,0.075,KEPT
lung function,SURFACE,3,0.075,KEPT
lymphadenopathy,SURFACE,3,0.075,KEPT
maintain,SURFACE,3,0.075,KEPT
malformations,SURFACE,3,0.075,KEPT
malignant,SURFACE,3,0.075,KEPT
marfan syndrome,SURFACE,3,0.075,KEPT
masses,SURFACE,3,0.075,KEPT
maternal,SURFACE,3,0.075,KEPT
measure,SURFACE,3,0.075,KEPT
mechanisms,SURFACE,3,0.075,KEPT
merits,SURFACE,3,0.075,KEPT
metabolic disorders,SURFACE,3,0.075,KEPT
metabolic pathways,SURFACE,3,0.075,KEPT
metabolites,SURFACE,3,0.075,KEPT
minimal,SURFACE,3,0.075,KEPT
minor,SURFACE,3,0.075,KEPT
mobility,SURFACE,3,0.075,KEPT
modality,SURFACE,3,0.075,KEPT
morphology,SURFACE,3,0.075,KEPT
multidisciplinary team,SURFACE,3,0.075,KEPT
multifocal,SURFACE,3,0.075,KEPT
mutation,SURFACE,3,0.075,KEPT
nasal bridge,SURFACE,3,0.075,KEPT
neck,SURFACE,3,0.075,KEPT
neurodegenerative disorder,SURFACE,3,0.075,KEPT
neurological deficits,SURFACE,3,0.075,KEPT
neuropsychological testing,SURFACE,3,0.075,KEPT
"normal.\"",\n\n  \""past medical history\",SURFACE,3,0.075,KEPT
older,SURFACE,3,0.075,KEPT
organ,SURFACE,3,0.075,KEPT
organize,SURFACE,3,0.075,KEPT
organizing,SURFACE,3,0.075,KEPT
organs,SURFACE,3,0.075,KEPT
overlapping conditions,SURFACE,3,0.075,KEPT
pain,SURFACE,3,0.075,KEPT
participation,SURFACE,3,0.075,KEPT
pathological,SURFACE,3,0.075,KEPT
patient outcomes,SURFACE,3,0.075,KEPT
patient’s case,SURFACE,3,0.075,KEPT
patient’s health,SURFACE,3,0.075,KEPT
patient’s needs,SURFACE,3,0.075,KEPT
pet,SURFACE,3,0.075,KEPT
physical characteristics,SURFACE,3,0.075,KEPT
physical features,SURFACE,3,0.075,KEPT
picture,SURFACE,3,0.075,KEPT
please feel free to,SURFACE,3,0.075,KEPT
pneumonia,SURFACE,3,0.075,KEPT
preliminary,SURFACE,3,0.075,KEPT
prenatal,SURFACE,3,0.075,KEPT
proband,SURFACE,3,0.075,KEPT
productive,SURFACE,3,0.075,KEPT
prognosis,SURFACE,3,0.075,KEPT
progresses,SURFACE,3,0.075,KEPT
prompting,SURFACE,3,0.075,KEPT
proposed,SURFACE,3,0.075,KEPT
protocols,SURFACE,3,0.075,KEPT
pulmonary complications,SURFACE,3,0.075,KEPT
pws,SURFACE,3,0.075,KEPT
quality of life,SURFACE,3,0.075,KEPT
rarity,SURFACE,3,0.075,KEPT
rate,SURFACE,3,0.075,KEPT
reasoning,SURFACE,3,0.075,KEPT
recommended tests**,SURFACE,3,0.075,KEPT
reconvene,SURFACE,3,0.075,KEPT
reevaluation,SURFACE,3,0.075,KEPT
referral,SURFACE,3,0.075,KEPT
referrals,SURFACE,3,0.075,KEPT
regular follow-ups,SURFACE,3,0.075,KEPT
reiteration,SURFACE,3,0.075,KEPT
renal imaging,SURFACE,3,0.075,KEPT
renal impairment,SURFACE,3,0.075,KEPT
renal ultrasound,SURFACE,3,0.075,KEPT
report,SURFACE,3,0.075,KEPT
reproductive health,SURFACE,3,0.075,KEPT
responsive,SURFACE,3,0.075,KEPT
revised,SURFACE,3,0.075,KEPT
revisit,SURFACE,3,0.075,KEPT
rheumatology,SURFACE,3,0.075,KEPT
safety,SURFACE,3,0.075,KEPT
satisfied,SURFACE,3,0.075,KEPT
scoliosis,SURFACE,3,0.075,KEPT
screen,SURFACE,3,0.075,KEPT
secondary,SURFACE,3,0.075,KEPT
seeing,SURFACE,3,0.075,KEPT
seizure,SURFACE,3,0.075,KEPT
serum levels,SURFACE,3,0.075,KEPT
shape,SURFACE,3,0.075,KEPT
sharing,SURFACE,3,0.075,KEPT
size,SURFACE,3,0.075,KEPT
skeletal deformities,SURFACE,3,0.075,KEPT
skeletal survey,SURFACE,3,0.075,KEPT
skeletal system,SURFACE,3,0.075,KEPT
skin manifestations,SURFACE,3,0.075,KEPT
smoking,SURFACE,3,0.075,KEPT
solid foundation,SURFACE,3,0.075,KEPT
solid plan,SURFACE,3,0.075,KEPT
specialists',SURFACE,3,0.075,KEPT
spirit,SURFACE,3,0.075,KEPT
stability,SURFACE,3,0.075,KEPT
staging,SURFACE,3,0.075,KEPT
stemming,SURFACE,3,0.075,KEPT
still's disease,SURFACE,3,0.075,KEPT
stress,SURFACE,3,0.075,KEPT
strokes,SURFACE,3,0.075,KEPT
stronger,SURFACE,3,0.075,KEPT
studies,SURFACE,3,0.075,KEPT
surgery,SURFACE,3,0.075,KEPT
surgical intervention,SURFACE,3,0.075,KEPT
surgical interventions,SURFACE,3,0.075,KEPT
susceptibility,SURFACE,3,0.075,KEPT
symptom progression,SURFACE,3,0.075,KEPT
synthesized,SURFACE,3,0.075,KEPT
systemic process,SURFACE,3,0.075,KEPT
systems,SURFACE,3,0.075,KEPT
table,SURFACE,3,0.075,KEPT
tall,SURFACE,3,0.075,KEPT
testing strategies,SURFACE,3,0.075,KEPT
thank,SURFACE,3,0.075,KEPT
therapies,SURFACE,3,0.075,KEPT
therapy,SURFACE,3,0.075,KEPT
thickness,SURFACE,3,0.075,KEPT
thorough,SURFACE,3,0.075,KEPT
thoughtful elaboration,SURFACE,3,0.075,KEPT
thyroid function tests,SURFACE,3,0.075,KEPT
tracking,SURFACE,3,0.075,KEPT
trajectory,SURFACE,3,0.075,KEPT
trisomy,SURFACE,3,0.075,KEPT
type,SURFACE,3,0.075,KEPT
types,SURFACE,3,0.075,KEPT
ultrasonography,SURFACE,3,0.075,KEPT
underlines,SURFACE,3,0.075,KEPT
unusual,SURFACE,3,0.075,KEPT
updates,SURFACE,3,0.075,KEPT
upper,SURFACE,3,0.075,KEPT
utilize,SURFACE,3,0.075,KEPT
viewpoints,SURFACE,3,0.075,KEPT
viruses,SURFACE,3,0.075,KEPT
visual disturbances,SURFACE,3,0.075,KEPT
walk,SURFACE,3,0.075,KEPT
weight loss,SURFACE,3,0.075,KEPT
well-founded,SURFACE,3,0.075,KEPT
well-structured,SURFACE,3,0.075,KEPT
words,SURFACE,3,0.075,KEPT
working diagnosis,SURFACE,3,0.075,KEPT
workup,SURFACE,3,0.075,KEPT
worth noting,SURFACE,3,0.075,KEPT
worthwhile,SURFACE,3,0.075,KEPT
x-rays,SURFACE,3,0.075,KEPT
young age,SURFACE,3,0.075,KEPT
**advanced,SURFACE,2,0.05,KEPT
**assessment,SURFACE,2,0.05,KEPT
**bilateral,SURFACE,2,0.05,KEPT
**bone marrow biopsy**,SURFACE,2,0.05,KEPT
**familial mediterranean,SURFACE,2,0.05,KEPT
**fluorescein angiography,SURFACE,2,0.05,KEPT
**follow-up,SURFACE,2,0.05,KEPT
**genetic counseling,SURFACE,2,0.05,KEPT
**genetic testing**,SURFACE,2,0.05,KEPT
**imaging studies,SURFACE,2,0.05,KEPT
**impact,SURFACE,2,0.05,KEPT
**infectious disease,SURFACE,2,0.05,KEPT
**juvenile idiopathic arthritis,SURFACE,2,0.05,KEPT
**lymphocyte subset analysis**,SURFACE,2,0.05,KEPT
**most,SURFACE,2,0.05,KEPT
**neuropsychological assessment**,SURFACE,2,0.05,KEPT
**prader-willi syndrome**,SURFACE,2,0.05,KEPT
**testing timeline**,SURFACE,2,0.05,KEPT
**ultrasound**,SURFACE,2,0.05,KEPT
"47,xxy",SURFACE,2,0.05,KEPT
"\""a",SURFACE,2,0.05,KEPT
"\""at age",SURFACE,2,0.05,KEPT
"\""initial",SURFACE,2,0.05,KEPT
"\""on admission",SURFACE,2,0.05,KEPT
abdomen**,SURFACE,2,0.05,KEPT
abdominal ultrasonography,SURFACE,2,0.05,KEPT
abnormality,SURFACE,2,0.05,KEPT
abscess formation,SURFACE,2,0.05,KEPT
achondroplasia,SURFACE,2,0.05,KEPT
acknowledge,SURFACE,2,0.05,KEPT
acknowledging,SURFACE,2,0.05,KEPT
acromegaly,SURFACE,2,0.05,KEPT
action points,SURFACE,2,0.05,KEPT
adaptation,SURFACE,2,0.05,KEPT
adherence,SURFACE,2,0.05,KEPT
administration,SURFACE,2,0.05,KEPT
adrenal function,SURFACE,2,0.05,KEPT
advanced,SURFACE,2,0.05,KEPT
advocacy,SURFACE,2,0.05,KEPT
advocating,SURFACE,2,0.05,KEPT
affected,SURFACE,2,0.05,KEPT
aggravated,SURFACE,2,0.05,KEPT
agile,SURFACE,2,0.05,KEPT
agreeing,SURFACE,2,0.05,KEPT
alcohol,SURFACE,2,0.05,KEPT
alterations,SURFACE,2,0.05,KEPT
alternative diagnoses,SURFACE,2,0.05,KEPT
ambiguous,SURFACE,2,0.05,KEPT
amendments,SURFACE,2,0.05,KEPT
amniotic fluid index,SURFACE,2,0.05,KEPT
analyzed,SURFACE,2,0.05,KEPT
anatomical abnormalities,SURFACE,2,0.05,KEPT
anatomical details,SURFACE,2,0.05,KEPT
anatomical findings,SURFACE,2,0.05,KEPT
anatomical overview,SURFACE,2,0.05,KEPT
aneuploidy,SURFACE,2,0.05,KEPT
ankylosing spondylitis,SURFACE,2,0.05,KEPT
annual,SURFACE,2,0.05,KEPT
anomaly,SURFACE,2,0.05,KEPT
antibiotics,SURFACE,2,0.05,KEPT
antibody responses,SURFACE,2,0.05,KEPT
antibody testing,SURFACE,2,0.05,KEPT
aortic dilation,SURFACE,2,0.05,KEPT
apgar scores,SURFACE,2,0.05,KEPT
appointments,SURFACE,2,0.05,KEPT
approval,SURFACE,2,0.05,KEPT
argument,SURFACE,2,0.05,KEPT
arrangements,SURFACE,2,0.05,KEPT
arthralgia,SURFACE,2,0.05,KEPT
asd,SURFACE,2,0.05,KEPT
aspirin,SURFACE,2,0.05,KEPT
associated conditions,SURFACE,2,0.05,KEPT
associated syndromes,SURFACE,2,0.05,KEPT
association with,SURFACE,2,0.05,KEPT
asymmetric,SURFACE,2,0.05,KEPT
ataxia,SURFACE,2,0.05,KEPT
atrophy,SURFACE,2,0.05,KEPT
auditory,SURFACE,2,0.05,KEPT
auscultation,SURFACE,2,0.05,KEPT
autoantibodies,SURFACE,2,0.05,KEPT
autoantibodies**,SURFACE,2,0.05,KEPT
autoimmune disorders,SURFACE,2,0.05,KEPT
autoimmune process,SURFACE,2,0.05,KEPT
autonomic dysfunction,SURFACE,2,0.05,KEPT
autosomal,SURFACE,2,0.05,KEPT
avenues,SURFACE,2,0.05,KEPT
awaiting,SURFACE,2,0.05,KEPT
away,SURFACE,2,0.05,KEPT
bal,SURFACE,2,0.05,KEPT
bal**,SURFACE,2,0.05,KEPT
balance,SURFACE,2,0.05,KEPT
balance issues,SURFACE,2,0.05,KEPT
bardet-biedl syndrome,SURFACE,2,0.05,KEPT
bardet-biedl syndrome**,SURFACE,2,0.05,KEPT
bbs,SURFACE,2,0.05,KEPT
beneficial,SURFACE,2,0.05,KEPT
benefits,SURFACE,2,0.05,KEPT
benign,SURFACE,2,0.05,KEPT
best-corrected visual acuity,SURFACE,2,0.05,KEPT
bilirubin,SURFACE,2,0.05,KEPT
biochemical,SURFACE,2,0.05,KEPT
biopsy**,SURFACE,2,0.05,KEPT
birth length,SURFACE,2,0.05,KEPT
blood flow,SURFACE,2,0.05,KEPT
bmi,SURFACE,2,0.05,KEPT
body,SURFACE,2,0.05,KEPT
body temperature,SURFACE,2,0.05,KEPT
bone fragility,SURFACE,2,0.05,KEPT
bowed,SURFACE,2,0.05,KEPT
brachydactyly,SURFACE,2,0.05,KEPT
breadth,SURFACE,2,0.05,KEPT
breakdown,SURFACE,2,0.05,KEPT
breast cancer,SURFACE,2,0.05,KEPT
broad,SURFACE,2,0.05,KEPT
broad forehead,SURFACE,2,0.05,KEPT
bronchoalveolar lavage,SURFACE,2,0.05,KEPT
bronchoscopy,SURFACE,2,0.05,KEPT
bronchoscopy with,SURFACE,2,0.05,KEPT
caesarean section,SURFACE,2,0.05,KEPT
camptodactyly,SURFACE,2,0.05,KEPT
candidates,SURFACE,2,0.05,KEPT
canine,SURFACE,2,0.05,KEPT
capacity,SURFACE,2,0.05,KEPT
cardiac abnormalities,SURFACE,2,0.05,KEPT
cardiac assessment,SURFACE,2,0.05,KEPT
cardiac defects,SURFACE,2,0.05,KEPT
cardiac evaluations,SURFACE,2,0.05,KEPT
cardiac events,SURFACE,2,0.05,KEPT
cardiac imaging,SURFACE,2,0.05,KEPT
cardiac structure,SURFACE,2,0.05,KEPT
cardiopulmonary,SURFACE,2,0.05,KEPT
cardiovascular history,SURFACE,2,0.05,KEPT
cardiovascular risk,SURFACE,2,0.05,KEPT
cardiovascular risk factors,SURFACE,2,0.05,KEPT
care protocols,SURFACE,2,0.05,KEPT
care strategies,SURFACE,2,0.05,KEPT
case evaluation,SURFACE,2,0.05,KEPT
case progresses,SURFACE,2,0.05,KEPT
catch,SURFACE,2,0.05,KEPT
cause of,SURFACE,2,0.05,KEPT
cbc,SURFACE,2,0.05,KEPT
centile,SURFACE,2,0.05,KEPT
cerebellar,SURFACE,2,0.05,KEPT
cerebellar ataxia,SURFACE,2,0.05,KEPT
cerebellar degeneration,SURFACE,2,0.05,KEPT
"challenges
1. **most likely diagnosis**",SURFACE,2,0.05,KEPT
chances,SURFACE,2,0.05,KEPT
character,SURFACE,2,0.05,KEPT
chest radiography,SURFACE,2,0.05,KEPT
china,SURFACE,2,0.05,KEPT
choice,SURFACE,2,0.05,KEPT
cholesterol levels,SURFACE,2,0.05,KEPT
chromosomal analysis,SURFACE,2,0.05,KEPT
chronic,SURFACE,2,0.05,KEPT
chronic cough,SURFACE,2,0.05,KEPT
chronic disease,SURFACE,2,0.05,KEPT
chronic nature,SURFACE,2,0.05,KEPT
chronic processes,SURFACE,2,0.05,KEPT
chronicity,SURFACE,2,0.05,KEPT
ckd,SURFACE,2,0.05,KEPT
classification,SURFACE,2,0.05,KEPT
clearance,SURFACE,2,0.05,KEPT
clinic,SURFACE,2,0.05,KEPT
clinical course,SURFACE,2,0.05,KEPT
clinical decisions,SURFACE,2,0.05,KEPT
clinical details,SURFACE,2,0.05,KEPT
clinical evidence,SURFACE,2,0.05,KEPT
clinical indicators,SURFACE,2,0.05,KEPT
clinical information,SURFACE,2,0.05,KEPT
clinical observation,SURFACE,2,0.05,KEPT
clinical observations,SURFACE,2,0.05,KEPT
clinical reasoning,SURFACE,2,0.05,KEPT
clinodactyly,SURFACE,2,0.05,KEPT
cma,SURFACE,2,0.05,KEPT
coexist,SURFACE,2,0.05,KEPT
cognitive changes,SURFACE,2,0.05,KEPT
cognitive deficits,SURFACE,2,0.05,KEPT
cognitive impairments,SURFACE,2,0.05,KEPT
cognitive status,SURFACE,2,0.05,KEPT
cohesive,SURFACE,2,0.05,KEPT
cohesive plan,SURFACE,2,0.05,KEPT
cohesive strategy,SURFACE,2,0.05,KEPT
collaborative discussions,SURFACE,2,0.05,KEPT
collecting,SURFACE,2,0.05,KEPT
collection,SURFACE,2,0.05,KEPT
colon,SURFACE,2,0.05,KEPT
commentary,SURFACE,2,0.05,KEPT
comorbidities,SURFACE,2,0.05,KEPT
compelling evidence,SURFACE,2,0.05,KEPT
complement,SURFACE,2,0.05,KEPT
complete,SURFACE,2,0.05,KEPT
complicated,SURFACE,2,0.05,KEPT
complication,SURFACE,2,0.05,KEPT
component,SURFACE,2,0.05,KEPT
components,SURFACE,2,0.05,KEPT
comprehensive analyses,SURFACE,2,0.05,KEPT
conclusive evidence,SURFACE,2,0.05,KEPT
concomitant,SURFACE,2,0.05,KEPT
condition's,SURFACE,2,0.05,KEPT
confident,SURFACE,2,0.05,KEPT
confirmations,SURFACE,2,0.05,KEPT
confusion,SURFACE,2,0.05,KEPT
congenital,SURFACE,2,0.05,KEPT
congenital abnormalities,SURFACE,2,0.05,KEPT
congenital disorder,SURFACE,2,0.05,KEPT
connective tissue disorder,SURFACE,2,0.05,KEPT
consensus discussion,SURFACE,2,0.05,KEPT
consensus summary,SURFACE,2,0.05,KEPT
consequences,SURFACE,2,0.05,KEPT
consolidate,SURFACE,2,0.05,KEPT
constellation,SURFACE,2,0.05,KEPT
constructive comments,SURFACE,2,0.05,KEPT
constructive feedback,SURFACE,2,0.05,KEPT
consult,SURFACE,2,0.05,KEPT
contemplate,SURFACE,2,0.05,KEPT
continuation,SURFACE,2,0.05,KEPT
continues,SURFACE,2,0.05,KEPT
continuing,SURFACE,2,0.05,KEPT
continuous observation,SURFACE,2,0.05,KEPT
contributors,SURFACE,2,0.05,KEPT
control,SURFACE,2,0.05,KEPT
conversations,SURFACE,2,0.05,KEPT
coronary arteries,SURFACE,2,0.05,KEPT
correlated,SURFACE,2,0.05,KEPT
corticosteroids,SURFACE,2,0.05,KEPT
course,SURFACE,2,0.05,KEPT
covid-19,SURFACE,2,0.05,KEPT
cranial structures,SURFACE,2,0.05,KEPT
craniofacial,SURFACE,2,0.05,KEPT
craniofacial abnormalities,SURFACE,2,0.05,KEPT
craniofacial dysmorphism,SURFACE,2,0.05,KEPT
craniofacial features,SURFACE,2,0.05,KEPT
craniosynostosis syndromes,SURFACE,2,0.05,KEPT
creatinine,SURFACE,2,0.05,KEPT
creation,SURFACE,2,0.05,KEPT
csf analysis,SURFACE,2,0.05,KEPT
ct scans,SURFACE,2,0.05,KEPT
cultures,SURFACE,2,0.05,KEPT
current,SURFACE,2,0.05,KEPT
current state,SURFACE,2,0.05,KEPT
cyanosis,SURFACE,2,0.05,KEPT
cystic changes,SURFACE,2,0.05,KEPT
cysts,SURFACE,2,0.05,KEPT
d-dimer testing,SURFACE,2,0.05,KEPT
decision-making process,SURFACE,2,0.05,KEPT
declined,SURFACE,2,0.05,KEPT
deep-set eyes,SURFACE,2,0.05,KEPT
defect,SURFACE,2,0.05,KEPT
deficiency,SURFACE,2,0.05,KEPT
deficits,SURFACE,2,0.05,KEPT
definition,SURFACE,2,0.05,KEPT
degeneration,SURFACE,2,0.05,KEPT
deletion,SURFACE,2,0.05,KEPT
delving,SURFACE,2,0.05,KEPT
demographic,SURFACE,2,0.05,KEPT
dental,SURFACE,2,0.05,KEPT
dental findings,SURFACE,2,0.05,KEPT
department,SURFACE,2,0.05,KEPT
depth,SURFACE,2,0.05,KEPT
detecting,SURFACE,2,0.05,KEPT
deteriorated,SURFACE,2,0.05,KEPT
developmental aspects,SURFACE,2,0.05,KEPT
developmental disabilities,SURFACE,2,0.05,KEPT
developmental milestones,SURFACE,2,0.05,KEPT
deviate,SURFACE,2,0.05,KEPT
"diagnosis
i",SURFACE,2,0.05,KEPT
diagnostic analysis,SURFACE,2,0.05,KEPT
diagnostic findings,SURFACE,2,0.05,KEPT
diagnostic imaging,SURFACE,2,0.05,KEPT
diagnostic information,SURFACE,2,0.05,KEPT
diagnostic investigations,SURFACE,2,0.05,KEPT
diagnostic journey,SURFACE,2,0.05,KEPT
diagnostic needs,SURFACE,2,0.05,KEPT
diagnostic outcomes,SURFACE,2,0.05,KEPT
diagnostic path,SURFACE,2,0.05,KEPT
diagnostic test,SURFACE,2,0.05,KEPT
diagnostic yield,SURFACE,2,0.05,KEPT
differentiation,SURFACE,2,0.05,KEPT
dimension,SURFACE,2,0.05,KEPT
dimensions,SURFACE,2,0.05,KEPT
disagreement/discussion,SURFACE,2,0.05,KEPT
discontinued,SURFACE,2,0.05,KEPT
disease course,SURFACE,2,0.05,KEPT
disease's,SURFACE,2,0.05,KEPT
dismiss,SURFACE,2,0.05,KEPT
disproportionate,SURFACE,2,0.05,KEPT
dissecting,SURFACE,2,0.05,KEPT
distribute,SURFACE,2,0.05,KEPT
dive,SURFACE,2,0.05,KEPT
dizziness,SURFACE,2,0.05,KEPT
doctor,SURFACE,2,0.05,KEPT
dose,SURFACE,2,0.05,KEPT
drug allergies,SURFACE,2,0.05,KEPT
duplicated,SURFACE,2,0.05,KEPT
duplications,SURFACE,2,0.05,KEPT
dvt,SURFACE,2,0.05,KEPT
dysarthria,SURFACE,2,0.05,KEPT
dyslipidemia,SURFACE,2,0.05,KEPT
dysmorphism,SURFACE,2,0.05,KEPT
early intervention,SURFACE,2,0.05,KEPT
echocardiograms,SURFACE,2,0.05,KEPT
ectodermal dysplasia,SURFACE,2,0.05,KEPT
educational materials,SURFACE,2,0.05,KEPT
educational needs,SURFACE,2,0.05,KEPT
eegs,SURFACE,2,0.05,KEPT
effects of,SURFACE,2,0.05,KEPT
efficient,SURFACE,2,0.05,KEPT
egfr,SURFACE,2,0.05,KEPT
ehlers-danlos syndrome,SURFACE,2,0.05,KEPT
elbow,SURFACE,2,0.05,KEPT
elective,SURFACE,2,0.05,KEPT
electromyography,SURFACE,2,0.05,KEPT
elements,SURFACE,2,0.05,KEPT
elevate,SURFACE,2,0.05,KEPT
elevated cholesterol,SURFACE,2,0.05,KEPT
elimination,SURFACE,2,0.05,KEPT
emg,SURFACE,2,0.05,KEPT
emotional,SURFACE,2,0.05,KEPT
emotional aspects,SURFACE,2,0.05,KEPT
encapsulated,SURFACE,2,0.05,KEPT
encapsulates,SURFACE,2,0.05,KEPT
encompasses,SURFACE,2,0.05,KEPT
endemic,SURFACE,2,0.05,KEPT
endocrine evaluation,SURFACE,2,0.05,KEPT
endocrinological assessments,SURFACE,2,0.05,KEPT
enhanced,SURFACE,2,0.05,KEPT
enriching,SURFACE,2,0.05,KEPT
ensure,SURFACE,2,0.05,KEPT
ensures,SURFACE,2,0.05,KEPT
environment,SURFACE,2,0.05,KEPT
environmental exposure,SURFACE,2,0.05,KEPT
enzyme deficiencies,SURFACE,2,0.05,KEPT
essential tests,SURFACE,2,0.05,KEPT
established,SURFACE,2,0.05,KEPT
exacerbate,SURFACE,2,0.05,KEPT
exacerbation,SURFACE,2,0.05,KEPT
expectations,SURFACE,2,0.05,KEPT
experiences,SURFACE,2,0.05,KEPT
exposure history,SURFACE,2,0.05,KEPT
expression,SURFACE,2,0.05,KEPT
expressions,SURFACE,2,0.05,KEPT
extended,SURFACE,2,0.05,KEPT
eye,SURFACE,2,0.05,KEPT
facial dysmorphisms,SURFACE,2,0.05,KEPT
failure,SURFACE,2,0.05,KEPT
familial background,SURFACE,2,0.05,KEPT
familial context,SURFACE,2,0.05,KEPT
familial mediterranean,SURFACE,2,0.05,KEPT
family histories,SURFACE,2,0.05,KEPT
family planning,SURFACE,2,0.05,KEPT
family screening,SURFACE,2,0.05,KEPT
family support,SURFACE,2,0.05,KEPT
family's history,SURFACE,2,0.05,KEPT
family’s future,SURFACE,2,0.05,KEPT
fat,SURFACE,2,0.05,KEPT
febrile,SURFACE,2,0.05,KEPT
feedback,SURFACE,2,0.05,KEPT
feels,SURFACE,2,0.05,KEPT
fellow,SURFACE,2,0.05,KEPT
fetal anomalies,SURFACE,2,0.05,KEPT
fevers,SURFACE,2,0.05,KEPT
finding,SURFACE,2,0.05,KEPT
fingers,SURFACE,2,0.05,KEPT
flat,SURFACE,2,0.05,KEPT
floor,SURFACE,2,0.05,KEPT
fluctuations,SURFACE,2,0.05,KEPT
fluorescein angiography,SURFACE,2,0.05,KEPT
fmf,SURFACE,2,0.05,KEPT
follicle-stimulating hormone,SURFACE,2,0.05,KEPT
follow up,SURFACE,2,0.05,KEPT
follow-up**,SURFACE,2,0.05,KEPT
forearm,SURFACE,2,0.05,KEPT
forefront,SURFACE,2,0.05,KEPT
formalize,SURFACE,2,0.05,KEPT
formulate,SURFACE,2,0.05,KEPT
foundational,SURFACE,2,0.05,KEPT
fractures,SURFACE,2,0.05,KEPT
frequency,SURFACE,2,0.05,KEPT
frontal hairline,SURFACE,2,0.05,KEPT
functional aspects,SURFACE,2,0.05,KEPT
fundus,SURFACE,2,0.05,KEPT
gaps,SURFACE,2,0.05,KEPT
general condition,SURFACE,2,0.05,KEPT
generalized hypotonia,SURFACE,2,0.05,KEPT
genetic alterations,SURFACE,2,0.05,KEPT
genetic considerations,SURFACE,2,0.05,KEPT
genetic counseling**,SURFACE,2,0.05,KEPT
genetic factors,SURFACE,2,0.05,KEPT
genetic implications,SURFACE,2,0.05,KEPT
genetic investigation,SURFACE,2,0.05,KEPT
genetic knowledge,SURFACE,2,0.05,KEPT
genetic mutation,SURFACE,2,0.05,KEPT
genetic mutations,SURFACE,2,0.05,KEPT
genetic nature,SURFACE,2,0.05,KEPT
genetic panels,SURFACE,2,0.05,KEPT
genetic risks,SURFACE,2,0.05,KEPT
genetic syndromes**,SURFACE,2,0.05,KEPT
genetically,SURFACE,2,0.05,KEPT
genomic analysis,SURFACE,2,0.05,KEPT
gestational age,SURFACE,2,0.05,KEPT
goal,SURFACE,2,0.05,KEPT
granulomas,SURFACE,2,0.05,KEPT
granulomatous inflammation,SURFACE,2,0.05,KEPT
gratitude,SURFACE,2,0.05,KEPT
groups,SURFACE,2,0.05,KEPT
growth restriction,SURFACE,2,0.05,KEPT
hand,SURFACE,2,0.05,KEPT
head,SURFACE,2,0.05,KEPT
heading,SURFACE,2,0.05,KEPT
heard,SURFACE,2,0.05,KEPT
heart defects,SURFACE,2,0.05,KEPT
heart failure,SURFACE,2,0.05,KEPT
heightened,SURFACE,2,0.05,KEPT
hematological,SURFACE,2,0.05,KEPT
hemodynamic,SURFACE,2,0.05,KEPT
hemodynamics,SURFACE,2,0.05,KEPT
hemoptysis,SURFACE,2,0.05,KEPT
hereditary component,SURFACE,2,0.05,KEPT
hereditary nature,SURFACE,2,0.05,KEPT
high priority,SURFACE,2,0.05,KEPT
high-resolution imaging,SURFACE,2,0.05,KEPT
higher,SURFACE,2,0.05,KEPT
histological examination,SURFACE,2,0.05,KEPT
histopathology,SURFACE,2,0.05,KEPT
historical context,SURFACE,2,0.05,KEPT
hla-b27,SURFACE,2,0.05,KEPT
holistic care,SURFACE,2,0.05,KEPT
holt-oram syndrome,SURFACE,2,0.05,KEPT
horizontal,SURFACE,2,0.05,KEPT
hormonal profile,SURFACE,2,0.05,KEPT
hormonal profiles,SURFACE,2,0.05,KEPT
hormone,SURFACE,2,0.05,KEPT
hormone levels,SURFACE,2,0.05,KEPT
hormones,SURFACE,2,0.05,KEPT
hours,SURFACE,2,0.05,KEPT
humerus,SURFACE,2,0.05,KEPT
hyperphagia,SURFACE,2,0.05,KEPT
hypogonadism,SURFACE,2,0.05,KEPT
hypothesis,SURFACE,2,0.05,KEPT
hypothyroid,SURFACE,2,0.05,KEPT
hypoxemia,SURFACE,2,0.05,KEPT
i advocate,SURFACE,2,0.05,KEPT
i feel,SURFACE,2,0.05,KEPT
i feel confident,SURFACE,2,0.05,KEPT
i will,SURFACE,2,0.05,KEPT
i will prepare,SURFACE,2,0.05,KEPT
i'm ready,SURFACE,2,0.05,KEPT
identifying,SURFACE,2,0.05,KEPT
idiopathic,SURFACE,2,0.05,KEPT
images,SURFACE,2,0.05,KEPT
imaging first,SURFACE,2,0.05,KEPT
imaging modalities,SURFACE,2,0.05,KEPT
imaging results,SURFACE,2,0.05,KEPT
imaging tests,SURFACE,2,0.05,KEPT
imbalance,SURFACE,2,0.05,KEPT
immobility,SURFACE,2,0.05,KEPT
immune function,SURFACE,2,0.05,KEPT
immunocompromised states,SURFACE,2,0.05,KEPT
immunocompromised status,SURFACE,2,0.05,KEPT
immunodeficiencies,SURFACE,2,0.05,KEPT
immunohistochemistry,SURFACE,2,0.05,KEPT
immunologic,SURFACE,2,0.05,KEPT
immunological,SURFACE,2,0.05,KEPT
immunosuppression,SURFACE,2,0.05,KEPT
implication,SURFACE,2,0.05,KEPT
important,SURFACE,2,0.05,KEPT
inability,SURFACE,2,0.05,KEPT
inconclusive results,SURFACE,2,0.05,KEPT
increases,SURFACE,2,0.05,KEPT
inflammatory activity,SURFACE,2,0.05,KEPT
inflammatory arthritis,SURFACE,2,0.05,KEPT
inflammatory conditions,SURFACE,2,0.05,KEPT
inflammatory process,SURFACE,2,0.05,KEPT
influenced,SURFACE,2,0.05,KEPT
informative,SURFACE,2,0.05,KEPT
informative results,SURFACE,2,0.05,KEPT
informing,SURFACE,2,0.05,KEPT
inherent,SURFACE,2,0.05,KEPT
inheritance,SURFACE,2,0.05,KEPT
insightful analysis,SURFACE,2,0.05,KEPT
instrumental,SURFACE,2,0.05,KEPT
insufficient,SURFACE,2,0.05,KEPT
insulin resistance,SURFACE,2,0.05,KEPT
intellectual,SURFACE,2,0.05,KEPT
intellectual disabilities,SURFACE,2,0.05,KEPT
interact,SURFACE,2,0.05,KEPT
interaction,SURFACE,2,0.05,KEPT
interdisciplinary collaboration,SURFACE,2,0.05,KEPT
interferon-gamma release assays,SURFACE,2,0.05,KEPT
intermittent,SURFACE,2,0.05,KEPT
internal structures,SURFACE,2,0.05,KEPT
intraocular pressure,SURFACE,2,0.05,KEPT
invaluable,SURFACE,2,0.05,KEPT
investigative approach,SURFACE,2,0.05,KEPT
isolation,SURFACE,2,0.05,KEPT
issue,SURFACE,2,0.05,KEPT
jaundice,SURFACE,2,0.05,KEPT
jia,SURFACE,2,0.05,KEPT
joint laxity,SURFACE,2,0.05,KEPT
joint pain,SURFACE,2,0.05,KEPT
joint swelling,SURFACE,2,0.05,KEPT
joint symptoms,SURFACE,2,0.05,KEPT
joints,SURFACE,2,0.05,KEPT
juvenile idiopathic arthritis,SURFACE,2,0.05,KEPT
keeping lines,SURFACE,2,0.05,KEPT
kidney sizes,SURFACE,2,0.05,KEPT
klinefelter syndrome,SURFACE,2,0.05,KEPT
lab tests,SURFACE,2,0.05,KEPT
laboratory evaluations,SURFACE,2,0.05,KEPT
laboratory results,SURFACE,2,0.05,KEPT
laboratory studies,SURFACE,2,0.05,KEPT
language,SURFACE,2,0.05,KEPT
last-minute,SURFACE,2,0.05,KEPT
late-onset,SURFACE,2,0.05,KEPT
ldh,SURFACE,2,0.05,KEPT
left eye,SURFACE,2,0.05,KEPT
left kidney,SURFACE,2,0.05,KEPT
left lower limb,SURFACE,2,0.05,KEPT
legs,SURFACE,2,0.05,KEPT
lens dislocation,SURFACE,2,0.05,KEPT
less,SURFACE,2,0.05,KEPT
let's refine,SURFACE,2,0.05,KEPT
lethal,SURFACE,2,0.05,KEPT
leukocyte counts,SURFACE,2,0.05,KEPT
limb abnormalities,SURFACE,2,0.05,KEPT
limb development,SURFACE,2,0.05,KEPT
lipodystrophy,SURFACE,2,0.05,KEPT
listed,SURFACE,2,0.05,KEPT
liver function,SURFACE,2,0.05,KEPT
localized,SURFACE,2,0.05,KEPT
logical,SURFACE,2,0.05,KEPT
long limbs,SURFACE,2,0.05,KEPT
long time,SURFACE,2,0.05,KEPT
longer-term,SURFACE,2,0.05,KEPT
longitudinal monitoring,SURFACE,2,0.05,KEPT
loss,SURFACE,2,0.05,KEPT
loss of,SURFACE,2,0.05,KEPT
lower extremity edema,SURFACE,2,0.05,KEPT
lung biopsy**,SURFACE,2,0.05,KEPT
lung cancer,SURFACE,2,0.05,KEPT
lung diseases,SURFACE,2,0.05,KEPT
luteinizing hormone,SURFACE,2,0.05,KEPT
lymphocyte subset analysis,SURFACE,2,0.05,KEPT
lymphoproliferative disorders,SURFACE,2,0.05,KEPT
males,SURFACE,2,0.05,KEPT
malignant processes,SURFACE,2,0.05,KEPT
management pathway,SURFACE,2,0.05,KEPT
management strategy,SURFACE,2,0.05,KEPT
masquerade,SURFACE,2,0.05,KEPT
mass,SURFACE,2,0.05,KEPT
mass lesion,SURFACE,2,0.05,KEPT
match,SURFACE,2,0.05,KEPT
medical team,SURFACE,2,0.05,KEPT
meetings,SURFACE,2,0.05,KEPT
melanoma,SURFACE,2,0.05,KEPT
menstrual,SURFACE,2,0.05,KEPT
metabolic abnormalities,SURFACE,2,0.05,KEPT
metabolic derangements,SURFACE,2,0.05,KEPT
metabolic issues,SURFACE,2,0.05,KEPT
metabolic status,SURFACE,2,0.05,KEPT
metabolic syndrome,SURFACE,2,0.05,KEPT
metabolic testing,SURFACE,2,0.05,KEPT
metabolic tests,SURFACE,2,0.05,KEPT
metabolism,SURFACE,2,0.05,KEPT
metastasis,SURFACE,2,0.05,KEPT
methylprednisolone,SURFACE,2,0.05,KEPT
meticulous,SURFACE,2,0.05,KEPT
microcephaly,SURFACE,2,0.05,KEPT
milestones,SURFACE,2,0.05,KEPT
minutes,SURFACE,2,0.05,KEPT
misdiagnosis,SURFACE,2,0.05,KEPT
miss,SURFACE,2,0.05,KEPT
missed,SURFACE,2,0.05,KEPT
modification,SURFACE,2,0.05,KEPT
modified,SURFACE,2,0.05,KEPT
momentum,SURFACE,2,0.05,KEPT
morphological,SURFACE,2,0.05,KEPT
mosaicism,SURFACE,2,0.05,KEPT
mother's,SURFACE,2,0.05,KEPT
motor symptoms,SURFACE,2,0.05,KEPT
mouth,SURFACE,2,0.05,KEPT
movements,SURFACE,2,0.05,KEPT
msa,SURFACE,2,0.05,KEPT
multi-disciplinary approach,SURFACE,2,0.05,KEPT
multi-faceted approach,SURFACE,2,0.05,KEPT
multidimensional approach,SURFACE,2,0.05,KEPT
multidisciplinary collaboration,SURFACE,2,0.05,KEPT
multifaceted aspects,SURFACE,2,0.05,KEPT
multiple system atrophy,SURFACE,2,0.05,KEPT
multiple systems,SURFACE,2,0.05,KEPT
myocardial infarction,SURFACE,2,0.05,KEPT
navigated,SURFACE,2,0.05,KEPT
navigating,SURFACE,2,0.05,KEPT
nephrologists,SURFACE,2,0.05,KEPT
neurodegenerative disorders,SURFACE,2,0.05,KEPT
neurological concerns,SURFACE,2,0.05,KEPT
neurological issues,SURFACE,2,0.05,KEPT
neuropsychological assessment,SURFACE,2,0.05,KEPT
neutrophil,SURFACE,2,0.05,KEPT
next steps**,SURFACE,2,0.05,KEPT
next week,SURFACE,2,0.05,KEPT
night,SURFACE,2,0.05,KEPT
night sweats,SURFACE,2,0.05,KEPT
no abnormalities,SURFACE,2,0.05,KEPT
no improvement,SURFACE,2,0.05,KEPT
non-consanguineous,SURFACE,2,0.05,KEPT
nose,SURFACE,2,0.05,KEPT
notes,SURFACE,2,0.05,KEPT
noting,SURFACE,2,0.05,KEPT
nsclc,SURFACE,2,0.05,KEPT
nuchal translucency,SURFACE,2,0.05,KEPT
nystagmus,SURFACE,2,0.05,KEPT
obstructions,SURFACE,2,0.05,KEPT
obtaining,SURFACE,2,0.05,KEPT
oct,SURFACE,2,0.05,KEPT
ocular condition,SURFACE,2,0.05,KEPT
ocular health,SURFACE,2,0.05,KEPT
ocular issues,SURFACE,2,0.05,KEPT
ocular symptoms,SURFACE,2,0.05,KEPT
older adults,SURFACE,2,0.05,KEPT
oligoarticular,SURFACE,2,0.05,KEPT
oligohydramnios,SURFACE,2,0.05,KEPT
onset,SURFACE,2,0.05,KEPT
onset of,SURFACE,2,0.05,KEPT
open communication,SURFACE,2,0.05,KEPT
open-minded,SURFACE,2,0.05,KEPT
ophthalmology,SURFACE,2,0.05,KEPT
optical coherence tomography,SURFACE,2,0.05,KEPT
oral,SURFACE,2,0.05,KEPT
organisms,SURFACE,2,0.05,KEPT
orthopedic,SURFACE,2,0.05,KEPT
osteogenesis imperfecta,SURFACE,2,0.05,KEPT
outline,SURFACE,2,0.05,KEPT
outlined tests,SURFACE,2,0.05,KEPT
outlines,SURFACE,2,0.05,KEPT
ovaries,SURFACE,2,0.05,KEPT
overgrowth,SURFACE,2,0.05,KEPT
overlapping,SURFACE,2,0.05,KEPT
overlapping features,SURFACE,2,0.05,KEPT
overlapping symptoms,SURFACE,2,0.05,KEPT
overlapping syndromes,SURFACE,2,0.05,KEPT
oxygen saturation,SURFACE,2,0.05,KEPT
pack-years,SURFACE,2,0.05,KEPT
page,SURFACE,2,0.05,KEPT
pancreatic disease,SURFACE,2,0.05,KEPT
pao2,SURFACE,2,0.05,KEPT
parenchymal lesions,SURFACE,2,0.05,KEPT
parental,SURFACE,2,0.05,KEPT
parkinsonism,SURFACE,2,0.05,KEPT
partial,SURFACE,2,0.05,KEPT
partnership,SURFACE,2,0.05,KEPT
pathogenic,SURFACE,2,0.05,KEPT
pathogenic variants,SURFACE,2,0.05,KEPT
pathologies,SURFACE,2,0.05,KEPT
paths,SURFACE,2,0.05,KEPT
pathways,SURFACE,2,0.05,KEPT
patient history,SURFACE,2,0.05,KEPT
patient matures,SURFACE,2,0.05,KEPT
patient safety,SURFACE,2,0.05,KEPT
patient's complex,SURFACE,2,0.05,KEPT
patient-centered approach,SURFACE,2,0.05,KEPT
patient’s age,SURFACE,2,0.05,KEPT
patient’s care,SURFACE,2,0.05,KEPT
patient’s history,SURFACE,2,0.05,KEPT
patient’s lifestyle,SURFACE,2,0.05,KEPT
patient’s presentation,SURFACE,2,0.05,KEPT
pcr,SURFACE,2,0.05,KEPT
pcr testing,SURFACE,2,0.05,KEPT
pelvis,SURFACE,2,0.05,KEPT
performing,SURFACE,2,0.05,KEPT
perfusion,SURFACE,2,0.05,KEPT
perinatal,SURFACE,2,0.05,KEPT
period,SURFACE,2,0.05,KEPT
peripheral,SURFACE,2,0.05,KEPT
peripheral blood,SURFACE,2,0.05,KEPT
phase,SURFACE,2,0.05,KEPT
phenotypes,SURFACE,2,0.05,KEPT
physical,SURFACE,2,0.05,KEPT
physical presentation,SURFACE,2,0.05,KEPT
physiological,SURFACE,2,0.05,KEPT
physiological aspects,SURFACE,2,0.05,KEPT
placement,SURFACE,2,0.05,KEPT
plasma,SURFACE,2,0.05,KEPT
please feel free,SURFACE,2,0.05,KEPT
please let me know,SURFACE,2,0.05,KEPT
polydactyly,SURFACE,2,0.05,KEPT
post-operative,SURFACE,2,0.05,KEPT
postnatally,SURFACE,2,0.05,KEPT
postoperative,SURFACE,2,0.05,KEPT
prader-willi,SURFACE,2,0.05,KEPT
precedence,SURFACE,2,0.05,KEPT
precision,SURFACE,2,0.05,KEPT
predisposition,SURFACE,2,0.05,KEPT
prednisolone,SURFACE,2,0.05,KEPT
preferred,SURFACE,2,0.05,KEPT
prenatal history,SURFACE,2,0.05,KEPT
prescribed,SURFACE,2,0.05,KEPT
primary focus,SURFACE,2,0.05,KEPT
prioritizing tests,SURFACE,2,0.05,KEPT
proactive management,SURFACE,2,0.05,KEPT
probability,SURFACE,2,0.05,KEPT
procedure,SURFACE,2,0.05,KEPT
proceed,SURFACE,2,0.05,KEPT
provides,SURFACE,2,0.05,KEPT
proximal,SURFACE,2,0.05,KEPT
psychiatric evaluation,SURFACE,2,0.05,KEPT
psychologists,SURFACE,2,0.05,KEPT
pulmonary,SURFACE,2,0.05,KEPT
pulmonary angiogram,SURFACE,2,0.05,KEPT
pulmonary embolism,SURFACE,2,0.05,KEPT
pulmonary function tests,SURFACE,2,0.05,KEPT
pulmonary hypertension,SURFACE,2,0.05,KEPT
pulmonary tuberculosis,SURFACE,2,0.05,KEPT
pursuing,SURFACE,2,0.05,KEPT
quality,SURFACE,2,0.05,KEPT
quotidian,SURFACE,2,0.05,KEPT
radar,SURFACE,2,0.05,KEPT
raised,SURFACE,2,0.05,KEPT
rash,SURFACE,2,0.05,KEPT
re-evaluate,SURFACE,2,0.05,KEPT
re-evaluation,SURFACE,2,0.05,KEPT
reactive arthritis,SURFACE,2,0.05,KEPT
real-time,SURFACE,2,0.05,KEPT
reasons,SURFACE,2,0.05,KEPT
reassessment,SURFACE,2,0.05,KEPT
recognition,SURFACE,2,0.05,KEPT
recognize,SURFACE,2,0.05,KEPT
recovery,SURFACE,2,0.05,KEPT
recurrences,SURFACE,2,0.05,KEPT
recurrent fevers,SURFACE,2,0.05,KEPT
recurrent infections,SURFACE,2,0.05,KEPT
redundant,SURFACE,2,0.05,KEPT
regurgitation,SURFACE,2,0.05,KEPT
reiterate,SURFACE,2,0.05,KEPT
remarks,SURFACE,2,0.05,KEPT
renal abnormalities,SURFACE,2,0.05,KEPT
renal anatomy,SURFACE,2,0.05,KEPT
renal anomalies,SURFACE,2,0.05,KEPT
renal disease,SURFACE,2,0.05,KEPT
renal dysplasia,SURFACE,2,0.05,KEPT
renal function tests,SURFACE,2,0.05,KEPT
renal structures,SURFACE,2,0.05,KEPT
repeated,SURFACE,2,0.05,KEPT
reproductive structures,SURFACE,2,0.05,KEPT
requirements,SURFACE,2,0.05,KEPT
residual,SURFACE,2,0.05,KEPT
resistant,SURFACE,2,0.05,KEPT
resolved,SURFACE,2,0.05,KEPT
resolving,SURFACE,2,0.05,KEPT
"respectively.\"",\n\n",SURFACE,2,0.05,KEPT
respiratory,SURFACE,2,0.05,KEPT
respiratory complications,SURFACE,2,0.05,KEPT
respiratory distress,SURFACE,2,0.05,KEPT
responsibilities,SURFACE,2,0.05,KEPT
responsibility,SURFACE,2,0.05,KEPT
responsiveness,SURFACE,2,0.05,KEPT
restrictive,SURFACE,2,0.05,KEPT
resultant,SURFACE,2,0.05,KEPT
retention,SURFACE,2,0.05,KEPT
retina,SURFACE,2,0.05,KEPT
retinal layers,SURFACE,2,0.05,KEPT
revisions,SURFACE,2,0.05,KEPT
rheumatoid arthritis,SURFACE,2,0.05,KEPT
rheumatoid factor,SURFACE,2,0.05,KEPT
right eye,SURFACE,2,0.05,KEPT
right heart,SURFACE,2,0.05,KEPT
right kidney,SURFACE,2,0.05,KEPT
right lower limb,SURFACE,2,0.05,KEPT
routine,SURFACE,2,0.05,KEPT
routine blood tests,SURFACE,2,0.05,KEPT
ruled out,SURFACE,2,0.05,KEPT
saccades,SURFACE,2,0.05,KEPT
sample,SURFACE,2,0.05,KEPT
samples,SURFACE,2,0.05,KEPT
schedule,SURFACE,2,0.05,KEPT
scheduled,SURFACE,2,0.05,KEPT
screening tests,SURFACE,2,0.05,KEPT
scrutiny,SURFACE,2,0.05,KEPT
sds,SURFACE,2,0.05,KEPT
secondary assessment,SURFACE,2,0.05,KEPT
secondary causes,SURFACE,2,0.05,KEPT
sedimentation,SURFACE,2,0.05,KEPT
sensorineural hearing loss,SURFACE,2,0.05,KEPT
sentiment,SURFACE,2,0.05,KEPT
sentiments,SURFACE,2,0.05,KEPT
sepsis,SURFACE,2,0.05,KEPT
serological markers,SURFACE,2,0.05,KEPT
serological testing,SURFACE,2,0.05,KEPT
serology,SURFACE,2,0.05,KEPT
serum creatinine,SURFACE,2,0.05,KEPT
serum testing,SURFACE,2,0.05,KEPT
shift,SURFACE,2,0.05,KEPT
shifts,SURFACE,2,0.05,KEPT
short philtrum,SURFACE,2,0.05,KEPT
shortening,SURFACE,2,0.05,KEPT
shortness,SURFACE,2,0.05,KEPT
showcases,SURFACE,2,0.05,KEPT
signs,SURFACE,2,0.05,KEPT
signs of infection,SURFACE,2,0.05,KEPT
similar,SURFACE,2,0.05,KEPT
similarities,SURFACE,2,0.05,KEPT
simultaneous,SURFACE,2,0.05,KEPT
skeletal changes,SURFACE,2,0.05,KEPT
skeletal manifestations,SURFACE,2,0.05,KEPT
skeletal structure,SURFACE,2,0.05,KEPT
skeleton,SURFACE,2,0.05,KEPT
sle,SURFACE,2,0.05,KEPT
small,SURFACE,2,0.05,KEPT
small ears,SURFACE,2,0.05,KEPT
small joints,SURFACE,2,0.05,KEPT
smith-magenis syndrome,SURFACE,2,0.05,KEPT
smoker,SURFACE,2,0.05,KEPT
soft tissue,SURFACE,2,0.05,KEPT
speaking,SURFACE,2,0.05,KEPT
specialists weigh,SURFACE,2,0.05,KEPT
specialists wish,SURFACE,2,0.05,KEPT
specialists**,SURFACE,2,0.05,KEPT
specification,SURFACE,2,0.05,KEPT
specifications,SURFACE,2,0.05,KEPT
specificity,SURFACE,2,0.05,KEPT
spikes,SURFACE,2,0.05,KEPT
spinal anomalies,SURFACE,2,0.05,KEPT
spine**,SURFACE,2,0.05,KEPT
splenomegaly,SURFACE,2,0.05,KEPT
sputum culture,SURFACE,2,0.05,KEPT
standard practice,SURFACE,2,0.05,KEPT
started,SURFACE,2,0.05,KEPT
state,SURFACE,2,0.05,KEPT
statement,SURFACE,2,0.05,KEPT
stature,SURFACE,2,0.05,KEPT
stenosis,SURFACE,2,0.05,KEPT
"steps
i",SURFACE,2,0.05,KEPT
still's disease**,SURFACE,2,0.05,KEPT
still’s disease,SURFACE,2,0.05,KEPT
strabismus,SURFACE,2,0.05,KEPT
strategic plan,SURFACE,2,0.05,KEPT
streamline,SURFACE,2,0.05,KEPT
strength,SURFACE,2,0.05,KEPT
strengthens,SURFACE,2,0.05,KEPT
structural anomaly,SURFACE,2,0.05,KEPT
structural chromosomal abnormalities,SURFACE,2,0.05,KEPT
structural findings,SURFACE,2,0.05,KEPT
structures,SURFACE,2,0.05,KEPT
study,SURFACE,2,0.05,KEPT
subtypes,SURFACE,2,0.05,KEPT
summation,SURFACE,2,0.05,KEPT
surgical management,SURFACE,2,0.05,KEPT
symptom pattern,SURFACE,2,0.05,KEPT
symptomology,SURFACE,2,0.05,KEPT
syndromic causes,SURFACE,2,0.05,KEPT
syndromic considerations,SURFACE,2,0.05,KEPT
system,SURFACE,2,0.05,KEPT
systemic contributors,SURFACE,2,0.05,KEPT
systemic disease,SURFACE,2,0.05,KEPT
systemic evaluation,SURFACE,2,0.05,KEPT
systemic evaluations,SURFACE,2,0.05,KEPT
systemic factors,SURFACE,2,0.05,KEPT
systemic health,SURFACE,2,0.05,KEPT
systemic vasculitis,SURFACE,2,0.05,KEPT
systemic workup,SURFACE,2,0.05,KEPT
systolic,SURFACE,2,0.05,KEPT
t-cell,SURFACE,2,0.05,KEPT
tachycardia,SURFACE,2,0.05,KEPT
tailoring,SURFACE,2,0.05,KEPT
tall stature,SURFACE,2,0.05,KEPT
tapering fingers,SURFACE,2,0.05,KEPT
target,SURFACE,2,0.05,KEPT
targeted approach,SURFACE,2,0.05,KEPT
targeting,SURFACE,2,0.05,KEPT
targets,SURFACE,2,0.05,KEPT
teamwork,SURFACE,2,0.05,KEPT
test priorities,SURFACE,2,0.05,KEPT
test suggestions,SURFACE,2,0.05,KEPT
testing approach,SURFACE,2,0.05,KEPT
testing options,SURFACE,2,0.05,KEPT
testing priority,SURFACE,2,0.05,KEPT
testing results,SURFACE,2,0.05,KEPT
testing**,SURFACE,2,0.05,KEPT
testosterone,SURFACE,2,0.05,KEPT
thank you!,SURFACE,2,0.05,KEPT
therapeutic,SURFACE,2,0.05,KEPT
therapeutic interventions,SURFACE,2,0.05,KEPT
though,SURFACE,2,0.05,KEPT
thoughtful analyses,SURFACE,2,0.05,KEPT
thoughtful conclusion,SURFACE,2,0.05,KEPT
thoughtful discussions,SURFACE,2,0.05,KEPT
thoughtful reflections,SURFACE,2,0.05,KEPT
thrive,SURFACE,2,0.05,KEPT
thromboembolic,SURFACE,2,0.05,KEPT
thromboembolic disease,SURFACE,2,0.05,KEPT
thrombus,SURFACE,2,0.05,KEPT
thyroid,SURFACE,2,0.05,KEPT
thyroid function tests**,SURFACE,2,0.05,KEPT
tibia,SURFACE,2,0.05,KEPT
tissues,SURFACE,2,0.05,KEPT
top priority,SURFACE,2,0.05,KEPT
topics,SURFACE,2,0.05,KEPT
total bilirubin,SURFACE,2,0.05,KEPT
total cholesterol,SURFACE,2,0.05,KEPT
transferred,SURFACE,2,0.05,KEPT
transient,SURFACE,2,0.05,KEPT
transition,SURFACE,2,0.05,KEPT
travel history,SURFACE,2,0.05,KEPT
treatment options,SURFACE,2,0.05,KEPT
treatment strategy,SURFACE,2,0.05,KEPT
triangular face,SURFACE,2,0.05,KEPT
triglycerides,SURFACE,2,0.05,KEPT
trisomy 21)**,SURFACE,2,0.05,KEPT
tst,SURFACE,2,0.05,KEPT
tuberculin skin test,SURFACE,2,0.05,KEPT
tuberculosis,SURFACE,2,0.05,KEPT
tumor,SURFACE,2,0.05,KEPT
uncertain,SURFACE,2,0.05,KEPT
uncertainty,SURFACE,2,0.05,KEPT
unilateral,SURFACE,2,0.05,KEPT
unsteadiness,SURFACE,2,0.05,KEPT
update,SURFACE,2,0.05,KEPT
upper limb,SURFACE,2,0.05,KEPT
urinary,SURFACE,2,0.05,KEPT
uterus,SURFACE,2,0.05,KEPT
validation,SURFACE,2,0.05,KEPT
valvular abnormalities,SURFACE,2,0.05,KEPT
variable expressivity,SURFACE,2,0.05,KEPT
vascular abnormalities,SURFACE,2,0.05,KEPT
vascular complications,SURFACE,2,0.05,KEPT
vascular malformation,SURFACE,2,0.05,KEPT
vascular surgeon,SURFACE,2,0.05,KEPT
venous doppler ultrasound,SURFACE,2,0.05,KEPT
venous obstruction,SURFACE,2,0.05,KEPT
vessels,SURFACE,2,0.05,KEPT
views,SURFACE,2,0.05,KEPT
viral causes,SURFACE,2,0.05,KEPT
viral panel,SURFACE,2,0.05,KEPT
viral panels,SURFACE,2,0.05,KEPT
viral pathogens,SURFACE,2,0.05,KEPT
visceral,SURFACE,2,0.05,KEPT
vision loss,SURFACE,2,0.05,KEPT
visual,SURFACE,2,0.05,KEPT
visual impairment,SURFACE,2,0.05,KEPT
vital information,SURFACE,2,0.05,KEPT
voice,SURFACE,2,0.05,KEPT
volume,SURFACE,2,0.05,KEPT
weakness,SURFACE,2,0.05,KEPT
weight gain,SURFACE,2,0.05,KEPT
well-being,SURFACE,2,0.05,KEPT
well-considered,SURFACE,2,0.05,KEPT
well-equipped,SURFACE,2,0.05,KEPT
well-reasoned,SURFACE,2,0.05,KEPT
wes,SURFACE,2,0.05,KEPT
whole exome sequencing,SURFACE,2,0.05,KEPT
whole-exome sequencing,SURFACE,2,0.05,KEPT
willingness,SURFACE,2,0.05,KEPT
wish,SURFACE,2,0.05,KEPT
workflow,SURFACE,2,0.05,KEPT
worsened,SURFACE,2,0.05,KEPT
wrist,SURFACE,2,0.05,KEPT
year,SURFACE,2,0.05,KEPT
"years.\"",\n\n",SURFACE,2,0.05,KEPT
younger sister,SURFACE,2,0.05,KEPT
’s history,SURFACE,2,0.05,KEPT
! i,SURFACE,1,0.025,KEPT
** evaluating,SURFACE,1,0.025,KEPT
** particularly,SURFACE,1,0.025,KEPT
** primarily,SURFACE,1,0.025,KEPT
** suggested,SURFACE,1,0.025,KEPT
**3d ultrasound imaging**,SURFACE,1,0.025,KEPT
**3d ultrasound imaging** -,SURFACE,1,0.025,KEPT
**3d ultrasound imaging:**,SURFACE,1,0.025,KEPT
**achondrogenesis,SURFACE,1,0.025,KEPT
**achondrogenesis**,SURFACE,1,0.025,KEPT
**achondrogenesis**.,SURFACE,1,0.025,KEPT
**acoustic neuroma** -,SURFACE,1,0.025,KEPT
"**acquired angioedema**
     - **venous insufficiency**
     - **lymphatic obstruction**
     - **systemic conditions",SURFACE,1,0.025,KEPT
"**acquired angioedema**
   - **venous insufficiency**
   - **lymphatic obstruction**
   - **systemic conditions",SURFACE,1,0.025,KEPT
**action plan,SURFACE,1,0.025,KEPT
**ad-hies**,SURFACE,1,0.025,KEPT
**additional,SURFACE,1,0.025,KEPT
**adenoviruses** and **enteroviruses**,SURFACE,1,0.025,KEPT
**adenoviruses** and **parvovirus b19** enhances,SURFACE,1,0.025,KEPT
**alagille syndrome**,SURFACE,1,0.025,KEPT
**allergic bronchopulmonary aspergillosis,SURFACE,1,0.025,KEPT
**alström syndrome**,SURFACE,1,0.025,KEPT
**ampa receptors** and **gaba(b) receptors**,SURFACE,1,0.025,KEPT
**ampa** and **gaba(b)** receptor antibodies,SURFACE,1,0.025,KEPT
**analysis,SURFACE,1,0.025,KEPT
**anca antibodies** makes,SURFACE,1,0.025,KEPT
**anca antibody testing**,SURFACE,1,0.025,KEPT
**androgen insensitivity syndrome,SURFACE,1,0.025,KEPT
**angelman syndrome**,SURFACE,1,0.025,KEPT
**anti-citrullinated protein antibodies,SURFACE,1,0.025,KEPT
**anti-nmda receptor encephalitis**,SURFACE,1,0.025,KEPT
**antinuclear antibodies,SURFACE,1,0.025,KEPT
**any signs of,SURFACE,1,0.025,KEPT
**apert syndrome**,SURFACE,1,0.025,KEPT
**apert syndrome** or **crouzon syndrome**),SURFACE,1,0.025,KEPT
**area for actions**,SURFACE,1,0.025,KEPT
**areas,SURFACE,1,0.025,KEPT
**atrial septal defect,SURFACE,1,0.025,KEPT
**autoantibody,SURFACE,1,0.025,KEPT
**autoantibody panel:**,SURFACE,1,0.025,KEPT
**autoimmune encephalitis**,SURFACE,1,0.025,KEPT
**autoimmune panel**,SURFACE,1,0.025,KEPT
**autosomal,SURFACE,1,0.025,KEPT
**autosomal dominant hyper-ige syndrome,SURFACE,1,0.025,KEPT
**bardet-biedl syndrome**,SURFACE,1,0.025,KEPT
**bardet-biedl syndrome** or **alström syndrome**,SURFACE,1,0.025,KEPT
"**bardet-biedl syndrome** or **congenital lipodystrophy**.

3. **developmental milestones**",SURFACE,1,0.025,KEPT
**behçet's disease** angle,SURFACE,1,0.025,KEPT
**benign course,SURFACE,1,0.025,KEPT
"**biopsies**. 
  - **priority",SURFACE,1,0.025,KEPT
**biopsy,SURFACE,1,0.025,KEPT
**biopsy**,SURFACE,1,0.025,KEPT
"**bone age assessment**

4. **action plan**",SURFACE,1,0.025,KEPT
**bone age assessment** serves,SURFACE,1,0.025,KEPT
**bone marrow biopsy** for,SURFACE,1,0.025,KEPT
**bronchoscopy,SURFACE,1,0.025,KEPT
**bronchoscopy with,SURFACE,1,0.025,KEPT
**c-reactive protein,SURFACE,1,0.025,KEPT
**candidate variants**,SURFACE,1,0.025,KEPT
**candidate variants** with,SURFACE,1,0.025,KEPT
**cardiac biomarkers**,SURFACE,1,0.025,KEPT
**careful,SURFACE,1,0.025,KEPT
**caspr2**,SURFACE,1,0.025,KEPT
**cellular models**,SURFACE,1,0.025,KEPT
**cerebellar degeneration:** given,SURFACE,1,0.025,KEPT
**cerebellar degeneration:** while,SURFACE,1,0.025,KEPT
**chest,SURFACE,1,0.025,KEPT
**chest high-resolution ct scan**,SURFACE,1,0.025,KEPT
**choroidal melanoma**.,SURFACE,1,0.025,KEPT
**choroidal nevus**,SURFACE,1,0.025,KEPT
**choroidal nevus**: i share,SURFACE,1,0.025,KEPT
**chronic granulomatous disease,SURFACE,1,0.025,KEPT
**chronic thromboembolic pulmonary hypertension,SURFACE,1,0.025,KEPT
**clinical observation,SURFACE,1,0.025,KEPT
**cocaine,SURFACE,1,0.025,KEPT
**cocaine intoxication**,SURFACE,1,0.025,KEPT
**coffin-siris syndrome** or **charge syndrome**,SURFACE,1,0.025,KEPT
**communicating findings**,SURFACE,1,0.025,KEPT
**communication,SURFACE,1,0.025,KEPT
**communication strategies**,SURFACE,1,0.025,KEPT
**communication tactics**,SURFACE,1,0.025,KEPT
**complement levels,SURFACE,1,0.025,KEPT
**complete blood count,SURFACE,1,0.025,KEPT
**comprehensive,SURFACE,1,0.025,KEPT
**comprehensive blood work**,SURFACE,1,0.025,KEPT
**comprehensive metabolic panel,SURFACE,1,0.025,KEPT
**comprehensive metabolic panel**,SURFACE,1,0.025,KEPT
**comprehensive renal imaging,SURFACE,1,0.025,KEPT
**comprehensive skeletal survey**,SURFACE,1,0.025,KEPT
**congenital adrenal hyperplasia**,SURFACE,1,0.025,KEPT
**congenital kidney disease**,SURFACE,1,0.025,KEPT
**congenital lipodystrophy**,SURFACE,1,0.025,KEPT
**congenital ureteral duplication,SURFACE,1,0.025,KEPT
**congenital ureteral duplication**,SURFACE,1,0.025,KEPT
**conjunctival nevus,SURFACE,1,0.025,KEPT
**conjunctival nevus/papilloma,SURFACE,1,0.025,KEPT
**consensus**,SURFACE,1,0.025,KEPT
**consider,SURFACE,1,0.025,KEPT
**considerations**,SURFACE,1,0.025,KEPT
**consultations,SURFACE,1,0.025,KEPT
**consultations**,SURFACE,1,0.025,KEPT
**continual feedback loop**,SURFACE,1,0.025,KEPT
**continuing the discussion**,SURFACE,1,0.025,KEPT
**cornelia,SURFACE,1,0.025,KEPT
**coronary artery complications**,SURFACE,1,0.025,KEPT
**craniofacial dysostosis syndrome**,SURFACE,1,0.025,KEPT
"**craniosynostosis syndrome**, specifically **apert syndrome**.",SURFACE,1,0.025,KEPT
**crouzon syndrome**,SURFACE,1,0.025,KEPT
**crouzon syndrome** and **oculodentodigital syndrome**,SURFACE,1,0.025,KEPT
**ct,SURFACE,1,0.025,KEPT
**ct angiography,SURFACE,1,0.025,KEPT
**ct imaging,SURFACE,1,0.025,KEPT
**ct imaging**: conduct a **ct scan**,SURFACE,1,0.025,KEPT
**ct scan**,SURFACE,1,0.025,KEPT
**cushing's syndrome**,SURFACE,1,0.025,KEPT
**cytokine profile,SURFACE,1,0.025,KEPT
**defining testing responsibilities**,SURFACE,1,0.025,KEPT
**delayed referrals**,SURFACE,1,0.025,KEPT
**detailed,SURFACE,1,0.025,KEPT
**detailed skeletal survey**,SURFACE,1,0.025,KEPT
**differential diagnoses,SURFACE,1,0.025,KEPT
**differential diagnoses insights**,SURFACE,1,0.025,KEPT
**differential diagnoses summary**,SURFACE,1,0.025,KEPT
**differential diagnoses** and **recommended tests**,SURFACE,1,0.025,KEPT
**differential diagnosis,SURFACE,1,0.025,KEPT
**differential diagnosis clarifications**,SURFACE,1,0.025,KEPT
**differential diagnosis consideration**,SURFACE,1,0.025,KEPT
**differential diagnosis considerations**,SURFACE,1,0.025,KEPT
**differential diagnosis expansion**,SURFACE,1,0.025,KEPT
**differential diagnosis:**,SURFACE,1,0.025,KEPT
**digital volume tomography,SURFACE,1,0.025,KEPT
**documentation for specialists**,SURFACE,1,0.025,KEPT
**documentation preparation**,SURFACE,1,0.025,KEPT
**documentation**,SURFACE,1,0.025,KEPT
**doppler ultrasound,SURFACE,1,0.025,KEPT
**down syndrome** and **cornelia,SURFACE,1,0.025,KEPT
"**dravet syndrome**
   - **atypical absence epilepsy**
   - **focal cortical dysplasia",SURFACE,1,0.025,KEPT
"**dravet syndrome** 
   - **atypical absence epilepsy** 
   - **focal cortical dysplasia",SURFACE,1,0.025,KEPT
**dyslipidemia-related vascular issues**,SURFACE,1,0.025,KEPT
**echocardiogram follow-up** to monitor,SURFACE,1,0.025,KEPT
**echocardiogram**,SURFACE,1,0.025,KEPT
**echocardiograms**,SURFACE,1,0.025,KEPT
**echocardiography**,SURFACE,1,0.025,KEPT
**echocardiography**: essential for,SURFACE,1,0.025,KEPT
**echocardiography:** given,SURFACE,1,0.025,KEPT
**echocardiography:** prioritizing,SURFACE,1,0.025,KEPT
**echocardiography:** since,SURFACE,1,0.025,KEPT
**educational outreach**,SURFACE,1,0.025,KEPT
**educational support**,SURFACE,1,0.025,KEPT
**electromyography,SURFACE,1,0.025,KEPT
**endocrine consultation**,SURFACE,1,0.025,KEPT
**endocrine profile tests**: outlining the need,SURFACE,1,0.025,KEPT
**endocrine testing schedule**,SURFACE,1,0.025,KEPT
**environmental factors**,SURFACE,1,0.025,KEPT
**environmental influences**,SURFACE,1,0.025,KEPT
"**epileptic encephalopathy**
   - **psychogenic non-epileptic seizures",SURFACE,1,0.025,KEPT
"**epileptic encephalopathy** 
   - **psychogenic non-epileptic seizures",SURFACE,1,0.025,KEPT
**establish,SURFACE,1,0.025,KEPT
**evaluation**,SURFACE,1,0.025,KEPT
**excisional biopsy**,SURFACE,1,0.025,KEPT
**expanded,SURFACE,1,0.025,KEPT
**expanded genetic testing**,SURFACE,1,0.025,KEPT
"**expanded genetic testing**
   - **detailed skeletal survey**
   - **echocardiogram follow-up**
   - **mri",SURFACE,1,0.025,KEPT
**extended,SURFACE,1,0.025,KEPT
**extended video eeg,SURFACE,1,0.025,KEPT
**extended viral panel,SURFACE,1,0.025,KEPT
**failure,SURFACE,1,0.025,KEPT
**familial adenomatous polyposis,SURFACE,1,0.025,KEPT
**familial considerations:**,SURFACE,1,0.025,KEPT
**familial impact:**,SURFACE,1,0.025,KEPT
**family,SURFACE,1,0.025,KEPT
**family engagement protocol**,SURFACE,1,0.025,KEPT
**family support mechanism**,SURFACE,1,0.025,KEPT
**fbn1** gene,SURFACE,1,0.025,KEPT
**ferritin,SURFACE,1,0.025,KEPT
**fetal alcohol spectrum disorder,SURFACE,1,0.025,KEPT
**fetal echocardiogram**,SURFACE,1,0.025,KEPT
**fetal echocardiogram** -,SURFACE,1,0.025,KEPT
**fetal echocardiogram** - given,SURFACE,1,0.025,KEPT
**fetal echocardiogram** - to,SURFACE,1,0.025,KEPT
**fetal mri**,SURFACE,1,0.025,KEPT
**fetal mri** with,SURFACE,1,0.025,KEPT
**fetal mri**: similarly agreed,SURFACE,1,0.025,KEPT
**fetal mri:** i,SURFACE,1,0.025,KEPT
**fibrodysplasia ossificans progressiva,SURFACE,1,0.025,KEPT
**fluorescein staining**,SURFACE,1,0.025,KEPT
**fluorescein staining** to,SURFACE,1,0.025,KEPT
**focal cortical dysplasia,SURFACE,1,0.025,KEPT
**follow-up plan**,SURFACE,1,0.025,KEPT
**follow-up strategy**,SURFACE,1,0.025,KEPT
**follow-up structures**,SURFACE,1,0.025,KEPT
**follow-up timeline**,SURFACE,1,0.025,KEPT
**follow-up**,SURFACE,1,0.025,KEPT
**for,SURFACE,1,0.025,KEPT
**framework,SURFACE,1,0.025,KEPT
**friedreich's ataxia**,SURFACE,1,0.025,KEPT
**genetic,SURFACE,1,0.025,KEPT
**genetic counseling**,SURFACE,1,0.025,KEPT
**genetic counseling** and **expanded testing**,SURFACE,1,0.025,KEPT
**genetic counseling** for the,SURFACE,1,0.025,KEPT
**genetic counseling** remains,SURFACE,1,0.025,KEPT
**genetic counseling** to,SURFACE,1,0.025,KEPT
**genetic testing first**,SURFACE,1,0.025,KEPT
**genetic testing**.,SURFACE,1,0.025,KEPT
**geneticist**,SURFACE,1,0.025,KEPT
**genetics,SURFACE,1,0.025,KEPT
**giant cell arteritis**,SURFACE,1,0.025,KEPT
**granulomatosis,SURFACE,1,0.025,KEPT
**hanta virus** and **chikungunya virus**,SURFACE,1,0.025,KEPT
**hantavirus**,SURFACE,1,0.025,KEPT
**hemangioma,SURFACE,1,0.025,KEPT
**hemangioma**,SURFACE,1,0.025,KEPT
**histological examination,SURFACE,1,0.025,KEPT
**histopathological,SURFACE,1,0.025,KEPT
**histopathological examination** of,SURFACE,1,0.025,KEPT
**hla-b27 test**,SURFACE,1,0.025,KEPT
**hla-b27**,SURFACE,1,0.025,KEPT
**hla-drb1,SURFACE,1,0.025,KEPT
**hla-drb1** alleles,SURFACE,1,0.025,KEPT
**how,SURFACE,1,0.025,KEPT
**hyper-igd syndrome,SURFACE,1,0.025,KEPT
**hyper-ige syndrome,SURFACE,1,0.025,KEPT
**hypochondrogenesis**,SURFACE,1,0.025,KEPT
**hypoplastic left heart syndrome**,SURFACE,1,0.025,KEPT
**hypothyroidism**,SURFACE,1,0.025,KEPT
**imaging,SURFACE,1,0.025,KEPT
**imaging**,SURFACE,1,0.025,KEPT
**immediate,SURFACE,1,0.025,KEPT
**immediate action**,SURFACE,1,0.025,KEPT
**immediate referrals**,SURFACE,1,0.025,KEPT
**immunoglobulin subclass,SURFACE,1,0.025,KEPT
**immunohistochemistry**,SURFACE,1,0.025,KEPT
**implications,SURFACE,1,0.025,KEPT
**infections,SURFACE,1,0.025,KEPT
**infections**,SURFACE,1,0.025,KEPT
**infectious arthritis**,SURFACE,1,0.025,KEPT
**infectious causes,SURFACE,1,0.025,KEPT
**infectious disease testing**,SURFACE,1,0.025,KEPT
**infectious workup:**,SURFACE,1,0.025,KEPT
**inflammatory,SURFACE,1,0.025,KEPT
**inflammatory markers,SURFACE,1,0.025,KEPT
**inflammatory markers**,SURFACE,1,0.025,KEPT
**inflammatory markers**: adding **crp**,SURFACE,1,0.025,KEPT
**initial imaging**,SURFACE,1,0.025,KEPT
**initial testing**: utilize **pcr,SURFACE,1,0.025,KEPT
**interdisciplinary approach**,SURFACE,1,0.025,KEPT
**interdisciplinary consultations**,SURFACE,1,0.025,KEPT
**interstitial lung disease,SURFACE,1,0.025,KEPT
**intestinal lymphangiectasia**,SURFACE,1,0.025,KEPT
**intravenous urography,SURFACE,1,0.025,KEPT
**isomerase activity assays**,SURFACE,1,0.025,KEPT
**karyotyping**,SURFACE,1,0.025,KEPT
**kidney function monitoring**,SURFACE,1,0.025,KEPT
**kishore syndrome**,SURFACE,1,0.025,KEPT
**klinefelter syndrome,SURFACE,1,0.025,KEPT
**krabbe disease**,SURFACE,1,0.025,KEPT
"**laboratory tests:**
   - **complete blood count",SURFACE,1,0.025,KEPT
**lennox-gastaut syndrome,SURFACE,1,0.025,KEPT
**lgi1** and **caspr2**.,SURFACE,1,0.025,KEPT
**li-fraumeni syndrome**,SURFACE,1,0.025,KEPT
**limb,SURFACE,1,0.025,KEPT
"**lipid panel**
   - **hepatitis panel**
   - **serum uric acid level**
   - **renal function tests**
   - **ct scan",SURFACE,1,0.025,KEPT
**lipid profile monitoring**,SURFACE,1,0.025,KEPT
**longitudinal limb deficiencies**,SURFACE,1,0.025,KEPT
**longitudinal monitoring**,SURFACE,1,0.025,KEPT
**lung biopsy**,SURFACE,1,0.025,KEPT
**lymph node,SURFACE,1,0.025,KEPT
**lymphatic obstruction**,SURFACE,1,0.025,KEPT
"**lymphocyte subset analysis**
     - **serological tests",SURFACE,1,0.025,KEPT
**lynch syndrome**. it’s,SURFACE,1,0.025,KEPT
**maffucci syndrome**,SURFACE,1,0.025,KEPT
"**maffucci syndrome** or **beckwith-wiedemann syndrome**.

4. **family history and inheritance patterns**",SURFACE,1,0.025,KEPT
**malignancies,SURFACE,1,0.025,KEPT
**malignancy,SURFACE,1,0.025,KEPT
**marfan,SURFACE,1,0.025,KEPT
**marfan syndrome**,SURFACE,1,0.025,KEPT
"**medication side effects**
     - **post-surgical complications**

3. **recommended diagnostic tests**",SURFACE,1,0.025,KEPT
"**medication side effects**
     - **post-surgical complications**

3. **recommended tests**",SURFACE,1,0.025,KEPT
"**medication side effects**
   - **post-surgical complications**

3. **recommended diagnostic tests**",SURFACE,1,0.025,KEPT
**metabolic,SURFACE,1,0.025,KEPT
**metabolic panel** and **echocardiography** without,SURFACE,1,0.025,KEPT
**metabolic panel** and **eeg**,SURFACE,1,0.025,KEPT
**metabolic panel:** continuous monitoring,SURFACE,1,0.025,KEPT
**metabolic panel:** given,SURFACE,1,0.025,KEPT
**metabolic panel:** this,SURFACE,1,0.025,KEPT
**metastatic carcinoma,SURFACE,1,0.025,KEPT
**metastatic carcinoma**,SURFACE,1,0.025,KEPT
**microbial,SURFACE,1,0.025,KEPT
**monitoring,SURFACE,1,0.025,KEPT
**monitoring framework**,SURFACE,1,0.025,KEPT
**monitoring timeline**,SURFACE,1,0.025,KEPT
**most likely diagnosis**,SURFACE,1,0.025,KEPT
**most likely diagnosis** remains as **cocaine,SURFACE,1,0.025,KEPT
**mri of,SURFACE,1,0.025,KEPT
**mri of the,SURFACE,1,0.025,KEPT
"**mri of the orbit**
   - **ultrasound biomicroscopy",SURFACE,1,0.025,KEPT
**mri**.,SURFACE,1,0.025,KEPT
**multicystic dysplastic kidney disease,SURFACE,1,0.025,KEPT
**multicystic dysplastic kidney disease**,SURFACE,1,0.025,KEPT
**multicystic dysplastic kidney disease**.,SURFACE,1,0.025,KEPT
**multidisciplinary reviews**,SURFACE,1,0.025,KEPT
**multidisciplinary team approach**,SURFACE,1,0.025,KEPT
**multidisciplinary team meeting**,SURFACE,1,0.025,KEPT
**multifocal electroretinography,SURFACE,1,0.025,KEPT
**nephronophthisis,SURFACE,1,0.025,KEPT
**nephronophthisis:**,SURFACE,1,0.025,KEPT
**neurodevelopmental issues**,SURFACE,1,0.025,KEPT
**neuroendocrine tumors**,SURFACE,1,0.025,KEPT
**neuropsychological assessments**,SURFACE,1,0.025,KEPT
**neuropsychological testing**,SURFACE,1,0.025,KEPT
**neuropsychological testing** - while,SURFACE,1,0.025,KEPT
**next generation sequencing**,SURFACE,1,0.025,KEPT
**niemann-pick disease**,SURFACE,1,0.025,KEPT
**non-epileptic seizures**,SURFACE,1,0.025,KEPT
**noonan syndrome**,SURFACE,1,0.025,KEPT
**obesity,SURFACE,1,0.025,KEPT
**obesity-related renal disease,SURFACE,1,0.025,KEPT
**obesity-related renal disease**,SURFACE,1,0.025,KEPT
**obesity-related renal disease** alongside,SURFACE,1,0.025,KEPT
**ocular ultrasound (b-scan)**,SURFACE,1,0.025,KEPT
**ocular ultrasound (b-scan)** if,SURFACE,1,0.025,KEPT
**ocupoglossal dysplasia** or **genetic syndromes,SURFACE,1,0.025,KEPT
**oligoarticular,SURFACE,1,0.025,KEPT
**optical coherence tomography,SURFACE,1,0.025,KEPT
**optical coherence tomography angiography,SURFACE,1,0.025,KEPT
**osteogenesis imperfecta,SURFACE,1,0.025,KEPT
**osteogenesis imperfecta**,SURFACE,1,0.025,KEPT
**panel,SURFACE,1,0.025,KEPT
**parallel approach,SURFACE,1,0.025,KEPT
**partnering with,SURFACE,1,0.025,KEPT
**patient education**,SURFACE,1,0.025,KEPT
**patterned dystrophies,SURFACE,1,0.025,KEPT
**patterned dystrophies**,SURFACE,1,0.025,KEPT
**pcr,SURFACE,1,0.025,KEPT
**pediatric orthopedic specialist**,SURFACE,1,0.025,KEPT
**pediatric rheumatologist**.,SURFACE,1,0.025,KEPT
**pediatric rheumatology**,SURFACE,1,0.025,KEPT
**pediatric uveitis specialist**,SURFACE,1,0.025,KEPT
**pediatric uveitis specialist** for targeted ocular management,SURFACE,1,0.025,KEPT
"**pelvic ultrasound**
   - **mri",SURFACE,1,0.025,KEPT
**pelvic ultrasound** and **mri** both,SURFACE,1,0.025,KEPT
**persistent symptoms**,SURFACE,1,0.025,KEPT
**pet imaging**,SURFACE,1,0.025,KEPT
**pet scans**,SURFACE,1,0.025,KEPT
**pfeiffer syndrome**,SURFACE,1,0.025,KEPT
**pfeiffer syndrome**. it's,SURFACE,1,0.025,KEPT
**phocomelia** or **limb,SURFACE,1,0.025,KEPT
**plan,SURFACE,1,0.025,KEPT
**plasma aldosterone,SURFACE,1,0.025,KEPT
"**plasma aldosterone level**
   - **plasma",SURFACE,1,0.025,KEPT
**plscr4 deletion's implications**,SURFACE,1,0.025,KEPT
**plscr4 deletion**,SURFACE,1,0.025,KEPT
**plscr4 deletion**.,SURFACE,1,0.025,KEPT
**possible,SURFACE,1,0.025,KEPT
**potential,SURFACE,1,0.025,KEPT
**prader-willi syndrome,SURFACE,1,0.025,KEPT
**prader-willi syndrome**—given,SURFACE,1,0.025,KEPT
**pre-meeting preparation**,SURFACE,1,0.025,KEPT
**prepare documentation**,SURFACE,1,0.025,KEPT
**prioritized order for testing**,SURFACE,1,0.025,KEPT
**psychiatric evaluation**,SURFACE,1,0.025,KEPT
**psychological support**,SURFACE,1,0.025,KEPT
**psychosocial support**,SURFACE,1,0.025,KEPT
**pulmonary function tests**,SURFACE,1,0.025,KEPT
**quantiferon gold test,SURFACE,1,0.025,KEPT
**quantiferon gold test**,SURFACE,1,0.025,KEPT
**rationale**,SURFACE,1,0.025,KEPT
**reactions,SURFACE,1,0.025,KEPT
**reactive arthritis**.,SURFACE,1,0.025,KEPT
**reassessment of,SURFACE,1,0.025,KEPT
**reassessment of test justifications**,SURFACE,1,0.025,KEPT
"**reassessment of test justifications:**
- **order of recommended tests**",SURFACE,1,0.025,KEPT
**recommended diagnostic tests**,SURFACE,1,0.025,KEPT
**recommended tests**,SURFACE,1,0.025,KEPT
**referral,SURFACE,1,0.025,KEPT
**referral considerations:** i,SURFACE,1,0.025,KEPT
**referral to,SURFACE,1,0.025,KEPT
**referral to specialists**,SURFACE,1,0.025,KEPT
**regular,SURFACE,1,0.025,KEPT
**regular follow-ups**,SURFACE,1,0.025,KEPT
**regular imaging,SURFACE,1,0.025,KEPT
**relevance,SURFACE,1,0.025,KEPT
**renal considerations**,SURFACE,1,0.025,KEPT
**renal function tests**,SURFACE,1,0.025,KEPT
**renal ultrasound:**,SURFACE,1,0.025,KEPT
**renal ultrasound:** after,SURFACE,1,0.025,KEPT
**renal ultrasound:** conducting the,SURFACE,1,0.025,KEPT
**renal ultrasound:** i,SURFACE,1,0.025,KEPT
**renal ultrasound:** this,SURFACE,1,0.025,KEPT
**repeat csf analysis**,SURFACE,1,0.025,KEPT
**repeat csf analysis** as crucial,SURFACE,1,0.025,KEPT
**repeat ultrasound assessments**,SURFACE,1,0.025,KEPT
**repeat ultrasound assessments** should focus,SURFACE,1,0.025,KEPT
**reproductive health implications**,SURFACE,1,0.025,KEPT
**responsibilities,SURFACE,1,0.025,KEPT
**retinal detachment**,SURFACE,1,0.025,KEPT
**retinal detachment** and **metastatic carcinoma**,SURFACE,1,0.025,KEPT
**reviewing,SURFACE,1,0.025,KEPT
"**rheumatoid factor (rf)**
   - **anti-cyclic",SURFACE,1,0.025,KEPT
**risks,SURFACE,1,0.025,KEPT
**routine follow-up imaging,SURFACE,1,0.025,KEPT
**sarcoidosis**,SURFACE,1,0.025,KEPT
**sarcoidosis**.,SURFACE,1,0.025,KEPT
**schedule,SURFACE,1,0.025,KEPT
**schedule specialist meeting**,SURFACE,1,0.025,KEPT
**screen,SURFACE,1,0.025,KEPT
**secondary retinal tumors**,SURFACE,1,0.025,KEPT
**sepsis-related encephalopathy**,SURFACE,1,0.025,KEPT
**sepsis-related encephalopathy** warranting,SURFACE,1,0.025,KEPT
**sequence of testing**,SURFACE,1,0.025,KEPT
**serial immunoglobulin levels measurement**,SURFACE,1,0.025,KEPT
**serological markers**: targeted tests,SURFACE,1,0.025,KEPT
**serological testing,SURFACE,1,0.025,KEPT
**serological testing**,SURFACE,1,0.025,KEPT
**serological tests,SURFACE,1,0.025,KEPT
**serum amyloid a,SURFACE,1,0.025,KEPT
**serum angiotensin-converting enzyme,SURFACE,1,0.025,KEPT
**serum autoantibody panel**,SURFACE,1,0.025,KEPT
**serum c4,SURFACE,1,0.025,KEPT
**serum igd levels**,SURFACE,1,0.025,KEPT
**serum uric acid level** test,SURFACE,1,0.025,KEPT
**severe,SURFACE,1,0.025,KEPT
**severe combined immunodeficiency (,SURFACE,1,0.025,KEPT
**significance,SURFACE,1,0.025,KEPT
**skeletal survey**,SURFACE,1,0.025,KEPT
**smith-magenis syndrome** or others,SURFACE,1,0.025,KEPT
**specialist meeting**: schedule,SURFACE,1,0.025,KEPT
**specific,SURFACE,1,0.025,KEPT
**specifying,SURFACE,1,0.025,KEPT
**sputum culture**,SURFACE,1,0.025,KEPT
**stage ii lung adenocarcinoma**,SURFACE,1,0.025,KEPT
**stage ii lung adenocarcinoma** (,SURFACE,1,0.025,KEPT
**stage ii lung adenocarcinoma** as,SURFACE,1,0.025,KEPT
**stage ii lung adenocarcinoma** remains,SURFACE,1,0.025,KEPT
**stage ii lung adenocarcinoma** remains well-supported,SURFACE,1,0.025,KEPT
**stage ii lung adenocarcinoma** with,SURFACE,1,0.025,KEPT
**still's disease,SURFACE,1,0.025,KEPT
**structural lesions** - it,SURFACE,1,0.025,KEPT
**structural lesions**: keeping the option,SURFACE,1,0.025,KEPT
**surveillance imaging**,SURFACE,1,0.025,KEPT
**surveillance protocols** tailored,SURFACE,1,0.025,KEPT
"**swyer syndrome**
   - **mixed gonadal dysgenesis**
   - **congenital adrenal hyperplasia",SURFACE,1,0.025,KEPT
**swyer syndrome** and **mixed,SURFACE,1,0.025,KEPT
**swyer syndrome** and **mixed gonadal dysgenesis**,SURFACE,1,0.025,KEPT
**syndromic osteogenesis imperfecta,SURFACE,1,0.025,KEPT
**syndromic osteogenesis imperfecta**,SURFACE,1,0.025,KEPT
**syphilis test** if uveitis,SURFACE,1,0.025,KEPT
**systemic imaging,SURFACE,1,0.025,KEPT
**systemic lab work**,SURFACE,1,0.025,KEPT
**systemic lupus erythematosus,SURFACE,1,0.025,KEPT
**systemic onset jia,SURFACE,1,0.025,KEPT
**systemic onset jia**,SURFACE,1,0.025,KEPT
**systemic onset jia**.,SURFACE,1,0.025,KEPT
**systemic onset juvenile idiopathic arthritis,SURFACE,1,0.025,KEPT
**systemic onset juvenile idiopathic arthritis**,SURFACE,1,0.025,KEPT
**systemic onset** and potentially **oligoarticular,SURFACE,1,0.025,KEPT
**systemic workup**,SURFACE,1,0.025,KEPT
**takayasu arteritis**,SURFACE,1,0.025,KEPT
"**takayasu arteritis**

2. **differential diagnoses**",SURFACE,1,0.025,KEPT
**takayasu arteritis** remains,SURFACE,1,0.025,KEPT
**tar syndrome** and **holt-oram syndrome**,SURFACE,1,0.025,KEPT
**targeted gene panels/next-generation sequencing**,SURFACE,1,0.025,KEPT
**targeted systemic evaluation**,SURFACE,1,0.025,KEPT
**tay-sachs disease**,SURFACE,1,0.025,KEPT
**temperature regulation issues**,SURFACE,1,0.025,KEPT
**terminate**,SURFACE,1,0.025,KEPT
**terminate** the current discussion,SURFACE,1,0.025,KEPT
**terminate** the discussion,SURFACE,1,0.025,KEPT
**test redundancy**,SURFACE,1,0.025,KEPT
**testing**,SURFACE,1,0.025,KEPT
**thanatophoric dysplasia**,SURFACE,1,0.025,KEPT
**thanatophoric dysplasia** remains,SURFACE,1,0.025,KEPT
**thanatophoric dysplasia** stands,SURFACE,1,0.025,KEPT
**thanatophoric dysplasia**.,SURFACE,1,0.025,KEPT
**thrombocytopenia-absence of radius (tar) syndrome** and **holt-oram syndrome**,SURFACE,1,0.025,KEPT
"**thyroid function tests**
     - **comprehensive metabolic panel**
     - **24-hour urinary c1 esterase inhibitor activity**
     - **complete blood count",SURFACE,1,0.025,KEPT
"**thyroid function tests**
   - **comprehensive metabolic panel**
   - **24-hour urinary c1 esterase inhibitor activity**
   - **complete blood count",SURFACE,1,0.025,KEPT
**thyroid function tests** to rule out any,SURFACE,1,0.025,KEPT
**tick-borne encephalitis virus,SURFACE,1,0.025,KEPT
**tick-borne encephalitis virus** (,SURFACE,1,0.025,KEPT
**timeline for tests**,SURFACE,1,0.025,KEPT
**timing of tests**,SURFACE,1,0.025,KEPT
**toxicology methodology**,SURFACE,1,0.025,KEPT
**toxicology timing**,SURFACE,1,0.025,KEPT
**tp53 testing**,SURFACE,1,0.025,KEPT
**transverse,SURFACE,1,0.025,KEPT
**treatment focus**,SURFACE,1,0.025,KEPT
**trisomy 18,SURFACE,1,0.025,KEPT
**tuberculosis,SURFACE,1,0.025,KEPT
**tuberculosis skin test,SURFACE,1,0.025,KEPT
**tuberculosis testing**,SURFACE,1,0.025,KEPT
**tuberculosis**,SURFACE,1,0.025,KEPT
**tumor markers monitoring**,SURFACE,1,0.025,KEPT
**type i hereditary angioedema (hae)**,SURFACE,1,0.025,KEPT
"**type i hereditary angioedema (hae)**
  
2. **differential diagnosis**",SURFACE,1,0.025,KEPT
**type i hereditary angioedema (hae)**.,SURFACE,1,0.025,KEPT
**type i hereditary angioedema (hae)**:,SURFACE,1,0.025,KEPT
**type i hereditary angioedema (hae)**: supported by,SURFACE,1,0.025,KEPT
**ultrasound,SURFACE,1,0.025,KEPT
**ultrasound biomicroscopy,SURFACE,1,0.025,KEPT
**ultrasound of joints:** offers better,SURFACE,1,0.025,KEPT
**ultrasound of joints:** useful,SURFACE,1,0.025,KEPT
**urinalysis with microscopy**,SURFACE,1,0.025,KEPT
**urine,SURFACE,1,0.025,KEPT
**uterine anomalies,SURFACE,1,0.025,KEPT
**utility,SURFACE,1,0.025,KEPT
**valvular heart disease**,SURFACE,1,0.025,KEPT
**vascular studies,SURFACE,1,0.025,KEPT
**vascular studies**,SURFACE,1,0.025,KEPT
**vasculitis:**,SURFACE,1,0.025,KEPT
**vasculitis:** conditions,SURFACE,1,0.025,KEPT
**venous insufficiency**,SURFACE,1,0.025,KEPT
**vernal keratoconjunctivitis,SURFACE,1,0.025,KEPT
**vestibular disorders,SURFACE,1,0.025,KEPT
**vestibular neuritis** or **bppv** - these,SURFACE,1,0.025,KEPT
**viral panel**,SURFACE,1,0.025,KEPT
**viral syndromes**,SURFACE,1,0.025,KEPT
**visual quality questionnaire**,SURFACE,1,0.025,KEPT
**vitamin levels**,SURFACE,1,0.025,KEPT
**wes**,SURFACE,1,0.025,KEPT
**west nile virus**,SURFACE,1,0.025,KEPT
**williams syndrome**,SURFACE,1,0.025,KEPT
**x-rays,SURFACE,1,0.025,KEPT
**zika virus**,SURFACE,1,0.025,KEPT
*craniosynostosis syndromes,SURFACE,1,0.025,KEPT
*dna methylation studies,SURFACE,1,0.025,KEPT
*prader-willi syndrome,SURFACE,1,0.025,KEPT
*smith-magenis syndrome,SURFACE,1,0.025,KEPT
*smith-magenis syndrome*,SURFACE,1,0.025,KEPT
0.067\u20130.087 mb,SURFACE,1,0.025,KEPT
17-hydroxyprogesterone,SURFACE,1,0.025,KEPT
20-week ultrasound,SURFACE,1,0.025,KEPT
22q11.2 deletion syndrome,SURFACE,1,0.025,KEPT
24-hour holter monitoring,SURFACE,1,0.025,KEPT
24-hour urine free,SURFACE,1,0.025,KEPT
24-year evolution,SURFACE,1,0.025,KEPT
24-year history,SURFACE,1,0.025,KEPT
37.0\u00b0c,SURFACE,1,0.025,KEPT
37.5\u00bac with,SURFACE,1,0.025,KEPT
38.5\u00b0c,SURFACE,1,0.025,KEPT
3d imaging,SURFACE,1,0.025,KEPT
3d reconstruction,SURFACE,1,0.025,KEPT
"45,x",SURFACE,1,0.025,KEPT
45x karyotype,SURFACE,1,0.025,KEPT
46xy karyotype,SURFACE,1,0.025,KEPT
4\u20135 days,SURFACE,1,0.025,KEPT
4th web space syndactyly,SURFACE,1,0.025,KEPT
5th pregnancy,SURFACE,1,0.025,KEPT
6-week cough,SURFACE,1,0.025,KEPT
"\""b-scan",SURFACE,1,0.025,KEPT
"\""biochemical investigations",SURFACE,1,0.025,KEPT
"\""blood hormone",SURFACE,1,0.025,KEPT
"\""blood test",SURFACE,1,0.025,KEPT
"\""dysmorphological examination",SURFACE,1,0.025,KEPT
"\""echocardiography",SURFACE,1,0.025,KEPT
"\""external examination",SURFACE,1,0.025,KEPT
"\""extraoral examination",SURFACE,1,0.025,KEPT
"\""facial abnormalities",SURFACE,1,0.025,KEPT
"\""facial examination",SURFACE,1,0.025,KEPT
"\""facial features",SURFACE,1,0.025,KEPT
"\""fasting blood glucose",SURFACE,1,0.025,KEPT
"\""growth",SURFACE,1,0.025,KEPT
"\""initial blood tests",SURFACE,1,0.025,KEPT
"\""initial investigations",SURFACE,1,0.025,KEPT
"\""investigation",SURFACE,1,0.025,KEPT
"\""laboratory",SURFACE,1,0.025,KEPT
"\""laboratory examinations",SURFACE,1,0.025,KEPT
"\""neurological examination",SURFACE,1,0.025,KEPT
"\""no family history",SURFACE,1,0.025,KEPT
"\""no history",SURFACE,1,0.025,KEPT
"\""no past",SURFACE,1,0.025,KEPT
"\""no significant",SURFACE,1,0.025,KEPT
"\""on examination",SURFACE,1,0.025,KEPT
"\""past medical history\",SURFACE,1,0.025,KEPT
"\""postnatal fetal",SURFACE,1,0.025,KEPT
"\""pregnancy",SURFACE,1,0.025,KEPT
"\""prenatal",SURFACE,1,0.025,KEPT
"\""preoperative blood tests",SURFACE,1,0.025,KEPT
"\""radiography",SURFACE,1,0.025,KEPT
"\""routine",SURFACE,1,0.025,KEPT
"\""since birth",SURFACE,1,0.025,KEPT
"\""thyroid",SURFACE,1,0.025,KEPT
"\""ultrasonography",SURFACE,1,0.025,KEPT
"\""wakeful background",SURFACE,1,0.025,KEPT
\u03b2-galactosidase activity,SURFACE,1,0.025,KEPT
\u03b22 microglobulin,SURFACE,1,0.025,KEPT
\u2161to iv,SURFACE,1,0.025,KEPT
\u22122.5,SURFACE,1,0.025,KEPT
\u22122.6,SURFACE,1,0.025,KEPT
\u22124.4,SURFACE,1,0.025,KEPT
a **brain mri**,SURFACE,1,0.025,KEPT
a **syphilis test**,SURFACE,1,0.025,KEPT
abdominal,SURFACE,1,0.025,KEPT
abdominal anatomy,SURFACE,1,0.025,KEPT
abdominal bowel,SURFACE,1,0.025,KEPT
abdominal circumference,SURFACE,1,0.025,KEPT
abdominal circumference ratio,SURFACE,1,0.025,KEPT
abdominal discomfort,SURFACE,1,0.025,KEPT
abdominal distension,SURFACE,1,0.025,KEPT
abdominal enlargement,SURFACE,1,0.025,KEPT
abdominal examination,SURFACE,1,0.025,KEPT
abdominal malignancy,SURFACE,1,0.025,KEPT
abdominal mass,SURFACE,1,0.025,KEPT
abdominal region,SURFACE,1,0.025,KEPT
abdominal structures,SURFACE,1,0.025,KEPT
abdominal x-rays,SURFACE,1,0.025,KEPT
abduction,SURFACE,1,0.025,KEPT
abilities,SURFACE,1,0.025,KEPT
abnormal fat,SURFACE,1,0.025,KEPT
"abnormal findings.\""\n",SURFACE,1,0.025,KEPT
abnormal masses,SURFACE,1,0.025,KEPT
abnormal posture,SURFACE,1,0.025,KEPT
"abnormalities.\""\n",SURFACE,1,0.025,KEPT
above,SURFACE,1,0.025,KEPT
abpa,SURFACE,1,0.025,KEPT
abrupt,SURFACE,1,0.025,KEPT
abscesses,SURFACE,1,0.025,KEPT
absence seizures,SURFACE,1,0.025,KEPT
absolute,SURFACE,1,0.025,KEPT
abstain,SURFACE,1,0.025,KEPT
acanthosis nigricans,SURFACE,1,0.025,KEPT
accepted,SURFACE,1,0.025,KEPT
accessible,SURFACE,1,0.025,KEPT
accident,SURFACE,1,0.025,KEPT
accuracy,SURFACE,1,0.025,KEPT
ace,SURFACE,1,0.025,KEPT
ace inhibitors,SURFACE,1,0.025,KEPT
acetabulum,SURFACE,1,0.025,KEPT
acetate,SURFACE,1,0.025,KEPT
ache,SURFACE,1,0.025,KEPT
achondrogenesis,SURFACE,1,0.025,KEPT
acidosis,SURFACE,1,0.025,KEPT
acknowledges,SURFACE,1,0.025,KEPT
acoustic neuroma,SURFACE,1,0.025,KEPT
acpa,SURFACE,1,0.025,KEPT
acquire,SURFACE,1,0.025,KEPT
acquired,SURFACE,1,0.025,KEPT
acquired angioedema,SURFACE,1,0.025,KEPT
acquired lipodystrophy,SURFACE,1,0.025,KEPT
acral,SURFACE,1,0.025,KEPT
acrofacial dysostosis,SURFACE,1,0.025,KEPT
action items,SURFACE,1,0.025,KEPT
action items**,SURFACE,1,0.025,KEPT
action-oriented next,SURFACE,1,0.025,KEPT
actionability,SURFACE,1,0.025,KEPT
actionable,SURFACE,1,0.025,KEPT
actioning,SURFACE,1,0.025,KEPT
activated partial thromboplastin time,SURFACE,1,0.025,KEPT
active,SURFACE,1,0.025,KEPT
active movement,SURFACE,1,0.025,KEPT
active participation,SURFACE,1,0.025,KEPT
active synovitis,SURFACE,1,0.025,KEPT
active tb,SURFACE,1,0.025,KEPT
activities,SURFACE,1,0.025,KEPT
acute bacterial pneumonia,SURFACE,1,0.025,KEPT
acute cardiac contributors,SURFACE,1,0.025,KEPT
acute changes,SURFACE,1,0.025,KEPT
acute cocaine use,SURFACE,1,0.025,KEPT
acute condition,SURFACE,1,0.025,KEPT
acute conditions,SURFACE,1,0.025,KEPT
acute coronary syndrome,SURFACE,1,0.025,KEPT
acute coronary syndrome** –,SURFACE,1,0.025,KEPT
acute coronary syndrome** – supported,SURFACE,1,0.025,KEPT
acute diagnostic tests,SURFACE,1,0.025,KEPT
acute exacerbations,SURFACE,1,0.025,KEPT
acute features,SURFACE,1,0.025,KEPT
acute imaging,SURFACE,1,0.025,KEPT
acute infection,SURFACE,1,0.025,KEPT
acute inflammation,SURFACE,1,0.025,KEPT
acute issues,SURFACE,1,0.025,KEPT
acute kidney injury,SURFACE,1,0.025,KEPT
acute management,SURFACE,1,0.025,KEPT
acute myocardial infarction,SURFACE,1,0.025,KEPT
acute pain,SURFACE,1,0.025,KEPT
acute phase,SURFACE,1,0.025,KEPT
acute phase reactants**,SURFACE,1,0.025,KEPT
acute pulmonary complications,SURFACE,1,0.025,KEPT
acute respiratory syndrome,SURFACE,1,0.025,KEPT
acute risk,SURFACE,1,0.025,KEPT
acute settings,SURFACE,1,0.025,KEPT
acute state first,SURFACE,1,0.025,KEPT
acute substance,SURFACE,1,0.025,KEPT
acute tb,SURFACE,1,0.025,KEPT
acute tests,SURFACE,1,0.025,KEPT
acute vascular incidents,SURFACE,1,0.025,KEPT
acyanosis,SURFACE,1,0.025,KEPT
acyanotic,SURFACE,1,0.025,KEPT
ad-hies,SURFACE,1,0.025,KEPT
adalimumab,SURFACE,1,0.025,KEPT
adaptability,SURFACE,1,0.025,KEPT
adaptations,SURFACE,1,0.025,KEPT
adapting care,SURFACE,1,0.025,KEPT
add-on,SURFACE,1,0.025,KEPT
additional,SURFACE,1,0.025,KEPT
adenomas,SURFACE,1,0.025,KEPT
adenovirus,SURFACE,1,0.025,KEPT
adequate space,SURFACE,1,0.025,KEPT
adjacent,SURFACE,1,0.025,KEPT
adjacent structures,SURFACE,1,0.025,KEPT
adjunct support,SURFACE,1,0.025,KEPT
adjuvant chemotherapy,SURFACE,1,0.025,KEPT
adjuvant osimertinib,SURFACE,1,0.025,KEPT
administered,SURFACE,1,0.025,KEPT
admitted to,SURFACE,1,0.025,KEPT
adopting,SURFACE,1,0.025,KEPT
adrenal,SURFACE,1,0.025,KEPT
adrenal glands,SURFACE,1,0.025,KEPT
adrenal insufficiency,SURFACE,1,0.025,KEPT
adult,SURFACE,1,0.025,KEPT
adult-onset forms,SURFACE,1,0.025,KEPT
adult-onset still's disease,SURFACE,1,0.025,KEPT
adult-onset still's disease**,SURFACE,1,0.025,KEPT
adult-onset still’s disease,SURFACE,1,0.025,KEPT
adults,SURFACE,1,0.025,KEPT
advance,SURFACE,1,0.025,KEPT
advanced cardiac imaging,SURFACE,1,0.025,KEPT
advanced endocrine testing,SURFACE,1,0.025,KEPT
advanced genetic testing,SURFACE,1,0.025,KEPT
advanced stages,SURFACE,1,0.025,KEPT
advantageous,SURFACE,1,0.025,KEPT
advocate,SURFACE,1,0.025,KEPT
advocated,SURFACE,1,0.025,KEPT
aeration,SURFACE,1,0.025,KEPT
aetiologies,SURFACE,1,0.025,KEPT
afebrile,SURFACE,1,0.025,KEPT
affecting development,SURFACE,1,0.025,KEPT
affecting function,SURFACE,1,0.025,KEPT
affirming response,SURFACE,1,0.025,KEPT
age factor,SURFACE,1,0.025,KEPT
age ranges,SURFACE,1,0.025,KEPT
age-related,SURFACE,1,0.025,KEPT
age-related cerebral atrophy,SURFACE,1,0.025,KEPT
age-related conditions,SURFACE,1,0.025,KEPT
age-related conditions**,SURFACE,1,0.025,KEPT
agenesis,SURFACE,1,0.025,KEPT
ages,SURFACE,1,0.025,KEPT
aggravating,SURFACE,1,0.025,KEPT
aggressive treatments,SURFACE,1,0.025,KEPT
agreeances,SURFACE,1,0.025,KEPT
agreed diagnosis,SURFACE,1,0.025,KEPT
agreed plan,SURFACE,1,0.025,KEPT
agreed-upon approach,SURFACE,1,0.025,KEPT
agreed-upon management plan,SURFACE,1,0.025,KEPT
agreed-upon strategy,SURFACE,1,0.025,KEPT
agreed-upon testing,SURFACE,1,0.025,KEPT
agreements,SURFACE,1,0.025,KEPT
ahead,SURFACE,1,0.025,KEPT
aiding differential diagnosis,SURFACE,1,0.025,KEPT
aids,SURFACE,1,0.025,KEPT
airway,SURFACE,1,0.025,KEPT
airway edema,SURFACE,1,0.025,KEPT
airways,SURFACE,1,0.025,KEPT
ais,SURFACE,1,0.025,KEPT
akinesia,SURFACE,1,0.025,KEPT
akinetic\u2013rigid,SURFACE,1,0.025,KEPT
alagille syndrome,SURFACE,1,0.025,KEPT
alagille syndrome 3,SURFACE,1,0.025,KEPT
alanine aminotransferase,SURFACE,1,0.025,KEPT
alanine transaminase,SURFACE,1,0.025,KEPT
albumin,SURFACE,1,0.025,KEPT
alcohol abuse,SURFACE,1,0.025,KEPT
alcohol cessation,SURFACE,1,0.025,KEPT
alcohol consumption,SURFACE,1,0.025,KEPT
alcohol daily,SURFACE,1,0.025,KEPT
alcohol intake,SURFACE,1,0.025,KEPT
alcohol use,SURFACE,1,0.025,KEPT
alcoholic,SURFACE,1,0.025,KEPT
"alcoholic hepatic fibrosis.\""\n",SURFACE,1,0.025,KEPT
alcoholic nephropathy,SURFACE,1,0.025,KEPT
alcoholic nephropathy**,SURFACE,1,0.025,KEPT
aldosterone,SURFACE,1,0.025,KEPT
aligning with,SURFACE,1,0.025,KEPT
aligns with,SURFACE,1,0.025,KEPT
alimentary canal,SURFACE,1,0.025,KEPT
alkaline phosphatase,SURFACE,1,0.025,KEPT
allergic bronchopulmonary aspergillosis,SURFACE,1,0.025,KEPT
allergic reactions,SURFACE,1,0.025,KEPT
allergic symptoms,SURFACE,1,0.025,KEPT
allergies,SURFACE,1,0.025,KEPT
allergy department,SURFACE,1,0.025,KEPT
allergy/immunology,SURFACE,1,0.025,KEPT
alleviate,SURFACE,1,0.025,KEPT
allied health specialists,SURFACE,1,0.025,KEPT
almond-shaped eyes,SURFACE,1,0.025,KEPT
alongside,SURFACE,1,0.025,KEPT
alport syndrome,SURFACE,1,0.025,KEPT
alström,SURFACE,1,0.025,KEPT
alström syndrome,SURFACE,1,0.025,KEPT
alternate diagnosis,SURFACE,1,0.025,KEPT
alternated,SURFACE,1,0.025,KEPT
alternates,SURFACE,1,0.025,KEPT
alternating edema,SURFACE,1,0.025,KEPT
alternating pattern,SURFACE,1,0.025,KEPT
alternation,SURFACE,1,0.025,KEPT
alternative therapies,SURFACE,1,0.025,KEPT
ambiguous genitalia,SURFACE,1,0.025,KEPT
ambiguous!,SURFACE,1,0.025,KEPT
amd,SURFACE,1,0.025,KEPT
amd**,SURFACE,1,0.025,KEPT
amelia,SURFACE,1,0.025,KEPT
amenorrhea,SURFACE,1,0.025,KEPT
"amenorrhea.\"",\n\n",SURFACE,1,0.025,KEPT
amino acid formula,SURFACE,1,0.025,KEPT
amlodipine,SURFACE,1,0.025,KEPT
amniocentesis,SURFACE,1,0.025,KEPT
amniotic band syndrome,SURFACE,1,0.025,KEPT
amniotic fluid,SURFACE,1,0.025,KEPT
ampa,SURFACE,1,0.025,KEPT
ampicillin/sulbactam,SURFACE,1,0.025,KEPT
amylase,SURFACE,1,0.025,KEPT
"ana.\""\n}",SURFACE,1,0.025,KEPT
anaerobic,SURFACE,1,0.025,KEPT
anal,SURFACE,1,0.025,KEPT
analogs,SURFACE,1,0.025,KEPT
analytical breakdown,SURFACE,1,0.025,KEPT
analyzing,SURFACE,1,0.025,KEPT
anamnesis,SURFACE,1,0.025,KEPT
anarthric,SURFACE,1,0.025,KEPT
anasarca,SURFACE,1,0.025,KEPT
anatomic,SURFACE,1,0.025,KEPT
anatomical anomalies,SURFACE,1,0.025,KEPT
anatomical assessments,SURFACE,1,0.025,KEPT
anatomical basis,SURFACE,1,0.025,KEPT
anatomical clarification,SURFACE,1,0.025,KEPT
anatomical concerns,SURFACE,1,0.025,KEPT
anatomical context,SURFACE,1,0.025,KEPT
anatomical identification,SURFACE,1,0.025,KEPT
anatomical insight,SURFACE,1,0.025,KEPT
anatomical issues,SURFACE,1,0.025,KEPT
anatomical landmarks,SURFACE,1,0.025,KEPT
anatomical ultrasound,SURFACE,1,0.025,KEPT
anatomical variations,SURFACE,1,0.025,KEPT
anca,SURFACE,1,0.025,KEPT
androgen,SURFACE,1,0.025,KEPT
androgen insensitivity syndrome,SURFACE,1,0.025,KEPT
androgen receptor,SURFACE,1,0.025,KEPT
androgens,SURFACE,1,0.025,KEPT
anesthesia,SURFACE,1,0.025,KEPT
angelman syndrome,SURFACE,1,0.025,KEPT
angelman syndrome**,SURFACE,1,0.025,KEPT
angelman syndromes**,SURFACE,1,0.025,KEPT
angina,SURFACE,1,0.025,KEPT
angioedema,SURFACE,1,0.025,KEPT
angioedema align,SURFACE,1,0.025,KEPT
angioedema control,SURFACE,1,0.025,KEPT
angioedema episodes,SURFACE,1,0.025,KEPT
angioedema triggers**,SURFACE,1,0.025,KEPT
angioedema**,SURFACE,1,0.025,KEPT
angiogram,SURFACE,1,0.025,KEPT
angioplasty,SURFACE,1,0.025,KEPT
angle,SURFACE,1,0.025,KEPT
angulated,SURFACE,1,0.025,KEPT
animals,SURFACE,1,0.025,KEPT
ankles,SURFACE,1,0.025,KEPT
annotated,SURFACE,1,0.025,KEPT
anorexia,SURFACE,1,0.025,KEPT
answers,SURFACE,1,0.025,KEPT
antegrade flow,SURFACE,1,0.025,KEPT
antenatal,SURFACE,1,0.025,KEPT
antepartum examinations,SURFACE,1,0.025,KEPT
anterior chamber,SURFACE,1,0.025,KEPT
anterior chamber cell,SURFACE,1,0.025,KEPT
anterior descending coronary artery,SURFACE,1,0.025,KEPT
anterior mitral valve prolapse,SURFACE,1,0.025,KEPT
anterior pituitary dysfunction,SURFACE,1,0.025,KEPT
anterior segment exam,SURFACE,1,0.025,KEPT
anterior segment examination,SURFACE,1,0.025,KEPT
anterior uveitis,SURFACE,1,0.025,KEPT
anteverted,SURFACE,1,0.025,KEPT
anti-ccp,SURFACE,1,0.025,KEPT
anti-ccp antibody,SURFACE,1,0.025,KEPT
anti-citrullinated protein antibodies,SURFACE,1,0.025,KEPT
anti-dna,SURFACE,1,0.025,KEPT
anti-inflammatory intake,SURFACE,1,0.025,KEPT
anti-inflammatory medications,SURFACE,1,0.025,KEPT
anti-lgi1,SURFACE,1,0.025,KEPT
anti-neutrophil cytoplasmic antibodies,SURFACE,1,0.025,KEPT
anti-nmda,SURFACE,1,0.025,KEPT
anti-nmda receptor,SURFACE,1,0.025,KEPT
anti-nmdar encephalitis,SURFACE,1,0.025,KEPT
anti-smith antibodies,SURFACE,1,0.025,KEPT
anti-tuberculosis medication,SURFACE,1,0.025,KEPT
antibody,SURFACE,1,0.025,KEPT
antibody encephalitis,SURFACE,1,0.025,KEPT
antibody production,SURFACE,1,0.025,KEPT
antibody responses**,SURFACE,1,0.025,KEPT
"antibody responses**
     - **",SURFACE,1,0.025,KEPT
antibody testing**,SURFACE,1,0.025,KEPT
antibody testing** alongside,SURFACE,1,0.025,KEPT
antibody testing** promptly,SURFACE,1,0.025,KEPT
antibody-mediated encephalitis,SURFACE,1,0.025,KEPT
anticipated,SURFACE,1,0.025,KEPT
anticipatory care,SURFACE,1,0.025,KEPT
anticoagulant,SURFACE,1,0.025,KEPT
anticoagulant therapy,SURFACE,1,0.025,KEPT
anticoagulation management,SURFACE,1,0.025,KEPT
anticoagulation status,SURFACE,1,0.025,KEPT
anticoagulation therapy,SURFACE,1,0.025,KEPT
anticonvulsants,SURFACE,1,0.025,KEPT
antiepileptic drugs,SURFACE,1,0.025,KEPT
antigenic,SURFACE,1,0.025,KEPT
antigens,SURFACE,1,0.025,KEPT
antihypertensive medications,SURFACE,1,0.025,KEPT
antimicrobial therapy,SURFACE,1,0.025,KEPT
antimongoloid,SURFACE,1,0.025,KEPT
antimongoloid deviation,SURFACE,1,0.025,KEPT
antinuclear antibody,SURFACE,1,0.025,KEPT
antiphospholipid antibodies,SURFACE,1,0.025,KEPT
antiphospholipid antibody,SURFACE,1,0.025,KEPT
antiphospholipid syndrome,SURFACE,1,0.025,KEPT
antithrombin deficiency,SURFACE,1,0.025,KEPT
antithrombin iii,SURFACE,1,0.025,KEPT
anxiety,SURFACE,1,0.025,KEPT
anyone feels,SURFACE,1,0.025,KEPT
anyone hesitant,SURFACE,1,0.025,KEPT
anything,SURFACE,1,0.025,KEPT
aorta,SURFACE,1,0.025,KEPT
aortic bicarotid bypass,SURFACE,1,0.025,KEPT
aortic pressure,SURFACE,1,0.025,KEPT
aortic root dilation,SURFACE,1,0.025,KEPT
apert,SURFACE,1,0.025,KEPT
apert syndrome,SURFACE,1,0.025,KEPT
apgar score,SURFACE,1,0.025,KEPT
apparent disease,SURFACE,1,0.025,KEPT
appetite,SURFACE,1,0.025,KEPT
appraisal,SURFACE,1,0.025,KEPT
appreciate everyone’s,SURFACE,1,0.025,KEPT
approach moving,SURFACE,1,0.025,KEPT
appropriateness,SURFACE,1,0.025,KEPT
ar gene,SURFACE,1,0.025,KEPT
ar testing,SURFACE,1,0.025,KEPT
"arch.\"",\n\n",SURFACE,1,0.025,KEPT
arched eyebrows,SURFACE,1,0.025,KEPT
architecture,SURFACE,1,0.025,KEPT
area of agreement,SURFACE,1,0.025,KEPT
areolar complex,SURFACE,1,0.025,KEPT
argue,SURFACE,1,0.025,KEPT
arm anomalies,SURFACE,1,0.025,KEPT
arm span,SURFACE,1,0.025,KEPT
arm-span,SURFACE,1,0.025,KEPT
arms,SURFACE,1,0.025,KEPT
arpkd,SURFACE,1,0.025,KEPT
arterial,SURFACE,1,0.025,KEPT
arterial blood gas analysis,SURFACE,1,0.025,KEPT
arterial disease,SURFACE,1,0.025,KEPT
arterial duct,SURFACE,1,0.025,KEPT
arterial occlusions,SURFACE,1,0.025,KEPT
arteries,SURFACE,1,0.025,KEPT
arthritis,SURFACE,1,0.025,KEPT
articulate response,SURFACE,1,0.025,KEPT
aspartate,SURFACE,1,0.025,KEPT
aspartate aminotransferase,SURFACE,1,0.025,KEPT
aspect,SURFACE,1,0.025,KEPT
aspergillosis,SURFACE,1,0.025,KEPT
aspiration,SURFACE,1,0.025,KEPT
aspiration pneumonia,SURFACE,1,0.025,KEPT
assays,SURFACE,1,0.025,KEPT
assertion,SURFACE,1,0.025,KEPT
assessing tissue transglutaminase,SURFACE,1,0.025,KEPT
assessing vascularity,SURFACE,1,0.025,KEPT
assessments**: schedule the,SURFACE,1,0.025,KEPT
assign,SURFACE,1,0.025,KEPT
assigned,SURFACE,1,0.025,KEPT
assigning,SURFACE,1,0.025,KEPT
assist,SURFACE,1,0.025,KEPT
assistant's,SURFACE,1,0.025,KEPT
associated cardiomyopathy,SURFACE,1,0.025,KEPT
associated disorders,SURFACE,1,0.025,KEPT
associated features**,SURFACE,1,0.025,KEPT
associated joint,SURFACE,1,0.025,KEPT
associated portal vein thrombosis,SURFACE,1,0.025,KEPT
associated respiratory issues,SURFACE,1,0.025,KEPT
associated uveitis,SURFACE,1,0.025,KEPT
associations,SURFACE,1,0.025,KEPT
asymmetric body features,SURFACE,1,0.025,KEPT
asymmetric facial palsies,SURFACE,1,0.025,KEPT
asymmetric nature,SURFACE,1,0.025,KEPT
asymmetrical cog-wheeling,SURFACE,1,0.025,KEPT
asymmetry,SURFACE,1,0.025,KEPT
ataxia telangiectasia,SURFACE,1,0.025,KEPT
ataxic presentation,SURFACE,1,0.025,KEPT
ataxic presentations,SURFACE,1,0.025,KEPT
ataxic symptoms,SURFACE,1,0.025,KEPT
ataxic syndromes,SURFACE,1,0.025,KEPT
atelectasis,SURFACE,1,0.025,KEPT
atorvastatin,SURFACE,1,0.025,KEPT
atresia,SURFACE,1,0.025,KEPT
atrial septal,SURFACE,1,0.025,KEPT
atrial septal defect,SURFACE,1,0.025,KEPT
atrophic,SURFACE,1,0.025,KEPT
atrophic area,SURFACE,1,0.025,KEPT
atrophic macular degeneration,SURFACE,1,0.025,KEPT
atrophic scars,SURFACE,1,0.025,KEPT
attack,SURFACE,1,0.025,KEPT
attacks,SURFACE,1,0.025,KEPT
attend school,SURFACE,1,0.025,KEPT
attended,SURFACE,1,0.025,KEPT
atypia,SURFACE,1,0.025,KEPT
atypical absence epilepsy,SURFACE,1,0.025,KEPT
atypical events,SURFACE,1,0.025,KEPT
atypical features,SURFACE,1,0.025,KEPT
atypical infections,SURFACE,1,0.025,KEPT
atypical joint,SURFACE,1,0.025,KEPT
atypical pathogens**,SURFACE,1,0.025,KEPT
atypical pathogens** - conducted in conjunction,SURFACE,1,0.025,KEPT
atypical pathogens** - since,SURFACE,1,0.025,KEPT
atypical pathogens** - to ensure,SURFACE,1,0.025,KEPT
atypical pneumonia,SURFACE,1,0.025,KEPT
atypical presentation,SURFACE,1,0.025,KEPT
atypical presentations,SURFACE,1,0.025,KEPT
atypical vessels,SURFACE,1,0.025,KEPT
atypical viral causes**,SURFACE,1,0.025,KEPT
atypical viruses,SURFACE,1,0.025,KEPT
audiological,SURFACE,1,0.025,KEPT
audiological assessment,SURFACE,1,0.025,KEPT
auditory markers,SURFACE,1,0.025,KEPT
auditory/visual symptoms,SURFACE,1,0.025,KEPT
aunt,SURFACE,1,0.025,KEPT
aura,SURFACE,1,0.025,KEPT
autism spectrum disorder,SURFACE,1,0.025,KEPT
auto-immune,SURFACE,1,0.025,KEPT
autoantibody,SURFACE,1,0.025,KEPT
autoantibody panel,SURFACE,1,0.025,KEPT
autoantibody testing,SURFACE,1,0.025,KEPT
autoantibody tests,SURFACE,1,0.025,KEPT
autofluorescence,SURFACE,1,0.025,KEPT
autoimmune background,SURFACE,1,0.025,KEPT
autoimmune causes,SURFACE,1,0.025,KEPT
autoimmune condition,SURFACE,1,0.025,KEPT
autoimmune conditions**,SURFACE,1,0.025,KEPT
autoimmune conditions** remains paramount,SURFACE,1,0.025,KEPT
autoimmune contributions,SURFACE,1,0.025,KEPT
autoimmune disease,SURFACE,1,0.025,KEPT
autoimmune diseases,SURFACE,1,0.025,KEPT
autoimmune encephalitides**,SURFACE,1,0.025,KEPT
autoimmune encephalitis,SURFACE,1,0.025,KEPT
autoimmune encephalitis workup,SURFACE,1,0.025,KEPT
autoimmune encephalitis**,SURFACE,1,0.025,KEPT
autoimmune etiologies,SURFACE,1,0.025,KEPT
autoimmune features,SURFACE,1,0.025,KEPT
autoimmune history,SURFACE,1,0.025,KEPT
autoimmune mechanisms,SURFACE,1,0.025,KEPT
autoimmune panel,SURFACE,1,0.025,KEPT
autoimmune panels,SURFACE,1,0.025,KEPT
autoimmune panels**,SURFACE,1,0.025,KEPT
autoimmune pathology,SURFACE,1,0.025,KEPT
autoimmune phenomena,SURFACE,1,0.025,KEPT
autoimmune predispositions,SURFACE,1,0.025,KEPT
autoimmune processes,SURFACE,1,0.025,KEPT
autoimmune screening tests,SURFACE,1,0.025,KEPT
autoimmune serologies,SURFACE,1,0.025,KEPT
autoimmune tendencies,SURFACE,1,0.025,KEPT
autoimmune uveitis,SURFACE,1,0.025,KEPT
autoinflammatory condition,SURFACE,1,0.025,KEPT
autoinflammatory processes,SURFACE,1,0.025,KEPT
autoinflammatory syndromes,SURFACE,1,0.025,KEPT
autoinflammatory syndromes**,SURFACE,1,0.025,KEPT
autonomic,SURFACE,1,0.025,KEPT
autonomic symptoms,SURFACE,1,0.025,KEPT
autopsy,SURFACE,1,0.025,KEPT
autopsy**,SURFACE,1,0.025,KEPT
autosomal dominant hyper-ige syndrome,SURFACE,1,0.025,KEPT
autosomal recessive polycystic kidney disease,SURFACE,1,0.025,KEPT
auxiliary ventilation,SURFACE,1,0.025,KEPT
availability,SURFACE,1,0.025,KEPT
avoidance,SURFACE,1,0.025,KEPT
await feedback,SURFACE,1,0.025,KEPT
await test,SURFACE,1,0.025,KEPT
awake,SURFACE,1,0.025,KEPT
axillary,SURFACE,1,0.025,KEPT
axillary hollowing,SURFACE,1,0.025,KEPT
azoospermia,SURFACE,1,0.025,KEPT
b cell,SURFACE,1,0.025,KEPT
b-cell deficiencies,SURFACE,1,0.025,KEPT
b-cell function,SURFACE,1,0.025,KEPT
b-cell populations,SURFACE,1,0.025,KEPT
b-cells,SURFACE,1,0.025,KEPT
b-scan,SURFACE,1,0.025,KEPT
b12,SURFACE,1,0.025,KEPT
baba,SURFACE,1,0.025,KEPT
back,SURFACE,1,0.025,KEPT
background factors,SURFACE,1,0.025,KEPT
baclofen,SURFACE,1,0.025,KEPT
bacteria/fungi,SURFACE,1,0.025,KEPT
bacterial infections,SURFACE,1,0.025,KEPT
bacterial pneumonia,SURFACE,1,0.025,KEPT
bal** -,SURFACE,1,0.025,KEPT
bal** to,SURFACE,1,0.025,KEPT
balanced approach,SURFACE,1,0.025,KEPT
balances,SURFACE,1,0.025,KEPT
balancing,SURFACE,1,0.025,KEPT
balloon angioplasty,SURFACE,1,0.025,KEPT
bardet-biedl,SURFACE,1,0.025,KEPT
bardet-biedl),SURFACE,1,0.025,KEPT
bare-metal stent,SURFACE,1,0.025,KEPT
basal ganglia,SURFACE,1,0.025,KEPT
base dimensions,SURFACE,1,0.025,KEPT
baseline imaging,SURFACE,1,0.025,KEPT
bathe,SURFACE,1,0.025,KEPT
bathroom,SURFACE,1,0.025,KEPT
bayley scales,SURFACE,1,0.025,KEPT
bbs**,SURFACE,1,0.025,KEPT
bcva,SURFACE,1,0.025,KEPT
bear,SURFACE,1,0.025,KEPT
beats,SURFACE,1,0.025,KEPT
beats/min,SURFACE,1,0.025,KEPT
beckwith-wiedemann syndrome,SURFACE,1,0.025,KEPT
bedside chest radiograph,SURFACE,1,0.025,KEPT
begin imaging,SURFACE,1,0.025,KEPT
begins,SURFACE,1,0.025,KEPT
behavioral issues,SURFACE,1,0.025,KEPT
behçet's disease**,SURFACE,1,0.025,KEPT
behçet’s,SURFACE,1,0.025,KEPT
beighton score,SURFACE,1,0.025,KEPT
benign course,SURFACE,1,0.025,KEPT
benign features,SURFACE,1,0.025,KEPT
benign growth,SURFACE,1,0.025,KEPT
best disease,SURFACE,1,0.025,KEPT
best vitelliform macular dystrophy)**,SURFACE,1,0.025,KEPT
betamethasone,SURFACE,1,0.025,KEPT
beyond,SURFACE,1,0.025,KEPT
biannual,SURFACE,1,0.025,KEPT
biannual imaging,SURFACE,1,0.025,KEPT
bicornuate,SURFACE,1,0.025,KEPT
bifid uvula,SURFACE,1,0.025,KEPT
big nostrils,SURFACE,1,0.025,KEPT
bigger,SURFACE,1,0.025,KEPT
bilateral anterior,SURFACE,1,0.025,KEPT
bilateral atrophic age-related macular degeneration,SURFACE,1,0.025,KEPT
bilateral club foot,SURFACE,1,0.025,KEPT
bilateral clubfeet,SURFACE,1,0.025,KEPT
bilateral cross bite,SURFACE,1,0.025,KEPT
bilateral eye redness,SURFACE,1,0.025,KEPT
bilateral failure,SURFACE,1,0.025,KEPT
bilateral foot inversion,SURFACE,1,0.025,KEPT
bilateral fractures,SURFACE,1,0.025,KEPT
bilateral genu valgum,SURFACE,1,0.025,KEPT
bilateral leg edema,SURFACE,1,0.025,KEPT
bilateral talipes,SURFACE,1,0.025,KEPT
bilaterality,SURFACE,1,0.025,KEPT
biochemical abnormalities,SURFACE,1,0.025,KEPT
biochemical analyses,SURFACE,1,0.025,KEPT
biochemical pathways,SURFACE,1,0.025,KEPT
biologic therapies,SURFACE,1,0.025,KEPT
biologic therapy,SURFACE,1,0.025,KEPT
biologics,SURFACE,1,0.025,KEPT
biomarkers,SURFACE,1,0.025,KEPT
biopsy considerations,SURFACE,1,0.025,KEPT
biopsy samples,SURFACE,1,0.025,KEPT
biphalangeal,SURFACE,1,0.025,KEPT
bitemporal narrowing,SURFACE,1,0.025,KEPT
biventricular,SURFACE,1,0.025,KEPT
biventricular function,SURFACE,1,0.025,KEPT
blanch,SURFACE,1,0.025,KEPT
blanching,SURFACE,1,0.025,KEPT
bleeding,SURFACE,1,0.025,KEPT
blend,SURFACE,1,0.025,KEPT
blepharoptosis,SURFACE,1,0.025,KEPT
blepharospasm,SURFACE,1,0.025,KEPT
blockage,SURFACE,1,0.025,KEPT
blood clots,SURFACE,1,0.025,KEPT
blood coagulation,SURFACE,1,0.025,KEPT
blood count,SURFACE,1,0.025,KEPT
blood counts,SURFACE,1,0.025,KEPT
blood cultures,SURFACE,1,0.025,KEPT
blood examination,SURFACE,1,0.025,KEPT
blood inflammatory,SURFACE,1,0.025,KEPT
blood loss,SURFACE,1,0.025,KEPT
blood pressure difference,SURFACE,1,0.025,KEPT
blood routine tests,SURFACE,1,0.025,KEPT
blood routines,SURFACE,1,0.025,KEPT
blood samples,SURFACE,1,0.025,KEPT
blood work,SURFACE,1,0.025,KEPT
blood-brain barrier,SURFACE,1,0.025,KEPT
bloodwork,SURFACE,1,0.025,KEPT
blurring,SURFACE,1,0.025,KEPT
blurry vision,SURFACE,1,0.025,KEPT
bmd,SURFACE,1,0.025,KEPT
bms,SURFACE,1,0.025,KEPT
bnp,SURFACE,1,0.025,KEPT
bodv-1,SURFACE,1,0.025,KEPT
bodv-1 infection,SURFACE,1,0.025,KEPT
bodv-1 rna,SURFACE,1,0.025,KEPT
bodv-1 x protein,SURFACE,1,0.025,KEPT
bodv-1-endemic region,SURFACE,1,0.025,KEPT
bodv-1-specific antibodies,SURFACE,1,0.025,KEPT
body length,SURFACE,1,0.025,KEPT
body mass index,SURFACE,1,0.025,KEPT
body parts,SURFACE,1,0.025,KEPT
body weight,SURFACE,1,0.025,KEPT
boggy swelling,SURFACE,1,0.025,KEPT
bolstered,SURFACE,1,0.025,KEPT
bolsters,SURFACE,1,0.025,KEPT
bone configuration,SURFACE,1,0.025,KEPT
bone density loss,SURFACE,1,0.025,KEPT
bone density study**,SURFACE,1,0.025,KEPT
bone marrow biopsy,SURFACE,1,0.025,KEPT
bone mineral,SURFACE,1,0.025,KEPT
bone mineral density,SURFACE,1,0.025,KEPT
bone structure,SURFACE,1,0.025,KEPT
bones,SURFACE,1,0.025,KEPT
bony abnormalities,SURFACE,1,0.025,KEPT
born full-term,SURFACE,1,0.025,KEPT
born prematurely,SURFACE,1,0.025,KEPT
born preterm,SURFACE,1,0.025,KEPT
borna disease virus,SURFACE,1,0.025,KEPT
borrelia species,SURFACE,1,0.025,KEPT
botulinum toxin injections,SURFACE,1,0.025,KEPT
bowel,SURFACE,1,0.025,KEPT
bowel habits,SURFACE,1,0.025,KEPT
bowel necrosis,SURFACE,1,0.025,KEPT
bowing,SURFACE,1,0.025,KEPT
boy,SURFACE,1,0.025,KEPT
brachial,SURFACE,1,0.025,KEPT
brachyphalangy,SURFACE,1,0.025,KEPT
bradykinesia,SURFACE,1,0.025,KEPT
braf,SURFACE,1,0.025,KEPT
brain anomalies,SURFACE,1,0.025,KEPT
brain development,SURFACE,1,0.025,KEPT
brain imaging,SURFACE,1,0.025,KEPT
brain lesions,SURFACE,1,0.025,KEPT
brain magnetic resonance imaging,SURFACE,1,0.025,KEPT
brain mri,SURFACE,1,0.025,KEPT
brain mri**,SURFACE,1,0.025,KEPT
brain parenchyma,SURFACE,1,0.025,KEPT
brain wave,SURFACE,1,0.025,KEPT
brain**: imaging,SURFACE,1,0.025,KEPT
brainstem,SURFACE,1,0.025,KEPT
brca1/brca2,SURFACE,1,0.025,KEPT
breast,SURFACE,1,0.025,KEPT
breast development,SURFACE,1,0.025,KEPT
breath,SURFACE,1,0.025,KEPT
breath sounds,SURFACE,1,0.025,KEPT
breech presentation,SURFACE,1,0.025,KEPT
brief analysis,SURFACE,1,0.025,KEPT
bright,SURFACE,1,0.025,KEPT
broad approach,SURFACE,1,0.025,KEPT
broad differential analysis,SURFACE,1,0.025,KEPT
broad mouth fold,SURFACE,1,0.025,KEPT
broad nasal base,SURFACE,1,0.025,KEPT
broad nose,SURFACE,1,0.025,KEPT
broad symptoms,SURFACE,1,0.025,KEPT
broad-based,SURFACE,1,0.025,KEPT
broad-spectrum antibiotics,SURFACE,1,0.025,KEPT
broader,SURFACE,1,0.025,KEPT
broader syndrome,SURFACE,1,0.025,KEPT
bronchiectases,SURFACE,1,0.025,KEPT
bronchiectasis,SURFACE,1,0.025,KEPT
brother,SURFACE,1,0.025,KEPT
bruising,SURFACE,1,0.025,KEPT
buffalo back,SURFACE,1,0.025,KEPT
building,SURFACE,1,0.025,KEPT
bulbar conjunctivae,SURFACE,1,0.025,KEPT
bulbous nasal tip,SURFACE,1,0.025,KEPT
bulbous tip,SURFACE,1,0.025,KEPT
bun,SURFACE,1,0.025,KEPT
burden,SURFACE,1,0.025,KEPT
c1 inhibitor,SURFACE,1,0.025,KEPT
c1-inh,SURFACE,1,0.025,KEPT
c1-inh antigen,SURFACE,1,0.025,KEPT
c1-inh levels**,SURFACE,1,0.025,KEPT
"c1-inh levels**
   - **doppler",SURFACE,1,0.025,KEPT
c4 level,SURFACE,1,0.025,KEPT
ca-125,SURFACE,1,0.025,KEPT
ca-125 post-surgery,SURFACE,1,0.025,KEPT
cachectic,SURFACE,1,0.025,KEPT
cah,SURFACE,1,0.025,KEPT
cais,SURFACE,1,0.025,KEPT
calls,SURFACE,1,0.025,KEPT
caloric tests,SURFACE,1,0.025,KEPT
calvarium,SURFACE,1,0.025,KEPT
campomelic dysplasia,SURFACE,1,0.025,KEPT
cancer,SURFACE,1,0.025,KEPT
cancer detection,SURFACE,1,0.025,KEPT
cancer history,SURFACE,1,0.025,KEPT
cancer risks,SURFACE,1,0.025,KEPT
cancers,SURFACE,1,0.025,KEPT
candidate,SURFACE,1,0.025,KEPT
canthal,SURFACE,1,0.025,KEPT
capabilities,SURFACE,1,0.025,KEPT
capturing,SURFACE,1,0.025,KEPT
capturing nuances,SURFACE,1,0.025,KEPT
carcinoembryonic antigen,SURFACE,1,0.025,KEPT
cardiac chamber,SURFACE,1,0.025,KEPT
cardiac complications,SURFACE,1,0.025,KEPT
cardiac component,SURFACE,1,0.025,KEPT
cardiac conditions,SURFACE,1,0.025,KEPT
cardiac damage,SURFACE,1,0.025,KEPT
cardiac deformities,SURFACE,1,0.025,KEPT
cardiac echocardiogram,SURFACE,1,0.025,KEPT
cardiac enzyme tests,SURFACE,1,0.025,KEPT
cardiac enzyme tests**,SURFACE,1,0.025,KEPT
cardiac enzyme tests** –,SURFACE,1,0.025,KEPT
cardiac examination,SURFACE,1,0.025,KEPT
cardiac features,SURFACE,1,0.025,KEPT
cardiac findings,SURFACE,1,0.025,KEPT
cardiac health,SURFACE,1,0.025,KEPT
cardiac interventions,SURFACE,1,0.025,KEPT
cardiac manifestations,SURFACE,1,0.025,KEPT
cardiac markers,SURFACE,1,0.025,KEPT
cardiac markers**,SURFACE,1,0.025,KEPT
cardiac monitoring,SURFACE,1,0.025,KEPT
cardiac morphology,SURFACE,1,0.025,KEPT
cardiac mri**,SURFACE,1,0.025,KEPT
cardiac needs,SURFACE,1,0.025,KEPT
cardiac pathology,SURFACE,1,0.025,KEPT
cardiac presentations,SURFACE,1,0.025,KEPT
cardiac pressures,SURFACE,1,0.025,KEPT
cardiac rhythm,SURFACE,1,0.025,KEPT
cardiac screening,SURFACE,1,0.025,KEPT
cardiac size,SURFACE,1,0.025,KEPT
cardiac structures,SURFACE,1,0.025,KEPT
cardiac ultrasound,SURFACE,1,0.025,KEPT
cardiologist,SURFACE,1,0.025,KEPT
cardiologists,SURFACE,1,0.025,KEPT
cardiomegaly,SURFACE,1,0.025,KEPT
cardiomyopathy,SURFACE,1,0.025,KEPT
cardiopulmonary symptoms,SURFACE,1,0.025,KEPT
cardiovascular abnormalities,SURFACE,1,0.025,KEPT
cardiovascular disease,SURFACE,1,0.025,KEPT
cardiovascular evaluations**,SURFACE,1,0.025,KEPT
cardiovascular events,SURFACE,1,0.025,KEPT
cardiovascular health,SURFACE,1,0.025,KEPT
cardiovascular issues,SURFACE,1,0.025,KEPT
cardiovascular profile,SURFACE,1,0.025,KEPT
cardiovascular risk assessment,SURFACE,1,0.025,KEPT
care coordination,SURFACE,1,0.025,KEPT
care coordination**,SURFACE,1,0.025,KEPT
care decisions,SURFACE,1,0.025,KEPT
care moving,SURFACE,1,0.025,KEPT
care strategy,SURFACE,1,0.025,KEPT
caries,SURFACE,1,0.025,KEPT
carina,SURFACE,1,0.025,KEPT
caring,SURFACE,1,0.025,KEPT
carotid,SURFACE,1,0.025,KEPT
carpal x-ray,SURFACE,1,0.025,KEPT
carvedilol,SURFACE,1,0.025,KEPT
case collaboratively,SURFACE,1,0.025,KEPT
case leans,SURFACE,1,0.025,KEPT
case management,SURFACE,1,0.025,KEPT
case mentions,SURFACE,1,0.025,KEPT
case moving forward,SURFACE,1,0.025,KEPT
case points,SURFACE,1,0.025,KEPT
case ready,SURFACE,1,0.025,KEPT
case rules,SURFACE,1,0.025,KEPT
case showcases,SURFACE,1,0.025,KEPT
case variations,SURFACE,1,0.025,KEPT
case**,SURFACE,1,0.025,KEPT
"case.\"",\n  \""initial test results\",SURFACE,1,0.025,KEPT
case’s journey,SURFACE,1,0.025,KEPT
caspr2,SURFACE,1,0.025,KEPT
"cataracts.\"",\n\n",SURFACE,1,0.025,KEPT
categorize,SURFACE,1,0.025,KEPT
categorize **candidate variants**,SURFACE,1,0.025,KEPT
categorized,SURFACE,1,0.025,KEPT
categorizing,SURFACE,1,0.025,KEPT
category,SURFACE,1,0.025,KEPT
catheterization,SURFACE,1,0.025,KEPT
caucasian,SURFACE,1,0.025,KEPT
causative agent,SURFACE,1,0.025,KEPT
causative factors,SURFACE,1,0.025,KEPT
cause of death,SURFACE,1,0.025,KEPT
caution,SURFACE,1,0.025,KEPT
cavitary lesions,SURFACE,1,0.025,KEPT
cavities,SURFACE,1,0.025,KEPT
cbc abnormalities,SURFACE,1,0.025,KEPT
cbc** sounds,SURFACE,1,0.025,KEPT
cbct,SURFACE,1,0.025,KEPT
cd19 cell,SURFACE,1,0.025,KEPT
cd3,SURFACE,1,0.025,KEPT
cdg,SURFACE,1,0.025,KEPT
cdls,SURFACE,1,0.025,KEPT
cea,SURFACE,1,0.025,KEPT
cect,SURFACE,1,0.025,KEPT
celiac disease,SURFACE,1,0.025,KEPT
celiac disease**,SURFACE,1,0.025,KEPT
cell,SURFACE,1,0.025,KEPT
cell count,SURFACE,1,0.025,KEPT
cell counts,SURFACE,1,0.025,KEPT
cellular composition,SURFACE,1,0.025,KEPT
cellular constituents,SURFACE,1,0.025,KEPT
cellular functions,SURFACE,1,0.025,KEPT
cellular infiltrate,SURFACE,1,0.025,KEPT
cellular models**,SURFACE,1,0.025,KEPT
cellular patterns,SURFACE,1,0.025,KEPT
cellular presentations,SURFACE,1,0.025,KEPT
cellular profile,SURFACE,1,0.025,KEPT
central areolar choroidal dystrophy)**,SURFACE,1,0.025,KEPT
central foveal thickness,SURFACE,1,0.025,KEPT
central foveal thinning,SURFACE,1,0.025,KEPT
central macula,SURFACE,1,0.025,KEPT
central nervous system activity,SURFACE,1,0.025,KEPT
central nervous system malformations,SURFACE,1,0.025,KEPT
central opening,SURFACE,1,0.025,KEPT
central scotoma,SURFACE,1,0.025,KEPT
central vision loss,SURFACE,1,0.025,KEPT
centrality,SURFACE,1,0.025,KEPT
centred midlines,SURFACE,1,0.025,KEPT
centronuclear myopathy,SURFACE,1,0.025,KEPT
cephalometry analysis,SURFACE,1,0.025,KEPT
cerebellar atrophy,SURFACE,1,0.025,KEPT
"cerebellar atrophy.\""\n",SURFACE,1,0.025,KEPT
cerebellar dysfunction,SURFACE,1,0.025,KEPT
cerebellar examination,SURFACE,1,0.025,KEPT
cerebellar hypoplasia,SURFACE,1,0.025,KEPT
cerebellar structures,SURFACE,1,0.025,KEPT
cerebellar syndrome,SURFACE,1,0.025,KEPT
cerebral vasculature,SURFACE,1,0.025,KEPT
cerebrospinal fluid,SURFACE,1,0.025,KEPT
cerebrospinal fluid analysis**,SURFACE,1,0.025,KEPT
cerebrovascular,SURFACE,1,0.025,KEPT
cerebrovascular accident,SURFACE,1,0.025,KEPT
cerebrovascular accidents,SURFACE,1,0.025,KEPT
cervical,SURFACE,1,0.025,KEPT
cervical lymph nodes,SURFACE,1,0.025,KEPT
cervical spine,SURFACE,1,0.025,KEPT
cervical spine mri,SURFACE,1,0.025,KEPT
cervical spine**,SURFACE,1,0.025,KEPT
cesarean delivery,SURFACE,1,0.025,KEPT
cessation,SURFACE,1,0.025,KEPT
cgd,SURFACE,1,0.025,KEPT
cgd-like,SURFACE,1,0.025,KEPT
"challenges
it",SURFACE,1,0.025,KEPT
characteristic hand morphology,SURFACE,1,0.025,KEPT
characteristic rash,SURFACE,1,0.025,KEPT
characterize,SURFACE,1,0.025,KEPT
check **ferritin,SURFACE,1,0.025,KEPT
check-ins,SURFACE,1,0.025,KEPT
checking,SURFACE,1,0.025,KEPT
checklists,SURFACE,1,0.025,KEPT
checks,SURFACE,1,0.025,KEPT
chest ct)**,SURFACE,1,0.025,KEPT
"chest ct)**

4",SURFACE,1,0.025,KEPT
chest high-resolution ct scan,SURFACE,1,0.025,KEPT
chest imaging,SURFACE,1,0.025,KEPT
chest movement,SURFACE,1,0.025,KEPT
chest radiographs,SURFACE,1,0.025,KEPT
chest wall deformity,SURFACE,1,0.025,KEPT
chest x-ray)**,SURFACE,1,0.025,KEPT
chest x-ray**,SURFACE,1,0.025,KEPT
chest**,SURFACE,1,0.025,KEPT
chest** – to rule,SURFACE,1,0.025,KEPT
chf,SURFACE,1,0.025,KEPT
child-specific acute presentations,SURFACE,1,0.025,KEPT
"child.\"",\n\n",SURFACE,1,0.025,KEPT
child’s,SURFACE,1,0.025,KEPT
child’s lack of,SURFACE,1,0.025,KEPT
chills,SURFACE,1,0.025,KEPT
chin,SURFACE,1,0.025,KEPT
chinese,SURFACE,1,0.025,KEPT
chinese origin,SURFACE,1,0.025,KEPT
chlamydia,SURFACE,1,0.025,KEPT
choanal atresia,SURFACE,1,0.025,KEPT
choices,SURFACE,1,0.025,KEPT
cholesterol,SURFACE,1,0.025,KEPT
cholesterol ester levels**,SURFACE,1,0.025,KEPT
cholesterol esters,SURFACE,1,0.025,KEPT
cholesterol fractions,SURFACE,1,0.025,KEPT
cholesterolosis,SURFACE,1,0.025,KEPT
choriocapillaris ischemia,SURFACE,1,0.025,KEPT
chorionic villus sampling,SURFACE,1,0.025,KEPT
choroid,SURFACE,1,0.025,KEPT
choroid thickness,SURFACE,1,0.025,KEPT
choroidal,SURFACE,1,0.025,KEPT
choroidal blood flow,SURFACE,1,0.025,KEPT
choroidal melanoma,SURFACE,1,0.025,KEPT
choroidal neovascularization,SURFACE,1,0.025,KEPT
choroidal nevus,SURFACE,1,0.025,KEPT
choroidal structure,SURFACE,1,0.025,KEPT
choroideremia,SURFACE,1,0.025,KEPT
chromosomal aberrations,SURFACE,1,0.025,KEPT
chromosomal abnormality,SURFACE,1,0.025,KEPT
chromosomal analyses,SURFACE,1,0.025,KEPT
chromosomal anomaly,SURFACE,1,0.025,KEPT
chromosomal changes,SURFACE,1,0.025,KEPT
chromosomal evaluation,SURFACE,1,0.025,KEPT
chromosomal findings,SURFACE,1,0.025,KEPT
chromosomal issues,SURFACE,1,0.025,KEPT
chromosomal microarray,SURFACE,1,0.025,KEPT
chromosomal structure,SURFACE,1,0.025,KEPT
chronic alcohol consumption,SURFACE,1,0.025,KEPT
chronic alcohol use,SURFACE,1,0.025,KEPT
chronic condition,SURFACE,1,0.025,KEPT
chronic conditions,SURFACE,1,0.025,KEPT
chronic conjunctival,SURFACE,1,0.025,KEPT
chronic elevation,SURFACE,1,0.025,KEPT
chronic embolic events,SURFACE,1,0.025,KEPT
chronic exposure,SURFACE,1,0.025,KEPT
chronic granulomatous disease,SURFACE,1,0.025,KEPT
chronic history,SURFACE,1,0.025,KEPT
chronic impact,SURFACE,1,0.025,KEPT
chronic infection,SURFACE,1,0.025,KEPT
chronic infections,SURFACE,1,0.025,KEPT
chronic inflammatory states,SURFACE,1,0.025,KEPT
chronic ischemia,SURFACE,1,0.025,KEPT
chronic issues stemming,SURFACE,1,0.025,KEPT
chronic kidney disease**,SURFACE,1,0.025,KEPT
chronic kidney issues,SURFACE,1,0.025,KEPT
chronic medical issues,SURFACE,1,0.025,KEPT
chronic obstructions,SURFACE,1,0.025,KEPT
chronic obstructive pulmonary disease,SURFACE,1,0.025,KEPT
chronic pancreatitis,SURFACE,1,0.025,KEPT
chronic renal dysfunction,SURFACE,1,0.025,KEPT
chronic renal function damage,SURFACE,1,0.025,KEPT
chronic renal issues,SURFACE,1,0.025,KEPT
chronic symptoms,SURFACE,1,0.025,KEPT
chronic thromboembolic,SURFACE,1,0.025,KEPT
chronic thromboembolic disease,SURFACE,1,0.025,KEPT
chronic thromboembolic pulmonary hypertension,SURFACE,1,0.025,KEPT
chronological age,SURFACE,1,0.025,KEPT
circulation,SURFACE,1,0.025,KEPT
circumstances,SURFACE,1,0.025,KEPT
circumstantial,SURFACE,1,0.025,KEPT
cjd,SURFACE,1,0.025,KEPT
ck-mb,SURFACE,1,0.025,KEPT
clarify,SURFACE,1,0.025,KEPT
clarithromycin,SURFACE,1,0.025,KEPT
classification criteria,SURFACE,1,0.025,KEPT
clear,SURFACE,1,0.025,KEPT
clearer pathway,SURFACE,1,0.025,KEPT
clearer time frame,SURFACE,1,0.025,KEPT
cleft palate,SURFACE,1,0.025,KEPT
clenched fists,SURFACE,1,0.025,KEPT
clinical action plan,SURFACE,1,0.025,KEPT
clinical assessment,SURFACE,1,0.025,KEPT
clinical case,SURFACE,1,0.025,KEPT
clinical characteristics,SURFACE,1,0.025,KEPT
clinical circumstances,SURFACE,1,0.025,KEPT
clinical decision-making,SURFACE,1,0.025,KEPT
clinical direction,SURFACE,1,0.025,KEPT
clinical evaluation,SURFACE,1,0.025,KEPT
clinical experience,SURFACE,1,0.025,KEPT
clinical follow-up,SURFACE,1,0.025,KEPT
clinical foundation,SURFACE,1,0.025,KEPT
clinical indications,SURFACE,1,0.025,KEPT
clinical interpretation,SURFACE,1,0.025,KEPT
clinical judgment,SURFACE,1,0.025,KEPT
clinical monitoring,SURFACE,1,0.025,KEPT
clinical needs,SURFACE,1,0.025,KEPT
clinical outcomes,SURFACE,1,0.025,KEPT
clinical parameters,SURFACE,1,0.025,KEPT
clinical picture change,SURFACE,1,0.025,KEPT
clinical progression,SURFACE,1,0.025,KEPT
clinical rationale,SURFACE,1,0.025,KEPT
clinical semiology,SURFACE,1,0.025,KEPT
clinical setting,SURFACE,1,0.025,KEPT
clinical situation,SURFACE,1,0.025,KEPT
clinical specialists,SURFACE,1,0.025,KEPT
clinical spectrum,SURFACE,1,0.025,KEPT
clinical symptoms**,SURFACE,1,0.025,KEPT
clinical tableau,SURFACE,1,0.025,KEPT
clinically evident,SURFACE,1,0.025,KEPT
clinvar,SURFACE,1,0.025,KEPT
clockwise,SURFACE,1,0.025,KEPT
clonidine,SURFACE,1,0.025,KEPT
clonidine stimulation test,SURFACE,1,0.025,KEPT
clopidogrel,SURFACE,1,0.025,KEPT
close,SURFACE,1,0.025,KEPT
closing,SURFACE,1,0.025,KEPT
closing insights,SURFACE,1,0.025,KEPT
closing remarks,SURFACE,1,0.025,KEPT
closing thoughts,SURFACE,1,0.025,KEPT
club feet,SURFACE,1,0.025,KEPT
clues,SURFACE,1,0.025,KEPT
cm/year,SURFACE,1,0.025,KEPT
cmv,SURFACE,1,0.025,KEPT
cns involvement**,SURFACE,1,0.025,KEPT
cnv,SURFACE,1,0.025,KEPT
co-existing,SURFACE,1,0.025,KEPT
co-occur,SURFACE,1,0.025,KEPT
coagulation factors,SURFACE,1,0.025,KEPT
coalescent,SURFACE,1,0.025,KEPT
coarse face,SURFACE,1,0.025,KEPT
cocaine,SURFACE,1,0.025,KEPT
cocaine abuse,SURFACE,1,0.025,KEPT
cocaine consumption,SURFACE,1,0.025,KEPT
cocaine effects,SURFACE,1,0.025,KEPT
cocaine exposure,SURFACE,1,0.025,KEPT
cocaine intoxication,SURFACE,1,0.025,KEPT
cocaine usage,SURFACE,1,0.025,KEPT
cocaine use,SURFACE,1,0.025,KEPT
cocaine's,SURFACE,1,0.025,KEPT
cochlear,SURFACE,1,0.025,KEPT
coexisting,SURFACE,1,0.025,KEPT
cognition,SURFACE,1,0.025,KEPT
cognitive aspects,SURFACE,1,0.025,KEPT
cognitive assessment score,SURFACE,1,0.025,KEPT
cognitive disorder,SURFACE,1,0.025,KEPT
cognitive dysfunction,SURFACE,1,0.025,KEPT
cognitive evaluation,SURFACE,1,0.025,KEPT
cognitive evaluation score,SURFACE,1,0.025,KEPT
cognitive functionality,SURFACE,1,0.025,KEPT
cognitive functions,SURFACE,1,0.025,KEPT
cognitive issues,SURFACE,1,0.025,KEPT
cognitive manifestations,SURFACE,1,0.025,KEPT
cognitive recovery,SURFACE,1,0.025,KEPT
cognitive state,SURFACE,1,0.025,KEPT
cognitive stimulation,SURFACE,1,0.025,KEPT
cognitive symptoms,SURFACE,1,0.025,KEPT
cognitive testing,SURFACE,1,0.025,KEPT
coherent,SURFACE,1,0.025,KEPT
cohesion,SURFACE,1,0.025,KEPT
cohesive management,SURFACE,1,0.025,KEPT
cohesive outlook,SURFACE,1,0.025,KEPT
cohesiveness,SURFACE,1,0.025,KEPT
col2a1,SURFACE,1,0.025,KEPT
col2a1 mutations,SURFACE,1,0.025,KEPT
cold,SURFACE,1,0.025,KEPT
collaborating,SURFACE,1,0.025,KEPT
collaborative analyses,SURFACE,1,0.025,KEPT
collaborative assessment,SURFACE,1,0.025,KEPT
collaborative atmosphere,SURFACE,1,0.025,KEPT
collaborative care,SURFACE,1,0.025,KEPT
collaborative conclusion,SURFACE,1,0.025,KEPT
collaborative environment,SURFACE,1,0.025,KEPT
collaborative management,SURFACE,1,0.025,KEPT
collaborative momentum,SURFACE,1,0.025,KEPT
collaborative path,SURFACE,1,0.025,KEPT
collaborative plan,SURFACE,1,0.025,KEPT
collaborative resolution,SURFACE,1,0.025,KEPT
collaborative specialist,SURFACE,1,0.025,KEPT
collateral circulation,SURFACE,1,0.025,KEPT
collateral contacts,SURFACE,1,0.025,KEPT
collateral information,SURFACE,1,0.025,KEPT
collecting samples,SURFACE,1,0.025,KEPT
collection methodology**,SURFACE,1,0.025,KEPT
collection methods,SURFACE,1,0.025,KEPT
collective analysis,SURFACE,1,0.025,KEPT
collective care,SURFACE,1,0.025,KEPT
colonoscopies,SURFACE,1,0.025,KEPT
colorectal,SURFACE,1,0.025,KEPT
colorectal adenocarcinoma,SURFACE,1,0.025,KEPT
colorectal cancer,SURFACE,1,0.025,KEPT
colorectal cancers,SURFACE,1,0.025,KEPT
colorectal malignancies,SURFACE,1,0.025,KEPT
coma,SURFACE,1,0.025,KEPT
comatose state,SURFACE,1,0.025,KEPT
comatose states,SURFACE,1,0.025,KEPT
combinations,SURFACE,1,0.025,KEPT
combined immunodeficiency,SURFACE,1,0.025,KEPT
come forth,SURFACE,1,0.025,KEPT
"commentary
i",SURFACE,1,0.025,KEPT
commitments,SURFACE,1,0.025,KEPT
common,SURFACE,1,0.025,KEPT
common variable immunodeficiency,SURFACE,1,0.025,KEPT
communal approach,SURFACE,1,0.025,KEPT
communal support system,SURFACE,1,0.025,KEPT
communicate,SURFACE,1,0.025,KEPT
communicated,SURFACE,1,0.025,KEPT
communicates,SURFACE,1,0.025,KEPT
communicating,SURFACE,1,0.025,KEPT
communications,SURFACE,1,0.025,KEPT
compare,SURFACE,1,0.025,KEPT
comparison,SURFACE,1,0.025,KEPT
compensatory,SURFACE,1,0.025,KEPT
complain,SURFACE,1,0.025,KEPT
complement levels,SURFACE,1,0.025,KEPT
complementary tests,SURFACE,1,0.025,KEPT
complementation,SURFACE,1,0.025,KEPT
complemented,SURFACE,1,0.025,KEPT
complete blood count**,SURFACE,1,0.025,KEPT
complete ocular examination** with,SURFACE,1,0.025,KEPT
completeness,SURFACE,1,0.025,KEPT
completion,SURFACE,1,0.025,KEPT
complex history,SURFACE,1,0.025,KEPT
complex syndrome,SURFACE,1,0.025,KEPT
complicating factor,SURFACE,1,0.025,KEPT
complicating factors,SURFACE,1,0.025,KEPT
compound,SURFACE,1,0.025,KEPT
compounds,SURFACE,1,0.025,KEPT
comprehension,SURFACE,1,0.025,KEPT
comprehensive **gene panel,SURFACE,1,0.025,KEPT
comprehensive analysis,SURFACE,1,0.025,KEPT
comprehensive autoantibody,SURFACE,1,0.025,KEPT
comprehensive care approach,SURFACE,1,0.025,KEPT
comprehensive care model,SURFACE,1,0.025,KEPT
comprehensive chest imaging,SURFACE,1,0.025,KEPT
comprehensive diagnosis overview,SURFACE,1,0.025,KEPT
comprehensive endocrine profile,SURFACE,1,0.025,KEPT
comprehensive lab work**,SURFACE,1,0.025,KEPT
comprehensive lifestyle history**,SURFACE,1,0.025,KEPT
comprehensive metabolic panel,SURFACE,1,0.025,KEPT
comprehensive neuropsychological testing,SURFACE,1,0.025,KEPT
comprehensive overview,SURFACE,1,0.025,KEPT
comprehensive pathway,SURFACE,1,0.025,KEPT
comprehensive renal imaging,SURFACE,1,0.025,KEPT
comprehensive review,SURFACE,1,0.025,KEPT
comprehensive skeletal survey,SURFACE,1,0.025,KEPT
comprehensive testing,SURFACE,1,0.025,KEPT
comprehensively,SURFACE,1,0.025,KEPT
comprehensiveness,SURFACE,1,0.025,KEPT
compressive lesions,SURFACE,1,0.025,KEPT
concentration,SURFACE,1,0.025,KEPT
concepts,SURFACE,1,0.025,KEPT
conceptual discrepancies,SURFACE,1,0.025,KEPT
concern,SURFACE,1,0.025,KEPT
concise case summary,SURFACE,1,0.025,KEPT
concise review,SURFACE,1,0.025,KEPT
concise summary,SURFACE,1,0.025,KEPT
concisive results,SURFACE,1,0.025,KEPT
conclude,SURFACE,1,0.025,KEPT
concluding remarks,SURFACE,1,0.025,KEPT
concluding thoughts,SURFACE,1,0.025,KEPT
conclusive agreement,SURFACE,1,0.025,KEPT
conclusive diagnosis,SURFACE,1,0.025,KEPT
conclusive refinement,SURFACE,1,0.025,KEPT
conclusive summary,SURFACE,1,0.025,KEPT
conclusive terminus,SURFACE,1,0.025,KEPT
concrete history,SURFACE,1,0.025,KEPT
concurrence,SURFACE,1,0.025,KEPT
conduct **isomerase activity assays**,SURFACE,1,0.025,KEPT
conduct mri,SURFACE,1,0.025,KEPT
conducting,SURFACE,1,0.025,KEPT
conducting **genetic testing**,SURFACE,1,0.025,KEPT
conducting lab tests,SURFACE,1,0.025,KEPT
conducting tests,SURFACE,1,0.025,KEPT
conductive,SURFACE,1,0.025,KEPT
cone,SURFACE,1,0.025,KEPT
cone beam computed tomography,SURFACE,1,0.025,KEPT
cone-rod dystrophy,SURFACE,1,0.025,KEPT
cones,SURFACE,1,0.025,KEPT
configuration,SURFACE,1,0.025,KEPT
confirmation process,SURFACE,1,0.025,KEPT
confirmed,SURFACE,1,0.025,KEPT
confirming **thanatophoric dysplasia**,SURFACE,1,0.025,KEPT
confounding factor,SURFACE,1,0.025,KEPT
congenital adrenal hyperplasia,SURFACE,1,0.025,KEPT
congenital anomaly,SURFACE,1,0.025,KEPT
congenital bone disorders,SURFACE,1,0.025,KEPT
congenital condition,SURFACE,1,0.025,KEPT
congenital conditions,SURFACE,1,0.025,KEPT
congenital defects,SURFACE,1,0.025,KEPT
congenital features,SURFACE,1,0.025,KEPT
congenital heart conditions,SURFACE,1,0.025,KEPT
congenital heart defect,SURFACE,1,0.025,KEPT
congenital heart defect syndromes,SURFACE,1,0.025,KEPT
congenital heart diseases,SURFACE,1,0.025,KEPT
congenital hip dysplasia,SURFACE,1,0.025,KEPT
congenital issues,SURFACE,1,0.025,KEPT
congenital kidney,SURFACE,1,0.025,KEPT
congenital kidney disorder,SURFACE,1,0.025,KEPT
congenital kidney disorders,SURFACE,1,0.025,KEPT
congenital limb anomalies,SURFACE,1,0.025,KEPT
congenital limb deformities**,SURFACE,1,0.025,KEPT
congenital lipodystrophy,SURFACE,1,0.025,KEPT
congenital malformation syndromes,SURFACE,1,0.025,KEPT
congenital muscular dystrophy,SURFACE,1,0.025,KEPT
congenital muscular dystrophy:**,SURFACE,1,0.025,KEPT
congenital myopathies,SURFACE,1,0.025,KEPT
congenital myopathy,SURFACE,1,0.025,KEPT
congenital myopathy**,SURFACE,1,0.025,KEPT
congenital renal,SURFACE,1,0.025,KEPT
congenital renal tubular disorder,SURFACE,1,0.025,KEPT
congenital ureteral,SURFACE,1,0.025,KEPT
congenital ureteral duplication,SURFACE,1,0.025,KEPT
congenital urinary tract obstruction,SURFACE,1,0.025,KEPT
congestion,SURFACE,1,0.025,KEPT
congestive heart failure,SURFACE,1,0.025,KEPT
conjunctiva,SURFACE,1,0.025,KEPT
conjunctival changes,SURFACE,1,0.025,KEPT
conjunctival lesions,SURFACE,1,0.025,KEPT
conjunctival melanoma,SURFACE,1,0.025,KEPT
conjunctival nevi,SURFACE,1,0.025,KEPT
conjunctival nevus,SURFACE,1,0.025,KEPT
conjunctival pallor,SURFACE,1,0.025,KEPT
conjunctival papilloma,SURFACE,1,0.025,KEPT
conjunctival papilloma)**,SURFACE,1,0.025,KEPT
conjunctivally,SURFACE,1,0.025,KEPT
conn's syndrome,SURFACE,1,0.025,KEPT
conn's syndrome)**,SURFACE,1,0.025,KEPT
connection,SURFACE,1,0.025,KEPT
connective tissue abnormalities,SURFACE,1,0.025,KEPT
connective tissue disease,SURFACE,1,0.025,KEPT
connective tissue disorders**,SURFACE,1,0.025,KEPT
connective tissues,SURFACE,1,0.025,KEPT
consanguineous background,SURFACE,1,0.025,KEPT
consanguineous context,SURFACE,1,0.025,KEPT
consanguineous marriage,SURFACE,1,0.025,KEPT
consanguineous relationships,SURFACE,1,0.025,KEPT
consanguineous unions,SURFACE,1,0.025,KEPT
consanguinity factor,SURFACE,1,0.025,KEPT
consanguinity strengthens,SURFACE,1,0.025,KEPT
conscious,SURFACE,1,0.025,KEPT
consciousness,SURFACE,1,0.025,KEPT
consensual,SURFACE,1,0.025,KEPT
consensus agrees,SURFACE,1,0.025,KEPT
consensus around **ad-hies** remains,SURFACE,1,0.025,KEPT
consensus diagnostic plan,SURFACE,1,0.025,KEPT
consensus document,SURFACE,1,0.025,KEPT
consensus identifies **lennox-gastaut syndrome,SURFACE,1,0.025,KEPT
consensus json,SURFACE,1,0.025,KEPT
consensus overview,SURFACE,1,0.025,KEPT
consensus proposal,SURFACE,1,0.025,KEPT
consensus ready,SURFACE,1,0.025,KEPT
consensus review,SURFACE,1,0.025,KEPT
consensus status,SURFACE,1,0.025,KEPT
consensus**,SURFACE,1,0.025,KEPT
consensus-determined,SURFACE,1,0.025,KEPT
consequence of,SURFACE,1,0.025,KEPT
consequences of,SURFACE,1,0.025,KEPT
"considerations
- **interdisciplinary collaboration**",SURFACE,1,0.025,KEPT
consistency,SURFACE,1,0.025,KEPT
consistent renal abnormalities,SURFACE,1,0.025,KEPT
consolidated analysis,SURFACE,1,0.025,KEPT
consolidated diagnosis state,SURFACE,1,0.025,KEPT
consolidates,SURFACE,1,0.025,KEPT
consolidating,SURFACE,1,0.025,KEPT
constant,SURFACE,1,0.025,KEPT
constant physiotherapy,SURFACE,1,0.025,KEPT
constructive engagement,SURFACE,1,0.025,KEPT
constructive summary,SURFACE,1,0.025,KEPT
"consultation.\"",\n\n",SURFACE,1,0.025,KEPT
consuming,SURFACE,1,0.025,KEPT
contact with,SURFACE,1,0.025,KEPT
contemplating,SURFACE,1,0.025,KEPT
contender,SURFACE,1,0.025,KEPT
contentions,SURFACE,1,0.025,KEPT
context of,SURFACE,1,0.025,KEPT
context**,SURFACE,1,0.025,KEPT
contextual factors,SURFACE,1,0.025,KEPT
contingent,SURFACE,1,0.025,KEPT
continued,SURFACE,1,0.025,KEPT
continuing discussions,SURFACE,1,0.025,KEPT
continuity,SURFACE,1,0.025,KEPT
continuity of care,SURFACE,1,0.025,KEPT
continuous assessments,SURFACE,1,0.025,KEPT
continuous discussion,SURFACE,1,0.025,KEPT
continuous discussion post-biopsy,SURFACE,1,0.025,KEPT
continuous follow-ups,SURFACE,1,0.025,KEPT
continuous learning,SURFACE,1,0.025,KEPT
continuous machine-like murmurs,SURFACE,1,0.025,KEPT
continuous review,SURFACE,1,0.025,KEPT
contractions,SURFACE,1,0.025,KEPT
contractures,SURFACE,1,0.025,KEPT
contrast flow,SURFACE,1,0.025,KEPT
contrast interactions,SURFACE,1,0.025,KEPT
contrast study,SURFACE,1,0.025,KEPT
contrast use,SURFACE,1,0.025,KEPT
contrast**,SURFACE,1,0.025,KEPT
contrasts,SURFACE,1,0.025,KEPT
contributions!,SURFACE,1,0.025,KEPT
controlled,SURFACE,1,0.025,KEPT
controlled hypertension,SURFACE,1,0.025,KEPT
convening,SURFACE,1,0.025,KEPT
conventional,SURFACE,1,0.025,KEPT
conventional imaging,SURFACE,1,0.025,KEPT
converge,SURFACE,1,0.025,KEPT
convergence,SURFACE,1,0.025,KEPT
cooperation,SURFACE,1,0.025,KEPT
coordinate care,SURFACE,1,0.025,KEPT
coordinating,SURFACE,1,0.025,KEPT
coordinating care,SURFACE,1,0.025,KEPT
copd,SURFACE,1,0.025,KEPT
core elements,SURFACE,1,0.025,KEPT
corneal,SURFACE,1,0.025,KEPT
corneal epithelium,SURFACE,1,0.025,KEPT
corneal opacities,SURFACE,1,0.025,KEPT
cornelia,SURFACE,1,0.025,KEPT
cornerstone,SURFACE,1,0.025,KEPT
coronary arterial,SURFACE,1,0.025,KEPT
"coronary arteries.\""\n",SURFACE,1,0.025,KEPT
coronary artery,SURFACE,1,0.025,KEPT
coronary artery disease,SURFACE,1,0.025,KEPT
coronary artery ectasia,SURFACE,1,0.025,KEPT
coronary issues,SURFACE,1,0.025,KEPT
coronary risk factors,SURFACE,1,0.025,KEPT
coronavirus,SURFACE,1,0.025,KEPT
coronavirus-2,SURFACE,1,0.025,KEPT
corrected gestational age,SURFACE,1,0.025,KEPT
corrected with,SURFACE,1,0.025,KEPT
correction,SURFACE,1,0.025,KEPT
correlational health,SURFACE,1,0.025,KEPT
corroborates,SURFACE,1,0.025,KEPT
cortical anomalies,SURFACE,1,0.025,KEPT
cortical structural abnormalities,SURFACE,1,0.025,KEPT
corticobasal,SURFACE,1,0.025,KEPT
corticobasal degeneration,SURFACE,1,0.025,KEPT
corticosteroid,SURFACE,1,0.025,KEPT
cosmetic concerns,SURFACE,1,0.025,KEPT
cough issues,SURFACE,1,0.025,KEPT
cough raise suspicion,SURFACE,1,0.025,KEPT
cough sputum,SURFACE,1,0.025,KEPT
cough suppressants,SURFACE,1,0.025,KEPT
coughing up,SURFACE,1,0.025,KEPT
counsel,SURFACE,1,0.025,KEPT
counseled,SURFACE,1,0.025,KEPT
counseling options,SURFACE,1,0.025,KEPT
counselor,SURFACE,1,0.025,KEPT
counselors,SURFACE,1,0.025,KEPT
count,SURFACE,1,0.025,KEPT
counts,SURFACE,1,0.025,KEPT
couple's,SURFACE,1,0.025,KEPT
couple's first,SURFACE,1,0.025,KEPT
coupling,SURFACE,1,0.025,KEPT
cousin,SURFACE,1,0.025,KEPT
cousins,SURFACE,1,0.025,KEPT
cover,SURFACE,1,0.025,KEPT
coverage,SURFACE,1,0.025,KEPT
covid-19 test,SURFACE,1,0.025,KEPT
cranial,SURFACE,1,0.025,KEPT
cranial areas,SURFACE,1,0.025,KEPT
cranial imaging,SURFACE,1,0.025,KEPT
cranial perimeter,SURFACE,1,0.025,KEPT
cranial suture,SURFACE,1,0.025,KEPT
craniofacial development,SURFACE,1,0.025,KEPT
craniofacial dysmorphisms,SURFACE,1,0.025,KEPT
craniofacial dysostosis syndromes,SURFACE,1,0.025,KEPT
craniofacial spectrum,SURFACE,1,0.025,KEPT
craniofacial syndromes,SURFACE,1,0.025,KEPT
craniosynostosis,SURFACE,1,0.025,KEPT
craniosynostosis genes,SURFACE,1,0.025,KEPT
craniosynostosis syndrome,SURFACE,1,0.025,KEPT
craniosynostosis-related genes,SURFACE,1,0.025,KEPT
craniosynostosis-related genes)**,SURFACE,1,0.025,KEPT
crease,SURFACE,1,0.025,KEPT
create,SURFACE,1,0.025,KEPT
creating **cellular models** derived,SURFACE,1,0.025,KEPT
creating **patient-derived cellular models**,SURFACE,1,0.025,KEPT
credibility,SURFACE,1,0.025,KEPT
creutzfeldt-jakob disease,SURFACE,1,0.025,KEPT
critical areas,SURFACE,1,0.025,KEPT
critical conditions,SURFACE,1,0.025,KEPT
critical considerations,SURFACE,1,0.025,KEPT
critical differential,SURFACE,1,0.025,KEPT
critical element,SURFACE,1,0.025,KEPT
critical elements,SURFACE,1,0.025,KEPT
critical information,SURFACE,1,0.025,KEPT
critical juncture,SURFACE,1,0.025,KEPT
critical symptoms,SURFACE,1,0.025,KEPT
critical test,SURFACE,1,0.025,KEPT
critical testing,SURFACE,1,0.025,KEPT
critical tests,SURFACE,1,0.025,KEPT
crohn's disease,SURFACE,1,0.025,KEPT
cross-sectional images,SURFACE,1,0.025,KEPT
cross-sectional imaging,SURFACE,1,0.025,KEPT
crossbite,SURFACE,1,0.025,KEPT
crossbites,SURFACE,1,0.025,KEPT
crouzon syndrome,SURFACE,1,0.025,KEPT
crouzon)**,SURFACE,1,0.025,KEPT
crp levels**,SURFACE,1,0.025,KEPT
cryptococcosis,SURFACE,1,0.025,KEPT
cryptorchidism,SURFACE,1,0.025,KEPT
crystal-induced arthropathies,SURFACE,1,0.025,KEPT
crystals,SURFACE,1,0.025,KEPT
csf analysis**,SURFACE,1,0.025,KEPT
csf**,SURFACE,1,0.025,KEPT
ct angiogram,SURFACE,1,0.025,KEPT
ct angiography**,SURFACE,1,0.025,KEPT
ct chest scan,SURFACE,1,0.025,KEPT
ct enterography)**,SURFACE,1,0.025,KEPT
ct pulmonary angiogram,SURFACE,1,0.025,KEPT
ct pulmonary angiography,SURFACE,1,0.025,KEPT
ct scan 3d urography,SURFACE,1,0.025,KEPT
ct scan)**,SURFACE,1,0.025,KEPT
"ct scan)**
- **quantiferon gold test",SURFACE,1,0.025,KEPT
ct scan**,SURFACE,1,0.025,KEPT
ct urography,SURFACE,1,0.025,KEPT
ct-guided biopsy,SURFACE,1,0.025,KEPT
cteph,SURFACE,1,0.025,KEPT
cubital deviation,SURFACE,1,0.025,KEPT
culprits,SURFACE,1,0.025,KEPT
cultural considerations,SURFACE,1,0.025,KEPT
cultural factors,SURFACE,1,0.025,KEPT
culture methods,SURFACE,1,0.025,KEPT
culture**,SURFACE,1,0.025,KEPT
cumulative,SURFACE,1,0.025,KEPT
current status,SURFACE,1,0.025,KEPT
cushing's,SURFACE,1,0.025,KEPT
cushing's syndrome,SURFACE,1,0.025,KEPT
cushing's syndrome**,SURFACE,1,0.025,KEPT
cushing’s,SURFACE,1,0.025,KEPT
cutaneous abscesses,SURFACE,1,0.025,KEPT
cutaneous syndactyly,SURFACE,1,0.025,KEPT
cutoff,SURFACE,1,0.025,KEPT
cva,SURFACE,1,0.025,KEPT
cva**,SURFACE,1,0.025,KEPT
cvid,SURFACE,1,0.025,KEPT
cvs,SURFACE,1,0.025,KEPT
cyanotic,SURFACE,1,0.025,KEPT
cyanotic progression,SURFACE,1,0.025,KEPT
cycles,SURFACE,1,0.025,KEPT
cyclic,SURFACE,1,0.025,KEPT
cyclic abdominal pain,SURFACE,1,0.025,KEPT
cyclic pain,SURFACE,1,0.025,KEPT
cyclical pain,SURFACE,1,0.025,KEPT
cyclophosphamide,SURFACE,1,0.025,KEPT
cystic dilation,SURFACE,1,0.025,KEPT
cystic enlargement**,SURFACE,1,0.025,KEPT
cystic fibrosis,SURFACE,1,0.025,KEPT
cystic formations,SURFACE,1,0.025,KEPT
cystic hygroma)**,SURFACE,1,0.025,KEPT
cystic kidney disease,SURFACE,1,0.025,KEPT
cystic kidney structures,SURFACE,1,0.025,KEPT
cystic kidneys,SURFACE,1,0.025,KEPT
cystic mass,SURFACE,1,0.025,KEPT
cystic masses,SURFACE,1,0.025,KEPT
cystic morphology,SURFACE,1,0.025,KEPT
cystic neoplasms,SURFACE,1,0.025,KEPT
cystic renal diseases,SURFACE,1,0.025,KEPT
cystic structure,SURFACE,1,0.025,KEPT
cystic structure post-surgery,SURFACE,1,0.025,KEPT
cystic teratoma,SURFACE,1,0.025,KEPT
cystic teratoma**,SURFACE,1,0.025,KEPT
cystine,SURFACE,1,0.025,KEPT
cystinosis,SURFACE,1,0.025,KEPT
cystoscopy,SURFACE,1,0.025,KEPT
cytogenetic testing,SURFACE,1,0.025,KEPT
cytotoxic agents,SURFACE,1,0.025,KEPT
d-dimer assay,SURFACE,1,0.025,KEPT
d-dimer levels,SURFACE,1,0.025,KEPT
d-dimer levels**,SURFACE,1,0.025,KEPT
d-dimer testing**,SURFACE,1,0.025,KEPT
d-dimer)**,SURFACE,1,0.025,KEPT
d-dimer)** - to assist,SURFACE,1,0.025,KEPT
d-dimer**,SURFACE,1,0.025,KEPT
da3,SURFACE,1,0.025,KEPT
danazol,SURFACE,1,0.025,KEPT
danazol therapy,SURFACE,1,0.025,KEPT
dapt,SURFACE,1,0.025,KEPT
dark-adapted (da,SURFACE,1,0.025,KEPT
data points,SURFACE,1,0.025,KEPT
dates,SURFACE,1,0.025,KEPT
datscan,SURFACE,1,0.025,KEPT
dawn,SURFACE,1,0.025,KEPT
dax1,SURFACE,1,0.025,KEPT
de-emphasizing **pediatric,SURFACE,1,0.025,KEPT
dead,SURFACE,1,0.025,KEPT
deafness,SURFACE,1,0.025,KEPT
deal,SURFACE,1,0.025,KEPT
dealing,SURFACE,1,0.025,KEPT
death,SURFACE,1,0.025,KEPT
deceased,SURFACE,1,0.025,KEPT
deceased’s,SURFACE,1,0.025,KEPT
declining,SURFACE,1,0.025,KEPT
decreased fev1/fvc,SURFACE,1,0.025,KEPT
decreasing,SURFACE,1,0.025,KEPT
deeming **neuropsychological assessments** less,SURFACE,1,0.025,KEPT
deemphasized,SURFACE,1,0.025,KEPT
deep coma,SURFACE,1,0.025,KEPT
deep inter-arytenoid groove,SURFACE,1,0.025,KEPT
deepen,SURFACE,1,0.025,KEPT
deepening,SURFACE,1,0.025,KEPT
deeply,SURFACE,1,0.025,KEPT
deficient,SURFACE,1,0.025,KEPT
define,SURFACE,1,0.025,KEPT
deformity,SURFACE,1,0.025,KEPT
degenerations,SURFACE,1,0.025,KEPT
degenerative processes,SURFACE,1,0.025,KEPT
dehydration,SURFACE,1,0.025,KEPT
"delay.\"",\n\n",SURFACE,1,0.025,KEPT
delayed,SURFACE,1,0.025,KEPT
delayed dental eruption,SURFACE,1,0.025,KEPT
delayed development,SURFACE,1,0.025,KEPT
deliberations,SURFACE,1,0.025,KEPT
dementia,SURFACE,1,0.025,KEPT
demographic details,SURFACE,1,0.025,KEPT
demographic norms,SURFACE,1,0.025,KEPT
demographics,SURFACE,1,0.025,KEPT
denies,SURFACE,1,0.025,KEPT
denser,SURFACE,1,0.025,KEPT
density loss,SURFACE,1,0.025,KEPT
dental abnormalities,SURFACE,1,0.025,KEPT
dental anatomy,SURFACE,1,0.025,KEPT
dental assessment,SURFACE,1,0.025,KEPT
dental assessments,SURFACE,1,0.025,KEPT
dental challenges,SURFACE,1,0.025,KEPT
dental ectopia,SURFACE,1,0.025,KEPT
dental evaluation,SURFACE,1,0.025,KEPT
dental evaluations,SURFACE,1,0.025,KEPT
dental features,SURFACE,1,0.025,KEPT
dental health,SURFACE,1,0.025,KEPT
dental manifestations,SURFACE,1,0.025,KEPT
dental morphology,SURFACE,1,0.025,KEPT
dental oral anomalies,SURFACE,1,0.025,KEPT
dental x-rays,SURFACE,1,0.025,KEPT
dental-related syndromes,SURFACE,1,0.025,KEPT
depending,SURFACE,1,0.025,KEPT
depicted,SURFACE,1,0.025,KEPT
deposition,SURFACE,1,0.025,KEPT
depressants,SURFACE,1,0.025,KEPT
depressed broad nasal bridge,SURFACE,1,0.025,KEPT
dermatoglyphic pattern,SURFACE,1,0.025,KEPT
des,SURFACE,1,0.025,KEPT
descent,SURFACE,1,0.025,KEPT
despite,SURFACE,1,0.025,KEPT
detail,SURFACE,1,0.025,KEPT
detailed history,SURFACE,1,0.025,KEPT
detailing,SURFACE,1,0.025,KEPT
detailing follow-up,SURFACE,1,0.025,KEPT
detectable,SURFACE,1,0.025,KEPT
detecting synovitis,SURFACE,1,0.025,KEPT
deteriorating,SURFACE,1,0.025,KEPT
develop,SURFACE,1,0.025,KEPT
developing **cellular models** to gauge,SURFACE,1,0.025,KEPT
development issues,SURFACE,1,0.025,KEPT
"development.\"",\n",SURFACE,1,0.025,KEPT
developmental abnormalities,SURFACE,1,0.025,KEPT
developmental anomalies,SURFACE,1,0.025,KEPT
developmental assessments**,SURFACE,1,0.025,KEPT
developmental conditions,SURFACE,1,0.025,KEPT
developmental disability,SURFACE,1,0.025,KEPT
developmental disability genes,SURFACE,1,0.025,KEPT
developmental evaluations,SURFACE,1,0.025,KEPT
"developmental evaluations
i",SURFACE,1,0.025,KEPT
developmental history,SURFACE,1,0.025,KEPT
developmental impairment,SURFACE,1,0.025,KEPT
developmental pediatricians,SURFACE,1,0.025,KEPT
developmental progress,SURFACE,1,0.025,KEPT
developmental quotient,SURFACE,1,0.025,KEPT
developmental specialists,SURFACE,1,0.025,KEPT
developmental stages,SURFACE,1,0.025,KEPT
developmental structures,SURFACE,1,0.025,KEPT
developmental support,SURFACE,1,0.025,KEPT
develops,SURFACE,1,0.025,KEPT
dhea,SURFACE,1,0.025,KEPT
"diagnoses
- **krabbe disease**",SURFACE,1,0.025,KEPT
"diagnoses
1. **down syndrome",SURFACE,1,0.025,KEPT
"diagnoses
1. **infectious diseases",SURFACE,1,0.025,KEPT
"diagnoses
1. **recurrent whipple's disease**",SURFACE,1,0.025,KEPT
"diagnoses
1. **tuberculosis",SURFACE,1,0.025,KEPT
diagnoses**,SURFACE,1,0.025,KEPT
"diagnosis
**acrofacial dysostosis",SURFACE,1,0.025,KEPT
"diagnosis
**bardet-biedl syndrome",SURFACE,1,0.025,KEPT
"diagnosis
**cholesterolosis",SURFACE,1,0.025,KEPT
"diagnosis
**cholesterolosis**",SURFACE,1,0.025,KEPT
"diagnosis
1. **differentiation",SURFACE,1,0.025,KEPT
"diagnosis
1. **most likely diagnosis**",SURFACE,1,0.025,KEPT
"diagnosis
absolutely",SURFACE,1,0.025,KEPT
"diagnosis
i align",SURFACE,1,0.025,KEPT
"diagnosis
if",SURFACE,1,0.025,KEPT
diagnosis analysis,SURFACE,1,0.025,KEPT
diagnosis process,SURFACE,1,0.025,KEPT
diagnosis summary,SURFACE,1,0.025,KEPT
diagnosis**,SURFACE,1,0.025,KEPT
diagnosis** is **,SURFACE,1,0.025,KEPT
diagnosis** of **,SURFACE,1,0.025,KEPT
diagnosis** of **choroidal melanoma**,SURFACE,1,0.025,KEPT
diagnosis** of **choroidal melanoma**.,SURFACE,1,0.025,KEPT
diagnosis** remains **,SURFACE,1,0.025,KEPT
diagnosis**.,SURFACE,1,0.025,KEPT
"diagnosis.\"",\n\n",SURFACE,1,0.025,KEPT
diagnostic approaches,SURFACE,1,0.025,KEPT
diagnostic atmosphere,SURFACE,1,0.025,KEPT
diagnostic capability,SURFACE,1,0.025,KEPT
diagnostic choices,SURFACE,1,0.025,KEPT
diagnostic clarification,SURFACE,1,0.025,KEPT
diagnostic clarity,SURFACE,1,0.025,KEPT
diagnostic components,SURFACE,1,0.025,KEPT
diagnostic concerns,SURFACE,1,0.025,KEPT
diagnostic conclusions,SURFACE,1,0.025,KEPT
diagnostic consensus,SURFACE,1,0.025,KEPT
diagnostic consideration,SURFACE,1,0.025,KEPT
diagnostic considerations**,SURFACE,1,0.025,KEPT
diagnostic discussion strengthens,SURFACE,1,0.025,KEPT
diagnostic discussions,SURFACE,1,0.025,KEPT
diagnostic hypothesis,SURFACE,1,0.025,KEPT
diagnostic impression,SURFACE,1,0.025,KEPT
diagnostic insights,SURFACE,1,0.025,KEPT
diagnostic intentions,SURFACE,1,0.025,KEPT
diagnostic journey ahead,SURFACE,1,0.025,KEPT
diagnostic label,SURFACE,1,0.025,KEPT
diagnostic mind,SURFACE,1,0.025,KEPT
diagnostic path forward,SURFACE,1,0.025,KEPT
diagnostic pathways,SURFACE,1,0.025,KEPT
diagnostic perspective,SURFACE,1,0.025,KEPT
diagnostic picture,SURFACE,1,0.025,KEPT
diagnostic procedures,SURFACE,1,0.025,KEPT
diagnostic purposes,SURFACE,1,0.025,KEPT
diagnostic reasoning,SURFACE,1,0.025,KEPT
diagnostic rigor,SURFACE,1,0.025,KEPT
diagnostic route,SURFACE,1,0.025,KEPT
diagnostic status,SURFACE,1,0.025,KEPT
diagnostic strategies,SURFACE,1,0.025,KEPT
diagnostic strategy**,SURFACE,1,0.025,KEPT
diagnostic testing plan**,SURFACE,1,0.025,KEPT
"diagnostic tests
1. **biopsy",SURFACE,1,0.025,KEPT
"diagnostic tests
1. **chest x-ray",SURFACE,1,0.025,KEPT
"diagnostic tests
1. **genetic testing**",SURFACE,1,0.025,KEPT
"diagnostic tests
1. **imaging studies",SURFACE,1,0.025,KEPT
"diagnostic tests
1. **repeat endoscopy",SURFACE,1,0.025,KEPT
diagnostic tests review,SURFACE,1,0.025,KEPT
diagnostic tool,SURFACE,1,0.025,KEPT
diagnostic work-up,SURFACE,1,0.025,KEPT
dialog,SURFACE,1,0.025,KEPT
dialogues,SURFACE,1,0.025,KEPT
diameter,SURFACE,1,0.025,KEPT
diastolic blood,SURFACE,1,0.025,KEPT
diastrophic dysplasia,SURFACE,1,0.025,KEPT
diet,SURFACE,1,0.025,KEPT
dietary deficiencies,SURFACE,1,0.025,KEPT
dieticians,SURFACE,1,0.025,KEPT
differential analysis,SURFACE,1,0.025,KEPT
differential blood pressures,SURFACE,1,0.025,KEPT
differential diagnoses**,SURFACE,1,0.025,KEPT
differential diagnoses:**,SURFACE,1,0.025,KEPT
"differential diagnosis
- **pediatric sle**",SURFACE,1,0.025,KEPT
"differential diagnosis
i",SURFACE,1,0.025,KEPT
"differential diagnosis
i support",SURFACE,1,0.025,KEPT
differential diagnosis**,SURFACE,1,0.025,KEPT
differential exploration,SURFACE,1,0.025,KEPT
differential function,SURFACE,1,0.025,KEPT
differential lists,SURFACE,1,0.025,KEPT
differential thought processes,SURFACE,1,0.025,KEPT
differentiate,SURFACE,1,0.025,KEPT
differentiations,SURFACE,1,0.025,KEPT
differs,SURFACE,1,0.025,KEPT
difficult,SURFACE,1,0.025,KEPT
difficulties,SURFACE,1,0.025,KEPT
difficulty,SURFACE,1,0.025,KEPT
difficulty breathing,SURFACE,1,0.025,KEPT
difficulty breathing/swallowing,SURFACE,1,0.025,KEPT
diffuse,SURFACE,1,0.025,KEPT
diffuse cerebral dysfunction,SURFACE,1,0.025,KEPT
diffuse infiltrates,SURFACE,1,0.025,KEPT
diffusion tensor imaging,SURFACE,1,0.025,KEPT
diffusion-weighted,SURFACE,1,0.025,KEPT
diffusion-weighted imaging,SURFACE,1,0.025,KEPT
digeorge syndrome)**,SURFACE,1,0.025,KEPT
digestible,SURFACE,1,0.025,KEPT
digital volume tomography,SURFACE,1,0.025,KEPT
dilated,SURFACE,1,0.025,KEPT
dilation,SURFACE,1,0.025,KEPT
diligent,SURFACE,1,0.025,KEPT
diligent efforts,SURFACE,1,0.025,KEPT
diminish,SURFACE,1,0.025,KEPT
diminishes,SURFACE,1,0.025,KEPT
directing,SURFACE,1,0.025,KEPT
directions,SURFACE,1,0.025,KEPT
directives,SURFACE,1,0.025,KEPT
directs,SURFACE,1,0.025,KEPT
disabilities,SURFACE,1,0.025,KEPT
disappearance,SURFACE,1,0.025,KEPT
disappeared,SURFACE,1,0.025,KEPT
discerned,SURFACE,1,0.025,KEPT
"discharge.\"",\n\n",SURFACE,1,0.025,KEPT
discomfort,SURFACE,1,0.025,KEPT
discourse,SURFACE,1,0.025,KEPT
discover,SURFACE,1,0.025,KEPT
discovery,SURFACE,1,0.025,KEPT
discussing metabolic,SURFACE,1,0.025,KEPT
disease activity,SURFACE,1,0.025,KEPT
disease history,SURFACE,1,0.025,KEPT
disease management,SURFACE,1,0.025,KEPT
disease mechanisms,SURFACE,1,0.025,KEPT
disease process,SURFACE,1,0.025,KEPT
disease progression,SURFACE,1,0.025,KEPT
disease state,SURFACE,1,0.025,KEPT
"diseases.\"",\n",SURFACE,1,0.025,KEPT
"diseases.\"",\n\n",SURFACE,1,0.025,KEPT
disparities,SURFACE,1,0.025,KEPT
disposal,SURFACE,1,0.025,KEPT
disproportional size,SURFACE,1,0.025,KEPT
disproportionate growth,SURFACE,1,0.025,KEPT
disrupted,SURFACE,1,0.025,KEPT
disruption,SURFACE,1,0.025,KEPT
dissemination,SURFACE,1,0.025,KEPT
dissociation,SURFACE,1,0.025,KEPT
distal obstruction,SURFACE,1,0.025,KEPT
distant,SURFACE,1,0.025,KEPT
distant sites,SURFACE,1,0.025,KEPT
distinct,SURFACE,1,0.025,KEPT
distinctive,SURFACE,1,0.025,KEPT
distinctive craniofacial anomalies,SURFACE,1,0.025,KEPT
distinguishing,SURFACE,1,0.025,KEPT
distort,SURFACE,1,0.025,KEPT
distortion,SURFACE,1,0.025,KEPT
district,SURFACE,1,0.025,KEPT
district's,SURFACE,1,0.025,KEPT
disturbance,SURFACE,1,0.025,KEPT
divergence,SURFACE,1,0.025,KEPT
diversifying,SURFACE,1,0.025,KEPT
diving,SURFACE,1,0.025,KEPT
dna,SURFACE,1,0.025,KEPT
dna methylation studies,SURFACE,1,0.025,KEPT
doctor0's analysis,SURFACE,1,0.025,KEPT
doctor1's analysis,SURFACE,1,0.025,KEPT
doctor2's,SURFACE,1,0.025,KEPT
doctor2's rationale,SURFACE,1,0.025,KEPT
doctor2's thoughts,SURFACE,1,0.025,KEPT
doctor2’s,SURFACE,1,0.025,KEPT
doctors0's,SURFACE,1,0.025,KEPT
documenting,SURFACE,1,0.025,KEPT
dog,SURFACE,1,0.025,KEPT
dominant,SURFACE,1,0.025,KEPT
dopamine transporter,SURFACE,1,0.025,KEPT
dopamine transporter scan)**,SURFACE,1,0.025,KEPT
dopaminergic,SURFACE,1,0.025,KEPT
doppler ultrasound,SURFACE,1,0.025,KEPT
dorsal side,SURFACE,1,0.025,KEPT
dorsiflexed,SURFACE,1,0.025,KEPT
dorsum,SURFACE,1,0.025,KEPT
double-check,SURFACE,1,0.025,KEPT
down syndrome)**,SURFACE,1,0.025,KEPT
down syndrome)** - while,SURFACE,1,0.025,KEPT
downturned corners,SURFACE,1,0.025,KEPT
draft,SURFACE,1,0.025,KEPT
drainage,SURFACE,1,0.025,KEPT
dravet,SURFACE,1,0.025,KEPT
dravet syndrome,SURFACE,1,0.025,KEPT
draw correlations,SURFACE,1,0.025,KEPT
dressing,SURFACE,1,0.025,KEPT
drop,SURFACE,1,0.025,KEPT
dropping,SURFACE,1,0.025,KEPT
drops,SURFACE,1,0.025,KEPT
drospirenone,SURFACE,1,0.025,KEPT
drowsy states,SURFACE,1,0.025,KEPT
drug activity,SURFACE,1,0.025,KEPT
drug dealing district,SURFACE,1,0.025,KEPT
drug metabolism,SURFACE,1,0.025,KEPT
drug panel,SURFACE,1,0.025,KEPT
drug therapies,SURFACE,1,0.025,KEPT
drug usage,SURFACE,1,0.025,KEPT
drug use,SURFACE,1,0.025,KEPT
drug users,SURFACE,1,0.025,KEPT
drug-eluting stent,SURFACE,1,0.025,KEPT
drug-induced,SURFACE,1,0.025,KEPT
drug-induced lung disease,SURFACE,1,0.025,KEPT
drug-use context,SURFACE,1,0.025,KEPT
dry cough,SURFACE,1,0.025,KEPT
dsd-related genes,SURFACE,1,0.025,KEPT
dsds,SURFACE,1,0.025,KEPT
dual antiplatelet therapy,SURFACE,1,0.025,KEPT
dual focus,SURFACE,1,0.025,KEPT
duly,SURFACE,1,0.025,KEPT
duodenal lesions,SURFACE,1,0.025,KEPT
duodenal portion,SURFACE,1,0.025,KEPT
duodenum,SURFACE,1,0.025,KEPT
duplication,SURFACE,1,0.025,KEPT
dwarfism,SURFACE,1,0.025,KEPT
dxa,SURFACE,1,0.025,KEPT
dxa scan,SURFACE,1,0.025,KEPT
dynamic examinations,SURFACE,1,0.025,KEPT
dynamic strategy,SURFACE,1,0.025,KEPT
dyschondrosteosis,SURFACE,1,0.025,KEPT
dysdiadochokinesia,SURFACE,1,0.025,KEPT
dysembryogenesis,SURFACE,1,0.025,KEPT
dysfunction,SURFACE,1,0.025,KEPT
dyslipidemia's,SURFACE,1,0.025,KEPT
dyslipidemia**,SURFACE,1,0.025,KEPT
dyslipidemia-induced coronary artery disease,SURFACE,1,0.025,KEPT
dyslipidemia-related,SURFACE,1,0.025,KEPT
dyslipidemia-related concerns,SURFACE,1,0.025,KEPT
dysmetria,SURFACE,1,0.025,KEPT
dysmorhpic,SURFACE,1,0.025,KEPT
dysmorphic facial features,SURFACE,1,0.025,KEPT
dysmorphisms,SURFACE,1,0.025,KEPT
dysplasias,SURFACE,1,0.025,KEPT
dysplastic,SURFACE,1,0.025,KEPT
dysplastic changes,SURFACE,1,0.025,KEPT
dysplastic multicystic right kidney,SURFACE,1,0.025,KEPT
dyspnea,SURFACE,1,0.025,KEPT
dysregulation,SURFACE,1,0.025,KEPT
dystonia,SURFACE,1,0.025,KEPT
dystrophic condition,SURFACE,1,0.025,KEPT
dystrophic process,SURFACE,1,0.025,KEPT
dystrophies,SURFACE,1,0.025,KEPT
eagerly,SURFACE,1,0.025,KEPT
early age,SURFACE,1,0.025,KEPT
early childhood,SURFACE,1,0.025,KEPT
early diagnosis,SURFACE,1,0.025,KEPT
early hours,SURFACE,1,0.025,KEPT
early infancy,SURFACE,1,0.025,KEPT
early interventions,SURFACE,1,0.025,KEPT
early referral,SURFACE,1,0.025,KEPT
early stages,SURFACE,1,0.025,KEPT
early testing,SURFACE,1,0.025,KEPT
early-stage,SURFACE,1,0.025,KEPT
eat,SURFACE,1,0.025,KEPT
ebv,SURFACE,1,0.025,KEPT
ecg,SURFACE,1,0.025,KEPT
echo your,SURFACE,1,0.025,KEPT
echo your thoughts,SURFACE,1,0.025,KEPT
echocardiogram alongside,SURFACE,1,0.025,KEPT
echocardiogram considerations,SURFACE,1,0.025,KEPT
echocardiogram follow-up,SURFACE,1,0.025,KEPT
echogenicity,SURFACE,1,0.025,KEPT
ectasia,SURFACE,1,0.025,KEPT
ectodermal features,SURFACE,1,0.025,KEPT
ectopic ureter,SURFACE,1,0.025,KEPT
edema attack,SURFACE,1,0.025,KEPT
edi-oct,SURFACE,1,0.025,KEPT
eds,SURFACE,1,0.025,KEPT
education**,SURFACE,1,0.025,KEPT
educational initiatives,SURFACE,1,0.025,KEPT
educational sessions,SURFACE,1,0.025,KEPT
educational support,SURFACE,1,0.025,KEPT
educational support sessions,SURFACE,1,0.025,KEPT
edwards syndrome,SURFACE,1,0.025,KEPT
edwards syndrome)**,SURFACE,1,0.025,KEPT
edwards syndrome)**.,SURFACE,1,0.025,KEPT
effect,SURFACE,1,0.025,KEPT
efficacy,SURFACE,1,0.025,KEPT
efficiently,SURFACE,1,0.025,KEPT
effusion,SURFACE,1,0.025,KEPT
egfr mutation,SURFACE,1,0.025,KEPT
ehlers-danlos,SURFACE,1,0.025,KEPT
elaborations,SURFACE,1,0.025,KEPT
elbow joint,SURFACE,1,0.025,KEPT
elbows,SURFACE,1,0.025,KEPT
elder brother,SURFACE,1,0.025,KEPT
elderly,SURFACE,1,0.025,KEPT
electrocardiogram,SURFACE,1,0.025,KEPT
electrocardiography,SURFACE,1,0.025,KEPT
electrodes,SURFACE,1,0.025,KEPT
electroencephalogram,SURFACE,1,0.025,KEPT
electroencephalography,SURFACE,1,0.025,KEPT
electrolyte panel,SURFACE,1,0.025,KEPT
electrolyte panel**,SURFACE,1,0.025,KEPT
electrolyte testing**,SURFACE,1,0.025,KEPT
electroretinogram,SURFACE,1,0.025,KEPT
electroretinography,SURFACE,1,0.025,KEPT
element,SURFACE,1,0.025,KEPT
elevated c-reactive protein,SURFACE,1,0.025,KEPT
elevations,SURFACE,1,0.025,KEPT
eliminating,SURFACE,1,0.025,KEPT
elisa,SURFACE,1,0.025,KEPT
ellipsoid zone,SURFACE,1,0.025,KEPT
elm,SURFACE,1,0.025,KEPT
else,SURFACE,1,0.025,KEPT
elucidation,SURFACE,1,0.025,KEPT
embarking,SURFACE,1,0.025,KEPT
embolic,SURFACE,1,0.025,KEPT
embryologic,SURFACE,1,0.025,KEPT
embryologic errors,SURFACE,1,0.025,KEPT
embryonic development,SURFACE,1,0.025,KEPT
emerges,SURFACE,1,0.025,KEPT
emerging thoughts,SURFACE,1,0.025,KEPT
emotional deficiency syndrome,SURFACE,1,0.025,KEPT
emotional development,SURFACE,1,0.025,KEPT
emotional examination,SURFACE,1,0.025,KEPT
emotional journey,SURFACE,1,0.025,KEPT
emotional support,SURFACE,1,0.025,KEPT
emotional weight,SURFACE,1,0.025,KEPT
emphasize analysis for **candidate variants**,SURFACE,1,0.025,KEPT
emphasizing,SURFACE,1,0.025,KEPT
employ,SURFACE,1,0.025,KEPT
empowered,SURFACE,1,0.025,KEPT
ena,SURFACE,1,0.025,KEPT
enamel hypoplasia,SURFACE,1,0.025,KEPT
encephalitic changes,SURFACE,1,0.025,KEPT
encephalitic processes,SURFACE,1,0.025,KEPT
encephalitis,SURFACE,1,0.025,KEPT
encephalitis**,SURFACE,1,0.025,KEPT
encephalitis-related patterns,SURFACE,1,0.025,KEPT
encourage,SURFACE,1,0.025,KEPT
end of life,SURFACE,1,0.025,KEPT
endemic context,SURFACE,1,0.025,KEPT
endemic region,SURFACE,1,0.025,KEPT
endemic regions,SURFACE,1,0.025,KEPT
endocarditis,SURFACE,1,0.025,KEPT
endochondromas,SURFACE,1,0.025,KEPT
endocrine consult,SURFACE,1,0.025,KEPT
endocrine contributions,SURFACE,1,0.025,KEPT
endocrine disorders,SURFACE,1,0.025,KEPT
endocrine dysfunction,SURFACE,1,0.025,KEPT
endocrine dysfunctions,SURFACE,1,0.025,KEPT
endocrine evaluations,SURFACE,1,0.025,KEPT
endocrine functions,SURFACE,1,0.025,KEPT
endocrine issues,SURFACE,1,0.025,KEPT
endocrine tumor,SURFACE,1,0.025,KEPT
endocrine tumor syndromes,SURFACE,1,0.025,KEPT
endocrine tumors,SURFACE,1,0.025,KEPT
endocrinological aspects,SURFACE,1,0.025,KEPT
endocrinologist,SURFACE,1,0.025,KEPT
endocrinologists,SURFACE,1,0.025,KEPT
endocrinology reviews,SURFACE,1,0.025,KEPT
endocrinology specialists,SURFACE,1,0.025,KEPT
endometriosis,SURFACE,1,0.025,KEPT
endorsed,SURFACE,1,0.025,KEPT
endoscopic,SURFACE,1,0.025,KEPT
endoscopic examination,SURFACE,1,0.025,KEPT
endoscopically,SURFACE,1,0.025,KEPT
endoscopically identified,SURFACE,1,0.025,KEPT
endoscopy,SURFACE,1,0.025,KEPT
endothelial dysfunction,SURFACE,1,0.025,KEPT
endotracheal intubation,SURFACE,1,0.025,KEPT
enhancements,SURFACE,1,0.025,KEPT
enhancing,SURFACE,1,0.025,KEPT
enlarged lymph nodes**,SURFACE,1,0.025,KEPT
enlarged ureter**,SURFACE,1,0.025,KEPT
ensuring,SURFACE,1,0.025,KEPT
enterovirus,SURFACE,1,0.025,KEPT
entity,SURFACE,1,0.025,KEPT
enumerate,SURFACE,1,0.025,KEPT
environment**,SURFACE,1,0.025,KEPT
environmental concerns,SURFACE,1,0.025,KEPT
environmental conditions,SURFACE,1,0.025,KEPT
environmental context,SURFACE,1,0.025,KEPT
environmental elements,SURFACE,1,0.025,KEPT
environmental interactions**,SURFACE,1,0.025,KEPT
environmental temperature,SURFACE,1,0.025,KEPT
environments,SURFACE,1,0.025,KEPT
enzymatic,SURFACE,1,0.025,KEPT
enzymatic function,SURFACE,1,0.025,KEPT
enzyme,SURFACE,1,0.025,KEPT
enzyme activity,SURFACE,1,0.025,KEPT
enzyme activity testing,SURFACE,1,0.025,KEPT
enzyme activity testing**,SURFACE,1,0.025,KEPT
enzyme activity tests,SURFACE,1,0.025,KEPT
enzyme assays,SURFACE,1,0.025,KEPT
enzyme deficiency,SURFACE,1,0.025,KEPT
enzyme function,SURFACE,1,0.025,KEPT
enzymes,SURFACE,1,0.025,KEPT
eosinophil,SURFACE,1,0.025,KEPT
eosinophilic,SURFACE,1,0.025,KEPT
eosinophilic pneumonia,SURFACE,1,0.025,KEPT
eosinophils,SURFACE,1,0.025,KEPT
epicanthic,SURFACE,1,0.025,KEPT
epiglottis,SURFACE,1,0.025,KEPT
epilepsy syndromes,SURFACE,1,0.025,KEPT
epilepsy syndromes**,SURFACE,1,0.025,KEPT
epileptic,SURFACE,1,0.025,KEPT
epileptic activity,SURFACE,1,0.025,KEPT
epileptic encephalopathy,SURFACE,1,0.025,KEPT
epileptic encephalopathy**,SURFACE,1,0.025,KEPT
epileptic seizures,SURFACE,1,0.025,KEPT
epileptic spasms,SURFACE,1,0.025,KEPT
epiphyses,SURFACE,1,0.025,KEPT
episodic,SURFACE,1,0.025,KEPT
episodic oxygen desaturation,SURFACE,1,0.025,KEPT
episodic postural,SURFACE,1,0.025,KEPT
"erectile dysfunction.\"",\n  \""physical",SURFACE,1,0.025,KEPT
erg,SURFACE,1,0.025,KEPT
eruption,SURFACE,1,0.025,KEPT
"erythema.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
essence,SURFACE,1,0.025,KEPT
essential factor,SURFACE,1,0.025,KEPT
establishing **specialist referrals**,SURFACE,1,0.025,KEPT
establishing intervals,SURFACE,1,0.025,KEPT
establishment,SURFACE,1,0.025,KEPT
"esters.\"",\n\n",SURFACE,1,0.025,KEPT
estimated,SURFACE,1,0.025,KEPT
estrogen,SURFACE,1,0.025,KEPT
estrogen exposure,SURFACE,1,0.025,KEPT
ethinylestradiol,SURFACE,1,0.025,KEPT
ethnic groups,SURFACE,1,0.025,KEPT
etiology**,SURFACE,1,0.025,KEPT
euthyroid,SURFACE,1,0.025,KEPT
evaluate **ferritin,SURFACE,1,0.025,KEPT
evaluates,SURFACE,1,0.025,KEPT
"evaluation
i",SURFACE,1,0.025,KEPT
evaluation method,SURFACE,1,0.025,KEPT
evaluation methods,SURFACE,1,0.025,KEPT
evaluation techniques,SURFACE,1,0.025,KEPT
evaluation**,SURFACE,1,0.025,KEPT
everyone concurs,SURFACE,1,0.025,KEPT
everyone else,SURFACE,1,0.025,KEPT
everyone!,SURFACE,1,0.025,KEPT
evidence-based,SURFACE,1,0.025,KEPT
"evident.\"",\n\n",SURFACE,1,0.025,KEPT
evocative,SURFACE,1,0.025,KEPT
evoked response,SURFACE,1,0.025,KEPT
evolution,SURFACE,1,0.025,KEPT
exacerbating gout,SURFACE,1,0.025,KEPT
exacerbations,SURFACE,1,0.025,KEPT
exam,SURFACE,1,0.025,KEPT
examination**,SURFACE,1,0.025,KEPT
examinations,SURFACE,1,0.025,KEPT
examples,SURFACE,1,0.025,KEPT
exceptions,SURFACE,1,0.025,KEPT
excised biopsy**,SURFACE,1,0.025,KEPT
excisional biopsy,SURFACE,1,0.025,KEPT
excited,SURFACE,1,0.025,KEPT
excluded,SURFACE,1,0.025,KEPT
excretory function,SURFACE,1,0.025,KEPT
execute,SURFACE,1,0.025,KEPT
execute family engagement**,SURFACE,1,0.025,KEPT
execute the **quantiferon gold test** and **pcr tests**,SURFACE,1,0.025,KEPT
execution,SURFACE,1,0.025,KEPT
executive dysfunction,SURFACE,1,0.025,KEPT
"executive dysfunction.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
executive function,SURFACE,1,0.025,KEPT
executive medical assessment,SURFACE,1,0.025,KEPT
exit,SURFACE,1,0.025,KEPT
exome libraries,SURFACE,1,0.025,KEPT
exome sequencing,SURFACE,1,0.025,KEPT
exon,SURFACE,1,0.025,KEPT
expanded,SURFACE,1,0.025,KEPT
expanded genomic sequencing,SURFACE,1,0.025,KEPT
expanded imaging,SURFACE,1,0.025,KEPT
expanding,SURFACE,1,0.025,KEPT
expansions,SURFACE,1,0.025,KEPT
expectantly,SURFACE,1,0.025,KEPT
expediting,SURFACE,1,0.025,KEPT
experience,SURFACE,1,0.025,KEPT
explanation,SURFACE,1,0.025,KEPT
exposures,SURFACE,1,0.025,KEPT
expressed,SURFACE,1,0.025,KEPT
expressing,SURFACE,1,0.025,KEPT
expressivity,SURFACE,1,0.025,KEPT
extended video eeg,SURFACE,1,0.025,KEPT
extends,SURFACE,1,0.025,KEPT
extensively monitoring,SURFACE,1,0.025,KEPT
external,SURFACE,1,0.025,KEPT
external factors,SURFACE,1,0.025,KEPT
external features,SURFACE,1,0.025,KEPT
external injuries,SURFACE,1,0.025,KEPT
external limiting membrane,SURFACE,1,0.025,KEPT
extrabulbar,SURFACE,1,0.025,KEPT
extranodal cases,SURFACE,1,0.025,KEPT
extranodal lymphoma,SURFACE,1,0.025,KEPT
extranodal process,SURFACE,1,0.025,KEPT
extraocular muscle,SURFACE,1,0.025,KEPT
extrapyramidal examination,SURFACE,1,0.025,KEPT
extrapyramidal symptoms,SURFACE,1,0.025,KEPT
exudative,SURFACE,1,0.025,KEPT
eye assessment,SURFACE,1,0.025,KEPT
eye discharge,SURFACE,1,0.025,KEPT
eye disease,SURFACE,1,0.025,KEPT
eye drops,SURFACE,1,0.025,KEPT
eye findings,SURFACE,1,0.025,KEPT
eye inflammation,SURFACE,1,0.025,KEPT
eye issues,SURFACE,1,0.025,KEPT
eye movement,SURFACE,1,0.025,KEPT
eye movement disorders,SURFACE,1,0.025,KEPT
eye tumor,SURFACE,1,0.025,KEPT
eye**,SURFACE,1,0.025,KEPT
eyebrows,SURFACE,1,0.025,KEPT
eyelids,SURFACE,1,0.025,KEPT
fabrication,SURFACE,1,0.025,KEPT
facial abnormalities,SURFACE,1,0.025,KEPT
facial anomalies,SURFACE,1,0.025,KEPT
facial asymmetries,SURFACE,1,0.025,KEPT
facial component,SURFACE,1,0.025,KEPT
facial dysmorphic,SURFACE,1,0.025,KEPT
facial dysmorphologies,SURFACE,1,0.025,KEPT
facial examination,SURFACE,1,0.025,KEPT
facial findings,SURFACE,1,0.025,KEPT
facial flushing,SURFACE,1,0.025,KEPT
facial grimacing,SURFACE,1,0.025,KEPT
facial implications,SURFACE,1,0.025,KEPT
facial muscle,SURFACE,1,0.025,KEPT
facial nerve,SURFACE,1,0.025,KEPT
facial nerves,SURFACE,1,0.025,KEPT
facial palsies,SURFACE,1,0.025,KEPT
facial palsy,SURFACE,1,0.025,KEPT
facial paralysis,SURFACE,1,0.025,KEPT
facial paresis,SURFACE,1,0.025,KEPT
facial presentation,SURFACE,1,0.025,KEPT
facial reanimation,SURFACE,1,0.025,KEPT
facial structure,SURFACE,1,0.025,KEPT
factor v,SURFACE,1,0.025,KEPT
"factors.\""\n",SURFACE,1,0.025,KEPT
faecal calprotectin,SURFACE,1,0.025,KEPT
faf,SURFACE,1,0.025,KEPT
fail,SURFACE,1,0.025,KEPT
failed,SURFACE,1,0.025,KEPT
fall,SURFACE,1,0.025,KEPT
fallopian tubes,SURFACE,1,0.025,KEPT
false reassurance,SURFACE,1,0.025,KEPT
familial adenomatous polyposis,SURFACE,1,0.025,KEPT
familial cancer,SURFACE,1,0.025,KEPT
familial cancer syndromes,SURFACE,1,0.025,KEPT
familial cases,SURFACE,1,0.025,KEPT
familial component,SURFACE,1,0.025,KEPT
familial consanguinity,SURFACE,1,0.025,KEPT
familial diseases,SURFACE,1,0.025,KEPT
familial dyslipidemia,SURFACE,1,0.025,KEPT
familial findings,SURFACE,1,0.025,KEPT
familial health,SURFACE,1,0.025,KEPT
familial histories,SURFACE,1,0.025,KEPT
familial information,SURFACE,1,0.025,KEPT
familial links,SURFACE,1,0.025,KEPT
familial lung cancer,SURFACE,1,0.025,KEPT
familial management,SURFACE,1,0.025,KEPT
familial mediterranean fever,SURFACE,1,0.025,KEPT
familial members,SURFACE,1,0.025,KEPT
familial nature,SURFACE,1,0.025,KEPT
familial nephropathies,SURFACE,1,0.025,KEPT
familial pattern,SURFACE,1,0.025,KEPT
familial patterns,SURFACE,1,0.025,KEPT
familial precedence,SURFACE,1,0.025,KEPT
familial renal disease,SURFACE,1,0.025,KEPT
familial risks,SURFACE,1,0.025,KEPT
familial settings,SURFACE,1,0.025,KEPT
familial skin,SURFACE,1,0.025,KEPT
familial support,SURFACE,1,0.025,KEPT
familial syndromes**,SURFACE,1,0.025,KEPT
"families.\"",\n\n",SURFACE,1,0.025,KEPT
family communication,SURFACE,1,0.025,KEPT
family counseling,SURFACE,1,0.025,KEPT
family discussions**,SURFACE,1,0.025,KEPT
family dynamic,SURFACE,1,0.025,KEPT
family dynamics,SURFACE,1,0.025,KEPT
family dynamics**,SURFACE,1,0.025,KEPT
family education,SURFACE,1,0.025,KEPT
family engagement**,SURFACE,1,0.025,KEPT
family genetic counseling,SURFACE,1,0.025,KEPT
family genetics,SURFACE,1,0.025,KEPT
family histories**,SURFACE,1,0.025,KEPT
family history assessment,SURFACE,1,0.025,KEPT
family history review,SURFACE,1,0.025,KEPT
"family history.\"",\n\n",SURFACE,1,0.025,KEPT
family medical history,SURFACE,1,0.025,KEPT
family meeting,SURFACE,1,0.025,KEPT
family member,SURFACE,1,0.025,KEPT
family member's,SURFACE,1,0.025,KEPT
family members**: consideration,SURFACE,1,0.025,KEPT
family planning discussions,SURFACE,1,0.025,KEPT
family receives,SURFACE,1,0.025,KEPT
family screening protocols,SURFACE,1,0.025,KEPT
family screening**,SURFACE,1,0.025,KEPT
family screenings,SURFACE,1,0.025,KEPT
family testing,SURFACE,1,0.025,KEPT
family testing**,SURFACE,1,0.025,KEPT
family tree,SURFACE,1,0.025,KEPT
family's consanguinity,SURFACE,1,0.025,KEPT
family's history of,SURFACE,1,0.025,KEPT
"family.\"",\n  \""initial test results\",SURFACE,1,0.025,KEPT
family’s,SURFACE,1,0.025,KEPT
family’s consanguinity factor,SURFACE,1,0.025,KEPT
family’s risk,SURFACE,1,0.025,KEPT
fap,SURFACE,1,0.025,KEPT
fashion,SURFACE,1,0.025,KEPT
fat density,SURFACE,1,0.025,KEPT
fat deposition,SURFACE,1,0.025,KEPT
fat distribution,SURFACE,1,0.025,KEPT
fat distribution patterns,SURFACE,1,0.025,KEPT
fat malabsorption,SURFACE,1,0.025,KEPT
fat malabsorption**,SURFACE,1,0.025,KEPT
fat mass,SURFACE,1,0.025,KEPT
fat masses,SURFACE,1,0.025,KEPT
father's,SURFACE,1,0.025,KEPT
father's history,SURFACE,1,0.025,KEPT
father’s history,SURFACE,1,0.025,KEPT
fatty deposits,SURFACE,1,0.025,KEPT
fatty masses,SURFACE,1,0.025,KEPT
favorable,SURFACE,1,0.025,KEPT
fbn1 gene,SURFACE,1,0.025,KEPT
fbn1 gene assessment,SURFACE,1,0.025,KEPT
fcd,SURFACE,1,0.025,KEPT
fears,SURFACE,1,0.025,KEPT
feasibility,SURFACE,1,0.025,KEPT
features**,SURFACE,1,0.025,KEPT
febuxostat,SURFACE,1,0.025,KEPT
fecal discharge,SURFACE,1,0.025,KEPT
feeding,SURFACE,1,0.025,KEPT
feeding himself,SURFACE,1,0.025,KEPT
feeding issues,SURFACE,1,0.025,KEPT
feel,SURFACE,1,0.025,KEPT
feelings,SURFACE,1,0.025,KEPT
female gender,SURFACE,1,0.025,KEPT
female genitalia,SURFACE,1,0.025,KEPT
femoral artery,SURFACE,1,0.025,KEPT
femoral head,SURFACE,1,0.025,KEPT
fenestrated,SURFACE,1,0.025,KEPT
ferritin,SURFACE,1,0.025,KEPT
fertility issues,SURFACE,1,0.025,KEPT
fertility options,SURFACE,1,0.025,KEPT
fetal condition,SURFACE,1,0.025,KEPT
fetal echocardiogram,SURFACE,1,0.025,KEPT
fetal growth,SURFACE,1,0.025,KEPT
fetal health,SURFACE,1,0.025,KEPT
fetal heart,SURFACE,1,0.025,KEPT
fetal mri,SURFACE,1,0.025,KEPT
fetus's,SURFACE,1,0.025,KEPT
fetus**,SURFACE,1,0.025,KEPT
fev1,SURFACE,1,0.025,KEPT
fever episodes,SURFACE,1,0.025,KEPT
fever pattern,SURFACE,1,0.025,KEPT
fever syndromes,SURFACE,1,0.025,KEPT
ffa,SURFACE,1,0.025,KEPT
fferg,SURFACE,1,0.025,KEPT
ffp,SURFACE,1,0.025,KEPT
fgfr1 genes,SURFACE,1,0.025,KEPT
fgfr2,SURFACE,1,0.025,KEPT
fgfr2**),SURFACE,1,0.025,KEPT
fgfr3,SURFACE,1,0.025,KEPT
fgfr3 gene,SURFACE,1,0.025,KEPT
fiberoptic bronchoscope,SURFACE,1,0.025,KEPT
fibrin d-dimer,SURFACE,1,0.025,KEPT
fibrinolytic activity,SURFACE,1,0.025,KEPT
fibrotic,SURFACE,1,0.025,KEPT
fibular,SURFACE,1,0.025,KEPT
fibular hypoplasia,SURFACE,1,0.025,KEPT
fibular hypoplasia**,SURFACE,1,0.025,KEPT
final,SURFACE,1,0.025,KEPT
final consideration,SURFACE,1,0.025,KEPT
final considerations,SURFACE,1,0.025,KEPT
finality,SURFACE,1,0.025,KEPT
finalized areas,SURFACE,1,0.025,KEPT
finalized state,SURFACE,1,0.025,KEPT
fine crackles,SURFACE,1,0.025,KEPT
fine joint,SURFACE,1,0.025,KEPT
fine motor quotient,SURFACE,1,0.025,KEPT
finger,SURFACE,1,0.025,KEPT
fio2,SURFACE,1,0.025,KEPT
firm,SURFACE,1,0.025,KEPT
first,SURFACE,1,0.025,KEPT
first test,SURFACE,1,0.025,KEPT
first trimester scans,SURFACE,1,0.025,KEPT
fish analysis,SURFACE,1,0.025,KEPT
fisherman,SURFACE,1,0.025,KEPT
fixation,SURFACE,1,0.025,KEPT
fixed flexion,SURFACE,1,0.025,KEPT
fl/ac,SURFACE,1,0.025,KEPT
flare,SURFACE,1,0.025,KEPT
flash full-field electroretinography,SURFACE,1,0.025,KEPT
flashing lights,SURFACE,1,0.025,KEPT
flat feet,SURFACE,1,0.025,KEPT
flexed knee,SURFACE,1,0.025,KEPT
flexibility,SURFACE,1,0.025,KEPT
flexion contracture,SURFACE,1,0.025,KEPT
flexion crease,SURFACE,1,0.025,KEPT
flow cytometry,SURFACE,1,0.025,KEPT
fluconazole,SURFACE,1,0.025,KEPT
fluctuating,SURFACE,1,0.025,KEPT
fluid,SURFACE,1,0.025,KEPT
fluid shifts,SURFACE,1,0.025,KEPT
fluid-filled,SURFACE,1,0.025,KEPT
fluorescein angiography**,SURFACE,1,0.025,KEPT
fluorescein staining,SURFACE,1,0.025,KEPT
fluorescein staining**,SURFACE,1,0.025,KEPT
fmf**,SURFACE,1,0.025,KEPT
fmq,SURFACE,1,0.025,KEPT
fna,SURFACE,1,0.025,KEPT
focal cortical dysplasia,SURFACE,1,0.025,KEPT
focal epilepsy,SURFACE,1,0.025,KEPT
focal limb deficiency,SURFACE,1,0.025,KEPT
focal spikes,SURFACE,1,0.025,KEPT
foci,SURFACE,1,0.025,KEPT
focused,SURFACE,1,0.025,KEPT
focused assessment,SURFACE,1,0.025,KEPT
focused imaging,SURFACE,1,0.025,KEPT
folds,SURFACE,1,0.025,KEPT
follow up with,SURFACE,1,0.025,KEPT
follow with **,SURFACE,1,0.025,KEPT
follow with **cma**,SURFACE,1,0.025,KEPT
"follow-up
4. **areas of disagreement**",SURFACE,1,0.025,KEPT
follow-up assessment,SURFACE,1,0.025,KEPT
follow-up assessments,SURFACE,1,0.025,KEPT
follow-up d-dimer testing,SURFACE,1,0.025,KEPT
follow-up imaging,SURFACE,1,0.025,KEPT
follow-up plan,SURFACE,1,0.025,KEPT
follow-up plan**,SURFACE,1,0.025,KEPT
follow-up plans,SURFACE,1,0.025,KEPT
follow-up plans**,SURFACE,1,0.025,KEPT
follow-up protocol,SURFACE,1,0.025,KEPT
follow-up renal ultrasound,SURFACE,1,0.025,KEPT
follow-up ultrasound,SURFACE,1,0.025,KEPT
followed up,SURFACE,1,0.025,KEPT
following,SURFACE,1,0.025,KEPT
food,SURFACE,1,0.025,KEPT
foremost,SURFACE,1,0.025,KEPT
forensic examinations,SURFACE,1,0.025,KEPT
forensic meteorological,SURFACE,1,0.025,KEPT
forensic specialists,SURFACE,1,0.025,KEPT
foresight,SURFACE,1,0.025,KEPT
formally **terminate**,SURFACE,1,0.025,KEPT
formally documented,SURFACE,1,0.025,KEPT
formations,SURFACE,1,0.025,KEPT
forms,SURFACE,1,0.025,KEPT
formula,SURFACE,1,0.025,KEPT
formulation,SURFACE,1,0.025,KEPT
foster,SURFACE,1,0.025,KEPT
fosters,SURFACE,1,0.025,KEPT
fovea,SURFACE,1,0.025,KEPT
foveal thinning,SURFACE,1,0.025,KEPT
fracture,SURFACE,1,0.025,KEPT
fractured,SURFACE,1,0.025,KEPT
fragile x syndrome,SURFACE,1,0.025,KEPT
fragility,SURFACE,1,0.025,KEPT
fragility fractures,SURFACE,1,0.025,KEPT
free thyroxine,SURFACE,1,0.025,KEPT
freezing,SURFACE,1,0.025,KEPT
frequent,SURFACE,1,0.025,KEPT
frequent falls,SURFACE,1,0.025,KEPT
fresh frozen,SURFACE,1,0.025,KEPT
friedreich's ataxia,SURFACE,1,0.025,KEPT
friedreich's ataxia** – a,SURFACE,1,0.025,KEPT
frontal bossing,SURFACE,1,0.025,KEPT
fsh,SURFACE,1,0.025,KEPT
full,SURFACE,1,0.025,KEPT
full metabolic panel,SURFACE,1,0.025,KEPT
functional assays,SURFACE,1,0.025,KEPT
functional assays**,SURFACE,1,0.025,KEPT
functional assessment,SURFACE,1,0.025,KEPT
functional fibrinogen,SURFACE,1,0.025,KEPT
functional gonads,SURFACE,1,0.025,KEPT
functional imaging,SURFACE,1,0.025,KEPT
functional impairment,SURFACE,1,0.025,KEPT
functional issues,SURFACE,1,0.025,KEPT
functional loss,SURFACE,1,0.025,KEPT
functional renal studies,SURFACE,1,0.025,KEPT
functional studies,SURFACE,1,0.025,KEPT
functionality,SURFACE,1,0.025,KEPT
functioning,SURFACE,1,0.025,KEPT
fundoplication,SURFACE,1,0.025,KEPT
fundus examination,SURFACE,1,0.025,KEPT
fundus examinations,SURFACE,1,0.025,KEPT
fundus fluorescein angiography,SURFACE,1,0.025,KEPT
fungi,SURFACE,1,0.025,KEPT
fungi)**,SURFACE,1,0.025,KEPT
further,SURFACE,1,0.025,KEPT
fvc,SURFACE,1,0.025,KEPT
g/day,SURFACE,1,0.025,KEPT
g=12.3,SURFACE,1,0.025,KEPT
g=5700g,SURFACE,1,0.025,KEPT
gabapentin,SURFACE,1,0.025,KEPT
gained,SURFACE,1,0.025,KEPT
gait,SURFACE,1,0.025,KEPT
gait difficulty,SURFACE,1,0.025,KEPT
gait pattern,SURFACE,1,0.025,KEPT
galactocerebrosidase deficiency,SURFACE,1,0.025,KEPT
galactose-containing oligosaccharides,SURFACE,1,0.025,KEPT
gamma ray surgery,SURFACE,1,0.025,KEPT
gangliosidosis,SURFACE,1,0.025,KEPT
gap,SURFACE,1,0.025,KEPT
garenoxacin,SURFACE,1,0.025,KEPT
gastric malignancies,SURFACE,1,0.025,KEPT
gastric malignancies**,SURFACE,1,0.025,KEPT
gastric tube,SURFACE,1,0.025,KEPT
gastro-esophageal reflux,SURFACE,1,0.025,KEPT
gastroenterologists,SURFACE,1,0.025,KEPT
gastroesophageal varices,SURFACE,1,0.025,KEPT
gastrointestinal,SURFACE,1,0.025,KEPT
gastrointestinal (,SURFACE,1,0.025,KEPT
gastrointestinal function,SURFACE,1,0.025,KEPT
gastrointestinal lesions,SURFACE,1,0.025,KEPT
gastrointestinal ones,SURFACE,1,0.025,KEPT
gastrointestinal symptoms,SURFACE,1,0.025,KEPT
"gastrointestinal symptoms.\"",\n\n",SURFACE,1,0.025,KEPT
gastrointestinal tract,SURFACE,1,0.025,KEPT
gastrointestinal tract**,SURFACE,1,0.025,KEPT
gathered,SURFACE,1,0.025,KEPT
gauging,SURFACE,1,0.025,KEPT
gaze,SURFACE,1,0.025,KEPT
gaze-evoked,SURFACE,1,0.025,KEPT
gene function,SURFACE,1,0.025,KEPT
gene issues,SURFACE,1,0.025,KEPT
gene panel,SURFACE,1,0.025,KEPT
gene panel results,SURFACE,1,0.025,KEPT
gene testing,SURFACE,1,0.025,KEPT
"gene.\""\n",SURFACE,1,0.025,KEPT
genealogy,SURFACE,1,0.025,KEPT
general endocrine function,SURFACE,1,0.025,KEPT
general health status,SURFACE,1,0.025,KEPT
general obesity,SURFACE,1,0.025,KEPT
general seizure,SURFACE,1,0.025,KEPT
general state of,SURFACE,1,0.025,KEPT
generalized 2\u20132.5,SURFACE,1,0.025,KEPT
generalized bradykinesia,SURFACE,1,0.025,KEPT
generalized dystonia,SURFACE,1,0.025,KEPT
generalized muscle wasting,SURFACE,1,0.025,KEPT
generalized paroxysmal fast activities,SURFACE,1,0.025,KEPT
generalized paroxysmal fast activity,SURFACE,1,0.025,KEPT
generalized seizure,SURFACE,1,0.025,KEPT
generalized slow spike-wave activity,SURFACE,1,0.025,KEPT
generalized syndromes,SURFACE,1,0.025,KEPT
generalized tonic seizures,SURFACE,1,0.025,KEPT
genes pertinent,SURFACE,1,0.025,KEPT
genesis,SURFACE,1,0.025,KEPT
genetic abnormalities,SURFACE,1,0.025,KEPT
genetic analyses,SURFACE,1,0.025,KEPT
genetic aspects,SURFACE,1,0.025,KEPT
genetic associations,SURFACE,1,0.025,KEPT
genetic backgrounds,SURFACE,1,0.025,KEPT
genetic basis,SURFACE,1,0.025,KEPT
genetic cause,SURFACE,1,0.025,KEPT
genetic clarification,SURFACE,1,0.025,KEPT
genetic concerns,SURFACE,1,0.025,KEPT
genetic confirmation,SURFACE,1,0.025,KEPT
genetic considerations**,SURFACE,1,0.025,KEPT
genetic consultation,SURFACE,1,0.025,KEPT
genetic counselor**,SURFACE,1,0.025,KEPT
genetic counselors**,SURFACE,1,0.025,KEPT
genetic deletions,SURFACE,1,0.025,KEPT
genetic diagnoses,SURFACE,1,0.025,KEPT
genetic diagnosis,SURFACE,1,0.025,KEPT
genetic diseases,SURFACE,1,0.025,KEPT
genetic disorders**,SURFACE,1,0.025,KEPT
genetic distinction,SURFACE,1,0.025,KEPT
genetic epilepsy,SURFACE,1,0.025,KEPT
genetic evidence,SURFACE,1,0.025,KEPT
genetic factor,SURFACE,1,0.025,KEPT
genetic imaging,SURFACE,1,0.025,KEPT
genetic information,SURFACE,1,0.025,KEPT
genetic inheritance,SURFACE,1,0.025,KEPT
genetic insights,SURFACE,1,0.025,KEPT
genetic issues,SURFACE,1,0.025,KEPT
genetic landscape,SURFACE,1,0.025,KEPT
genetic management,SURFACE,1,0.025,KEPT
genetic markers,SURFACE,1,0.025,KEPT
genetic myopathies,SURFACE,1,0.025,KEPT
genetic outpatient clinic,SURFACE,1,0.025,KEPT
genetic overlaps,SURFACE,1,0.025,KEPT
genetic panel**,SURFACE,1,0.025,KEPT
genetic perspective,SURFACE,1,0.025,KEPT
genetic prevalence,SURFACE,1,0.025,KEPT
genetic profile,SURFACE,1,0.025,KEPT
genetic results,SURFACE,1,0.025,KEPT
genetic risk factors,SURFACE,1,0.025,KEPT
genetic screen,SURFACE,1,0.025,KEPT
genetic screening,SURFACE,1,0.025,KEPT
genetic screening alongside,SURFACE,1,0.025,KEPT
genetic screening**,SURFACE,1,0.025,KEPT
genetic skeletal disorder,SURFACE,1,0.025,KEPT
genetic specialist,SURFACE,1,0.025,KEPT
genetic specialists,SURFACE,1,0.025,KEPT
genetic structure,SURFACE,1,0.025,KEPT
genetic testing consideration**,SURFACE,1,0.025,KEPT
genetic testing coordination**,SURFACE,1,0.025,KEPT
genetic testing methods,SURFACE,1,0.025,KEPT
genetic testing panel**,SURFACE,1,0.025,KEPT
genetic testing timelines,SURFACE,1,0.025,KEPT
genetic testing** and **genetic counseling** adds significant,SURFACE,1,0.025,KEPT
"genetic testing**, **detailed",SURFACE,1,0.025,KEPT
genetic underpinnings,SURFACE,1,0.025,KEPT
genetic variants,SURFACE,1,0.025,KEPT
genetic variations,SURFACE,1,0.025,KEPT
genetic verification,SURFACE,1,0.025,KEPT
geneticist specializing,SURFACE,1,0.025,KEPT
genetics**,SURFACE,1,0.025,KEPT
genital,SURFACE,1,0.025,KEPT
genome aggregation database,SURFACE,1,0.025,KEPT
genomic assays,SURFACE,1,0.025,KEPT
genomic dna,SURFACE,1,0.025,KEPT
genomic panels,SURFACE,1,0.025,KEPT
genomic studies,SURFACE,1,0.025,KEPT
genomic testing**,SURFACE,1,0.025,KEPT
genotype-phenotype correlation,SURFACE,1,0.025,KEPT
"genotypes.\"",\n  \""initial test results\",SURFACE,1,0.025,KEPT
genu valgum,SURFACE,1,0.025,KEPT
"geographic location.\"",\n  \""clinical",SURFACE,1,0.025,KEPT
geographical,SURFACE,1,0.025,KEPT
geographical background,SURFACE,1,0.025,KEPT
geographical context,SURFACE,1,0.025,KEPT
germline,SURFACE,1,0.025,KEPT
"gestation.\"",\n\n",SURFACE,1,0.025,KEPT
gestational,SURFACE,1,0.025,KEPT
gh therapy,SURFACE,1,0.025,KEPT
gh treatment,SURFACE,1,0.025,KEPT
giant cell,SURFACE,1,0.025,KEPT
giant cell arteritis,SURFACE,1,0.025,KEPT
gigantism,SURFACE,1,0.025,KEPT
gingivitis,SURFACE,1,0.025,KEPT
"girl.\"",\n\n",SURFACE,1,0.025,KEPT
given** to **lymph node,SURFACE,1,0.025,KEPT
glb1,SURFACE,1,0.025,KEPT
glb1 gene,SURFACE,1,0.025,KEPT
glean,SURFACE,1,0.025,KEPT
glild,SURFACE,1,0.025,KEPT
globe,SURFACE,1,0.025,KEPT
globoid cell leukodystrophy,SURFACE,1,0.025,KEPT
glomerular,SURFACE,1,0.025,KEPT
glutamyl transpeptidase,SURFACE,1,0.025,KEPT
glycaemic status,SURFACE,1,0.025,KEPT
glycogen storage disorders,SURFACE,1,0.025,KEPT
glycosylation,SURFACE,1,0.025,KEPT
glycosylation disorders,SURFACE,1,0.025,KEPT
glycosylation pathways,SURFACE,1,0.025,KEPT
glycosylation)—are,SURFACE,1,0.025,KEPT
gm1,SURFACE,1,0.025,KEPT
gm1 gangliosidosis**,SURFACE,1,0.025,KEPT
gmq,SURFACE,1,0.025,KEPT
gnrh,SURFACE,1,0.025,KEPT
goldenhar,SURFACE,1,0.025,KEPT
goldenhar syndrome,SURFACE,1,0.025,KEPT
gonadal dysgenesis,SURFACE,1,0.025,KEPT
gonadal dysgenesis**,SURFACE,1,0.025,KEPT
gonadal dysgenesis**.,SURFACE,1,0.025,KEPT
gone,SURFACE,1,0.025,KEPT
good,SURFACE,1,0.025,KEPT
gore-tex,SURFACE,1,0.025,KEPT
gorlin syndrome,SURFACE,1,0.025,KEPT
gout,SURFACE,1,0.025,KEPT
gout points,SURFACE,1,0.025,KEPT
gouty arthritis,SURFACE,1,0.025,KEPT
gpfa,SURFACE,1,0.025,KEPT
gpfas,SURFACE,1,0.025,KEPT
gradual vision,SURFACE,1,0.025,KEPT
granular,SURFACE,1,0.025,KEPT
granulomatosis,SURFACE,1,0.025,KEPT
granulomatous,SURFACE,1,0.025,KEPT
granulomatous conditions,SURFACE,1,0.025,KEPT
granulomatous disease,SURFACE,1,0.025,KEPT
granulomatous diseases,SURFACE,1,0.025,KEPT
granulomatous lymphocytic interstitial lung disease,SURFACE,1,0.025,KEPT
gravida 2 para,SURFACE,1,0.025,KEPT
great!,SURFACE,1,0.025,KEPT
gripped hands,SURFACE,1,0.025,KEPT
gross motor quotient,SURFACE,1,0.025,KEPT
ground-glass,SURFACE,1,0.025,KEPT
group's,SURFACE,1,0.025,KEPT
group’s thoughts,SURFACE,1,0.025,KEPT
grow,SURFACE,1,0.025,KEPT
grows,SURFACE,1,0.025,KEPT
growth abnormalities,SURFACE,1,0.025,KEPT
growth anomalies,SURFACE,1,0.025,KEPT
growth asymmetry,SURFACE,1,0.025,KEPT
growth characteristics,SURFACE,1,0.025,KEPT
growth concerns,SURFACE,1,0.025,KEPT
growth deficiencies,SURFACE,1,0.025,KEPT
growth delay,SURFACE,1,0.025,KEPT
growth delays,SURFACE,1,0.025,KEPT
growth disorders,SURFACE,1,0.025,KEPT
growth dynamics,SURFACE,1,0.025,KEPT
growth failure,SURFACE,1,0.025,KEPT
growth history,SURFACE,1,0.025,KEPT
growth hormone deficiency,SURFACE,1,0.025,KEPT
growth hormone stimulation test,SURFACE,1,0.025,KEPT
growth pattern,SURFACE,1,0.025,KEPT
growth problems,SURFACE,1,0.025,KEPT
growth retardation,SURFACE,1,0.025,KEPT
growth slowing,SURFACE,1,0.025,KEPT
grs,SURFACE,1,0.025,KEPT
guidelines,SURFACE,1,0.025,KEPT
guides,SURFACE,1,0.025,KEPT
hae,SURFACE,1,0.025,KEPT
hae**,SURFACE,1,0.025,KEPT
haematological,SURFACE,1,0.025,KEPT
haemogram,SURFACE,1,0.025,KEPT
hair,SURFACE,1,0.025,KEPT
half-brother,SURFACE,1,0.025,KEPT
half-life,SURFACE,1,0.025,KEPT
hallmark,SURFACE,1,0.025,KEPT
hallucination,SURFACE,1,0.025,KEPT
halting recurrent vascular events,SURFACE,1,0.025,KEPT
hand anomalies,SURFACE,1,0.025,KEPT
hand deformities,SURFACE,1,0.025,KEPT
hand morphology,SURFACE,1,0.025,KEPT
hand/wrist,SURFACE,1,0.025,KEPT
"hands.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
happen,SURFACE,1,0.025,KEPT
hard palate,SURFACE,1,0.025,KEPT
hasan sadikin hospital,SURFACE,1,0.025,KEPT
hba1c,SURFACE,1,0.025,KEPT
hcg,SURFACE,1,0.025,KEPT
head impulse tests,SURFACE,1,0.025,KEPT
head position,SURFACE,1,0.025,KEPT
headache,SURFACE,1,0.025,KEPT
headaches,SURFACE,1,0.025,KEPT
health assessment,SURFACE,1,0.025,KEPT
health challenges,SURFACE,1,0.025,KEPT
health conditions,SURFACE,1,0.025,KEPT
health considerations,SURFACE,1,0.025,KEPT
health context,SURFACE,1,0.025,KEPT
health discussions,SURFACE,1,0.025,KEPT
health management,SURFACE,1,0.025,KEPT
health outcomes,SURFACE,1,0.025,KEPT
health patterns,SURFACE,1,0.025,KEPT
health risks,SURFACE,1,0.025,KEPT
health service,SURFACE,1,0.025,KEPT
health trajectory,SURFACE,1,0.025,KEPT
"health.\"",\n  \""initial test results\",SURFACE,1,0.025,KEPT
"health.\"",\n  \""physical",SURFACE,1,0.025,KEPT
"health.\"",\n\n  \""initial test results\",SURFACE,1,0.025,KEPT
healthcare,SURFACE,1,0.025,KEPT
healthcare interventions,SURFACE,1,0.025,KEPT
healthcare providers,SURFACE,1,0.025,KEPT
hear confirmations,SURFACE,1,0.025,KEPT
"hearing aids.\"",\n\n",SURFACE,1,0.025,KEPT
hearing difficulties,SURFACE,1,0.025,KEPT
hearing problems,SURFACE,1,0.025,KEPT
heart function,SURFACE,1,0.025,KEPT
heart function assessment,SURFACE,1,0.025,KEPT
heart rate,SURFACE,1,0.025,KEPT
heart structure,SURFACE,1,0.025,KEPT
heart valves,SURFACE,1,0.025,KEPT
heartening,SURFACE,1,0.025,KEPT
heavier,SURFACE,1,0.025,KEPT
heds,SURFACE,1,0.025,KEPT
height issues,SURFACE,1,0.025,KEPT
height measurements,SURFACE,1,0.025,KEPT
height sds,SURFACE,1,0.025,KEPT
height velocity,SURFACE,1,0.025,KEPT
helping visualize,SURFACE,1,0.025,KEPT
hemangioma,SURFACE,1,0.025,KEPT
hemangiomas,SURFACE,1,0.025,KEPT
hematochezia,SURFACE,1,0.025,KEPT
hematocolpos,SURFACE,1,0.025,KEPT
"hematocolpos.\""\n",SURFACE,1,0.025,KEPT
hematocolpos/hematometra,SURFACE,1,0.025,KEPT
hematocolpos/hematometra presentation,SURFACE,1,0.025,KEPT
hematocrit,SURFACE,1,0.025,KEPT
hematological disorders,SURFACE,1,0.025,KEPT
hematological malignancies,SURFACE,1,0.025,KEPT
hematological testing,SURFACE,1,0.025,KEPT
hematologist,SURFACE,1,0.025,KEPT
hematology,SURFACE,1,0.025,KEPT
hematometra,SURFACE,1,0.025,KEPT
hematometra support,SURFACE,1,0.025,KEPT
hemifacial microsomia,SURFACE,1,0.025,KEPT
hemodynamic behaviors,SURFACE,1,0.025,KEPT
hemodynamic change,SURFACE,1,0.025,KEPT
hemoglobin,SURFACE,1,0.025,KEPT
hemoglobin tests,SURFACE,1,0.025,KEPT
hemoptysis**,SURFACE,1,0.025,KEPT
hemorrhage,SURFACE,1,0.025,KEPT
hemorrhagic,SURFACE,1,0.025,KEPT
hemorrhagic processes,SURFACE,1,0.025,KEPT
hemorrhagic strokes,SURFACE,1,0.025,KEPT
hepatic change,SURFACE,1,0.025,KEPT
hepatic fibrosis,SURFACE,1,0.025,KEPT
hepatic function,SURFACE,1,0.025,KEPT
hepatitis panel,SURFACE,1,0.025,KEPT
hepatomegaly,SURFACE,1,0.025,KEPT
her body mass index,SURFACE,1,0.025,KEPT
hereditary angioedema,SURFACE,1,0.025,KEPT
hereditary ataxia,SURFACE,1,0.025,KEPT
hereditary ataxias**,SURFACE,1,0.025,KEPT
hereditary autoinflammatory conditions,SURFACE,1,0.025,KEPT
hereditary breast,SURFACE,1,0.025,KEPT
hereditary cancer,SURFACE,1,0.025,KEPT
hereditary cancer syndrome,SURFACE,1,0.025,KEPT
hereditary cancer syndromes**,SURFACE,1,0.025,KEPT
hereditary components,SURFACE,1,0.025,KEPT
hereditary concerns,SURFACE,1,0.025,KEPT
hereditary dyslipidemias,SURFACE,1,0.025,KEPT
hereditary kidney diseases,SURFACE,1,0.025,KEPT
hereditary kidney disorders,SURFACE,1,0.025,KEPT
hereditary macular dystrophies,SURFACE,1,0.025,KEPT
hereditary nephropathies,SURFACE,1,0.025,KEPT
hereditary risks,SURFACE,1,0.025,KEPT
hereditary syndromes**,SURFACE,1,0.025,KEPT
hereditary thrombophilia,SURFACE,1,0.025,KEPT
heredity,SURFACE,1,0.025,KEPT
heritable epilepsy,SURFACE,1,0.025,KEPT
herpes simplex virus,SURFACE,1,0.025,KEPT
hesitate,SURFACE,1,0.025,KEPT
heterozygous,SURFACE,1,0.025,KEPT
hexosaminidase a deficiency,SURFACE,1,0.025,KEPT
hg19,SURFACE,1,0.025,KEPT
hidden,SURFACE,1,0.025,KEPT
hidden abnormalities,SURFACE,1,0.025,KEPT
hidden endocrine disorders,SURFACE,1,0.025,KEPT
hidden infectious,SURFACE,1,0.025,KEPT
hidden inflammatory sites,SURFACE,1,0.025,KEPT
hids,SURFACE,1,0.025,KEPT
high bilirubin,SURFACE,1,0.025,KEPT
high blood pressure,SURFACE,1,0.025,KEPT
high-arched palate,SURFACE,1,0.025,KEPT
high-density lipoprotein 25,SURFACE,1,0.025,KEPT
high-dose,SURFACE,1,0.025,KEPT
high-dose steroids,SURFACE,1,0.025,KEPT
high-grade,SURFACE,1,0.025,KEPT
high-grade fever,SURFACE,1,0.025,KEPT
high-grade fevers,SURFACE,1,0.025,KEPT
high-pitched voice,SURFACE,1,0.025,KEPT
high-priority diagnostic test,SURFACE,1,0.025,KEPT
high-priority test,SURFACE,1,0.025,KEPT
high-quality,SURFACE,1,0.025,KEPT
high-resolution ct,SURFACE,1,0.025,KEPT
high-resolution ct scan**,SURFACE,1,0.025,KEPT
high-resolution ct scan** next,SURFACE,1,0.025,KEPT
high-resolution imaging**,SURFACE,1,0.025,KEPT
high-risk family members,SURFACE,1,0.025,KEPT
highlighting areas,SURFACE,1,0.025,KEPT
hilar lymphadenopathy,SURFACE,1,0.025,KEPT
hilar shadow,SURFACE,1,0.025,KEPT
himself,SURFACE,1,0.025,KEPT
hip ultrasound,SURFACE,1,0.025,KEPT
"hip ultrasound.\"",\n  \""past medical history\",SURFACE,1,0.025,KEPT
hips,SURFACE,1,0.025,KEPT
his birth weight,SURFACE,1,0.025,KEPT
his body temperature,SURFACE,1,0.025,KEPT
histological analysis,SURFACE,1,0.025,KEPT
histological examination** –,SURFACE,1,0.025,KEPT
histological samples,SURFACE,1,0.025,KEPT
histopathological examination**,SURFACE,1,0.025,KEPT
historical,SURFACE,1,0.025,KEPT
historical factors,SURFACE,1,0.025,KEPT
historical representation,SURFACE,1,0.025,KEPT
histories,SURFACE,1,0.025,KEPT
history align,SURFACE,1,0.025,KEPT
history procurement,SURFACE,1,0.025,KEPT
history-taking,SURFACE,1,0.025,KEPT
history-taking approach,SURFACE,1,0.025,KEPT
hla-drb1,SURFACE,1,0.025,KEPT
hodgkin's,SURFACE,1,0.025,KEPT
hodgkin's lymphoma,SURFACE,1,0.025,KEPT
holistic autopsy approach**,SURFACE,1,0.025,KEPT
holistic care plan,SURFACE,1,0.025,KEPT
holoprosencephaly,SURFACE,1,0.025,KEPT
homocystinuria,SURFACE,1,0.025,KEPT
homozygotes,SURFACE,1,0.025,KEPT
homozygous,SURFACE,1,0.025,KEPT
hone,SURFACE,1,0.025,KEPT
hormonal analysis,SURFACE,1,0.025,KEPT
hormonal changes,SURFACE,1,0.025,KEPT
hormonal conditions,SURFACE,1,0.025,KEPT
hormonal evaluations**,SURFACE,1,0.025,KEPT
hormonal function,SURFACE,1,0.025,KEPT
hormonal imbalance**,SURFACE,1,0.025,KEPT
hormonal profile assessment,SURFACE,1,0.025,KEPT
hormonal profile leans,SURFACE,1,0.025,KEPT
hormonal profile post-surgery,SURFACE,1,0.025,KEPT
hormonal profiling,SURFACE,1,0.025,KEPT
hormonal status,SURFACE,1,0.025,KEPT
hormone analysis,SURFACE,1,0.025,KEPT
hormone deficiencies,SURFACE,1,0.025,KEPT
hormone dysregulation,SURFACE,1,0.025,KEPT
hormone elevation,SURFACE,1,0.025,KEPT
hormone profile,SURFACE,1,0.025,KEPT
hormone profiles,SURFACE,1,0.025,KEPT
hormone-related,SURFACE,1,0.025,KEPT
hormone-related concerns,SURFACE,1,0.025,KEPT
hospital admission,SURFACE,1,0.025,KEPT
hospital visit,SURFACE,1,0.025,KEPT
"hospital.\"",\n  \""clinical",SURFACE,1,0.025,KEPT
hsg,SURFACE,1,0.025,KEPT
hsv,SURFACE,1,0.025,KEPT
human chorionic gonadotropin,SURFACE,1,0.025,KEPT
human reference genome,SURFACE,1,0.025,KEPT
humidity changes,SURFACE,1,0.025,KEPT
humoral immunity,SURFACE,1,0.025,KEPT
hunan,SURFACE,1,0.025,KEPT
hydrocephalus,SURFACE,1,0.025,KEPT
hydronephrosis,SURFACE,1,0.025,KEPT
hymen,SURFACE,1,0.025,KEPT
hyper-igd syndrome,SURFACE,1,0.025,KEPT
hyper-ige syndrome,SURFACE,1,0.025,KEPT
hyper-igm syndrome,SURFACE,1,0.025,KEPT
hyperaldosteronism,SURFACE,1,0.025,KEPT
hyperautofluorescence,SURFACE,1,0.025,KEPT
hypercholesterolemia,SURFACE,1,0.025,KEPT
hyperdivergent,SURFACE,1,0.025,KEPT
hyperextensibility,SURFACE,1,0.025,KEPT
hyperfluorescence,SURFACE,1,0.025,KEPT
hyperglycemia,SURFACE,1,0.025,KEPT
hyperkalemia,SURFACE,1,0.025,KEPT
hyperlactacidemia,SURFACE,1,0.025,KEPT
hyperlipidemia,SURFACE,1,0.025,KEPT
hypermetabolic,SURFACE,1,0.025,KEPT
hypermobile,SURFACE,1,0.025,KEPT
hypermobile ehlers-danlos syndrome,SURFACE,1,0.025,KEPT
hypermobile type,SURFACE,1,0.025,KEPT
"hypertension.\"",\n  \""initial test results\",SURFACE,1,0.025,KEPT
hyperthermia,SURFACE,1,0.025,KEPT
hyperthermia**,SURFACE,1,0.025,KEPT
hyperthermia** – given,SURFACE,1,0.025,KEPT
hyperthermia**.,SURFACE,1,0.025,KEPT
hypertrophy,SURFACE,1,0.025,KEPT
hyperuricemia,SURFACE,1,0.025,KEPT
hypoautofluorescence,SURFACE,1,0.025,KEPT
hypocalcemia,SURFACE,1,0.025,KEPT
hypochondrogenesis,SURFACE,1,0.025,KEPT
hypodysplastic,SURFACE,1,0.025,KEPT
hypogonadal state,SURFACE,1,0.025,KEPT
hypogonadotropic hypogonadism,SURFACE,1,0.025,KEPT
hypogonadotropic hypogonadism**,SURFACE,1,0.025,KEPT
hypokalemia,SURFACE,1,0.025,KEPT
hypopituitarism,SURFACE,1,0.025,KEPT
hypopituitarism**,SURFACE,1,0.025,KEPT
hypoplastic,SURFACE,1,0.025,KEPT
hypoplastic left heart syndrome**,SURFACE,1,0.025,KEPT
hypostasis,SURFACE,1,0.025,KEPT
hypothermia,SURFACE,1,0.025,KEPT
hypothermia** –,SURFACE,1,0.025,KEPT
hypothermia/environmental exposure** –,SURFACE,1,0.025,KEPT
hypothermic,SURFACE,1,0.025,KEPT
hypothesized immunodeficiency,SURFACE,1,0.025,KEPT
hypothetical,SURFACE,1,0.025,KEPT
hypothetical case,SURFACE,1,0.025,KEPT
hypothetical scenario,SURFACE,1,0.025,KEPT
hypoxia,SURFACE,1,0.025,KEPT
hypoxic-ischemic changes,SURFACE,1,0.025,KEPT
hysterosalpingography,SURFACE,1,0.025,KEPT
hz alpha rhythm,SURFACE,1,0.025,KEPT
i align,SURFACE,1,0.025,KEPT
i am confident,SURFACE,1,0.025,KEPT
i appreciate,SURFACE,1,0.025,KEPT
i commend,SURFACE,1,0.025,KEPT
i emphasize,SURFACE,1,0.025,KEPT
i encourage,SURFACE,1,0.025,KEPT
i endorse,SURFACE,1,0.025,KEPT
i maintain,SURFACE,1,0.025,KEPT
i propose,SURFACE,1,0.025,KEPT
i value,SURFACE,1,0.025,KEPT
i will compile,SURFACE,1,0.025,KEPT
i will conclude,SURFACE,1,0.025,KEPT
i will document,SURFACE,1,0.025,KEPT
i will move,SURFACE,1,0.025,KEPT
i wish,SURFACE,1,0.025,KEPT
i'm curious,SURFACE,1,0.025,KEPT
i'm looking,SURFACE,1,0.025,KEPT
ibuprofen,SURFACE,1,0.025,KEPT
icg,SURFACE,1,0.025,KEPT
ideal,SURFACE,1,0.025,KEPT
ideally,SURFACE,1,0.025,KEPT
identical,SURFACE,1,0.025,KEPT
identifiable,SURFACE,1,0.025,KEPT
identified **candidate variants**,SURFACE,1,0.025,KEPT
identity,SURFACE,1,0.025,KEPT
idiopathic parkinson's,SURFACE,1,0.025,KEPT
idiopathic parkinson's disease,SURFACE,1,0.025,KEPT
idiopathic pulmonary arterial hypertension,SURFACE,1,0.025,KEPT
idiopathic spinocerebellar ataxias,SURFACE,1,0.025,KEPT
iga,SURFACE,1,0.025,KEPT
iga deficiency,SURFACE,1,0.025,KEPT
ige,SURFACE,1,0.025,KEPT
igf,SURFACE,1,0.025,KEPT
igf-1,SURFACE,1,0.025,KEPT
igg,SURFACE,1,0.025,KEPT
igm,SURFACE,1,0.025,KEPT
igra,SURFACE,1,0.025,KEPT
igra**,SURFACE,1,0.025,KEPT
iifa,SURFACE,1,0.025,KEPT
il-2 receptor,SURFACE,1,0.025,KEPT
il-2 receptor levels**,SURFACE,1,0.025,KEPT
ild,SURFACE,1,0.025,KEPT
ill-defined,SURFACE,1,0.025,KEPT
"illicit substances.\"",\n\n  \""initial test results\",SURFACE,1,0.025,KEPT
illnesses,SURFACE,1,0.025,KEPT
illuminating,SURFACE,1,0.025,KEPT
im-persistent,SURFACE,1,0.025,KEPT
image examinations,SURFACE,1,0.025,KEPT
imagery,SURFACE,1,0.025,KEPT
imaging method,SURFACE,1,0.025,KEPT
imaging options,SURFACE,1,0.025,KEPT
imaging plans,SURFACE,1,0.025,KEPT
imaging protocol,SURFACE,1,0.025,KEPT
imaging protocols,SURFACE,1,0.025,KEPT
imaging studies**,SURFACE,1,0.025,KEPT
imaging technique,SURFACE,1,0.025,KEPT
imaging test,SURFACE,1,0.025,KEPT
imaging**,SURFACE,1,0.025,KEPT
immediate **,SURFACE,1,0.025,KEPT
immobile,SURFACE,1,0.025,KEPT
immobilization,SURFACE,1,0.025,KEPT
immune cell,SURFACE,1,0.025,KEPT
immune cell types,SURFACE,1,0.025,KEPT
immune compromise,SURFACE,1,0.025,KEPT
immune defect,SURFACE,1,0.025,KEPT
immune deficiency,SURFACE,1,0.025,KEPT
immune dysfunction,SURFACE,1,0.025,KEPT
immune functionality,SURFACE,1,0.025,KEPT
immune profile,SURFACE,1,0.025,KEPT
immune response,SURFACE,1,0.025,KEPT
immune status,SURFACE,1,0.025,KEPT
immune system,SURFACE,1,0.025,KEPT
immune system's,SURFACE,1,0.025,KEPT
immune-related aspects,SURFACE,1,0.025,KEPT
immunity,SURFACE,1,0.025,KEPT
immunization,SURFACE,1,0.025,KEPT
immunocompromised,SURFACE,1,0.025,KEPT
immunocompromised patient,SURFACE,1,0.025,KEPT
immunodeficiency,SURFACE,1,0.025,KEPT
immunodeficiency profile,SURFACE,1,0.025,KEPT
immunodeficiency status,SURFACE,1,0.025,KEPT
immunodeficiency-related,SURFACE,1,0.025,KEPT
immunoglobulin deficiencies,SURFACE,1,0.025,KEPT
immunoglobulin levels,SURFACE,1,0.025,KEPT
immunoglobulin levels measurement,SURFACE,1,0.025,KEPT
immunoglobulin levels measurement**,SURFACE,1,0.025,KEPT
immunoglobulin replacement,SURFACE,1,0.025,KEPT
immunoglobulin subclasses testing** and **,SURFACE,1,0.025,KEPT
immunoglobulin therapy,SURFACE,1,0.025,KEPT
immunoglobulins,SURFACE,1,0.025,KEPT
immunologic abnormalities,SURFACE,1,0.025,KEPT
immunologic testing,SURFACE,1,0.025,KEPT
immunological abnormalities,SURFACE,1,0.025,KEPT
immunological disorder,SURFACE,1,0.025,KEPT
immunologists,SURFACE,1,0.025,KEPT
immunology specialists,SURFACE,1,0.025,KEPT
immunomodulatory therapies,SURFACE,1,0.025,KEPT
immunosuppressive therapy,SURFACE,1,0.025,KEPT
impacted renal function,SURFACE,1,0.025,KEPT
impacting,SURFACE,1,0.025,KEPT
impaction,SURFACE,1,0.025,KEPT
impaction issues,SURFACE,1,0.025,KEPT
impactions,SURFACE,1,0.025,KEPT
impair,SURFACE,1,0.025,KEPT
impaired gait,SURFACE,1,0.025,KEPT
impaired tandem walk,SURFACE,1,0.025,KEPT
imperfecta,SURFACE,1,0.025,KEPT
implantation,SURFACE,1,0.025,KEPT
implement **isomerase activity assays**,SURFACE,1,0.025,KEPT
implement **isomerase activity assays** post-sequencing,SURFACE,1,0.025,KEPT
implement **pet imaging**,SURFACE,1,0.025,KEPT
implemented,SURFACE,1,0.025,KEPT
improbability,SURFACE,1,0.025,KEPT
improved,SURFACE,1,0.025,KEPT
improves,SURFACE,1,0.025,KEPT
in vitro,SURFACE,1,0.025,KEPT
inaccurate,SURFACE,1,0.025,KEPT
inadequate,SURFACE,1,0.025,KEPT
inadequate blood supply,SURFACE,1,0.025,KEPT
inadequate response,SURFACE,1,0.025,KEPT
incidental finding,SURFACE,1,0.025,KEPT
incision,SURFACE,1,0.025,KEPT
incisors,SURFACE,1,0.025,KEPT
includes,SURFACE,1,0.025,KEPT
including **a26 antibodies**,SURFACE,1,0.025,KEPT
"including **anti-nmda receptor encephalitis**, **anti-lgi1**",SURFACE,1,0.025,KEPT
inclusive,SURFACE,1,0.025,KEPT
inconsistent,SURFACE,1,0.025,KEPT
incorporate,SURFACE,1,0.025,KEPT
independent,SURFACE,1,0.025,KEPT
index,SURFACE,1,0.025,KEPT
indirect ophthalmoscopy,SURFACE,1,0.025,KEPT
indispensable,SURFACE,1,0.025,KEPT
indocyanine green angiography,SURFACE,1,0.025,KEPT
indolent,SURFACE,1,0.025,KEPT
indonesia,SURFACE,1,0.025,KEPT
induced,SURFACE,1,0.025,KEPT
induction,SURFACE,1,0.025,KEPT
infant development ii,SURFACE,1,0.025,KEPT
infant's care,SURFACE,1,0.025,KEPT
infant's case,SURFACE,1,0.025,KEPT
infantile spasms,SURFACE,1,0.025,KEPT
infection** –,SURFACE,1,0.025,KEPT
infection-related,SURFACE,1,0.025,KEPT
infection/inflammation,SURFACE,1,0.025,KEPT
"infections**
     - **routine follow-up imaging",SURFACE,1,0.025,KEPT
infectious cause,SURFACE,1,0.025,KEPT
infectious components,SURFACE,1,0.025,KEPT
infectious concerns,SURFACE,1,0.025,KEPT
infectious disease work-up**,SURFACE,1,0.025,KEPT
infectious etiologies**,SURFACE,1,0.025,KEPT
infectious evaluations,SURFACE,1,0.025,KEPT
infectious features,SURFACE,1,0.025,KEPT
infectious granulomatous conditions,SURFACE,1,0.025,KEPT
infectious granulomatous conditions**,SURFACE,1,0.025,KEPT
infectious processes**,SURFACE,1,0.025,KEPT
infectious triggers,SURFACE,1,0.025,KEPT
infective endocarditis,SURFACE,1,0.025,KEPT
inferior molars,SURFACE,1,0.025,KEPT
infertility,SURFACE,1,0.025,KEPT
infiltrates,SURFACE,1,0.025,KEPT
inflammatory cells,SURFACE,1,0.025,KEPT
inflammatory changes,SURFACE,1,0.025,KEPT
inflammatory etiology,SURFACE,1,0.025,KEPT
inflammatory features,SURFACE,1,0.025,KEPT
inflammatory joint,SURFACE,1,0.025,KEPT
inflammatory joint pain,SURFACE,1,0.025,KEPT
inflammatory markers*,SURFACE,1,0.025,KEPT
inflammatory markers**,SURFACE,1,0.025,KEPT
inflammatory patterns,SURFACE,1,0.025,KEPT
inflammatory responses,SURFACE,1,0.025,KEPT
inflammatory source,SURFACE,1,0.025,KEPT
inflammatory state,SURFACE,1,0.025,KEPT
inflammatory status,SURFACE,1,0.025,KEPT
inflammatory symptoms,SURFACE,1,0.025,KEPT
inflammatory syndrome,SURFACE,1,0.025,KEPT
influencing,SURFACE,1,0.025,KEPT
inform,SURFACE,1,0.025,KEPT
informant,SURFACE,1,0.025,KEPT
information emerges,SURFACE,1,0.025,KEPT
"information.\""\n",SURFACE,1,0.025,KEPT
informational materials,SURFACE,1,0.025,KEPT
informing family,SURFACE,1,0.025,KEPT
informs,SURFACE,1,0.025,KEPT
inhalation,SURFACE,1,0.025,KEPT
inhalers,SURFACE,1,0.025,KEPT
inherent thrombophilias,SURFACE,1,0.025,KEPT
inheritance patterns,SURFACE,1,0.025,KEPT
initial,SURFACE,1,0.025,KEPT
initial imaging,SURFACE,1,0.025,KEPT
initiate imaging,SURFACE,1,0.025,KEPT
initiate testing,SURFACE,1,0.025,KEPT
initiating,SURFACE,1,0.025,KEPT
initiating therapy,SURFACE,1,0.025,KEPT
initiation,SURFACE,1,0.025,KEPT
injected conjunctivae,SURFACE,1,0.025,KEPT
injection,SURFACE,1,0.025,KEPT
injuries,SURFACE,1,0.025,KEPT
injury,SURFACE,1,0.025,KEPT
inner,SURFACE,1,0.025,KEPT
innovative therapies,SURFACE,1,0.025,KEPT
insertion,SURFACE,1,0.025,KEPT
insidious,SURFACE,1,0.025,KEPT
insidious fashion,SURFACE,1,0.025,KEPT
insidious presentation,SURFACE,1,0.025,KEPT
insignificant,SURFACE,1,0.025,KEPT
instability,SURFACE,1,0.025,KEPT
instructions,SURFACE,1,0.025,KEPT
instructive alternatives,SURFACE,1,0.025,KEPT
insufficiencies,SURFACE,1,0.025,KEPT
insufficiency,SURFACE,1,0.025,KEPT
insulin,SURFACE,1,0.025,KEPT
insulin resistance**,SURFACE,1,0.025,KEPT
intake,SURFACE,1,0.025,KEPT
integrated,SURFACE,1,0.025,KEPT
integrated management approach,SURFACE,1,0.025,KEPT
integrates,SURFACE,1,0.025,KEPT
intelligence quotient,SURFACE,1,0.025,KEPT
intend,SURFACE,1,0.025,KEPT
intensity,SURFACE,1,0.025,KEPT
inter-malleolar,SURFACE,1,0.025,KEPT
interactions,SURFACE,1,0.025,KEPT
interconnected,SURFACE,1,0.025,KEPT
interdisciplinary,SURFACE,1,0.025,KEPT
interdisciplinary approach,SURFACE,1,0.025,KEPT
interdisciplinary discussions,SURFACE,1,0.025,KEPT
interdisciplinary perspectives,SURFACE,1,0.025,KEPT
interested,SURFACE,1,0.025,KEPT
interests moving forward,SURFACE,1,0.025,KEPT
interictal,SURFACE,1,0.025,KEPT
interictal eeg,SURFACE,1,0.025,KEPT
interim,SURFACE,1,0.025,KEPT
intermittent back,SURFACE,1,0.025,KEPT
intermittent diarrhea,SURFACE,1,0.025,KEPT
intermittent edema,SURFACE,1,0.025,KEPT
intermittent fever,SURFACE,1,0.025,KEPT
internal,SURFACE,1,0.025,KEPT
internal anomalies,SURFACE,1,0.025,KEPT
internal evaluations,SURFACE,1,0.025,KEPT
internal factors,SURFACE,1,0.025,KEPT
internal organ,SURFACE,1,0.025,KEPT
internal organ anomalies,SURFACE,1,0.025,KEPT
internal reproductive structures,SURFACE,1,0.025,KEPT
internal structure,SURFACE,1,0.025,KEPT
interphalangeal epiphyses,SURFACE,1,0.025,KEPT
interphalangeal joints,SURFACE,1,0.025,KEPT
interpretations,SURFACE,1,0.025,KEPT
interpretative value,SURFACE,1,0.025,KEPT
interpupillary distance,SURFACE,1,0.025,KEPT
interrelate,SURFACE,1,0.025,KEPT
interstitial lung diseases**,SURFACE,1,0.025,KEPT
interventional,SURFACE,1,0.025,KEPT
interventional strategies,SURFACE,1,0.025,KEPT
intestinal wall,SURFACE,1,0.025,KEPT
intoxication,SURFACE,1,0.025,KEPT
intracardiac thrombus,SURFACE,1,0.025,KEPT
intractable,SURFACE,1,0.025,KEPT
intraocular tumors,SURFACE,1,0.025,KEPT
intraoral examination,SURFACE,1,0.025,KEPT
intrastent restenosis,SURFACE,1,0.025,KEPT
intratracheally,SURFACE,1,0.025,KEPT
intrauterine,SURFACE,1,0.025,KEPT
intrauterine abnormalities,SURFACE,1,0.025,KEPT
intravenous,SURFACE,1,0.025,KEPT
intravenous injection,SURFACE,1,0.025,KEPT
intravenous treatment,SURFACE,1,0.025,KEPT
intravenous urography,SURFACE,1,0.025,KEPT
intricate,SURFACE,1,0.025,KEPT
intrinsic progressive disease,SURFACE,1,0.025,KEPT
intubated,SURFACE,1,0.025,KEPT
intubation,SURFACE,1,0.025,KEPT
invasive approach,SURFACE,1,0.025,KEPT
invasive moderately,SURFACE,1,0.025,KEPT
invasiveness,SURFACE,1,0.025,KEPT
investigative framework,SURFACE,1,0.025,KEPT
investigative process,SURFACE,1,0.025,KEPT
involution,SURFACE,1,0.025,KEPT
ion ampliseq exome,SURFACE,1,0.025,KEPT
ion proton sequencing platform,SURFACE,1,0.025,KEPT
ion reporter,SURFACE,1,0.025,KEPT
ipah,SURFACE,1,0.025,KEPT
iq scores,SURFACE,1,0.025,KEPT
irregular,SURFACE,1,0.025,KEPT
irregular borders,SURFACE,1,0.025,KEPT
irregularities,SURFACE,1,0.025,KEPT
ischemia,SURFACE,1,0.025,KEPT
ischemic,SURFACE,1,0.025,KEPT
ischemic changes,SURFACE,1,0.025,KEPT
ischemic conditions,SURFACE,1,0.025,KEPT
ischemic events,SURFACE,1,0.025,KEPT
ischemic heart changes,SURFACE,1,0.025,KEPT
ishihara test,SURFACE,1,0.025,KEPT
isomerase activity assays,SURFACE,1,0.025,KEPT
isosorbide,SURFACE,1,0.025,KEPT
issues stemming,SURFACE,1,0.025,KEPT
isvt,SURFACE,1,0.025,KEPT
italian,SURFACE,1,0.025,KEPT
iteration,SURFACE,1,0.025,KEPT
itraconazole,SURFACE,1,0.025,KEPT
ivf,SURFACE,1,0.025,KEPT
ivu,SURFACE,1,0.025,KEPT
i’d recommend,SURFACE,1,0.025,KEPT
january,SURFACE,1,0.025,KEPT
japan,SURFACE,1,0.025,KEPT
"japan.\"",\n",SURFACE,1,0.025,KEPT
japanese encephalitis,SURFACE,1,0.025,KEPT
jaw joint issues,SURFACE,1,0.025,KEPT
jaw structure,SURFACE,1,0.025,KEPT
"jia
**differentiating systemic onset",SURFACE,1,0.025,KEPT
jia**.,SURFACE,1,0.025,KEPT
jia**—is,SURFACE,1,0.025,KEPT
joint damage,SURFACE,1,0.025,KEPT
joint deformities,SURFACE,1,0.025,KEPT
joint description,SURFACE,1,0.025,KEPT
joint destruction,SURFACE,1,0.025,KEPT
joint effusions,SURFACE,1,0.025,KEPT
joint features,SURFACE,1,0.025,KEPT
joint hypermobility,SURFACE,1,0.025,KEPT
joint inflammation,SURFACE,1,0.025,KEPT
joint inheritance,SURFACE,1,0.025,KEPT
joint morphology,SURFACE,1,0.025,KEPT
joint pains,SURFACE,1,0.025,KEPT
joint structure,SURFACE,1,0.025,KEPT
joint symptoms leans,SURFACE,1,0.025,KEPT
joint ultrasound,SURFACE,1,0.025,KEPT
joint-related symptoms,SURFACE,1,0.025,KEPT
justification,SURFACE,1,0.025,KEPT
justifications,SURFACE,1,0.025,KEPT
justifies,SURFACE,1,0.025,KEPT
juvenile age,SURFACE,1,0.025,KEPT
kappa chain,SURFACE,1,0.025,KEPT
karyotype analysis**,SURFACE,1,0.025,KEPT
karyotype context,SURFACE,1,0.025,KEPT
keeping sensitivity,SURFACE,1,0.025,KEPT
key areas,SURFACE,1,0.025,KEPT
key confirmation points,SURFACE,1,0.025,KEPT
key confirmations,SURFACE,1,0.025,KEPT
key discussions,SURFACE,1,0.025,KEPT
key elements,SURFACE,1,0.025,KEPT
kidney abnormalities,SURFACE,1,0.025,KEPT
kidney assessment,SURFACE,1,0.025,KEPT
kidney biopsy,SURFACE,1,0.025,KEPT
kidney concerns,SURFACE,1,0.025,KEPT
kidney condition,SURFACE,1,0.025,KEPT
kidney disease,SURFACE,1,0.025,KEPT
kidney drainage,SURFACE,1,0.025,KEPT
kidney functions,SURFACE,1,0.025,KEPT
kidney structure,SURFACE,1,0.025,KEPT
kidney viability,SURFACE,1,0.025,KEPT
kishore syndrome,SURFACE,1,0.025,KEPT
klinefelter features,SURFACE,1,0.025,KEPT
klippel-trenaunay syndrome,SURFACE,1,0.025,KEPT
knee,SURFACE,1,0.025,KEPT
knee joints,SURFACE,1,0.025,KEPT
knock,SURFACE,1,0.025,KEPT
knock knees,SURFACE,1,0.025,KEPT
knowledge,SURFACE,1,0.025,KEPT
krabbe,SURFACE,1,0.025,KEPT
krabbe disease,SURFACE,1,0.025,KEPT
kras,SURFACE,1,0.025,KEPT
kyphoscoliosis,SURFACE,1,0.025,KEPT
kyphosis,SURFACE,1,0.025,KEPT
l/min of,SURFACE,1,0.025,KEPT
l/min oxygen,SURFACE,1,0.025,KEPT
lab results,SURFACE,1,0.025,KEPT
lab work,SURFACE,1,0.025,KEPT
labeling,SURFACE,1,0.025,KEPT
labetalol,SURFACE,1,0.025,KEPT
laboratory changes,SURFACE,1,0.025,KEPT
laboratory confirmations,SURFACE,1,0.025,KEPT
laboratory data,SURFACE,1,0.025,KEPT
laboratory information,SURFACE,1,0.025,KEPT
laboratory results come back positive,SURFACE,1,0.025,KEPT
laboratory work,SURFACE,1,0.025,KEPT
labs,SURFACE,1,0.025,KEPT
labs**,SURFACE,1,0.025,KEPT
labyrinthine sedatives,SURFACE,1,0.025,KEPT
lacking,SURFACE,1,0.025,KEPT
lactate,SURFACE,1,0.025,KEPT
lactic acid,SURFACE,1,0.025,KEPT
lactic acid level,SURFACE,1,0.025,KEPT
lad,SURFACE,1,0.025,KEPT
lambda chain,SURFACE,1,0.025,KEPT
landscape,SURFACE,1,0.025,KEPT
lanes,SURFACE,1,0.025,KEPT
laparoscopic,SURFACE,1,0.025,KEPT
laparoscopic hysterectomy,SURFACE,1,0.025,KEPT
laparoscopic intervention,SURFACE,1,0.025,KEPT
laparoscopy,SURFACE,1,0.025,KEPT
large,SURFACE,1,0.025,KEPT
laryngomalacia,SURFACE,1,0.025,KEPT
last-minute feedback,SURFACE,1,0.025,KEPT
late 40s,SURFACE,1,0.025,KEPT
late gestation,SURFACE,1,0.025,KEPT
late onset,SURFACE,1,0.025,KEPT
late sequelae,SURFACE,1,0.025,KEPT
late sequelae of takayasu,SURFACE,1,0.025,KEPT
late-emerging,SURFACE,1,0.025,KEPT
late-onset forms,SURFACE,1,0.025,KEPT
latent endocrine disorders,SURFACE,1,0.025,KEPT
latent issues,SURFACE,1,0.025,KEPT
latent tuberculosis,SURFACE,1,0.025,KEPT
lateralization,SURFACE,1,0.025,KEPT
latino,SURFACE,1,0.025,KEPT
lbs,SURFACE,1,0.025,KEPT
ldl,SURFACE,1,0.025,KEPT
lead diagnosis,SURFACE,1,0.025,KEPT
leading contender,SURFACE,1,0.025,KEPT
leading possibilities,SURFACE,1,0.025,KEPT
leakage,SURFACE,1,0.025,KEPT
lean towards **systemic onset jia** or **oligoarticular jia**,SURFACE,1,0.025,KEPT
learned,SURFACE,1,0.025,KEPT
learning,SURFACE,1,0.025,KEPT
learning difficulties,SURFACE,1,0.025,KEPT
learning disabilities,SURFACE,1,0.025,KEPT
leaving,SURFACE,1,0.025,KEPT
"left 26\u00b0.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
"left 26\u00b0.\"",\n\n  \""physical",SURFACE,1,0.025,KEPT
left abdominal pain,SURFACE,1,0.025,KEPT
left dysfunction,SURFACE,1,0.025,KEPT
left eye exam,SURFACE,1,0.025,KEPT
left eye redness,SURFACE,1,0.025,KEPT
left fifth toe,SURFACE,1,0.025,KEPT
left hand,SURFACE,1,0.025,KEPT
left heart structures,SURFACE,1,0.025,KEPT
left lateral incisor,SURFACE,1,0.025,KEPT
left second finger,SURFACE,1,0.025,KEPT
left side mass,SURFACE,1,0.025,KEPT
left torticollis,SURFACE,1,0.025,KEPT
left upper,SURFACE,1,0.025,KEPT
left upper limb,SURFACE,1,0.025,KEPT
left ureter,SURFACE,1,0.025,KEPT
left ureteral,SURFACE,1,0.025,KEPT
left ventricle,SURFACE,1,0.025,KEPT
"left ventricular systolic function.\""\n",SURFACE,1,0.025,KEPT
left-convex lumbar rotoscoliosis,SURFACE,1,0.025,KEPT
left-sided peripheral eye tumor,SURFACE,1,0.025,KEPT
"left-sided peripheral eye tumor.\"",\n\n",SURFACE,1,0.025,KEPT
left-sided peripheral tumor,SURFACE,1,0.025,KEPT
leiden mutation,SURFACE,1,0.025,KEPT
lend significant,SURFACE,1,0.025,KEPT
lennox-gastaut syndrome,SURFACE,1,0.025,KEPT
leri-weill,SURFACE,1,0.025,KEPT
leri-weill dyschondrosteosis,SURFACE,1,0.025,KEPT
leri-weill dyschondrosteosis**,SURFACE,1,0.025,KEPT
lesions**,SURFACE,1,0.025,KEPT
lesion’s,SURFACE,1,0.025,KEPT
let's examine,SURFACE,1,0.025,KEPT
lethargy,SURFACE,1,0.025,KEPT
let’s,SURFACE,1,0.025,KEPT
leucocyte,SURFACE,1,0.025,KEPT
leucocytes/\u03bcl,SURFACE,1,0.025,KEPT
leukemogenic,SURFACE,1,0.025,KEPT
leukocyte,SURFACE,1,0.025,KEPT
leukocyte count,SURFACE,1,0.025,KEPT
leukocyte levels,SURFACE,1,0.025,KEPT
leukocytes,SURFACE,1,0.025,KEPT
leukocytosis,SURFACE,1,0.025,KEPT
leukopenia,SURFACE,1,0.025,KEPT
levodopa,SURFACE,1,0.025,KEPT
levofloxacin,SURFACE,1,0.025,KEPT
lgi1,SURFACE,1,0.025,KEPT
lgs,SURFACE,1,0.025,KEPT
li-fraumeni,SURFACE,1,0.025,KEPT
li-fraumeni syndrome,SURFACE,1,0.025,KEPT
life changes,SURFACE,1,0.025,KEPT
life technologies,SURFACE,1,0.025,KEPT
life-threatening,SURFACE,1,0.025,KEPT
"life.\"",\n\n",SURFACE,1,0.025,KEPT
lifestyle aspects,SURFACE,1,0.025,KEPT
lifestyle choices,SURFACE,1,0.025,KEPT
lifestyle habits,SURFACE,1,0.025,KEPT
lifestyle history,SURFACE,1,0.025,KEPT
lifetime,SURFACE,1,0.025,KEPT
light sedation,SURFACE,1,0.025,KEPT
light-adapted (la) 3,SURFACE,1,0.025,KEPT
like **fgfr1,SURFACE,1,0.025,KEPT
likelihood diminished,SURFACE,1,0.025,KEPT
limb assessment,SURFACE,1,0.025,KEPT
limb dysmorphologies,SURFACE,1,0.025,KEPT
limb fractures,SURFACE,1,0.025,KEPT
limb length,SURFACE,1,0.025,KEPT
limb proportions,SURFACE,1,0.025,KEPT
limb reduction,SURFACE,1,0.025,KEPT
limb reduction defects,SURFACE,1,0.025,KEPT
limb reduction**,SURFACE,1,0.025,KEPT
limb structure,SURFACE,1,0.025,KEPT
limits,SURFACE,1,0.025,KEPT
lipase,SURFACE,1,0.025,KEPT
lipectomy,SURFACE,1,0.025,KEPT
lipid abnormalities,SURFACE,1,0.025,KEPT
lipid metabolism,SURFACE,1,0.025,KEPT
lipid panel,SURFACE,1,0.025,KEPT
lipid profile assessment,SURFACE,1,0.025,KEPT
lipid profile testing**,SURFACE,1,0.025,KEPT
lipid profile**,SURFACE,1,0.025,KEPT
lipid profiles**,SURFACE,1,0.025,KEPT
lipid profiling,SURFACE,1,0.025,KEPT
lipofuscin,SURFACE,1,0.025,KEPT
lipoid,SURFACE,1,0.025,KEPT
lips,SURFACE,1,0.025,KEPT
lists,SURFACE,1,0.025,KEPT
literature,SURFACE,1,0.025,KEPT
live,SURFACE,1,0.025,KEPT
liver complications,SURFACE,1,0.025,KEPT
liver disease,SURFACE,1,0.025,KEPT
liver dysfunction,SURFACE,1,0.025,KEPT
liver enzymes,SURFACE,1,0.025,KEPT
liver findings,SURFACE,1,0.025,KEPT
liver health,SURFACE,1,0.025,KEPT
liver profiles,SURFACE,1,0.025,KEPT
liver transaminases,SURFACE,1,0.025,KEPT
liver ultrasound,SURFACE,1,0.025,KEPT
liver ultrasound scan,SURFACE,1,0.025,KEPT
liver-related complications,SURFACE,1,0.025,KEPT
lkc,SURFACE,1,0.025,KEPT
local hospital,SURFACE,1,0.025,KEPT
local invasion,SURFACE,1,0.025,KEPT
local substances,SURFACE,1,0.025,KEPT
localization,SURFACE,1,0.025,KEPT
localize,SURFACE,1,0.025,KEPT
localized disease,SURFACE,1,0.025,KEPT
localized edema,SURFACE,1,0.025,KEPT
localized joint,SURFACE,1,0.025,KEPT
localized swelling,SURFACE,1,0.025,KEPT
loeys-dietz syndrome,SURFACE,1,0.025,KEPT
loeys-dietz syndrome)** - might,SURFACE,1,0.025,KEPT
logical sequence,SURFACE,1,0.025,KEPT
logical sequencing,SURFACE,1,0.025,KEPT
logically,SURFACE,1,0.025,KEPT
long,SURFACE,1,0.025,KEPT
long arm of chromosome 3,SURFACE,1,0.025,KEPT
long eyelashes,SURFACE,1,0.025,KEPT
long periods,SURFACE,1,0.025,KEPT
long philtrum,SURFACE,1,0.025,KEPT
long thin philtrum,SURFACE,1,0.025,KEPT
longitudinal changes,SURFACE,1,0.025,KEPT
longitudinal limb deficiencies,SURFACE,1,0.025,KEPT
longitudinal studies,SURFACE,1,0.025,KEPT
longstanding,SURFACE,1,0.025,KEPT
loop,SURFACE,1,0.025,KEPT
losartan,SURFACE,1,0.025,KEPT
"loss.\"",\n\n",SURFACE,1,0.025,KEPT
low columella position,SURFACE,1,0.025,KEPT
low growth hormone,SURFACE,1,0.025,KEPT
low risk,SURFACE,1,0.025,KEPT
low school,SURFACE,1,0.025,KEPT
low-density,SURFACE,1,0.025,KEPT
low-density lesions,SURFACE,1,0.025,KEPT
low-density lipoprotein 132,SURFACE,1,0.025,KEPT
low-dose,SURFACE,1,0.025,KEPT
low-grade,SURFACE,1,0.025,KEPT
lower extremities,SURFACE,1,0.025,KEPT
lower extremities*,SURFACE,1,0.025,KEPT
lower extremities**,SURFACE,1,0.025,KEPT
"lower extremity edema.\"",\n\n",SURFACE,1,0.025,KEPT
lower likelihood,SURFACE,1,0.025,KEPT
lower limb,SURFACE,1,0.025,KEPT
lower limbs,SURFACE,1,0.025,KEPT
"lower limbs.\"",\n  \""past medical history\",SURFACE,1,0.025,KEPT
lower lip,SURFACE,1,0.025,KEPT
lower lobes,SURFACE,1,0.025,KEPT
lower lumbar spine,SURFACE,1,0.025,KEPT
lower reproductive tract development,SURFACE,1,0.025,KEPT
lowering,SURFACE,1,0.025,KEPT
lumbar spine,SURFACE,1,0.025,KEPT
lump,SURFACE,1,0.025,KEPT
lung abscess)**,SURFACE,1,0.025,KEPT
lung adenocarcinoma,SURFACE,1,0.025,KEPT
lung biopsies**,SURFACE,1,0.025,KEPT
lung biopsies** if imaging,SURFACE,1,0.025,KEPT
lung biopsy,SURFACE,1,0.025,KEPT
lung cancer**,SURFACE,1,0.025,KEPT
lung capacity,SURFACE,1,0.025,KEPT
lung development,SURFACE,1,0.025,KEPT
lung disease,SURFACE,1,0.025,KEPT
lung disease**,SURFACE,1,0.025,KEPT
lung fields,SURFACE,1,0.025,KEPT
"lung fields.\"",\n",SURFACE,1,0.025,KEPT
lung infection,SURFACE,1,0.025,KEPT
lung infections,SURFACE,1,0.025,KEPT
lung infiltrates,SURFACE,1,0.025,KEPT
lung issues,SURFACE,1,0.025,KEPT
lung lesions,SURFACE,1,0.025,KEPT
lung opacity,SURFACE,1,0.025,KEPT
lung pathology,SURFACE,1,0.025,KEPT
lung status,SURFACE,1,0.025,KEPT
lung tissue,SURFACE,1,0.025,KEPT
lupus,SURFACE,1,0.025,KEPT
lying down,SURFACE,1,0.025,KEPT
lyme disease,SURFACE,1,0.025,KEPT
lymph nodes,SURFACE,1,0.025,KEPT
lymph nodes**,SURFACE,1,0.025,KEPT
lymphatic obstruction,SURFACE,1,0.025,KEPT
lymphocyte,SURFACE,1,0.025,KEPT
lymphocyte subset,SURFACE,1,0.025,KEPT
lymphocytes,SURFACE,1,0.025,KEPT
lymphoid hyperplasia**,SURFACE,1,0.025,KEPT
lymphomas,SURFACE,1,0.025,KEPT
lymphopenia,SURFACE,1,0.025,KEPT
lymphoproliferative conditions,SURFACE,1,0.025,KEPT
lymphoproliferative issues,SURFACE,1,0.025,KEPT
lynch syndrome,SURFACE,1,0.025,KEPT
lysosomal,SURFACE,1,0.025,KEPT
lysosomal disorders,SURFACE,1,0.025,KEPT
lysosomal enzymes,SURFACE,1,0.025,KEPT
lysosomal storage disorder,SURFACE,1,0.025,KEPT
lysosomal storage disorders,SURFACE,1,0.025,KEPT
macula,SURFACE,1,0.025,KEPT
macular,SURFACE,1,0.025,KEPT
macular degeneration,SURFACE,1,0.025,KEPT
macular issues,SURFACE,1,0.025,KEPT
macular rash,SURFACE,1,0.025,KEPT
macular region,SURFACE,1,0.025,KEPT
"made.\"",\n\n",SURFACE,1,0.025,KEPT
maffucci syndrome,SURFACE,1,0.025,KEPT
magnesium,SURFACE,1,0.025,KEPT
magnetic resonance urography,SURFACE,1,0.025,KEPT
magnetic resonance venography,SURFACE,1,0.025,KEPT
magnetoencephalography,SURFACE,1,0.025,KEPT
maintain **bone marrow biopsy**,SURFACE,1,0.025,KEPT
maintained,SURFACE,1,0.025,KEPT
maintenance therapy,SURFACE,1,0.025,KEPT
malabsorption,SURFACE,1,0.025,KEPT
malabsorption issues,SURFACE,1,0.025,KEPT
malabsorption syndrome,SURFACE,1,0.025,KEPT
"male
- **",SURFACE,1,0.025,KEPT
male population,SURFACE,1,0.025,KEPT
malformation,SURFACE,1,0.025,KEPT
malformed kidney,SURFACE,1,0.025,KEPT
malignancy screening,SURFACE,1,0.025,KEPT
malignant cells,SURFACE,1,0.025,KEPT
malignant ocular tumor,SURFACE,1,0.025,KEPT
malignant process,SURFACE,1,0.025,KEPT
malocclusion,SURFACE,1,0.025,KEPT
mama,SURFACE,1,0.025,KEPT
manage,SURFACE,1,0.025,KEPT
management discussions,SURFACE,1,0.025,KEPT
management history,SURFACE,1,0.025,KEPT
management options,SURFACE,1,0.025,KEPT
management pathways,SURFACE,1,0.025,KEPT
management planning,SURFACE,1,0.025,KEPT
management strategies,SURFACE,1,0.025,KEPT
managing,SURFACE,1,0.025,KEPT
mandible,SURFACE,1,0.025,KEPT
mandibular,SURFACE,1,0.025,KEPT
mandibular rotation,SURFACE,1,0.025,KEPT
manifests,SURFACE,1,0.025,KEPT
manufacturer's,SURFACE,1,0.025,KEPT
marfan,SURFACE,1,0.025,KEPT
marfan syndrome**,SURFACE,1,0.025,KEPT
marfanoid syndrome,SURFACE,1,0.025,KEPT
margin,SURFACE,1,0.025,KEPT
marker,SURFACE,1,0.025,KEPT
married,SURFACE,1,0.025,KEPT
mass effect,SURFACE,1,0.025,KEPT
masses**,SURFACE,1,0.025,KEPT
masses** to,SURFACE,1,0.025,KEPT
masses**.,SURFACE,1,0.025,KEPT
masseteric,SURFACE,1,0.025,KEPT
matches,SURFACE,1,0.025,KEPT
maternal history,SURFACE,1,0.025,KEPT
matter,SURFACE,1,0.025,KEPT
matters,SURFACE,1,0.025,KEPT
maximizes,SURFACE,1,0.025,KEPT
may,SURFACE,1,0.025,KEPT
maybe,SURFACE,1,0.025,KEPT
mdkd,SURFACE,1,0.025,KEPT
mean,SURFACE,1,0.025,KEPT
measurements,SURFACE,1,0.025,KEPT
mechanical murmur,SURFACE,1,0.025,KEPT
mechanically ventilated,SURFACE,1,0.025,KEPT
median,SURFACE,1,0.025,KEPT
median line,SURFACE,1,0.025,KEPT
mediastinal lymphadenopathy,SURFACE,1,0.025,KEPT
medical analysis,SURFACE,1,0.025,KEPT
medical aspects,SURFACE,1,0.025,KEPT
medical collaboration,SURFACE,1,0.025,KEPT
medical conditions,SURFACE,1,0.025,KEPT
medical diagnostics,SURFACE,1,0.025,KEPT
medical events,SURFACE,1,0.025,KEPT
medical genetics department,SURFACE,1,0.025,KEPT
"medical history
- **family history:**",SURFACE,1,0.025,KEPT
medical history review,SURFACE,1,0.025,KEPT
medical management,SURFACE,1,0.025,KEPT
medical records,SURFACE,1,0.025,KEPT
medical renal disease,SURFACE,1,0.025,KEPT
medical standards,SURFACE,1,0.025,KEPT
medication,SURFACE,1,0.025,KEPT
medication adherence,SURFACE,1,0.025,KEPT
medication changes,SURFACE,1,0.025,KEPT
medication history,SURFACE,1,0.025,KEPT
medication initiation,SURFACE,1,0.025,KEPT
medication side effects,SURFACE,1,0.025,KEPT
mediterranean,SURFACE,1,0.025,KEPT
meetings**,SURFACE,1,0.025,KEPT
mefv gene,SURFACE,1,0.025,KEPT
mefv gene)**,SURFACE,1,0.025,KEPT
meg,SURFACE,1,0.025,KEPT
melanocytic differentiation,SURFACE,1,0.025,KEPT
memory,SURFACE,1,0.025,KEPT
memory impairment,SURFACE,1,0.025,KEPT
menarche,SURFACE,1,0.025,KEPT
menstrual blood,SURFACE,1,0.025,KEPT
menstrual cycle,SURFACE,1,0.025,KEPT
menstrual function,SURFACE,1,0.025,KEPT
menstrual patterns,SURFACE,1,0.025,KEPT
menstrual regulation,SURFACE,1,0.025,KEPT
menstruation,SURFACE,1,0.025,KEPT
mental health professionals,SURFACE,1,0.025,KEPT
mental status,SURFACE,1,0.025,KEPT
mental well-being,SURFACE,1,0.025,KEPT
mention **adenovirus** and **parvovirus b19**,SURFACE,1,0.025,KEPT
mentioned,SURFACE,1,0.025,KEPT
"mentioned.\"",\n\n",SURFACE,1,0.025,KEPT
mentioning,SURFACE,1,0.025,KEPT
mentions,SURFACE,1,0.025,KEPT
merges,SURFACE,1,0.025,KEPT
merit,SURFACE,1,0.025,KEPT
meriting,SURFACE,1,0.025,KEPT
meropenem,SURFACE,1,0.025,KEPT
mesenteric circulation,SURFACE,1,0.025,KEPT
mesenteric ischemia,SURFACE,1,0.025,KEPT
mesially,SURFACE,1,0.025,KEPT
message,SURFACE,1,0.025,KEPT
metabolic acidosis,SURFACE,1,0.025,KEPT
metabolic activity,SURFACE,1,0.025,KEPT
metabolic aspects,SURFACE,1,0.025,KEPT
metabolic assessment,SURFACE,1,0.025,KEPT
metabolic assessment**,SURFACE,1,0.025,KEPT
metabolic assessments,SURFACE,1,0.025,KEPT
metabolic derangements**,SURFACE,1,0.025,KEPT
metabolic derangements** –,SURFACE,1,0.025,KEPT
metabolic derangements** – it,SURFACE,1,0.025,KEPT
metabolic dysfunction,SURFACE,1,0.025,KEPT
metabolic dysregulation,SURFACE,1,0.025,KEPT
metabolic encephalopathy,SURFACE,1,0.025,KEPT
metabolic encephalopathy**,SURFACE,1,0.025,KEPT
metabolic factors,SURFACE,1,0.025,KEPT
metabolic management,SURFACE,1,0.025,KEPT
metabolic panel** –,SURFACE,1,0.025,KEPT
metabolic panels**,SURFACE,1,0.025,KEPT
metabolic profile,SURFACE,1,0.025,KEPT
metabolic specialists,SURFACE,1,0.025,KEPT
metabolic syndromes,SURFACE,1,0.025,KEPT
metabolic testing**,SURFACE,1,0.025,KEPT
metabolic tests**,SURFACE,1,0.025,KEPT
metabolic workup,SURFACE,1,0.025,KEPT
metabolics,SURFACE,1,0.025,KEPT
metacarpophalangeal,SURFACE,1,0.025,KEPT
metaphyseal dysplasia,SURFACE,1,0.025,KEPT
metastatic carcinoma,SURFACE,1,0.025,KEPT
metastatic disease,SURFACE,1,0.025,KEPT
metatropic dysplasia,SURFACE,1,0.025,KEPT
metformin,SURFACE,1,0.025,KEPT
methodically,SURFACE,1,0.025,KEPT
methodologies,SURFACE,1,0.025,KEPT
methodology,SURFACE,1,0.025,KEPT
methods,SURFACE,1,0.025,KEPT
methylation analysis,SURFACE,1,0.025,KEPT
meticulous evaluation,SURFACE,1,0.025,KEPT
metrics,SURFACE,1,0.025,KEPT
mferg,SURFACE,1,0.025,KEPT
mg/day,SURFACE,1,0.025,KEPT
micro-retrognathia,SURFACE,1,0.025,KEPT
microbial,SURFACE,1,0.025,KEPT
microbial culture,SURFACE,1,0.025,KEPT
microbiological assessment,SURFACE,1,0.025,KEPT
microbiological cultures,SURFACE,1,0.025,KEPT
microbiological perspectives,SURFACE,1,0.025,KEPT
microdeletions,SURFACE,1,0.025,KEPT
microdeletions/duplications,SURFACE,1,0.025,KEPT
micrognathia,SURFACE,1,0.025,KEPT
microretrognathia,SURFACE,1,0.025,KEPT
microscopy,SURFACE,1,0.025,KEPT
mid-gestation,SURFACE,1,0.025,KEPT
mid-palmar crease,SURFACE,1,0.025,KEPT
mid-trimester,SURFACE,1,0.025,KEPT
midbrain,SURFACE,1,0.025,KEPT
middle,SURFACE,1,0.025,KEPT
middle 3,SURFACE,1,0.025,KEPT
middle phalanges,SURFACE,1,0.025,KEPT
middle socio-economic,SURFACE,1,0.025,KEPT
miglustat,SURFACE,1,0.025,KEPT
migration,SURFACE,1,0.025,KEPT
migratory,SURFACE,1,0.025,KEPT
mild discomfort,SURFACE,1,0.025,KEPT
mild ectasia,SURFACE,1,0.025,KEPT
mild impairment,SURFACE,1,0.025,KEPT
mild joint,SURFACE,1,0.025,KEPT
mild joint hyperextensibility,SURFACE,1,0.025,KEPT
mild joint hypermobility,SURFACE,1,0.025,KEPT
mild kyphoscoliosis,SURFACE,1,0.025,KEPT
mild mental retardation,SURFACE,1,0.025,KEPT
mild mitral regurgitation,SURFACE,1,0.025,KEPT
mild ocular abnormalities,SURFACE,1,0.025,KEPT
mild ocular hypertension,SURFACE,1,0.025,KEPT
mild polyhydramnios,SURFACE,1,0.025,KEPT
mild tachycardia,SURFACE,1,0.025,KEPT
milk aspiration,SURFACE,1,0.025,KEPT
mimic,SURFACE,1,0.025,KEPT
mimic encephalitis,SURFACE,1,0.025,KEPT
mimic marfan syndrome,SURFACE,1,0.025,KEPT
minds,SURFACE,1,0.025,KEPT
minimize,SURFACE,1,0.025,KEPT
mis-c,SURFACE,1,0.025,KEPT
mis-c**.,SURFACE,1,0.025,KEPT
"mis-c.

**current consolidation",SURFACE,1,0.025,KEPT
miscellaneous diseases,SURFACE,1,0.025,KEPT
misdiagnosed,SURFACE,1,0.025,KEPT
misdiagnoses,SURFACE,1,0.025,KEPT
mismatch repair proteins,SURFACE,1,0.025,KEPT
missense mutation,SURFACE,1,0.025,KEPT
mitral valve prolapse,SURFACE,1,0.025,KEPT
mm hg,SURFACE,1,0.025,KEPT
"mm.\""\n",SURFACE,1,0.025,KEPT
mobile,SURFACE,1,0.025,KEPT
moca,SURFACE,1,0.025,KEPT
modalities,SURFACE,1,0.025,KEPT
modifiable,SURFACE,1,0.025,KEPT
moist rales,SURFACE,1,0.025,KEPT
molecular assays,SURFACE,1,0.025,KEPT
molecular characteristics,SURFACE,1,0.025,KEPT
molecular diagnosis,SURFACE,1,0.025,KEPT
molecular profiling,SURFACE,1,0.025,KEPT
molecular testing**,SURFACE,1,0.025,KEPT
mom,SURFACE,1,0.025,KEPT
monitor development,SURFACE,1,0.025,KEPT
monitor growth,SURFACE,1,0.025,KEPT
monitor hormone,SURFACE,1,0.025,KEPT
monitor real-time,SURFACE,1,0.025,KEPT
monitoring **tumor markers** post-surgery,SURFACE,1,0.025,KEPT
monitoring approach,SURFACE,1,0.025,KEPT
monitoring intraocular pressure,SURFACE,1,0.025,KEPT
monitoring phase,SURFACE,1,0.025,KEPT
monitoring progression,SURFACE,1,0.025,KEPT
monitoring strategy,SURFACE,1,0.025,KEPT
mononitrate,SURFACE,1,0.025,KEPT
"month.\"",\n",SURFACE,1,0.025,KEPT
monthly,SURFACE,1,0.025,KEPT
montreal cognitive assessment,SURFACE,1,0.025,KEPT
montreal cognitive assessment score,SURFACE,1,0.025,KEPT
moony,SURFACE,1,0.025,KEPT
morbidity,SURFACE,1,0.025,KEPT
morphologies,SURFACE,1,0.025,KEPT
morphology scan,SURFACE,1,0.025,KEPT
mortality,SURFACE,1,0.025,KEPT
mosaic condition,SURFACE,1,0.025,KEPT
mossy skin,SURFACE,1,0.025,KEPT
mother's complex,SURFACE,1,0.025,KEPT
motion,SURFACE,1,0.025,KEPT
motor decline,SURFACE,1,0.025,KEPT
motor delays,SURFACE,1,0.025,KEPT
motor development,SURFACE,1,0.025,KEPT
motor dysfunction,SURFACE,1,0.025,KEPT
motor examinations,SURFACE,1,0.025,KEPT
motor responses,SURFACE,1,0.025,KEPT
motor skills,SURFACE,1,0.025,KEPT
moved,SURFACE,1,0.025,KEPT
movement,SURFACE,1,0.025,KEPT
movement disorders,SURFACE,1,0.025,KEPT
"moving forward
let's",SURFACE,1,0.025,KEPT
mowat-wilson syndrome,SURFACE,1,0.025,KEPT
mr imaging,SURFACE,1,0.025,KEPT
mri alongside,SURFACE,1,0.025,KEPT
mri emphasis,SURFACE,1,0.025,KEPT
mri sequence,SURFACE,1,0.025,KEPT
mri)**,SURFACE,1,0.025,KEPT
mri/ct,SURFACE,1,0.025,KEPT
mris,SURFACE,1,0.025,KEPT
mrkh,SURFACE,1,0.025,KEPT
mrkh syndrome,SURFACE,1,0.025,KEPT
mrkh syndrome)**,SURFACE,1,0.025,KEPT
mru,SURFACE,1,0.025,KEPT
mrv,SURFACE,1,0.025,KEPT
msafp,SURFACE,1,0.025,KEPT
mucopolysaccharidosis,SURFACE,1,0.025,KEPT
mucosal lymphoma,SURFACE,1,0.025,KEPT
multi-disciplinary collaboration**,SURFACE,1,0.025,KEPT
multi-faceted care strategy,SURFACE,1,0.025,KEPT
multi-faceted exploration,SURFACE,1,0.025,KEPT
multi-gene disorder approach,SURFACE,1,0.025,KEPT
multi-joint,SURFACE,1,0.025,KEPT
multi-symptomatic,SURFACE,1,0.025,KEPT
multi-systemic symptoms,SURFACE,1,0.025,KEPT
multicystic dysplastic kidney,SURFACE,1,0.025,KEPT
multicystic dysplastic kidney disease,SURFACE,1,0.025,KEPT
multicystic kidneys,SURFACE,1,0.025,KEPT
multidisciplinary specialists,SURFACE,1,0.025,KEPT
multidisciplinary team approach,SURFACE,1,0.025,KEPT
multifaceted plan,SURFACE,1,0.025,KEPT
multifactorial,SURFACE,1,0.025,KEPT
multifocal electroretinography,SURFACE,1,0.025,KEPT
multifocal spikes,SURFACE,1,0.025,KEPT
multiple areas,SURFACE,1,0.025,KEPT
multiple brainstem reflexes,SURFACE,1,0.025,KEPT
multiple cancers,SURFACE,1,0.025,KEPT
multiple cysts,SURFACE,1,0.025,KEPT
multiple dental caries,SURFACE,1,0.025,KEPT
multiple joint pain,SURFACE,1,0.025,KEPT
multiple joints,SURFACE,1,0.025,KEPT
multiple pulmonary infiltrates,SURFACE,1,0.025,KEPT
multiples,SURFACE,1,0.025,KEPT
multisystem inflammatory syndrome,SURFACE,1,0.025,KEPT
multisystemic dysfunction,SURFACE,1,0.025,KEPT
murmur,SURFACE,1,0.025,KEPT
murmurs,SURFACE,1,0.025,KEPT
muscle atrophy,SURFACE,1,0.025,KEPT
muscle motor sensor,SURFACE,1,0.025,KEPT
muscle wasting,SURFACE,1,0.025,KEPT
muscle weakness,SURFACE,1,0.025,KEPT
muscles,SURFACE,1,0.025,KEPT
muscular dystrophy,SURFACE,1,0.025,KEPT
muscular pathologies,SURFACE,1,0.025,KEPT
musculoskeletal,SURFACE,1,0.025,KEPT
musculoskeletal anomalies,SURFACE,1,0.025,KEPT
musculoskeletal complaints,SURFACE,1,0.025,KEPT
musculoskeletal exam,SURFACE,1,0.025,KEPT
musculoskeletal examination,SURFACE,1,0.025,KEPT
musculoskeletal health,SURFACE,1,0.025,KEPT
mutation's,SURFACE,1,0.025,KEPT
mutation*,SURFACE,1,0.025,KEPT
mutation**,SURFACE,1,0.025,KEPT
"mutation.\"",\n\n",SURFACE,1,0.025,KEPT
myalgias,SURFACE,1,0.025,KEPT
mycobacteria,SURFACE,1,0.025,KEPT
mycobacterial,SURFACE,1,0.025,KEPT
mycobacterium,SURFACE,1,0.025,KEPT
mycobacterium tuberculosis,SURFACE,1,0.025,KEPT
mycobacterium tuberculosis**,SURFACE,1,0.025,KEPT
myeloproliferative disorders,SURFACE,1,0.025,KEPT
myocardial complications,SURFACE,1,0.025,KEPT
myocardial damage,SURFACE,1,0.025,KEPT
myocardial events,SURFACE,1,0.025,KEPT
myocardial function,SURFACE,1,0.025,KEPT
myocardial infarctions,SURFACE,1,0.025,KEPT
myocardial injury,SURFACE,1,0.025,KEPT
myoclonic seizures,SURFACE,1,0.025,KEPT
myoclonic seizures**,SURFACE,1,0.025,KEPT
myopathies,SURFACE,1,0.025,KEPT
myopathy,SURFACE,1,0.025,KEPT
myopia,SURFACE,1,0.025,KEPT
mystery,SURFACE,1,0.025,KEPT
möbius,SURFACE,1,0.025,KEPT
möbius syndrome,SURFACE,1,0.025,KEPT
möbius syndromes,SURFACE,1,0.025,KEPT
müllerian agenesis,SURFACE,1,0.025,KEPT
müllerian anomalies,SURFACE,1,0.025,KEPT
müllerian duct anomalies,SURFACE,1,0.025,KEPT
müllerian ducts,SURFACE,1,0.025,KEPT
müllerian remnants,SURFACE,1,0.025,KEPT
müllerian structures,SURFACE,1,0.025,KEPT
nager syndrome,SURFACE,1,0.025,KEPT
nager syndrome)**,SURFACE,1,0.025,KEPT
nail,SURFACE,1,0.025,KEPT
nail abnormalities,SURFACE,1,0.025,KEPT
nares,SURFACE,1,0.025,KEPT
narrow,SURFACE,1,0.025,KEPT
narrow bridge,SURFACE,1,0.025,KEPT
narrowing down,SURFACE,1,0.025,KEPT
nasal canula oxygen,SURFACE,1,0.025,KEPT
nasal congestion,SURFACE,1,0.025,KEPT
nasal largyngoscopy,SURFACE,1,0.025,KEPT
nasogastric tube,SURFACE,1,0.025,KEPT
nasopharyngeal swab,SURFACE,1,0.025,KEPT
ncs,SURFACE,1,0.025,KEPT
near term,SURFACE,1,0.025,KEPT
near-continuous symptom,SURFACE,1,0.025,KEPT
neck femur,SURFACE,1,0.025,KEPT
neck region,SURFACE,1,0.025,KEPT
neck vessel imaging,SURFACE,1,0.025,KEPT
needle aspiration,SURFACE,1,0.025,KEPT
negate,SURFACE,1,0.025,KEPT
negative hla-b27 test,SURFACE,1,0.025,KEPT
"negative range.\""\n",SURFACE,1,0.025,KEPT
"negative result.\""\n",SURFACE,1,0.025,KEPT
negative rheumatoid factor,SURFACE,1,0.025,KEPT
negative tests,SURFACE,1,0.025,KEPT
"negative.\""\n",SURFACE,1,0.025,KEPT
neighborhood,SURFACE,1,0.025,KEPT
neonate,SURFACE,1,0.025,KEPT
neonate's,SURFACE,1,0.025,KEPT
neonate's condition,SURFACE,1,0.025,KEPT
neonate's limb abnormalities,SURFACE,1,0.025,KEPT
neoplasia,SURFACE,1,0.025,KEPT
neoplastic,SURFACE,1,0.025,KEPT
neoplastic process,SURFACE,1,0.025,KEPT
neoplastic processes,SURFACE,1,0.025,KEPT
neovascular,SURFACE,1,0.025,KEPT
neovascularization,SURFACE,1,0.025,KEPT
nephrogram,SURFACE,1,0.025,KEPT
nephrolithiasis,SURFACE,1,0.025,KEPT
nephrology department,SURFACE,1,0.025,KEPT
nephron damage,SURFACE,1,0.025,KEPT
nephronophthisis,SURFACE,1,0.025,KEPT
nephropathy,SURFACE,1,0.025,KEPT
nephrotoxic,SURFACE,1,0.025,KEPT
nephroureterectomy,SURFACE,1,0.025,KEPT
nerve,SURFACE,1,0.025,KEPT
nerve conduction studies,SURFACE,1,0.025,KEPT
networks,SURFACE,1,0.025,KEPT
neural,SURFACE,1,0.025,KEPT
neural antibodies,SURFACE,1,0.025,KEPT
neural protein antibodies,SURFACE,1,0.025,KEPT
neural tube,SURFACE,1,0.025,KEPT
neural tube defects,SURFACE,1,0.025,KEPT
neurocognitive disabilities,SURFACE,1,0.025,KEPT
neurodegeneration,SURFACE,1,0.025,KEPT
neurodegenerative,SURFACE,1,0.025,KEPT
neurodegenerative conditions,SURFACE,1,0.025,KEPT
neurodegenerative diagnoses,SURFACE,1,0.025,KEPT
neurodegenerative diseases,SURFACE,1,0.025,KEPT
neurodegenerative process,SURFACE,1,0.025,KEPT
neurodevelopmental abnormalities,SURFACE,1,0.025,KEPT
neurodevelopmental aspects,SURFACE,1,0.025,KEPT
neurodevelopmental degeneration,SURFACE,1,0.025,KEPT
neurodevelopmental history,SURFACE,1,0.025,KEPT
neurodevelopmental issues,SURFACE,1,0.025,KEPT
neurodevelopmental status,SURFACE,1,0.025,KEPT
neuroendocrine,SURFACE,1,0.025,KEPT
neuroendocrine features,SURFACE,1,0.025,KEPT
neuroendocrine tumor,SURFACE,1,0.025,KEPT
neuroendocrine tumors,SURFACE,1,0.025,KEPT
neurogenic,SURFACE,1,0.025,KEPT
neuroinvasive viruses,SURFACE,1,0.025,KEPT
neurologic,SURFACE,1,0.025,KEPT
neurological assessment,SURFACE,1,0.025,KEPT
neurological complications,SURFACE,1,0.025,KEPT
neurological decline**,SURFACE,1,0.025,KEPT
neurological etiology,SURFACE,1,0.025,KEPT
neurological evaluation,SURFACE,1,0.025,KEPT
neurological features,SURFACE,1,0.025,KEPT
neurological function,SURFACE,1,0.025,KEPT
neurological functions,SURFACE,1,0.025,KEPT
neurological history,SURFACE,1,0.025,KEPT
neurological illness,SURFACE,1,0.025,KEPT
neurological manifestations,SURFACE,1,0.025,KEPT
neurological outcomes,SURFACE,1,0.025,KEPT
neurological picture,SURFACE,1,0.025,KEPT
neurological presentation,SURFACE,1,0.025,KEPT
neurological signs,SURFACE,1,0.025,KEPT
neurological state,SURFACE,1,0.025,KEPT
neurological status,SURFACE,1,0.025,KEPT
neuron,SURFACE,1,0.025,KEPT
neuronal antibodies,SURFACE,1,0.025,KEPT
neurons,SURFACE,1,0.025,KEPT
neuropathies,SURFACE,1,0.025,KEPT
neuropsychological aspects,SURFACE,1,0.025,KEPT
neuropsychological assessment**,SURFACE,1,0.025,KEPT
neuropsychological assessments,SURFACE,1,0.025,KEPT
neuropsychological tests,SURFACE,1,0.025,KEPT
neurotoxicity,SURFACE,1,0.025,KEPT
neurotropic,SURFACE,1,0.025,KEPT
neurotropism,SURFACE,1,0.025,KEPT
neutrophilia,SURFACE,1,0.025,KEPT
neutrophilic leukocytosis,SURFACE,1,0.025,KEPT
never,SURFACE,1,0.025,KEPT
nevi,SURFACE,1,0.025,KEPT
nevoid basal cell carcinoma syndrome,SURFACE,1,0.025,KEPT
nevoid basal cell carcinoma syndrome)**,SURFACE,1,0.025,KEPT
nevus,SURFACE,1,0.025,KEPT
new symptoms,SURFACE,1,0.025,KEPT
newborn,SURFACE,1,0.025,KEPT
newborn's,SURFACE,1,0.025,KEPT
next actions,SURFACE,1,0.025,KEPT
next generation sequencing,SURFACE,1,0.025,KEPT
next generation sequencing)**,SURFACE,1,0.025,KEPT
next phases,SURFACE,1,0.025,KEPT
next stages,SURFACE,1,0.025,KEPT
"next steps

1. **bardet-biedl syndrome",SURFACE,1,0.025,KEPT
"next steps
1. **implementation",SURFACE,1,0.025,KEPT
"next steps
i",SURFACE,1,0.025,KEPT
next steps commence,SURFACE,1,0.025,KEPT
niche,SURFACE,1,0.025,KEPT
niemann-pick,SURFACE,1,0.025,KEPT
niemann-pick disease,SURFACE,1,0.025,KEPT
nighttime hours,SURFACE,1,0.025,KEPT
nighttime temperatures,SURFACE,1,0.025,KEPT
nipt,SURFACE,1,0.025,KEPT
nitroblue tetrazolium,SURFACE,1,0.025,KEPT
nmda,SURFACE,1,0.025,KEPT
nmda receptor,SURFACE,1,0.025,KEPT
nmol/hr/mg protein,SURFACE,1,0.025,KEPT
no 't' sign,SURFACE,1,0.025,KEPT
no adverse effects,SURFACE,1,0.025,KEPT
no allergies,SURFACE,1,0.025,KEPT
no bulge,SURFACE,1,0.025,KEPT
no distant disease,SURFACE,1,0.025,KEPT
no food,SURFACE,1,0.025,KEPT
no heart murmurs,SURFACE,1,0.025,KEPT
no history of,SURFACE,1,0.025,KEPT
no joint,SURFACE,1,0.025,KEPT
no left ureteral,SURFACE,1,0.025,KEPT
no organomegaly,SURFACE,1,0.025,KEPT
no pain,SURFACE,1,0.025,KEPT
no protein,SURFACE,1,0.025,KEPT
no ptosis,SURFACE,1,0.025,KEPT
no rashes,SURFACE,1,0.025,KEPT
no recurrences,SURFACE,1,0.025,KEPT
no red blood cells,SURFACE,1,0.025,KEPT
no reflux,SURFACE,1,0.025,KEPT
nodding,SURFACE,1,0.025,KEPT
nodular anterior scleritis,SURFACE,1,0.025,KEPT
nodular lesions,SURFACE,1,0.025,KEPT
nodules,SURFACE,1,0.025,KEPT
non-accidental fractures,SURFACE,1,0.025,KEPT
"non-consanguineous.\"",\n\n  \""clinical",SURFACE,1,0.025,KEPT
non-contrast,SURFACE,1,0.025,KEPT
non-contrast ct,SURFACE,1,0.025,KEPT
non-detectable,SURFACE,1,0.025,KEPT
non-disjunction,SURFACE,1,0.025,KEPT
non-epileptic,SURFACE,1,0.025,KEPT
non-epileptic events,SURFACE,1,0.025,KEPT
non-epileptic seizure,SURFACE,1,0.025,KEPT
non-epileptic seizures,SURFACE,1,0.025,KEPT
non-epileptic seizures**,SURFACE,1,0.025,KEPT
non-functional,SURFACE,1,0.025,KEPT
non-hodgkin's,SURFACE,1,0.025,KEPT
non-hodgkin's lymphoma,SURFACE,1,0.025,KEPT
non-infectious,SURFACE,1,0.025,KEPT
non-infectious autoimmune uveitides,SURFACE,1,0.025,KEPT
non-invasively,SURFACE,1,0.025,KEPT
non-lethal outcome,SURFACE,1,0.025,KEPT
non-lethal prognosis,SURFACE,1,0.025,KEPT
non-pruritic,SURFACE,1,0.025,KEPT
non-small cell lung cancer,SURFACE,1,0.025,KEPT
non-steroidal,SURFACE,1,0.025,KEPT
non-tender white papules,SURFACE,1,0.025,KEPT
non-verbal gestures,SURFACE,1,0.025,KEPT
noncompliant,SURFACE,1,0.025,KEPT
nonconsanguineous,SURFACE,1,0.025,KEPT
noninvasive,SURFACE,1,0.025,KEPT
noninvasive screening,SURFACE,1,0.025,KEPT
noninvasive testing,SURFACE,1,0.025,KEPT
nonspecific,SURFACE,1,0.025,KEPT
noonan syndrome,SURFACE,1,0.025,KEPT
normal,SURFACE,1,0.025,KEPT
normal arm span/height ratio,SURFACE,1,0.025,KEPT
normal atrial rhythm,SURFACE,1,0.025,KEPT
normal blood glucose,SURFACE,1,0.025,KEPT
normal bowel sounds,SURFACE,1,0.025,KEPT
normal cell count,SURFACE,1,0.025,KEPT
normal echocardiogram,SURFACE,1,0.025,KEPT
normal intraocular pressure,SURFACE,1,0.025,KEPT
normal libido,SURFACE,1,0.025,KEPT
normal range,SURFACE,1,0.025,KEPT
normal ranges,SURFACE,1,0.025,KEPT
normal results,SURFACE,1,0.025,KEPT
normal ribs,SURFACE,1,0.025,KEPT
normal stature,SURFACE,1,0.025,KEPT
normal structure,SURFACE,1,0.025,KEPT
normal valvular structure,SURFACE,1,0.025,KEPT
"normal.\"",\n\n",SURFACE,1,0.025,KEPT
normalized,SURFACE,1,0.025,KEPT
"normally.\"",\n\n",SURFACE,1,0.025,KEPT
normocytic anemia,SURFACE,1,0.025,KEPT
nose tip,SURFACE,1,0.025,KEPT
not,SURFACE,1,0.025,KEPT
notable,SURFACE,1,0.025,KEPT
"noted.\"",\n",SURFACE,1,0.025,KEPT
"noted.\"",\n  \""past medical history\",SURFACE,1,0.025,KEPT
nphp,SURFACE,1,0.025,KEPT
nras,SURFACE,1,0.025,KEPT
nrds,SURFACE,1,0.025,KEPT
nuchal fold,SURFACE,1,0.025,KEPT
nuclear layer,SURFACE,1,0.025,KEPT
numerical values,SURFACE,1,0.025,KEPT
nutrition,SURFACE,1,0.025,KEPT
nutritional,SURFACE,1,0.025,KEPT
nutritionists,SURFACE,1,0.025,KEPT
obesity syndromes,SURFACE,1,0.025,KEPT
obesity-related renal disease,SURFACE,1,0.025,KEPT
obesity-related renal disease**,SURFACE,1,0.025,KEPT
obesity-related syndromes,SURFACE,1,0.025,KEPT
obligatory,SURFACE,1,0.025,KEPT
obliquely,SURFACE,1,0.025,KEPT
observant,SURFACE,1,0.025,KEPT
observe changes,SURFACE,1,0.025,KEPT
obstructed,SURFACE,1,0.025,KEPT
obstructive,SURFACE,1,0.025,KEPT
obstructive patterns,SURFACE,1,0.025,KEPT
obstructive process,SURFACE,1,0.025,KEPT
obstructive pulmonary ventilation dysfunction,SURFACE,1,0.025,KEPT
obstructive thrombi,SURFACE,1,0.025,KEPT
obstructive thrombus,SURFACE,1,0.025,KEPT
obstructive uropathy,SURFACE,1,0.025,KEPT
obstructs,SURFACE,1,0.025,KEPT
obvious cysts,SURFACE,1,0.025,KEPT
occasional,SURFACE,1,0.025,KEPT
occasional hemoptysis,SURFACE,1,0.025,KEPT
occipital,SURFACE,1,0.025,KEPT
occipital discharges,SURFACE,1,0.025,KEPT
occipital regions,SURFACE,1,0.025,KEPT
occipitofrontal circumference,SURFACE,1,0.025,KEPT
occlusion,SURFACE,1,0.025,KEPT
occlusions,SURFACE,1,0.025,KEPT
occurrence,SURFACE,1,0.025,KEPT
octa,SURFACE,1,0.025,KEPT
ocular abduction failure,SURFACE,1,0.025,KEPT
ocular anomalies,SURFACE,1,0.025,KEPT
ocular complications,SURFACE,1,0.025,KEPT
ocular emergency,SURFACE,1,0.025,KEPT
ocular examination,SURFACE,1,0.025,KEPT
ocular examinations,SURFACE,1,0.025,KEPT
ocular features,SURFACE,1,0.025,KEPT
ocular findings,SURFACE,1,0.025,KEPT
ocular function,SURFACE,1,0.025,KEPT
ocular hypertelorism,SURFACE,1,0.025,KEPT
ocular hypertension,SURFACE,1,0.025,KEPT
ocular inflammation,SURFACE,1,0.025,KEPT
ocular mass,SURFACE,1,0.025,KEPT
ocular masses,SURFACE,1,0.025,KEPT
ocular motility,SURFACE,1,0.025,KEPT
ocular motor abnormalities,SURFACE,1,0.025,KEPT
ocular pathology,SURFACE,1,0.025,KEPT
ocular problems,SURFACE,1,0.025,KEPT
ocular ultrasound,SURFACE,1,0.025,KEPT
oculoauriculovertebral spectrum,SURFACE,1,0.025,KEPT
oculodentodigital syndrome,SURFACE,1,0.025,KEPT
ofc,SURFACE,1,0.025,KEPT
older sister,SURFACE,1,0.025,KEPT
older test,SURFACE,1,0.025,KEPT
oligodactyly,SURFACE,1,0.025,KEPT
oliguria,SURFACE,1,0.025,KEPT
omalizumab,SURFACE,1,0.025,KEPT
omission,SURFACE,1,0.025,KEPT
once results,SURFACE,1,0.025,KEPT
once stabilization,SURFACE,1,0.025,KEPT
oncological evaluations,SURFACE,1,0.025,KEPT
oncologist,SURFACE,1,0.025,KEPT
oncologists,SURFACE,1,0.025,KEPT
onl,SURFACE,1,0.025,KEPT
onset ages,SURFACE,1,0.025,KEPT
onset edema,SURFACE,1,0.025,KEPT
onsets,SURFACE,1,0.025,KEPT
opacity,SURFACE,1,0.025,KEPT
open bite,SURFACE,1,0.025,KEPT
opening,SURFACE,1,0.025,KEPT
openness,SURFACE,1,0.025,KEPT
operation,SURFACE,1,0.025,KEPT
operations,SURFACE,1,0.025,KEPT
ophthalmic evaluations,SURFACE,1,0.025,KEPT
ophthalmologic,SURFACE,1,0.025,KEPT
ophthalmologic assessment,SURFACE,1,0.025,KEPT
ophthalmologic evaluation,SURFACE,1,0.025,KEPT
ophthalmologic examination,SURFACE,1,0.025,KEPT
ophthalmological analysis,SURFACE,1,0.025,KEPT
ophthalmological assessment,SURFACE,1,0.025,KEPT
ophthalmological examination,SURFACE,1,0.025,KEPT
ophthalmology teams,SURFACE,1,0.025,KEPT
ophthalmoplegia,SURFACE,1,0.025,KEPT
opportunistic infection,SURFACE,1,0.025,KEPT
opportunities,SURFACE,1,0.025,KEPT
optic discs,SURFACE,1,0.025,KEPT
optical coherence tomography angiography,SURFACE,1,0.025,KEPT
optimal care,SURFACE,1,0.025,KEPT
optimally prepares,SURFACE,1,0.025,KEPT
opting,SURFACE,1,0.025,KEPT
option,SURFACE,1,0.025,KEPT
optokinetic,SURFACE,1,0.025,KEPT
oral administration,SURFACE,1,0.025,KEPT
oral anomalies,SURFACE,1,0.025,KEPT
oral corticosteroids,SURFACE,1,0.025,KEPT
oral glucose tolerance test,SURFACE,1,0.025,KEPT
oral intake,SURFACE,1,0.025,KEPT
oral rivaroxaban,SURFACE,1,0.025,KEPT
oral voriconazole,SURFACE,1,0.025,KEPT
oral/dental,SURFACE,1,0.025,KEPT
orbit,SURFACE,1,0.025,KEPT
orbit**,SURFACE,1,0.025,KEPT
orbital lesions,SURFACE,1,0.025,KEPT
order,SURFACE,1,0.025,KEPT
ordering,SURFACE,1,0.025,KEPT
organ dysfunction,SURFACE,1,0.025,KEPT
organ function tests**,SURFACE,1,0.025,KEPT
organic,SURFACE,1,0.025,KEPT
organic acid profile,SURFACE,1,0.025,KEPT
organic brain lesions,SURFACE,1,0.025,KEPT
organizational structure,SURFACE,1,0.025,KEPT
organizing discussions,SURFACE,1,0.025,KEPT
organomegaly,SURFACE,1,0.025,KEPT
origin,SURFACE,1,0.025,KEPT
original,SURFACE,1,0.025,KEPT
oromandibular,SURFACE,1,0.025,KEPT
orphanage,SURFACE,1,0.025,KEPT
orthodontic evaluation,SURFACE,1,0.025,KEPT
orthodontic evaluation**,SURFACE,1,0.025,KEPT
orthodontic issues,SURFACE,1,0.025,KEPT
orthodontics,SURFACE,1,0.025,KEPT
orthopaedic consultant,SURFACE,1,0.025,KEPT
orthopanoramic x-ray,SURFACE,1,0.025,KEPT
orthopedic interventions,SURFACE,1,0.025,KEPT
orthopedic specialist,SURFACE,1,0.025,KEPT
orthopedic specialist sooner,SURFACE,1,0.025,KEPT
orthopedics,SURFACE,1,0.025,KEPT
orthosis,SURFACE,1,0.025,KEPT
oscillating,SURFACE,1,0.025,KEPT
oscillopsia,SURFACE,1,0.025,KEPT
osteogenesis,SURFACE,1,0.025,KEPT
osteogenesis imperfecta**,SURFACE,1,0.025,KEPT
osteoporosis,SURFACE,1,0.025,KEPT
otolaryngologist,SURFACE,1,0.025,KEPT
"ou.\"",\n\n",SURFACE,1,0.025,KEPT
outdoor,SURFACE,1,0.025,KEPT
outer,SURFACE,1,0.025,KEPT
outer nuclear layer,SURFACE,1,0.025,KEPT
outflow,SURFACE,1,0.025,KEPT
outflow obstruction,SURFACE,1,0.025,KEPT
outflow obstruction**,SURFACE,1,0.025,KEPT
outflow obstruction**.,SURFACE,1,0.025,KEPT
"outline

1. **tuberculosis",SURFACE,1,0.025,KEPT
outlined path,SURFACE,1,0.025,KEPT
outlined testing,SURFACE,1,0.025,KEPT
outpatient,SURFACE,1,0.025,KEPT
outpatient clinic,SURFACE,1,0.025,KEPT
outpatient examinations,SURFACE,1,0.025,KEPT
outpatient procedure,SURFACE,1,0.025,KEPT
output,SURFACE,1,0.025,KEPT
outputs,SURFACE,1,0.025,KEPT
outward bending,SURFACE,1,0.025,KEPT
outwardly,SURFACE,1,0.025,KEPT
ovarian cancer,SURFACE,1,0.025,KEPT
ovarian cancer syndrome,SURFACE,1,0.025,KEPT
ovarian cancer syndrome**,SURFACE,1,0.025,KEPT
ovarian cysts,SURFACE,1,0.025,KEPT
ovarian cysts**,SURFACE,1,0.025,KEPT
ovarian function,SURFACE,1,0.025,KEPT
ovaries',SURFACE,1,0.025,KEPT
overall assessment,SURFACE,1,0.025,KEPT
overall care plan,SURFACE,1,0.025,KEPT
overall syndrome,SURFACE,1,0.025,KEPT
overarching,SURFACE,1,0.025,KEPT
overlap syndromes,SURFACE,1,0.025,KEPT
overlapping anomalies,SURFACE,1,0.025,KEPT
overlapping domains,SURFACE,1,0.025,KEPT
overlapping features**,SURFACE,1,0.025,KEPT
overlapping pathologies,SURFACE,1,0.025,KEPT
overload,SURFACE,1,0.025,KEPT
oversee,SURFACE,1,0.025,KEPT
overstated,SURFACE,1,0.025,KEPT
overt joint,SURFACE,1,0.025,KEPT
overt symptoms,SURFACE,1,0.025,KEPT
overview,SURFACE,1,0.025,KEPT
overwhelming,SURFACE,1,0.025,KEPT
oxidative burst activity,SURFACE,1,0.025,KEPT
oxidative stress,SURFACE,1,0.025,KEPT
oxygen,SURFACE,1,0.025,KEPT
p13 latency,SURFACE,1,0.025,KEPT
pachyonychia congenita,SURFACE,1,0.025,KEPT
paco2,SURFACE,1,0.025,KEPT
pah-targeted therapy,SURFACE,1,0.025,KEPT
"pain.\"",\n\n  \""physical",SURFACE,1,0.025,KEPT
painful,SURFACE,1,0.025,KEPT
"pakistan.\"",\n\n",SURFACE,1,0.025,KEPT
palatoversion,SURFACE,1,0.025,KEPT
palpation,SURFACE,1,0.025,KEPT
pan-systolic,SURFACE,1,0.025,KEPT
panbio\u2122,SURFACE,1,0.025,KEPT
pancreas,SURFACE,1,0.025,KEPT
pancreatic diseases,SURFACE,1,0.025,KEPT
pancreatic malignancy,SURFACE,1,0.025,KEPT
pancreatitis,SURFACE,1,0.025,KEPT
panel,SURFACE,1,0.025,KEPT
pantonal,SURFACE,1,0.025,KEPT
pap,SURFACE,1,0.025,KEPT
papilloma,SURFACE,1,0.025,KEPT
papilloma**,SURFACE,1,0.025,KEPT
papp-a,SURFACE,1,0.025,KEPT
papular,SURFACE,1,0.025,KEPT
parallel,SURFACE,1,0.025,KEPT
parallels,SURFACE,1,0.025,KEPT
parameters**,SURFACE,1,0.025,KEPT
parasitic infections**,SURFACE,1,0.025,KEPT
parenchymal abnormalities,SURFACE,1,0.025,KEPT
parenchymal issues,SURFACE,1,0.025,KEPT
parents',SURFACE,1,0.025,KEPT
paretic issues,SURFACE,1,0.025,KEPT
parkinson's disease,SURFACE,1,0.025,KEPT
parkinsonian,SURFACE,1,0.025,KEPT
parkinsonian disorders,SURFACE,1,0.025,KEPT
parkinsonian syndromes,SURFACE,1,0.025,KEPT
parkinsonian-type syndromes,SURFACE,1,0.025,KEPT
parkinsonism features,SURFACE,1,0.025,KEPT
parous woman,SURFACE,1,0.025,KEPT
participant,SURFACE,1,0.025,KEPT
participant's,SURFACE,1,0.025,KEPT
participants,SURFACE,1,0.025,KEPT
particle size,SURFACE,1,0.025,KEPT
particularly,SURFACE,1,0.025,KEPT
partner,SURFACE,1,0.025,KEPT
parvovirus b19,SURFACE,1,0.025,KEPT
"parvovirus b19, hantavirus)",SURFACE,1,0.025,KEPT
pasp,SURFACE,1,0.025,KEPT
patau syndrome,SURFACE,1,0.025,KEPT
patau syndrome**,SURFACE,1,0.025,KEPT
patchy infiltrates,SURFACE,1,0.025,KEPT
patency,SURFACE,1,0.025,KEPT
patent ductus arteriosus,SURFACE,1,0.025,KEPT
path forward,SURFACE,1,0.025,KEPT
pathogen,SURFACE,1,0.025,KEPT
pathogenesis,SURFACE,1,0.025,KEPT
pathogenic mutations,SURFACE,1,0.025,KEPT
pathogenic virus,SURFACE,1,0.025,KEPT
pathogenicity,SURFACE,1,0.025,KEPT
pathologic evaluation,SURFACE,1,0.025,KEPT
pathological analysis,SURFACE,1,0.025,KEPT
pathological process,SURFACE,1,0.025,KEPT
pathologist,SURFACE,1,0.025,KEPT
pathology**,SURFACE,1,0.025,KEPT
pathophysiological,SURFACE,1,0.025,KEPT
pathophysiology,SURFACE,1,0.025,KEPT
patient assessment,SURFACE,1,0.025,KEPT
patient case:**,SURFACE,1,0.025,KEPT
"patient case:**

i",SURFACE,1,0.025,KEPT
"patient case:**

thank",SURFACE,1,0.025,KEPT
patient communication,SURFACE,1,0.025,KEPT
patient context,SURFACE,1,0.025,KEPT
patient development,SURFACE,1,0.025,KEPT
patient diagnosis,SURFACE,1,0.025,KEPT
patient education,SURFACE,1,0.025,KEPT
patient education early**,SURFACE,1,0.025,KEPT
patient evolution,SURFACE,1,0.025,KEPT
patient histography,SURFACE,1,0.025,KEPT
patient lacks,SURFACE,1,0.025,KEPT
patient overview,SURFACE,1,0.025,KEPT
patient response,SURFACE,1,0.025,KEPT
patient samples,SURFACE,1,0.025,KEPT
patient stayed,SURFACE,1,0.025,KEPT
patient!,SURFACE,1,0.025,KEPT
patient's age,SURFACE,1,0.025,KEPT
patient's age**,SURFACE,1,0.025,KEPT
patient's care plan,SURFACE,1,0.025,KEPT
patient's care!,SURFACE,1,0.025,KEPT
patient's condition,SURFACE,1,0.025,KEPT
patient's cough,SURFACE,1,0.025,KEPT
patient's death,SURFACE,1,0.025,KEPT
patient's decline,SURFACE,1,0.025,KEPT
patient's epiglottis,SURFACE,1,0.025,KEPT
patient's family,SURFACE,1,0.025,KEPT
patient's history of complex,SURFACE,1,0.025,KEPT
patient's profile,SURFACE,1,0.025,KEPT
patient's reproductive,SURFACE,1,0.025,KEPT
patient's situation,SURFACE,1,0.025,KEPT
patient's tumor,SURFACE,1,0.025,KEPT
patient**,SURFACE,1,0.025,KEPT
patient-centered,SURFACE,1,0.025,KEPT
patient-centered outcomes,SURFACE,1,0.025,KEPT
patient-centered plan,SURFACE,1,0.025,KEPT
patient-derived cellular models,SURFACE,1,0.025,KEPT
patient-specific presentations,SURFACE,1,0.025,KEPT
patient\u2019s height sds,SURFACE,1,0.025,KEPT
patient’s daily,SURFACE,1,0.025,KEPT
patient’s death,SURFACE,1,0.025,KEPT
patient’s developmental,SURFACE,1,0.025,KEPT
patient’s family,SURFACE,1,0.025,KEPT
patient’s growth,SURFACE,1,0.025,KEPT
patient’s growth hormone deficiency,SURFACE,1,0.025,KEPT
patient’s immunodeficiency,SURFACE,1,0.025,KEPT
patient’s joint,SURFACE,1,0.025,KEPT
patient’s management,SURFACE,1,0.025,KEPT
patient’s neurologic status,SURFACE,1,0.025,KEPT
patient’s prognosis,SURFACE,1,0.025,KEPT
patient’s pulmonary pressures,SURFACE,1,0.025,KEPT
patient’s recurrent abdominal pain,SURFACE,1,0.025,KEPT
patient’s state,SURFACE,1,0.025,KEPT
patient’s tall stature,SURFACE,1,0.025,KEPT
patient’s trajectory,SURFACE,1,0.025,KEPT
patterned,SURFACE,1,0.025,KEPT
patterned dystrophies,SURFACE,1,0.025,KEPT
pc=42,SURFACE,1,0.025,KEPT
pc=47,SURFACE,1,0.025,KEPT
pc=51,SURFACE,1,0.025,KEPT
pcr**,SURFACE,1,0.025,KEPT
pda,SURFACE,1,0.025,KEPT
pdi,SURFACE,1,0.025,KEPT
pdms-2,SURFACE,1,0.025,KEPT
peabody developmental motor scale ii,SURFACE,1,0.025,KEPT
peak times,SURFACE,1,0.025,KEPT
pectoralis major,SURFACE,1,0.025,KEPT
pediatric rheumatology,SURFACE,1,0.025,KEPT
peer,SURFACE,1,0.025,KEPT
peers,SURFACE,1,0.025,KEPT
peg-fed,SURFACE,1,0.025,KEPT
peg-shaped incisors,SURFACE,1,0.025,KEPT
pelvic,SURFACE,1,0.025,KEPT
pelvic abscess,SURFACE,1,0.025,KEPT
pelvic anatomy,SURFACE,1,0.025,KEPT
pelvic structures,SURFACE,1,0.025,KEPT
pelvic ultrasound,SURFACE,1,0.025,KEPT
pelvicalyceal system,SURFACE,1,0.025,KEPT
pelvis**,SURFACE,1,0.025,KEPT
"pelvis**
   - **comprehensive endocrine profile tests**",SURFACE,1,0.025,KEPT
pelvis** and **hysterosalpingography,SURFACE,1,0.025,KEPT
pelvocalyectasis,SURFACE,1,0.025,KEPT
penetrance,SURFACE,1,0.025,KEPT
people,SURFACE,1,0.025,KEPT
peptide antibodies,SURFACE,1,0.025,KEPT
percentile,SURFACE,1,0.025,KEPT
percentiles,SURFACE,1,0.025,KEPT
perform **anca antibody testing**,SURFACE,1,0.025,KEPT
perform **pcr,SURFACE,1,0.025,KEPT
performance,SURFACE,1,0.025,KEPT
"perimetry.\""\n",SURFACE,1,0.025,KEPT
perinatal history,SURFACE,1,0.025,KEPT
perindopril,SURFACE,1,0.025,KEPT
periodic edema,SURFACE,1,0.025,KEPT
periodic fever syndrome**,SURFACE,1,0.025,KEPT
periodic fevers,SURFACE,1,0.025,KEPT
perioperative,SURFACE,1,0.025,KEPT
peripheral blood karyotype,SURFACE,1,0.025,KEPT
peripheral blood lymphocyte subset analysis**,SURFACE,1,0.025,KEPT
peripheral blood smears,SURFACE,1,0.025,KEPT
peripheral edema,SURFACE,1,0.025,KEPT
peripheral neuropathies,SURFACE,1,0.025,KEPT
peripheral oxygen saturation,SURFACE,1,0.025,KEPT
peripheral pulses,SURFACE,1,0.025,KEPT
peripheral retina,SURFACE,1,0.025,KEPT
peripheral tortuous vessels,SURFACE,1,0.025,KEPT
peripheral vision,SURFACE,1,0.025,KEPT
periprocedural management,SURFACE,1,0.025,KEPT
permanent teeth,SURFACE,1,0.025,KEPT
persist,SURFACE,1,0.025,KEPT
persisted,SURFACE,1,0.025,KEPT
persistence,SURFACE,1,0.025,KEPT
persistent cough,SURFACE,1,0.025,KEPT
persistent deficiency,SURFACE,1,0.025,KEPT
persistent edema,SURFACE,1,0.025,KEPT
persistent headache,SURFACE,1,0.025,KEPT
persistent hypertension,SURFACE,1,0.025,KEPT
persistent hypertension**,SURFACE,1,0.025,KEPT
persistent symptoms,SURFACE,1,0.025,KEPT
person,SURFACE,1,0.025,KEPT
personal,SURFACE,1,0.025,KEPT
personal history,SURFACE,1,0.025,KEPT
personal life,SURFACE,1,0.025,KEPT
personality,SURFACE,1,0.025,KEPT
personalized,SURFACE,1,0.025,KEPT
persons,SURFACE,1,0.025,KEPT
perspective**,SURFACE,1,0.025,KEPT
pertinent aspects,SURFACE,1,0.025,KEPT
pertinent consideration,SURFACE,1,0.025,KEPT
pertinent differentials,SURFACE,1,0.025,KEPT
pertinent points,SURFACE,1,0.025,KEPT
pet imaging**,SURFACE,1,0.025,KEPT
pet scan,SURFACE,1,0.025,KEPT
pet scans,SURFACE,1,0.025,KEPT
pet scans**,SURFACE,1,0.025,KEPT
pet/ct scan,SURFACE,1,0.025,KEPT
pet/ct scan)**,SURFACE,1,0.025,KEPT
"pet/ct scan)**

4. **areas of disagreement**",SURFACE,1,0.025,KEPT
pfeiffer syndrome,SURFACE,1,0.025,KEPT
pfts,SURFACE,1,0.025,KEPT
phagocyte function,SURFACE,1,0.025,KEPT
phalanx,SURFACE,1,0.025,KEPT
phase consideration,SURFACE,1,0.025,KEPT
phases,SURFACE,1,0.025,KEPT
phenobarbital,SURFACE,1,0.025,KEPT
phenomena,SURFACE,1,0.025,KEPT
phenomenon,SURFACE,1,0.025,KEPT
phenotypic abnormalities,SURFACE,1,0.025,KEPT
phenotypic spectrum,SURFACE,1,0.025,KEPT
phenotypical presentation,SURFACE,1,0.025,KEPT
phenylephrine,SURFACE,1,0.025,KEPT
philtrum,SURFACE,1,0.025,KEPT
phlebotomist,SURFACE,1,0.025,KEPT
phocomelia,SURFACE,1,0.025,KEPT
phosphorus,SURFACE,1,0.025,KEPT
photon emission computed tomography,SURFACE,1,0.025,KEPT
photophobia,SURFACE,1,0.025,KEPT
photopic,SURFACE,1,0.025,KEPT
photoreceptor function,SURFACE,1,0.025,KEPT
photoreceptors,SURFACE,1,0.025,KEPT
physical abnormalities,SURFACE,1,0.025,KEPT
physical anomalies,SURFACE,1,0.025,KEPT
physical changes,SURFACE,1,0.025,KEPT
physical disabilities,SURFACE,1,0.025,KEPT
physical dysmorphic,SURFACE,1,0.025,KEPT
physical health,SURFACE,1,0.025,KEPT
physical imaging,SURFACE,1,0.025,KEPT
physical manifestations,SURFACE,1,0.025,KEPT
physical signs,SURFACE,1,0.025,KEPT
physicians,SURFACE,1,0.025,KEPT
physiological changes,SURFACE,1,0.025,KEPT
physiological complications,SURFACE,1,0.025,KEPT
physiological responses,SURFACE,1,0.025,KEPT
physiological stabilization,SURFACE,1,0.025,KEPT
physiological state,SURFACE,1,0.025,KEPT
physiotherapy,SURFACE,1,0.025,KEPT
pictures,SURFACE,1,0.025,KEPT
piece,SURFACE,1,0.025,KEPT
pigment cells,SURFACE,1,0.025,KEPT
pigmentation,SURFACE,1,0.025,KEPT
pigmented,SURFACE,1,0.025,KEPT
pinkish,SURFACE,1,0.025,KEPT
pinpointing,SURFACE,1,0.025,KEPT
pints,SURFACE,1,0.025,KEPT
pip,SURFACE,1,0.025,KEPT
pituitary abnormalities,SURFACE,1,0.025,KEPT
pituitary adenomas,SURFACE,1,0.025,KEPT
pituitary tumors,SURFACE,1,0.025,KEPT
pkd,SURFACE,1,0.025,KEPT
placenta,SURFACE,1,0.025,KEPT
plan moving forward,SURFACE,1,0.025,KEPT
"plan moving forward:**

1",SURFACE,1,0.025,KEPT
plan recap,SURFACE,1,0.025,KEPT
planned management,SURFACE,1,0.025,KEPT
planning,SURFACE,1,0.025,KEPT
planning future care,SURFACE,1,0.025,KEPT
plasma aldosterone,SURFACE,1,0.025,KEPT
plasma amino acids,SURFACE,1,0.025,KEPT
plasma n-terminal pro-brain natriuretic peptide,SURFACE,1,0.025,KEPT
plasma protein,SURFACE,1,0.025,KEPT
plasma protein c activity,SURFACE,1,0.025,KEPT
plastic surgeons,SURFACE,1,0.025,KEPT
plastic surgery,SURFACE,1,0.025,KEPT
"playful.\"",\n",SURFACE,1,0.025,KEPT
please feel,SURFACE,1,0.025,KEPT
please voice,SURFACE,1,0.025,KEPT
pleural effusion,SURFACE,1,0.025,KEPT
plod2,SURFACE,1,0.025,KEPT
plod2 gene,SURFACE,1,0.025,KEPT
plscr4,SURFACE,1,0.025,KEPT
plscr4 deletion**,SURFACE,1,0.025,KEPT
plscr4 gene,SURFACE,1,0.025,KEPT
pmm2,SURFACE,1,0.025,KEPT
pmm2 analysis,SURFACE,1,0.025,KEPT
pmm2 gene,SURFACE,1,0.025,KEPT
pmm2 gene mutations,SURFACE,1,0.025,KEPT
pmm2 mutation,SURFACE,1,0.025,KEPT
pmm2 mutation**,SURFACE,1,0.025,KEPT
pmm2 protein,SURFACE,1,0.025,KEPT
pmm2 region,SURFACE,1,0.025,KEPT
pmm2 sequencing,SURFACE,1,0.025,KEPT
pmm2 variant’s impact,SURFACE,1,0.025,KEPT
pmm2**,SURFACE,1,0.025,KEPT
pnes,SURFACE,1,0.025,KEPT
"pneumonia.\"",\n\n",SURFACE,1,0.025,KEPT
pneumonia/infectious lung process**,SURFACE,1,0.025,KEPT
point,SURFACE,1,0.025,KEPT
point mutations,SURFACE,1,0.025,KEPT
pointed,SURFACE,1,0.025,KEPT
points i,SURFACE,1,0.025,KEPT
points surrounding **chronic thromboembolic pulmonary hypertension,SURFACE,1,0.025,KEPT
poland,SURFACE,1,0.025,KEPT
poland's,SURFACE,1,0.025,KEPT
poland-m\u00f6bius syndrome,SURFACE,1,0.025,KEPT
poland-möbius syndrome,SURFACE,1,0.025,KEPT
polyangiitis,SURFACE,1,0.025,KEPT
polyangiitis)**,SURFACE,1,0.025,KEPT
polyangiitis**,SURFACE,1,0.025,KEPT
"polyangiitis**
   - **anca testing**",SURFACE,1,0.025,KEPT
"polyangiitis**
   - **testing**",SURFACE,1,0.025,KEPT
polyarteritis nodosa,SURFACE,1,0.025,KEPT
polyarticular,SURFACE,1,0.025,KEPT
polycythemia,SURFACE,1,0.025,KEPT
polyhydramnios,SURFACE,1,0.025,KEPT
polyps,SURFACE,1,0.025,KEPT
polysaccharide,SURFACE,1,0.025,KEPT
poor sucking,SURFACE,1,0.025,KEPT
poorly,SURFACE,1,0.025,KEPT
portal,SURFACE,1,0.025,KEPT
portal system,SURFACE,1,0.025,KEPT
portal vein,SURFACE,1,0.025,KEPT
portal vein thrombosis,SURFACE,1,0.025,KEPT
portal venous system,SURFACE,1,0.025,KEPT
posing,SURFACE,1,0.025,KEPT
positional aggravation,SURFACE,1,0.025,KEPT
positioning,SURFACE,1,0.025,KEPT
positive autoantibody,SURFACE,1,0.025,KEPT
positron emission tomography-ct,SURFACE,1,0.025,KEPT
possible,SURFACE,1,0.025,KEPT
post,SURFACE,1,0.025,KEPT
post-18,SURFACE,1,0.025,KEPT
post-activity chest pain,SURFACE,1,0.025,KEPT
post-amniocentesis,SURFACE,1,0.025,KEPT
post-biopsy,SURFACE,1,0.025,KEPT
post-hemoptysis,SURFACE,1,0.025,KEPT
post-imaging,SURFACE,1,0.025,KEPT
post-infectious,SURFACE,1,0.025,KEPT
post-infectious arthritis**,SURFACE,1,0.025,KEPT
post-infectious inflammatory process,SURFACE,1,0.025,KEPT
post-infectious process,SURFACE,1,0.025,KEPT
post-inflammatory response,SURFACE,1,0.025,KEPT
post-intervention,SURFACE,1,0.025,KEPT
post-ischemic changes,SURFACE,1,0.025,KEPT
post-mortem,SURFACE,1,0.025,KEPT
post-mortem analysis,SURFACE,1,0.025,KEPT
post-mortem hypothermia** –,SURFACE,1,0.025,KEPT
post-mortem interval,SURFACE,1,0.025,KEPT
post-mortem serum,SURFACE,1,0.025,KEPT
post-operative edema,SURFACE,1,0.025,KEPT
post-operative imaging,SURFACE,1,0.025,KEPT
post-operative state,SURFACE,1,0.025,KEPT
post-specialist,SURFACE,1,0.025,KEPT
post-surgical,SURFACE,1,0.025,KEPT
post-surgical assessment,SURFACE,1,0.025,KEPT
post-surgical complications,SURFACE,1,0.025,KEPT
post-surgical evaluation,SURFACE,1,0.025,KEPT
post-surgical follow-up,SURFACE,1,0.025,KEPT
post-testing,SURFACE,1,0.025,KEPT
post-thrombolysis,SURFACE,1,0.025,KEPT
post-treatment,SURFACE,1,0.025,KEPT
posterior,SURFACE,1,0.025,KEPT
posterior segment exam,SURFACE,1,0.025,KEPT
posterior subcapsular,SURFACE,1,0.025,KEPT
posterior subcapsular cataract,SURFACE,1,0.025,KEPT
posterior synechiae,SURFACE,1,0.025,KEPT
posterior temporal regions,SURFACE,1,0.025,KEPT
posterior urethral valves,SURFACE,1,0.025,KEPT
posterior urethral valves**,SURFACE,1,0.025,KEPT
postictal states,SURFACE,1,0.025,KEPT
postmortem,SURFACE,1,0.025,KEPT
postnatal,SURFACE,1,0.025,KEPT
postoperatively,SURFACE,1,0.025,KEPT
postural changes,SURFACE,1,0.025,KEPT
postural drop,SURFACE,1,0.025,KEPT
postural instability,SURFACE,1,0.025,KEPT
potassium,SURFACE,1,0.025,KEPT
potential alternatives,SURFACE,1,0.025,KEPT
potentially,SURFACE,1,0.025,KEPT
potentially affecting,SURFACE,1,0.025,KEPT
practical list,SURFACE,1,0.025,KEPT
practice,SURFACE,1,0.025,KEPT
practices,SURFACE,1,0.025,KEPT
pre-existing,SURFACE,1,0.025,KEPT
precaution,SURFACE,1,0.025,KEPT
precautionary measure,SURFACE,1,0.025,KEPT
precipitated joint,SURFACE,1,0.025,KEPT
precision medicine,SURFACE,1,0.025,KEPT
predicting,SURFACE,1,0.025,KEPT
predispose,SURFACE,1,0.025,KEPT
prednisone,SURFACE,1,0.025,KEPT
predominant,SURFACE,1,0.025,KEPT
predominant focus,SURFACE,1,0.025,KEPT
preeclampsia prevention,SURFACE,1,0.025,KEPT
preemptive care,SURFACE,1,0.025,KEPT
pregnancy discussions,SURFACE,1,0.025,KEPT
pregnancy management,SURFACE,1,0.025,KEPT
pregnancy outcomes,SURFACE,1,0.025,KEPT
pregnancy progresses,SURFACE,1,0.025,KEPT
pregnancy-associated plasma protein-a,SURFACE,1,0.025,KEPT
"pregnancy.\"",\n\n",SURFACE,1,0.025,KEPT
premature coronary artery disease,SURFACE,1,0.025,KEPT
prenatal scans,SURFACE,1,0.025,KEPT
prenatal screen,SURFACE,1,0.025,KEPT
prenatal screening,SURFACE,1,0.025,KEPT
prenatal testing,SURFACE,1,0.025,KEPT
prenatal ultrasound,SURFACE,1,0.025,KEPT
preparation,SURFACE,1,0.025,KEPT
preparations,SURFACE,1,0.025,KEPT
prepubertal results,SURFACE,1,0.025,KEPT
prescription,SURFACE,1,0.025,KEPT
presented,SURFACE,1,0.025,KEPT
presenting,SURFACE,1,0.025,KEPT
preservation,SURFACE,1,0.025,KEPT
pressure,SURFACE,1,0.025,KEPT
pressure overload,SURFACE,1,0.025,KEPT
presurgical,SURFACE,1,0.025,KEPT
prevailing diagnosis,SURFACE,1,0.025,KEPT
prevalence,SURFACE,1,0.025,KEPT
prevalent,SURFACE,1,0.025,KEPT
prevent,SURFACE,1,0.025,KEPT
preventative,SURFACE,1,0.025,KEPT
preventative therapies,SURFACE,1,0.025,KEPT
preventive measure,SURFACE,1,0.025,KEPT
preventive measures,SURFACE,1,0.025,KEPT
preview,SURFACE,1,0.025,KEPT
primary amenorrhea,SURFACE,1,0.025,KEPT
primary approach,SURFACE,1,0.025,KEPT
primary area,SURFACE,1,0.025,KEPT
primary care,SURFACE,1,0.025,KEPT
primary diagnosis leans,SURFACE,1,0.025,KEPT
primary diagnosis of **chronic thromboembolic pulmonary hypertension,SURFACE,1,0.025,KEPT
primary diagnosis of **type i hereditary angioedema (hae)**.,SURFACE,1,0.025,KEPT
primary finding,SURFACE,1,0.025,KEPT
primary goals,SURFACE,1,0.025,KEPT
primary hyperaldosteronism,SURFACE,1,0.025,KEPT
primary hypogonadism,SURFACE,1,0.025,KEPT
primary immunodeficiencies,SURFACE,1,0.025,KEPT
primary immunodeficiencies**,SURFACE,1,0.025,KEPT
primary immunodeficiency,SURFACE,1,0.025,KEPT
primary immunodeficiency database,SURFACE,1,0.025,KEPT
primary infertility,SURFACE,1,0.025,KEPT
primary lesion,SURFACE,1,0.025,KEPT
primary lung cancers,SURFACE,1,0.025,KEPT
primary lung infection,SURFACE,1,0.025,KEPT
primary malignancy,SURFACE,1,0.025,KEPT
primary malignant tumor,SURFACE,1,0.025,KEPT
primary ocular,SURFACE,1,0.025,KEPT
primary ovarian insufficiency,SURFACE,1,0.025,KEPT
primary ovarian insufficiency**,SURFACE,1,0.025,KEPT
primary presentation,SURFACE,1,0.025,KEPT
primary suspect,SURFACE,1,0.025,KEPT
primary symptoms,SURFACE,1,0.025,KEPT
prime,SURFACE,1,0.025,KEPT
"primers.\"",\n",SURFACE,1,0.025,KEPT
prion disease,SURFACE,1,0.025,KEPT
prioritization reflection,SURFACE,1,0.025,KEPT
prioritize **biopsies**,SURFACE,1,0.025,KEPT
prioritize **isomerase activity assays**,SURFACE,1,0.025,KEPT
prioritize **lymph node,SURFACE,1,0.025,KEPT
prioritize scheduling,SURFACE,1,0.025,KEPT
prioritize testing,SURFACE,1,0.025,KEPT
prioritized approach,SURFACE,1,0.025,KEPT
prioritized tests,SURFACE,1,0.025,KEPT
prioritizing **genetic testing,SURFACE,1,0.025,KEPT
prioritizing **repeat,SURFACE,1,0.025,KEPT
prioritizing echocardiography,SURFACE,1,0.025,KEPT
prioritizing significant,SURFACE,1,0.025,KEPT
proactive engagement,SURFACE,1,0.025,KEPT
proactive familial counseling,SURFACE,1,0.025,KEPT
proactive investigations,SURFACE,1,0.025,KEPT
proactive measures,SURFACE,1,0.025,KEPT
proactive planning,SURFACE,1,0.025,KEPT
proactive suggestions,SURFACE,1,0.025,KEPT
proactive systemic workup,SURFACE,1,0.025,KEPT
proactive watchfulness,SURFACE,1,0.025,KEPT
proactively engage,SURFACE,1,0.025,KEPT
probable diagnosis,SURFACE,1,0.025,KEPT
proband's,SURFACE,1,0.025,KEPT
probe,SURFACE,1,0.025,KEPT
probes,SURFACE,1,0.025,KEPT
problematic,SURFACE,1,0.025,KEPT
problematic gait,SURFACE,1,0.025,KEPT
problems,SURFACE,1,0.025,KEPT
procedures,SURFACE,1,0.025,KEPT
processes,SURFACE,1,0.025,KEPT
processing,SURFACE,1,0.025,KEPT
proctor foundation,SURFACE,1,0.025,KEPT
procure,SURFACE,1,0.025,KEPT
procurement,SURFACE,1,0.025,KEPT
productive exchange,SURFACE,1,0.025,KEPT
professionals,SURFACE,1,0.025,KEPT
profile testing,SURFACE,1,0.025,KEPT
profiling,SURFACE,1,0.025,KEPT
progesterone,SURFACE,1,0.025,KEPT
prognostic information,SURFACE,1,0.025,KEPT
prognostication,SURFACE,1,0.025,KEPT
projected route forward,SURFACE,1,0.025,KEPT
projection,SURFACE,1,0.025,KEPT
prolactin,SURFACE,1,0.025,KEPT
prolonged history,SURFACE,1,0.025,KEPT
prominent jaw,SURFACE,1,0.025,KEPT
prompts,SURFACE,1,0.025,KEPT
pronounce,SURFACE,1,0.025,KEPT
properties,SURFACE,1,0.025,KEPT
prophylactic,SURFACE,1,0.025,KEPT
proportions,SURFACE,1,0.025,KEPT
proposed **genetic counseling**,SURFACE,1,0.025,KEPT
proposed final,SURFACE,1,0.025,KEPT
proposed pathway,SURFACE,1,0.025,KEPT
proposed testing pathways,SURFACE,1,0.025,KEPT
proposed tests,SURFACE,1,0.025,KEPT
prospective referrals,SURFACE,1,0.025,KEPT
prostate cancer,SURFACE,1,0.025,KEPT
protein,SURFACE,1,0.025,KEPT
protein 925,SURFACE,1,0.025,KEPT
protein c,SURFACE,1,0.025,KEPT
protein immunoassay,SURFACE,1,0.025,KEPT
protein levels,SURFACE,1,0.025,KEPT
protein s deficiency,SURFACE,1,0.025,KEPT
proteinosis,SURFACE,1,0.025,KEPT
proteinuria,SURFACE,1,0.025,KEPT
prothrombin gene mutation,SURFACE,1,0.025,KEPT
prothrombin time,SURFACE,1,0.025,KEPT
protracted symptoms,SURFACE,1,0.025,KEPT
protruding frontal region,SURFACE,1,0.025,KEPT
"provided.\"",\n\n",SURFACE,1,0.025,KEPT
"provided.\""\n",SURFACE,1,0.025,KEPT
provisional summary,SURFACE,1,0.025,KEPT
proximal dilation,SURFACE,1,0.025,KEPT
proximal splenic vein,SURFACE,1,0.025,KEPT
prudent,SURFACE,1,0.025,KEPT
pruritus,SURFACE,1,0.025,KEPT
psl,SURFACE,1,0.025,KEPT
psoriasis,SURFACE,1,0.025,KEPT
psoriatic,SURFACE,1,0.025,KEPT
psoriatic arthritis**,SURFACE,1,0.025,KEPT
psp,SURFACE,1,0.025,KEPT
psychoeducational resources,SURFACE,1,0.025,KEPT
psychogenic,SURFACE,1,0.025,KEPT
psychogenic non-epileptic seizures,SURFACE,1,0.025,KEPT
psychological aspects,SURFACE,1,0.025,KEPT
psychological factors,SURFACE,1,0.025,KEPT
psychological issues,SURFACE,1,0.025,KEPT
psychological preparedness,SURFACE,1,0.025,KEPT
psychologist,SURFACE,1,0.025,KEPT
psychomotor,SURFACE,1,0.025,KEPT
psychomotor development,SURFACE,1,0.025,KEPT
psychomotor development index,SURFACE,1,0.025,KEPT
psychosocial,SURFACE,1,0.025,KEPT
psychosocial aspects,SURFACE,1,0.025,KEPT
psychosocial concerns,SURFACE,1,0.025,KEPT
psychosocial dynamics,SURFACE,1,0.025,KEPT
psychosocial stressors,SURFACE,1,0.025,KEPT
psychosocial support,SURFACE,1,0.025,KEPT
psychosocial well-being,SURFACE,1,0.025,KEPT
pterygium,SURFACE,1,0.025,KEPT
pterygium**,SURFACE,1,0.025,KEPT
puberty,SURFACE,1,0.025,KEPT
pulmonary angiogram**,SURFACE,1,0.025,KEPT
pulmonary angiography**,SURFACE,1,0.025,KEPT
pulmonary arterial hypertension,SURFACE,1,0.025,KEPT
pulmonary arteries,SURFACE,1,0.025,KEPT
pulmonary artery pressure,SURFACE,1,0.025,KEPT
pulmonary artery pressures,SURFACE,1,0.025,KEPT
pulmonary artery systolic pressure,SURFACE,1,0.025,KEPT
pulmonary bulla,SURFACE,1,0.025,KEPT
pulmonary circulation,SURFACE,1,0.025,KEPT
pulmonary conditions,SURFACE,1,0.025,KEPT
pulmonary cryptococcosis,SURFACE,1,0.025,KEPT
pulmonary edema,SURFACE,1,0.025,KEPT
pulmonary emboli,SURFACE,1,0.025,KEPT
pulmonary embolic events,SURFACE,1,0.025,KEPT
pulmonary embolism assessment,SURFACE,1,0.025,KEPT
pulmonary embolism** –,SURFACE,1,0.025,KEPT
pulmonary embolism** – given,SURFACE,1,0.025,KEPT
pulmonary function,SURFACE,1,0.025,KEPT
pulmonary function test,SURFACE,1,0.025,KEPT
pulmonary function tests**,SURFACE,1,0.025,KEPT
pulmonary haemorrhage,SURFACE,1,0.025,KEPT
pulmonary hemodynamics,SURFACE,1,0.025,KEPT
pulmonary hypoplasia,SURFACE,1,0.025,KEPT
pulmonary infiltrates,SURFACE,1,0.025,KEPT
pulmonary involvement,SURFACE,1,0.025,KEPT
pulmonary lesions,SURFACE,1,0.025,KEPT
pulmonary nodules,SURFACE,1,0.025,KEPT
pulmonary pathology,SURFACE,1,0.025,KEPT
pulmonary pressures,SURFACE,1,0.025,KEPT
"pulmonary shadows.\"",\n  \""physical",SURFACE,1,0.025,KEPT
pulmonary surfactant,SURFACE,1,0.025,KEPT
pulmonary surfactant therapy,SURFACE,1,0.025,KEPT
pulmonary tb,SURFACE,1,0.025,KEPT
pulmonary valve,SURFACE,1,0.025,KEPT
pulmonary valve insufficiency,SURFACE,1,0.025,KEPT
pulmonary valve stenosis,SURFACE,1,0.025,KEPT
pulmonary vascular resistance,SURFACE,1,0.025,KEPT
pulmonary vasculature,SURFACE,1,0.025,KEPT
pulmonary/scarring,SURFACE,1,0.025,KEPT
pulmonologist specializing,SURFACE,1,0.025,KEPT
pulmonology,SURFACE,1,0.025,KEPT
pulse,SURFACE,1,0.025,KEPT
pulse rate,SURFACE,1,0.025,KEPT
pupillary,SURFACE,1,0.025,KEPT
pure-tone audiogram,SURFACE,1,0.025,KEPT
purelink genomic dna mini kit,SURFACE,1,0.025,KEPT
pursue,SURFACE,1,0.025,KEPT
pursue **bronchoscopy,SURFACE,1,0.025,KEPT
pursuing **lymph node,SURFACE,1,0.025,KEPT
pursuit,SURFACE,1,0.025,KEPT
push,SURFACE,1,0.025,KEPT
pws**,SURFACE,1,0.025,KEPT
q angle,SURFACE,1,0.025,KEPT
q22.1,SURFACE,1,0.025,KEPT
q24,SURFACE,1,0.025,KEPT
qrt-pcr,SURFACE,1,0.025,KEPT
quantiferon gold,SURFACE,1,0.025,KEPT
quantiferon gold test,SURFACE,1,0.025,KEPT
quantiferon tb gold test**,SURFACE,1,0.025,KEPT
quantify,SURFACE,1,0.025,KEPT
quantitative,SURFACE,1,0.025,KEPT
quarterly follow-ups,SURFACE,1,0.025,KEPT
queries,SURFACE,1,0.025,KEPT
quest,SURFACE,1,0.025,KEPT
questionnaire,SURFACE,1,0.025,KEPT
questionnaires,SURFACE,1,0.025,KEPT
questions center,SURFACE,1,0.025,KEPT
quick assessment,SURFACE,1,0.025,KEPT
quicker,SURFACE,1,0.025,KEPT
quickly,SURFACE,1,0.025,KEPT
race,SURFACE,1,0.025,KEPT
radial arteries,SURFACE,1,0.025,KEPT
radiation,SURFACE,1,0.025,KEPT
radiation exposure,SURFACE,1,0.025,KEPT
radiographic,SURFACE,1,0.025,KEPT
radiographically,SURFACE,1,0.025,KEPT
radiography,SURFACE,1,0.025,KEPT
radiological,SURFACE,1,0.025,KEPT
radiological analysis,SURFACE,1,0.025,KEPT
radiological changes,SURFACE,1,0.025,KEPT
radiological examinations,SURFACE,1,0.025,KEPT
radiosurgery,SURFACE,1,0.025,KEPT
radius,SURFACE,1,0.025,KEPT
raise,SURFACE,1,0.025,KEPT
raise questions,SURFACE,1,0.025,KEPT
raise significant,SURFACE,1,0.025,KEPT
raise suspicion,SURFACE,1,0.025,KEPT
rashes,SURFACE,1,0.025,KEPT
rates,SURFACE,1,0.025,KEPT
rating,SURFACE,1,0.025,KEPT
ratio,SURFACE,1,0.025,KEPT
rdy kit,SURFACE,1,0.025,KEPT
re-admitted,SURFACE,1,0.025,KEPT
re-consultation,SURFACE,1,0.025,KEPT
re-emphasize,SURFACE,1,0.025,KEPT
re-emphasizing,SURFACE,1,0.025,KEPT
re-engage,SURFACE,1,0.025,KEPT
re-evaluating,SURFACE,1,0.025,KEPT
re-initiating,SURFACE,1,0.025,KEPT
re-initiation,SURFACE,1,0.025,KEPT
reactive arthritis**,SURFACE,1,0.025,KEPT
reactive arthritis** given,SURFACE,1,0.025,KEPT
reactivity,SURFACE,1,0.025,KEPT
readings,SURFACE,1,0.025,KEPT
readmitted,SURFACE,1,0.025,KEPT
reaffirm,SURFACE,1,0.025,KEPT
reaffirming,SURFACE,1,0.025,KEPT
real-time adaptations,SURFACE,1,0.025,KEPT
real-time assessments,SURFACE,1,0.025,KEPT
real-time monitoring,SURFACE,1,0.025,KEPT
reasonable,SURFACE,1,0.025,KEPT
reassessing,SURFACE,1,0.025,KEPT
reassessing conditions,SURFACE,1,0.025,KEPT
reassurance,SURFACE,1,0.025,KEPT
recanalization,SURFACE,1,0.025,KEPT
recapitulation,SURFACE,1,0.025,KEPT
receives,SURFACE,1,0.025,KEPT
receptor-associated periodic syndrome,SURFACE,1,0.025,KEPT
recessive disorders,SURFACE,1,0.025,KEPT
recessive genetic disorders,SURFACE,1,0.025,KEPT
recessive polycystic kidney disease,SURFACE,1,0.025,KEPT
recognizing right heart dysfunction,SURFACE,1,0.025,KEPT
recommendations**,SURFACE,1,0.025,KEPT
recommended assays,SURFACE,1,0.025,KEPT
recommended testing plan,SURFACE,1,0.025,KEPT
record,SURFACE,1,0.025,KEPT
record-keeping,SURFACE,1,0.025,KEPT
recorded,SURFACE,1,0.025,KEPT
recorded body temperature,SURFACE,1,0.025,KEPT
recording symptoms,SURFACE,1,0.025,KEPT
records,SURFACE,1,0.025,KEPT
recovered,SURFACE,1,0.025,KEPT
"recreational drug use.\"",\n\n",SURFACE,1,0.025,KEPT
recur,SURFACE,1,0.025,KEPT
recurrent abdominal pain,SURFACE,1,0.025,KEPT
recurrent cough,SURFACE,1,0.025,KEPT
recurrent fever,SURFACE,1,0.025,KEPT
recurrent infection,SURFACE,1,0.025,KEPT
recurrent pneumonia,SURFACE,1,0.025,KEPT
recurrent redness,SURFACE,1,0.025,KEPT
recurrent symptoms,SURFACE,1,0.025,KEPT
recurrent uveitis,SURFACE,1,0.025,KEPT
recurrent vomiting,SURFACE,1,0.025,KEPT
recurrent whipple's disease,SURFACE,1,0.025,KEPT
recurs,SURFACE,1,0.025,KEPT
red blood cells,SURFACE,1,0.025,KEPT
reduce,SURFACE,1,0.025,KEPT
reduces,SURFACE,1,0.025,KEPT
reduction,SURFACE,1,0.025,KEPT
reference,SURFACE,1,0.025,KEPT
"reference ranges.\""\n}"" **analysis",SURFACE,1,0.025,KEPT
referral list,SURFACE,1,0.025,KEPT
refine groundwork imaging,SURFACE,1,0.025,KEPT
refined,SURFACE,1,0.025,KEPT
refined testing,SURFACE,1,0.025,KEPT
refinement,SURFACE,1,0.025,KEPT
reflective,SURFACE,1,0.025,KEPT
refractory epilepsy,SURFACE,1,0.025,KEPT
refutation,SURFACE,1,0.025,KEPT
regarding,SURFACE,1,0.025,KEPT
region,SURFACE,1,0.025,KEPT
regional context**,SURFACE,1,0.025,KEPT
regional differences,SURFACE,1,0.025,KEPT
regional lymph node dissection,SURFACE,1,0.025,KEPT
regions,SURFACE,1,0.025,KEPT
registration,SURFACE,1,0.025,KEPT
regular **follow-up imaging**,SURFACE,1,0.025,KEPT
regular assessment,SURFACE,1,0.025,KEPT
regular assessments,SURFACE,1,0.025,KEPT
regular evaluations,SURFACE,1,0.025,KEPT
regular medications,SURFACE,1,0.025,KEPT
regular monitoring,SURFACE,1,0.025,KEPT
regular ocular assessments,SURFACE,1,0.025,KEPT
regular psychomotor development,SURFACE,1,0.025,KEPT
regular review,SURFACE,1,0.025,KEPT
regularities,SURFACE,1,0.025,KEPT
regularization,SURFACE,1,0.025,KEPT
regularly assessing,SURFACE,1,0.025,KEPT
regulate,SURFACE,1,0.025,KEPT
rehabilitation,SURFACE,1,0.025,KEPT
rehabilitation specialists,SURFACE,1,0.025,KEPT
reinforced**,SURFACE,1,0.025,KEPT
reinforcing key areas,SURFACE,1,0.025,KEPT
reinforcing responsibility,SURFACE,1,0.025,KEPT
reiterating,SURFACE,1,0.025,KEPT
relationships,SURFACE,1,0.025,KEPT
"relatives.\"",\n\n",SURFACE,1,0.025,KEPT
relay,SURFACE,1,0.025,KEPT
release,SURFACE,1,0.025,KEPT
relief,SURFACE,1,0.025,KEPT
relieve,SURFACE,1,0.025,KEPT
remaining,SURFACE,1,0.025,KEPT
remind,SURFACE,1,0.025,KEPT
reminder,SURFACE,1,0.025,KEPT
remnants,SURFACE,1,0.025,KEPT
removed,SURFACE,1,0.025,KEPT
renal arteries,SURFACE,1,0.025,KEPT
"renal arteries.\"",\n\n",SURFACE,1,0.025,KEPT
renal assessment,SURFACE,1,0.025,KEPT
renal causes,SURFACE,1,0.025,KEPT
renal consequences,SURFACE,1,0.025,KEPT
renal contributions,SURFACE,1,0.025,KEPT
renal cysts,SURFACE,1,0.025,KEPT
renal damage,SURFACE,1,0.025,KEPT
renal dysfunction)**,SURFACE,1,0.025,KEPT
renal function impairment,SURFACE,1,0.025,KEPT
renal insufficiency,SURFACE,1,0.025,KEPT
renal malformations,SURFACE,1,0.025,KEPT
renal manifestation,SURFACE,1,0.025,KEPT
renal manifestations,SURFACE,1,0.025,KEPT
renal parenchymal disease,SURFACE,1,0.025,KEPT
renal pathologies,SURFACE,1,0.025,KEPT
renal pathology,SURFACE,1,0.025,KEPT
renal profile,SURFACE,1,0.025,KEPT
renal structure,SURFACE,1,0.025,KEPT
renal studies,SURFACE,1,0.025,KEPT
renal symptoms,SURFACE,1,0.025,KEPT
renal ultrasound)**,SURFACE,1,0.025,KEPT
renin,SURFACE,1,0.025,KEPT
renin activity**,SURFACE,1,0.025,KEPT
repeating,SURFACE,1,0.025,KEPT
replenishment,SURFACE,1,0.025,KEPT
"reported.\"",\n  \""initial test results\",SURFACE,1,0.025,KEPT
"reported.\"",\n\n",SURFACE,1,0.025,KEPT
reports,SURFACE,1,0.025,KEPT
representation,SURFACE,1,0.025,KEPT
reproductive,SURFACE,1,0.025,KEPT
reproductive anatomy,SURFACE,1,0.025,KEPT
reproductive choices,SURFACE,1,0.025,KEPT
reproductive function,SURFACE,1,0.025,KEPT
reproductive hormone function,SURFACE,1,0.025,KEPT
reproductive options,SURFACE,1,0.025,KEPT
reproductive organs,SURFACE,1,0.025,KEPT
reproductive technologies,SURFACE,1,0.025,KEPT
reproductive tract,SURFACE,1,0.025,KEPT
request,SURFACE,1,0.025,KEPT
requested format,SURFACE,1,0.025,KEPT
reservations,SURFACE,1,0.025,KEPT
reserved,SURFACE,1,0.025,KEPT
reservoir mask,SURFACE,1,0.025,KEPT
resides,SURFACE,1,0.025,KEPT
residual disease,SURFACE,1,0.025,KEPT
residual issues,SURFACE,1,0.025,KEPT
resistance,SURFACE,1,0.025,KEPT
resonate,SURFACE,1,0.025,KEPT
resort,SURFACE,1,0.025,KEPT
respecting,SURFACE,1,0.025,KEPT
"respectively.\""\n",SURFACE,1,0.025,KEPT
respiratory acidosis,SURFACE,1,0.025,KEPT
respiratory assessment,SURFACE,1,0.025,KEPT
respiratory decline,SURFACE,1,0.025,KEPT
respiratory distress syndrome,SURFACE,1,0.025,KEPT
respiratory failure,SURFACE,1,0.025,KEPT
respiratory insufficiency,SURFACE,1,0.025,KEPT
"respiratory insufficiency.\"",\n\n",SURFACE,1,0.025,KEPT
respiratory manifestations,SURFACE,1,0.025,KEPT
respiratory pathogens**,SURFACE,1,0.025,KEPT
respiratory pathology,SURFACE,1,0.025,KEPT
respiratory problems,SURFACE,1,0.025,KEPT
respiratory secretions,SURFACE,1,0.025,KEPT
respiratory status,SURFACE,1,0.025,KEPT
respiratory support,SURFACE,1,0.025,KEPT
respond quickly,SURFACE,1,0.025,KEPT
response to therapy,SURFACE,1,0.025,KEPT
restenosis,SURFACE,1,0.025,KEPT
restricted,SURFACE,1,0.025,KEPT
restrictive lung disease,SURFACE,1,0.025,KEPT
result,SURFACE,1,0.025,KEPT
retained,SURFACE,1,0.025,KEPT
retesting,SURFACE,1,0.025,KEPT
reteval,SURFACE,1,0.025,KEPT
retina thinning,SURFACE,1,0.025,KEPT
retinal,SURFACE,1,0.025,KEPT
retinal degeneration,SURFACE,1,0.025,KEPT
retinal detachment,SURFACE,1,0.025,KEPT
retinal diseases,SURFACE,1,0.025,KEPT
retinal disorders,SURFACE,1,0.025,KEPT
retinal dystrophies,SURFACE,1,0.025,KEPT
retinal dystrophies**,SURFACE,1,0.025,KEPT
retinal function,SURFACE,1,0.025,KEPT
retinal layer loss,SURFACE,1,0.025,KEPT
retinal pigment epithelium,SURFACE,1,0.025,KEPT
retinal thinning,SURFACE,1,0.025,KEPT
retrobulbar anesthesia,SURFACE,1,0.025,KEPT
retromicrognathia,SURFACE,1,0.025,KEPT
return inconclusive,SURFACE,1,0.025,KEPT
return pertinent,SURFACE,1,0.025,KEPT
return sooner,SURFACE,1,0.025,KEPT
return two-and-half months,SURFACE,1,0.025,KEPT
returned,SURFACE,1,0.025,KEPT
revealed,SURFACE,1,0.025,KEPT
revealing adenocarcinoma,SURFACE,1,0.025,KEPT
review family history**,SURFACE,1,0.025,KEPT
review**,SURFACE,1,0.025,KEPT
revised consensus,SURFACE,1,0.025,KEPT
revised differential diagnosis,SURFACE,1,0.025,KEPT
revised prioritization,SURFACE,1,0.025,KEPT
revised summary,SURFACE,1,0.025,KEPT
rheumatoid arthritis**,SURFACE,1,0.025,KEPT
rheumatological skin condition,SURFACE,1,0.025,KEPT
rheumatologist,SURFACE,1,0.025,KEPT
rheumatology department,SURFACE,1,0.025,KEPT
"rhizomelic arms.\"",\n\n",SURFACE,1,0.025,KEPT
rib pairs,SURFACE,1,0.025,KEPT
"right 28\u00b0,",SURFACE,1,0.025,KEPT
right calf,SURFACE,1,0.025,KEPT
right dysplastic kidney,SURFACE,1,0.025,KEPT
right extremity,SURFACE,1,0.025,KEPT
right eye conjunctivitis,SURFACE,1,0.025,KEPT
right eye exam,SURFACE,1,0.025,KEPT
right feet,SURFACE,1,0.025,KEPT
right fingers,SURFACE,1,0.025,KEPT
right foot with,SURFACE,1,0.025,KEPT
right hand,SURFACE,1,0.025,KEPT
right heart catheterization,SURFACE,1,0.025,KEPT
right heart dysfunction)** -,SURFACE,1,0.025,KEPT
right heart failure,SURFACE,1,0.025,KEPT
right heart function,SURFACE,1,0.025,KEPT
right heart pressures,SURFACE,1,0.025,KEPT
right heart status,SURFACE,1,0.025,KEPT
right heart volume overload,SURFACE,1,0.025,KEPT
right lower quadrant lymphadenopathy,SURFACE,1,0.025,KEPT
right superior central incisor,SURFACE,1,0.025,KEPT
right t5,SURFACE,1,0.025,KEPT
right track focusing,SURFACE,1,0.025,KEPT
right upper lobe mass,SURFACE,1,0.025,KEPT
right upper lobe opacity,SURFACE,1,0.025,KEPT
"right upper lobe opacity

**analysis",SURFACE,1,0.025,KEPT
right upper lobectomy,SURFACE,1,0.025,KEPT
right ureteral,SURFACE,1,0.025,KEPT
right ventricle,SURFACE,1,0.025,KEPT
right ventricle size,SURFACE,1,0.025,KEPT
right ventricular function,SURFACE,1,0.025,KEPT
right ventricular overload,SURFACE,1,0.025,KEPT
right ventricular performance,SURFACE,1,0.025,KEPT
right ventricular pressure overload,SURFACE,1,0.025,KEPT
right ventricular strain,SURFACE,1,0.025,KEPT
right-convex,SURFACE,1,0.025,KEPT
right-sided facial palsy,SURFACE,1,0.025,KEPT
rigidity,SURFACE,1,0.025,KEPT
rigor mortis,SURFACE,1,0.025,KEPT
rigorous,SURFACE,1,0.025,KEPT
rigorous analysis,SURFACE,1,0.025,KEPT
ring fingers,SURFACE,1,0.025,KEPT
risk assessment,SURFACE,1,0.025,KEPT
risk exposures,SURFACE,1,0.025,KEPT
risk factor,SURFACE,1,0.025,KEPT
risk factor layers,SURFACE,1,0.025,KEPT
risk management,SURFACE,1,0.025,KEPT
rivaroxaban,SURFACE,1,0.025,KEPT
rna,SURFACE,1,0.025,KEPT
rna levels,SURFACE,1,0.025,KEPT
roadmap,SURFACE,1,0.025,KEPT
robust **multidisciplinary team**,SURFACE,1,0.025,KEPT
robustness,SURFACE,1,0.025,KEPT
rods,SURFACE,1,0.025,KEPT
roles,SURFACE,1,0.025,KEPT
room,SURFACE,1,0.025,KEPT
rooted,SURFACE,1,0.025,KEPT
roots,SURFACE,1,0.025,KEPT
rotated,SURFACE,1,0.025,KEPT
rotatory,SURFACE,1,0.025,KEPT
round face,SURFACE,1,0.025,KEPT
round subcutaneous fat masses,SURFACE,1,0.025,KEPT
rounds,SURFACE,1,0.025,KEPT
routine follow-up imaging,SURFACE,1,0.025,KEPT
rpe,SURFACE,1,0.025,KEPT
rpe atrophy,SURFACE,1,0.025,KEPT
rs80338708,SURFACE,1,0.025,KEPT
rul,SURFACE,1,0.025,KEPT
rule out lymphoma,SURFACE,1,0.025,KEPT
running,SURFACE,1,0.025,KEPT
running difficulty,SURFACE,1,0.025,KEPT
runny nose,SURFACE,1,0.025,KEPT
"rural areas.\"",\n\n",SURFACE,1,0.025,KEPT
russell-silver syndrome,SURFACE,1,0.025,KEPT
s activity,SURFACE,1,0.025,KEPT
saa,SURFACE,1,0.025,KEPT
sacroiliac joints,SURFACE,1,0.025,KEPT
salivary pooling,SURFACE,1,0.025,KEPT
salmon-colored rashes,SURFACE,1,0.025,KEPT
salmonella,SURFACE,1,0.025,KEPT
sample collection,SURFACE,1,0.025,KEPT
sampling,SURFACE,1,0.025,KEPT
sandal,SURFACE,1,0.025,KEPT
sanger,SURFACE,1,0.025,KEPT
sanger sequencing,SURFACE,1,0.025,KEPT
sanger sequencing results**,SURFACE,1,0.025,KEPT
sara scale,SURFACE,1,0.025,KEPT
sars-cov-2,SURFACE,1,0.025,KEPT
sars-cov-2 infection,SURFACE,1,0.025,KEPT
saving,SURFACE,1,0.025,KEPT
sca,SURFACE,1,0.025,KEPT
sca**,SURFACE,1,0.025,KEPT
sca** – testing,SURFACE,1,0.025,KEPT
sca1,SURFACE,1,0.025,KEPT
sca2,SURFACE,1,0.025,KEPT
sca3,SURFACE,1,0.025,KEPT
scalp,SURFACE,1,0.025,KEPT
scanning,SURFACE,1,0.025,KEPT
scanning speech,SURFACE,1,0.025,KEPT
scant sputum,SURFACE,1,0.025,KEPT
scas,SURFACE,1,0.025,KEPT
scene,SURFACE,1,0.025,KEPT
schedule **regular ocular follow-ups**,SURFACE,1,0.025,KEPT
scheduled testing,SURFACE,1,0.025,KEPT
scheduled tests,SURFACE,1,0.025,KEPT
scid,SURFACE,1,0.025,KEPT
scleral thickness,SURFACE,1,0.025,KEPT
scoring,SURFACE,1,0.025,KEPT
screened,SURFACE,1,0.025,KEPT
screening techniques,SURFACE,1,0.025,KEPT
scrutinized,SURFACE,1,0.025,KEPT
second-degree,SURFACE,1,0.025,KEPT
second-degree consanguineous,SURFACE,1,0.025,KEPT
secondary changes,SURFACE,1,0.025,KEPT
secondary complications,SURFACE,1,0.025,KEPT
secondary consequence,SURFACE,1,0.025,KEPT
secondary generalization,SURFACE,1,0.025,KEPT
secondary generalization**,SURFACE,1,0.025,KEPT
secondary glaucoma,SURFACE,1,0.025,KEPT
secondary hospital,SURFACE,1,0.025,KEPT
secondary hypertension,SURFACE,1,0.025,KEPT
secondary hypertension**,SURFACE,1,0.025,KEPT
secondary hypertension**.,SURFACE,1,0.025,KEPT
secondary impacts,SURFACE,1,0.025,KEPT
secondary infections,SURFACE,1,0.025,KEPT
secondary option,SURFACE,1,0.025,KEPT
secondary processes,SURFACE,1,0.025,KEPT
secondary pulmonary hypertension,SURFACE,1,0.025,KEPT
secondary retinal tumors,SURFACE,1,0.025,KEPT
secondary retinal tumors**,SURFACE,1,0.025,KEPT
secondary step,SURFACE,1,0.025,KEPT
secondary to mis-c**,SURFACE,1,0.025,KEPT
secondary to oligohydramnios:**,SURFACE,1,0.025,KEPT
secondary tumors,SURFACE,1,0.025,KEPT
section,SURFACE,1,0.025,KEPT
secukinumab,SURFACE,1,0.025,KEPT
secure,SURFACE,1,0.025,KEPT
securing,SURFACE,1,0.025,KEPT
sedentary lifestyle,SURFACE,1,0.025,KEPT
sees,SURFACE,1,0.025,KEPT
segment,SURFACE,1,0.025,KEPT
segment elevation,SURFACE,1,0.025,KEPT
seizure-like events,SURFACE,1,0.025,KEPT
self-discontinuation,SURFACE,1,0.025,KEPT
self-discontinuing prednisone,SURFACE,1,0.025,KEPT
sella turcica,SURFACE,1,0.025,KEPT
sella turcica**,SURFACE,1,0.025,KEPT
semen analysis,SURFACE,1,0.025,KEPT
semiology,SURFACE,1,0.025,KEPT
senescent,SURFACE,1,0.025,KEPT
sensible,SURFACE,1,0.025,KEPT
sensitivity testing,SURFACE,1,0.025,KEPT
sensitivity testing**,SURFACE,1,0.025,KEPT
sensor,SURFACE,1,0.025,KEPT
"sensorineural hearing loss.\""\n",SURFACE,1,0.025,KEPT
sensory,SURFACE,1,0.025,KEPT
sent,SURFACE,1,0.025,KEPT
sentences,SURFACE,1,0.025,KEPT
sepsis-related encephalopathy,SURFACE,1,0.025,KEPT
septate uterus,SURFACE,1,0.025,KEPT
septate uterus)**,SURFACE,1,0.025,KEPT
septation,SURFACE,1,0.025,KEPT
septic arthritis,SURFACE,1,0.025,KEPT
septic processes,SURFACE,1,0.025,KEPT
septic signs,SURFACE,1,0.025,KEPT
septum,SURFACE,1,0.025,KEPT
sequelae,SURFACE,1,0.025,KEPT
sequelae-related,SURFACE,1,0.025,KEPT
sequenced,SURFACE,1,0.025,KEPT
sequencing outcomes,SURFACE,1,0.025,KEPT
sequencing results,SURFACE,1,0.025,KEPT
seretide,SURFACE,1,0.025,KEPT
series,SURFACE,1,0.025,KEPT
serious,SURFACE,1,0.025,KEPT
seroconversion,SURFACE,1,0.025,KEPT
serologic,SURFACE,1,0.025,KEPT
serologic tests,SURFACE,1,0.025,KEPT
serological evaluations,SURFACE,1,0.025,KEPT
serological indicators,SURFACE,1,0.025,KEPT
serological studies,SURFACE,1,0.025,KEPT
serologies,SURFACE,1,0.025,KEPT
serology**,SURFACE,1,0.025,KEPT
serositis,SURFACE,1,0.025,KEPT
serum ace**,SURFACE,1,0.025,KEPT
serum amyloid a,SURFACE,1,0.025,KEPT
serum amyloid protein,SURFACE,1,0.025,KEPT
serum autoantibody,SURFACE,1,0.025,KEPT
serum c4,SURFACE,1,0.025,KEPT
serum glucose concentration,SURFACE,1,0.025,KEPT
serum hormone levels**,SURFACE,1,0.025,KEPT
serum igd,SURFACE,1,0.025,KEPT
serum lactate dehydrogenase,SURFACE,1,0.025,KEPT
serum potassium ion,SURFACE,1,0.025,KEPT
serum tests,SURFACE,1,0.025,KEPT
serum total ige,SURFACE,1,0.025,KEPT
serum uric acid,SURFACE,1,0.025,KEPT
serum-free calcium,SURFACE,1,0.025,KEPT
sessions,SURFACE,1,0.025,KEPT
set aside,SURFACE,1,0.025,KEPT
set up,SURFACE,1,0.025,KEPT
setting,SURFACE,1,0.025,KEPT
severely restricted,SURFACE,1,0.025,KEPT
sex chromosome aneuploidy,SURFACE,1,0.025,KEPT
sexual characteristics,SURFACE,1,0.025,KEPT
sexual characters,SURFACE,1,0.025,KEPT
sexual development,SURFACE,1,0.025,KEPT
sexual organs,SURFACE,1,0.025,KEPT
sexually ambiguous genitalia,SURFACE,1,0.025,KEPT
shade,SURFACE,1,0.025,KEPT
shaping,SURFACE,1,0.025,KEPT
shared accountability,SURFACE,1,0.025,KEPT
shared accountability system,SURFACE,1,0.025,KEPT
shared decision-making,SURFACE,1,0.025,KEPT
shared features,SURFACE,1,0.025,KEPT
shared symptoms,SURFACE,1,0.025,KEPT
shares,SURFACE,1,0.025,KEPT
shed light,SURFACE,1,0.025,KEPT
shifted,SURFACE,1,0.025,KEPT
short,SURFACE,1,0.025,KEPT
short femur length,SURFACE,1,0.025,KEPT
short half-life,SURFACE,1,0.025,KEPT
short hands,SURFACE,1,0.025,KEPT
short hypoplastic,SURFACE,1,0.025,KEPT
short limbs,SURFACE,1,0.025,KEPT
short long bones,SURFACE,1,0.025,KEPT
shoulder,SURFACE,1,0.025,KEPT
"shoulder.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
shoulders,SURFACE,1,0.025,KEPT
shunt,SURFACE,1,0.025,KEPT
sichuan province,SURFACE,1,0.025,KEPT
side,SURFACE,1,0.025,KEPT
side effects**,SURFACE,1,0.025,KEPT
side effects** could factor,SURFACE,1,0.025,KEPT
"side.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
sides,SURFACE,1,0.025,KEPT
sigmoid,SURFACE,1,0.025,KEPT
signaling,SURFACE,1,0.025,KEPT
signs of **end-organ damage**,SURFACE,1,0.025,KEPT
"signs.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
sildenafil,SURFACE,1,0.025,KEPT
simon\u2013binnet test,SURFACE,1,0.025,KEPT
simple words,SURFACE,1,0.025,KEPT
simulate,SURFACE,1,0.025,KEPT
simultaneously,SURFACE,1,0.025,KEPT
simultaneously conduct the **quantiferon gold test**,SURFACE,1,0.025,KEPT
single transverse crease,SURFACE,1,0.025,KEPT
single-gene disorders,SURFACE,1,0.025,KEPT
sinus tachycardia,SURFACE,1,0.025,KEPT
sister,SURFACE,1,0.025,KEPT
sister's,SURFACE,1,0.025,KEPT
sister's case,SURFACE,1,0.025,KEPT
sit steady,SURFACE,1,0.025,KEPT
site,SURFACE,1,0.025,KEPT
sitting,SURFACE,1,0.025,KEPT
situational stressors,SURFACE,1,0.025,KEPT
skeletal anomalies**,SURFACE,1,0.025,KEPT
skeletal assessment,SURFACE,1,0.025,KEPT
skeletal characteristics,SURFACE,1,0.025,KEPT
skeletal class iii,SURFACE,1,0.025,KEPT
skeletal condition,SURFACE,1,0.025,KEPT
skeletal conditions,SURFACE,1,0.025,KEPT
skeletal configuration,SURFACE,1,0.025,KEPT
skeletal deficiencies,SURFACE,1,0.025,KEPT
skeletal deficiency,SURFACE,1,0.025,KEPT
skeletal deficits,SURFACE,1,0.025,KEPT
skeletal development,SURFACE,1,0.025,KEPT
skeletal dysplasia**,SURFACE,1,0.025,KEPT
skeletal dysplasias**,SURFACE,1,0.025,KEPT
"skeletal dysplasias**

3. **recommended",SURFACE,1,0.025,KEPT
skeletal facial,SURFACE,1,0.025,KEPT
skeletal findings,SURFACE,1,0.025,KEPT
skeletal fragility,SURFACE,1,0.025,KEPT
skeletal issues,SURFACE,1,0.025,KEPT
skeletal malformations,SURFACE,1,0.025,KEPT
skeletal maturity,SURFACE,1,0.025,KEPT
skeletal outcome,SURFACE,1,0.025,KEPT
skeletal pathologies,SURFACE,1,0.025,KEPT
skeletal structure abnormalities,SURFACE,1,0.025,KEPT
skeletal structures,SURFACE,1,0.025,KEPT
skeletal survey**,SURFACE,1,0.025,KEPT
skeletal surveys,SURFACE,1,0.025,KEPT
skeletal surveys**,SURFACE,1,0.025,KEPT
skeletal system**,SURFACE,1,0.025,KEPT
skeletal visualization,SURFACE,1,0.025,KEPT
skeleton**,SURFACE,1,0.025,KEPT
skin,SURFACE,1,0.025,KEPT
skin changes,SURFACE,1,0.025,KEPT
skin examination,SURFACE,1,0.025,KEPT
skin features,SURFACE,1,0.025,KEPT
skin findings,SURFACE,1,0.025,KEPT
skin infections,SURFACE,1,0.025,KEPT
skin issues,SURFACE,1,0.025,KEPT
skin lesions,SURFACE,1,0.025,KEPT
skin rash,SURFACE,1,0.025,KEPT
skin rashes,SURFACE,1,0.025,KEPT
skull,SURFACE,1,0.025,KEPT
slant,SURFACE,1,0.025,KEPT
slanting eyes,SURFACE,1,0.025,KEPT
sleep,SURFACE,1,0.025,KEPT
sleep disturbance,SURFACE,1,0.025,KEPT
slight prognathism,SURFACE,1,0.025,KEPT
slow,SURFACE,1,0.025,KEPT
slow cognitive decline,SURFACE,1,0.025,KEPT
slow progression,SURFACE,1,0.025,KEPT
slowly growing,SURFACE,1,0.025,KEPT
slowness,SURFACE,1,0.025,KEPT
sma,SURFACE,1,0.025,KEPT
small hands,SURFACE,1,0.025,KEPT
small intestine,SURFACE,1,0.025,KEPT
small stature,SURFACE,1,0.025,KEPT
small uterus,SURFACE,1,0.025,KEPT
small-vessel vasculitis,SURFACE,1,0.025,KEPT
smith-magenis syndrome**,SURFACE,1,0.025,KEPT
smith-magenis syndromes,SURFACE,1,0.025,KEPT
smith-magenis syndromes**,SURFACE,1,0.025,KEPT
smn1,SURFACE,1,0.025,KEPT
smoking status,SURFACE,1,0.025,KEPT
smoother,SURFACE,1,0.025,KEPT
sms,SURFACE,1,0.025,KEPT
sms's profile,SURFACE,1,0.025,KEPT
snellen test,SURFACE,1,0.025,KEPT
so2,SURFACE,1,0.025,KEPT
social circle,SURFACE,1,0.025,KEPT
social development,SURFACE,1,0.025,KEPT
social domains,SURFACE,1,0.025,KEPT
sodium,SURFACE,1,0.025,KEPT
soft markers,SURFACE,1,0.025,KEPT
soft masses,SURFACE,1,0.025,KEPT
soft tissue composition,SURFACE,1,0.025,KEPT
soft tissues,SURFACE,1,0.025,KEPT
software console,SURFACE,1,0.025,KEPT
sojia,SURFACE,1,0.025,KEPT
solid clinical rationale,SURFACE,1,0.025,KEPT
solid consensus towards **juvenile idiopathic arthritis,SURFACE,1,0.025,KEPT
solid diagnosis,SURFACE,1,0.025,KEPT
solid diagnostic framework,SURFACE,1,0.025,KEPT
solid diagnostic workup,SURFACE,1,0.025,KEPT
solid list,SURFACE,1,0.025,KEPT
solid mass,SURFACE,1,0.025,KEPT
solid path,SURFACE,1,0.025,KEPT
solid rationale,SURFACE,1,0.025,KEPT
soluble,SURFACE,1,0.025,KEPT
somatotropin deficiency,SURFACE,1,0.025,KEPT
someone,SURFACE,1,0.025,KEPT
son,SURFACE,1,0.025,KEPT
sore throat,SURFACE,1,0.025,KEPT
sound,SURFACE,1,0.025,KEPT
source,SURFACE,1,0.025,KEPT
sources,SURFACE,1,0.025,KEPT
sources of,SURFACE,1,0.025,KEPT
south india,SURFACE,1,0.025,KEPT
southern,SURFACE,1,0.025,KEPT
southern germany,SURFACE,1,0.025,KEPT
sox9,SURFACE,1,0.025,KEPT
span,SURFACE,1,0.025,KEPT
spares,SURFACE,1,0.025,KEPT
sparse hair,SURFACE,1,0.025,KEPT
"sparse.\"",\n\n",SURFACE,1,0.025,KEPT
spasmodic,SURFACE,1,0.025,KEPT
spasms,SURFACE,1,0.025,KEPT
speaks,SURFACE,1,0.025,KEPT
special,SURFACE,1,0.025,KEPT
special school,SURFACE,1,0.025,KEPT
specialist collaboration**,SURFACE,1,0.025,KEPT
specialist meeting**,SURFACE,1,0.025,KEPT
specialist** familiar,SURFACE,1,0.025,KEPT
specialization,SURFACE,1,0.025,KEPT
specialized care,SURFACE,1,0.025,KEPT
specialized hospital,SURFACE,1,0.025,KEPT
specialized imaging,SURFACE,1,0.025,KEPT
specializes,SURFACE,1,0.025,KEPT
"specified.\"",\n\n  \""clinical",SURFACE,1,0.025,KEPT
specifying,SURFACE,1,0.025,KEPT
spect,SURFACE,1,0.025,KEPT
speech development,SURFACE,1,0.025,KEPT
sphingomyelinase deficiency,SURFACE,1,0.025,KEPT
spike protein,SURFACE,1,0.025,KEPT
spike waves,SURFACE,1,0.025,KEPT
spike-wave activity,SURFACE,1,0.025,KEPT
spinal abnormalities,SURFACE,1,0.025,KEPT
spinal assessment,SURFACE,1,0.025,KEPT
spinal cord,SURFACE,1,0.025,KEPT
spinal muscular atrophy,SURFACE,1,0.025,KEPT
spinal surgery,SURFACE,1,0.025,KEPT
spine,SURFACE,1,0.025,KEPT
spine x-ray,SURFACE,1,0.025,KEPT
spinocerebellar,SURFACE,1,0.025,KEPT
spinocerebellar ataxia,SURFACE,1,0.025,KEPT
spinocerebellar ataxias,SURFACE,1,0.025,KEPT
spirit moving,SURFACE,1,0.025,KEPT
splenic,SURFACE,1,0.025,KEPT
splenic circulation,SURFACE,1,0.025,KEPT
splenic region,SURFACE,1,0.025,KEPT
splenic vein,SURFACE,1,0.025,KEPT
splenic vein obstruction,SURFACE,1,0.025,KEPT
splenic vein thrombosis,SURFACE,1,0.025,KEPT
spo2,SURFACE,1,0.025,KEPT
spondyloarthritis,SURFACE,1,0.025,KEPT
spontaneous,SURFACE,1,0.025,KEPT
spontaneous thrombosis,SURFACE,1,0.025,KEPT
spontaneously,SURFACE,1,0.025,KEPT
sputum analysis,SURFACE,1,0.025,KEPT
sputum collection,SURFACE,1,0.025,KEPT
sputum cultures,SURFACE,1,0.025,KEPT
sputum cytology,SURFACE,1,0.025,KEPT
sputum production,SURFACE,1,0.025,KEPT
squamous papilloma)** -,SURFACE,1,0.025,KEPT
square wave jerks,SURFACE,1,0.025,KEPT
squint,SURFACE,1,0.025,KEPT
squint vision,SURFACE,1,0.025,KEPT
sry,SURFACE,1,0.025,KEPT
sry gene,SURFACE,1,0.025,KEPT
ssws,SURFACE,1,0.025,KEPT
stabilization,SURFACE,1,0.025,KEPT
stabilize,SURFACE,1,0.025,KEPT
stabilized,SURFACE,1,0.025,KEPT
stabilizes,SURFACE,1,0.025,KEPT
"stable.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
stage 1b,SURFACE,1,0.025,KEPT
stage ii,SURFACE,1,0.025,KEPT
stage ii lung adenocarcinoma,SURFACE,1,0.025,KEPT
staining,SURFACE,1,0.025,KEPT
standard evaluation,SURFACE,1,0.025,KEPT
standard examination,SURFACE,1,0.025,KEPT
standard examinations,SURFACE,1,0.025,KEPT
standard fetal,SURFACE,1,0.025,KEPT
standard fetal echocardiogram,SURFACE,1,0.025,KEPT
standard growth measurement techniques,SURFACE,1,0.025,KEPT
standard imaging,SURFACE,1,0.025,KEPT
standard karyotyping,SURFACE,1,0.025,KEPT
standard procedure,SURFACE,1,0.025,KEPT
standard recommendation,SURFACE,1,0.025,KEPT
standard sputum,SURFACE,1,0.025,KEPT
standard ultrasound,SURFACE,1,0.025,KEPT
standard x-ray,SURFACE,1,0.025,KEPT
standard x-rays,SURFACE,1,0.025,KEPT
standardized,SURFACE,1,0.025,KEPT
standardized a-/b-scan ultrasound,SURFACE,1,0.025,KEPT
standardized questionnaires,SURFACE,1,0.025,KEPT
standardized visual quality,SURFACE,1,0.025,KEPT
standards,SURFACE,1,0.025,KEPT
staphylococcus aureus,SURFACE,1,0.025,KEPT
stargardt,SURFACE,1,0.025,KEPT
stargardt disease,SURFACE,1,0.025,KEPT
stat3,SURFACE,1,0.025,KEPT
stated,SURFACE,1,0.025,KEPT
states,SURFACE,1,0.025,KEPT
static perimetry,SURFACE,1,0.025,KEPT
status checks,SURFACE,1,0.025,KEPT
staying,SURFACE,1,0.025,KEPT
steer,SURFACE,1,0.025,KEPT
stem,SURFACE,1,0.025,KEPT
stemi,SURFACE,1,0.025,KEPT
stems,SURFACE,1,0.025,KEPT
step,SURFACE,1,0.025,KEPT
"steps
1",SURFACE,1,0.025,KEPT
"steps
i advocate",SURFACE,1,0.025,KEPT
steps forward,SURFACE,1,0.025,KEPT
steroid hormones,SURFACE,1,0.025,KEPT
steroid therapy,SURFACE,1,0.025,KEPT
sth,SURFACE,1,0.025,KEPT
stiffness,SURFACE,1,0.025,KEPT
stigma,SURFACE,1,0.025,KEPT
stigmata,SURFACE,1,0.025,KEPT
still's,SURFACE,1,0.025,KEPT
still’s disease**,SURFACE,1,0.025,KEPT
still’s disease/reactive arthritis**,SURFACE,1,0.025,KEPT
stimulant,SURFACE,1,0.025,KEPT
stimulants,SURFACE,1,0.025,KEPT
stimulation test,SURFACE,1,0.025,KEPT
stipulated,SURFACE,1,0.025,KEPT
stomach,SURFACE,1,0.025,KEPT
stool tests,SURFACE,1,0.025,KEPT
stopped,SURFACE,1,0.025,KEPT
stopping,SURFACE,1,0.025,KEPT
storage function,SURFACE,1,0.025,KEPT
strategic pathway,SURFACE,1,0.025,KEPT
strategic recommendation,SURFACE,1,0.025,KEPT
"strategy
in light",SURFACE,1,0.025,KEPT
stratification,SURFACE,1,0.025,KEPT
streamlining,SURFACE,1,0.025,KEPT
street,SURFACE,1,0.025,KEPT
street context,SURFACE,1,0.025,KEPT
strengthening,SURFACE,1,0.025,KEPT
strengths,SURFACE,1,0.025,KEPT
stressed,SURFACE,1,0.025,KEPT
stressing,SURFACE,1,0.025,KEPT
stressors,SURFACE,1,0.025,KEPT
striae,SURFACE,1,0.025,KEPT
striae distensae,SURFACE,1,0.025,KEPT
strip,SURFACE,1,0.025,KEPT
stroke,SURFACE,1,0.025,KEPT
structural analysis,SURFACE,1,0.025,KEPT
structural assessment,SURFACE,1,0.025,KEPT
structural brain,SURFACE,1,0.025,KEPT
structural brain imaging,SURFACE,1,0.025,KEPT
structural causes,SURFACE,1,0.025,KEPT
structural changes,SURFACE,1,0.025,KEPT
structural context,SURFACE,1,0.025,KEPT
structural defects,SURFACE,1,0.025,KEPT
structural diagnosis,SURFACE,1,0.025,KEPT
structural etiologies,SURFACE,1,0.025,KEPT
structural evaluation,SURFACE,1,0.025,KEPT
structural heart,SURFACE,1,0.025,KEPT
structural heart conditions,SURFACE,1,0.025,KEPT
structural heart defects,SURFACE,1,0.025,KEPT
structural kidney assessment,SURFACE,1,0.025,KEPT
structural kidney issues,SURFACE,1,0.025,KEPT
structural lesions,SURFACE,1,0.025,KEPT
structural malformations,SURFACE,1,0.025,KEPT
structural obstruction,SURFACE,1,0.025,KEPT
structural renal issues,SURFACE,1,0.025,KEPT
structured action plan,SURFACE,1,0.025,KEPT
structured plan,SURFACE,1,0.025,KEPT
structured planning,SURFACE,1,0.025,KEPT
structured questionnaire,SURFACE,1,0.025,KEPT
struggles,SURFACE,1,0.025,KEPT
stub case,SURFACE,1,0.025,KEPT
stubby fingers,SURFACE,1,0.025,KEPT
sub-intensive care unit,SURFACE,1,0.025,KEPT
subclavian,SURFACE,1,0.025,KEPT
subcutaneous layer,SURFACE,1,0.025,KEPT
subcutaneous tissues,SURFACE,1,0.025,KEPT
subjective,SURFACE,1,0.025,KEPT
submicroscopic,SURFACE,1,0.025,KEPT
submicroscopic chromosomal abnormalities,SURFACE,1,0.025,KEPT
subsequent,SURFACE,1,0.025,KEPT
substance,SURFACE,1,0.025,KEPT
substance exposure,SURFACE,1,0.025,KEPT
substance use,SURFACE,1,0.025,KEPT
substance use**,SURFACE,1,0.025,KEPT
substances,SURFACE,1,0.025,KEPT
substantiate,SURFACE,1,0.025,KEPT
substantiates,SURFACE,1,0.025,KEPT
subtler presentations,SURFACE,1,0.025,KEPT
subtlety,SURFACE,1,0.025,KEPT
subtype,SURFACE,1,0.025,KEPT
succinct,SURFACE,1,0.025,KEPT
succumbed,SURFACE,1,0.025,KEPT
sudden,SURFACE,1,0.025,KEPT
sudden cardiac event,SURFACE,1,0.025,KEPT
sudden cardiac issue,SURFACE,1,0.025,KEPT
sudden death,SURFACE,1,0.025,KEPT
sudden sweat,SURFACE,1,0.025,KEPT
sudden temperature,SURFACE,1,0.025,KEPT
suggested final,SURFACE,1,0.025,KEPT
suggestions moving,SURFACE,1,0.025,KEPT
sulfamethoxazole,SURFACE,1,0.025,KEPT
summaries,SURFACE,1,0.025,KEPT
summarized current state,SURFACE,1,0.025,KEPT
summarized final,SURFACE,1,0.025,KEPT
summer,SURFACE,1,0.025,KEPT
superficial gastritis,SURFACE,1,0.025,KEPT
superior lateral incisors,SURFACE,1,0.025,KEPT
supplement,SURFACE,1,0.025,KEPT
supplementation,SURFACE,1,0.025,KEPT
support**,SURFACE,1,0.025,KEPT
"support.\"",\n\n",SURFACE,1,0.025,KEPT
supportive,SURFACE,1,0.025,KEPT
supportive evidence,SURFACE,1,0.025,KEPT
supportive interventions,SURFACE,1,0.025,KEPT
supportive investigations,SURFACE,1,0.025,KEPT
supportive testing,SURFACE,1,0.025,KEPT
supportive tests,SURFACE,1,0.025,KEPT
supportive tone,SURFACE,1,0.025,KEPT
supports,SURFACE,1,0.025,KEPT
supra-pubic pressure,SURFACE,1,0.025,KEPT
supranuclear palsy,SURFACE,1,0.025,KEPT
surface,SURFACE,1,0.025,KEPT
surfaced,SURFACE,1,0.025,KEPT
surfaces,SURFACE,1,0.025,KEPT
"surgery.\"",\n\n",SURFACE,1,0.025,KEPT
surgical,SURFACE,1,0.025,KEPT
surgical biopsy,SURFACE,1,0.025,KEPT
surgical complications,SURFACE,1,0.025,KEPT
surgical consideration,SURFACE,1,0.025,KEPT
surgical considerations,SURFACE,1,0.025,KEPT
surgical contexts,SURFACE,1,0.025,KEPT
surgical correction,SURFACE,1,0.025,KEPT
surgical decisions,SURFACE,1,0.025,KEPT
surgical discussions,SURFACE,1,0.025,KEPT
surgical exploration,SURFACE,1,0.025,KEPT
surgical history,SURFACE,1,0.025,KEPT
surgical intervention**,SURFACE,1,0.025,KEPT
surgical outcomes,SURFACE,1,0.025,KEPT
surgical planning,SURFACE,1,0.025,KEPT
surgical plans,SURFACE,1,0.025,KEPT
surgical procedure,SURFACE,1,0.025,KEPT
surgical recovery,SURFACE,1,0.025,KEPT
surgical resection,SURFACE,1,0.025,KEPT
surgical stress,SURFACE,1,0.025,KEPT
surrounding,SURFACE,1,0.025,KEPT
surrounding structures,SURFACE,1,0.025,KEPT
surveillance ct scan,SURFACE,1,0.025,KEPT
surveillance plan,SURFACE,1,0.025,KEPT
surveillance plans,SURFACE,1,0.025,KEPT
surveillance procedures,SURFACE,1,0.025,KEPT
surveillance protocols,SURFACE,1,0.025,KEPT
surveillance protocols**,SURFACE,1,0.025,KEPT
surveillance strategy,SURFACE,1,0.025,KEPT
survive,SURFACE,1,0.025,KEPT
susceptible,SURFACE,1,0.025,KEPT
suspicions,SURFACE,1,0.025,KEPT
suspicious,SURFACE,1,0.025,KEPT
suture fusion,SURFACE,1,0.025,KEPT
svt,SURFACE,1,0.025,KEPT
swallow food,SURFACE,1,0.025,KEPT
swallowing,SURFACE,1,0.025,KEPT
swallowing difficulties,SURFACE,1,0.025,KEPT
swallowing issues,SURFACE,1,0.025,KEPT
swaying,SURFACE,1,0.025,KEPT
sweat,SURFACE,1,0.025,KEPT
swelling,SURFACE,1,0.025,KEPT
swift,SURFACE,1,0.025,KEPT
swift processing,SURFACE,1,0.025,KEPT
swyer syndrome,SURFACE,1,0.025,KEPT
symbrachydactyly,SURFACE,1,0.025,KEPT
symmetrical growth,SURFACE,1,0.025,KEPT
symmetrical stature,SURFACE,1,0.025,KEPT
symptom,SURFACE,1,0.025,KEPT
symptom changes,SURFACE,1,0.025,KEPT
symptom control,SURFACE,1,0.025,KEPT
symptom monitoring,SURFACE,1,0.025,KEPT
symptom overlap,SURFACE,1,0.025,KEPT
symptom resolution,SURFACE,1,0.025,KEPT
symptoms align,SURFACE,1,0.025,KEPT
symptoms change,SURFACE,1,0.025,KEPT
syndactylized,SURFACE,1,0.025,KEPT
syndrome's,SURFACE,1,0.025,KEPT
syndromes like **down syndrome** and **cornelia,SURFACE,1,0.025,KEPT
syndromes like **thrombocytopenia-absent radius,SURFACE,1,0.025,KEPT
syndromic association,SURFACE,1,0.025,KEPT
syndromic bone disorders,SURFACE,1,0.025,KEPT
syndromic cases,SURFACE,1,0.025,KEPT
syndromic condition,SURFACE,1,0.025,KEPT
syndromic conditions 2,SURFACE,1,0.025,KEPT
syndromic conditions**,SURFACE,1,0.025,KEPT
syndromic context,SURFACE,1,0.025,KEPT
syndromic contexts,SURFACE,1,0.025,KEPT
syndromic disorders,SURFACE,1,0.025,KEPT
syndromic etiologies,SURFACE,1,0.025,KEPT
syndromic origin,SURFACE,1,0.025,KEPT
syndromic osteogenesis imperfecta,SURFACE,1,0.025,KEPT
syndromic osteogenesis imperfecta**,SURFACE,1,0.025,KEPT
syndromic overlap,SURFACE,1,0.025,KEPT
syndromic overlaps,SURFACE,1,0.025,KEPT
syndromic presentation,SURFACE,1,0.025,KEPT
syndromic relationships,SURFACE,1,0.025,KEPT
syndromic skeletal disorders,SURFACE,1,0.025,KEPT
synthesize,SURFACE,1,0.025,KEPT
synthetic,SURFACE,1,0.025,KEPT
synthetic cannabinoids,SURFACE,1,0.025,KEPT
synthetic drugs,SURFACE,1,0.025,KEPT
synthetic substances,SURFACE,1,0.025,KEPT
synthetics,SURFACE,1,0.025,KEPT
syphilis test,SURFACE,1,0.025,KEPT
system diseases,SURFACE,1,0.025,KEPT
systematic,SURFACE,1,0.025,KEPT
systematic assessments,SURFACE,1,0.025,KEPT
systematic follow-up,SURFACE,1,0.025,KEPT
systematic review,SURFACE,1,0.025,KEPT
systematic visits,SURFACE,1,0.025,KEPT
systemic autoimmune disorders,SURFACE,1,0.025,KEPT
systemic component,SURFACE,1,0.025,KEPT
systemic components,SURFACE,1,0.025,KEPT
systemic concerns,SURFACE,1,0.025,KEPT
systemic condition,SURFACE,1,0.025,KEPT
systemic conditions**,SURFACE,1,0.025,KEPT
systemic diseases,SURFACE,1,0.025,KEPT
systemic dysfunction,SURFACE,1,0.025,KEPT
systemic edema,SURFACE,1,0.025,KEPT
systemic effects,SURFACE,1,0.025,KEPT
systemic evaluations**,SURFACE,1,0.025,KEPT
systemic examinations,SURFACE,1,0.025,KEPT
systemic fever position,SURFACE,1,0.025,KEPT
systemic findings,SURFACE,1,0.025,KEPT
systemic imaging,SURFACE,1,0.025,KEPT
systemic infection,SURFACE,1,0.025,KEPT
systemic inflammatory,SURFACE,1,0.025,KEPT
systemic involvements,SURFACE,1,0.025,KEPT
systemic juvenile idiopathic arthritis,SURFACE,1,0.025,KEPT
systemic juvenile idiopathic arthritis)**,SURFACE,1,0.025,KEPT
"systemic juvenile idiopathic arthritis)**
   - **hyper-igd syndrome",SURFACE,1,0.025,KEPT
systemic lab,SURFACE,1,0.025,KEPT
systemic lab work,SURFACE,1,0.025,KEPT
systemic lab work contingent,SURFACE,1,0.025,KEPT
systemic lab work**,SURFACE,1,0.025,KEPT
systemic lymphoma,SURFACE,1,0.025,KEPT
systemic malignancies,SURFACE,1,0.025,KEPT
systemic markers,SURFACE,1,0.025,KEPT
systemic nature,SURFACE,1,0.025,KEPT
systemic onset jia,SURFACE,1,0.025,KEPT
systemic onset juvenile idiopathic arthritis,SURFACE,1,0.025,KEPT
systemic signs,SURFACE,1,0.025,KEPT
systemic signs or,SURFACE,1,0.025,KEPT
systemic therapy,SURFACE,1,0.025,KEPT
systemic thrombolysis,SURFACE,1,0.025,KEPT
systemic-onset juvenile idiopathic arthritis,SURFACE,1,0.025,KEPT
t cell,SURFACE,1,0.025,KEPT
t-cell populations,SURFACE,1,0.025,KEPT
t-cells,SURFACE,1,0.025,KEPT
t-score,SURFACE,1,0.025,KEPT
t1/t2,SURFACE,1,0.025,KEPT
t21,SURFACE,1,0.025,KEPT
t2wi,SURFACE,1,0.025,KEPT
t4/t5,SURFACE,1,0.025,KEPT
t=148,SURFACE,1,0.025,KEPT
tablet,SURFACE,1,0.025,KEPT
tablets,SURFACE,1,0.025,KEPT
tailored care,SURFACE,1,0.025,KEPT
tailored imaging,SURFACE,1,0.025,KEPT
tailored support,SURFACE,1,0.025,KEPT
takayasu,SURFACE,1,0.025,KEPT
takayasu arteritis,SURFACE,1,0.025,KEPT
takayasu arteritis history,SURFACE,1,0.025,KEPT
takayasu arteritis**,SURFACE,1,0.025,KEPT
takayasu arteritis:**,SURFACE,1,0.025,KEPT
takayasu disease,SURFACE,1,0.025,KEPT
takeaways,SURFACE,1,0.025,KEPT
taking,SURFACE,1,0.025,KEPT
talipes,SURFACE,1,0.025,KEPT
taller-than-average height,SURFACE,1,0.025,KEPT
tallest,SURFACE,1,0.025,KEPT
tandem,SURFACE,1,0.025,KEPT
tapering,SURFACE,1,0.025,KEPT
targeted fluorescence in situ hybridization,SURFACE,1,0.025,KEPT
targeted gene,SURFACE,1,0.025,KEPT
targeted gene panels/next-generation sequencing,SURFACE,1,0.025,KEPT
targeted genetic panel,SURFACE,1,0.025,KEPT
targeted genetic testing**,SURFACE,1,0.025,KEPT
targeted imaging,SURFACE,1,0.025,KEPT
targeted panel,SURFACE,1,0.025,KEPT
targeted screening,SURFACE,1,0.025,KEPT
targeted screening plans**,SURFACE,1,0.025,KEPT
targeted sequencing,SURFACE,1,0.025,KEPT
targeted tb tests,SURFACE,1,0.025,KEPT
targeted therapies,SURFACE,1,0.025,KEPT
targeted views,SURFACE,1,0.025,KEPT
targeted work,SURFACE,1,0.025,KEPT
targeted workup,SURFACE,1,0.025,KEPT
tay-sachs,SURFACE,1,0.025,KEPT
tay-sachs disease,SURFACE,1,0.025,KEPT
tb testing,SURFACE,1,0.025,KEPT
tb**,SURFACE,1,0.025,KEPT
"tb**
- **ct scan",SURFACE,1,0.025,KEPT
tbev,SURFACE,1,0.025,KEPT
tc/ac,SURFACE,1,0.025,KEPT
team members,SURFACE,1,0.025,KEPT
teams,SURFACE,1,0.025,KEPT
technetium-99m dtpa scan,SURFACE,1,0.025,KEPT
techniques,SURFACE,1,0.025,KEPT
teg,SURFACE,1,0.025,KEPT
teicoplanin,SURFACE,1,0.025,KEPT
telangiectasia,SURFACE,1,0.025,KEPT
telangiectasias,SURFACE,1,0.025,KEPT
telemetry,SURFACE,1,0.025,KEPT
temperature regulation,SURFACE,1,0.025,KEPT
temperature regulation issues,SURFACE,1,0.025,KEPT
temporal,SURFACE,1,0.025,KEPT
temporal artery changes,SURFACE,1,0.025,KEPT
tenderness,SURFACE,1,0.025,KEPT
tendon reflexes,SURFACE,1,0.025,KEPT
teratogenic exposure,SURFACE,1,0.025,KEPT
termination,SURFACE,1,0.025,KEPT
terminus,SURFACE,1,0.025,KEPT
tertiary centre,SURFACE,1,0.025,KEPT
test bolsters,SURFACE,1,0.025,KEPT
test necessity**,SURFACE,1,0.025,KEPT
test prioritization,SURFACE,1,0.025,KEPT
test recommendations,SURFACE,1,0.025,KEPT
test sequencing,SURFACE,1,0.025,KEPT
testament,SURFACE,1,0.025,KEPT
tested,SURFACE,1,0.025,KEPT
testicular,SURFACE,1,0.025,KEPT
testing appointments,SURFACE,1,0.025,KEPT
testing endeavors,SURFACE,1,0.025,KEPT
testing moving,SURFACE,1,0.025,KEPT
testing pathways,SURFACE,1,0.025,KEPT
testing rationale,SURFACE,1,0.025,KEPT
testing suggestions,SURFACE,1,0.025,KEPT
tests suggestion**,SURFACE,1,0.025,KEPT
tests**,SURFACE,1,0.025,KEPT
thanatophoric dysplasia,SURFACE,1,0.025,KEPT
thanatophoric dysplasia**,SURFACE,1,0.025,KEPT
"thank you! 

**terminate**",SURFACE,1,0.025,KEPT
thank you! **final confirmation of case overview,SURFACE,1,0.025,KEPT
thenar crease,SURFACE,1,0.025,KEPT
thenar musculature,SURFACE,1,0.025,KEPT
theoretical applications,SURFACE,1,0.025,KEPT
therapeutic approaches,SURFACE,1,0.025,KEPT
therapeutic decision-making,SURFACE,1,0.025,KEPT
therapeutic journey,SURFACE,1,0.025,KEPT
therapeutic strategies,SURFACE,1,0.025,KEPT
therapists,SURFACE,1,0.025,KEPT
thin,SURFACE,1,0.025,KEPT
thinking,SURFACE,1,0.025,KEPT
thinning,SURFACE,1,0.025,KEPT
thoracic assessments,SURFACE,1,0.025,KEPT
thoracic cavity,SURFACE,1,0.025,KEPT
thoracic circumference,SURFACE,1,0.025,KEPT
thoracic evaluation,SURFACE,1,0.025,KEPT
thoracic scoliosis,SURFACE,1,0.025,KEPT
thoracic structures,SURFACE,1,0.025,KEPT
thoracic-abdominal (tc/ac) circumference,SURFACE,1,0.025,KEPT
thoughtful additions,SURFACE,1,0.025,KEPT
thoughtful adjustments,SURFACE,1,0.025,KEPT
thoughtful analysis,SURFACE,1,0.025,KEPT
thoughtful approach,SURFACE,1,0.025,KEPT
thoughtful commentary,SURFACE,1,0.025,KEPT
thoughtful considerations,SURFACE,1,0.025,KEPT
thoughtful contribution,SURFACE,1,0.025,KEPT
thoughtful diagnostic pathway,SURFACE,1,0.025,KEPT
thoughtful elaborations,SURFACE,1,0.025,KEPT
thoughtful engagement,SURFACE,1,0.025,KEPT
thoughtful evaluation,SURFACE,1,0.025,KEPT
thoughtful expansion,SURFACE,1,0.025,KEPT
thoughtful extraction,SURFACE,1,0.025,KEPT
thoughtful reiteration,SURFACE,1,0.025,KEPT
thoughts:**,SURFACE,1,0.025,KEPT
thousand/\u00b5l,SURFACE,1,0.025,KEPT
three-point thermoplastic mask,SURFACE,1,0.025,KEPT
threshold,SURFACE,1,0.025,KEPT
thresholds,SURFACE,1,0.025,KEPT
thrive explanation,SURFACE,1,0.025,KEPT
thrombelastography,SURFACE,1,0.025,KEPT
thrombi,SURFACE,1,0.025,KEPT
thrombocytopenia,SURFACE,1,0.025,KEPT
thrombocytopenia-absence,SURFACE,1,0.025,KEPT
thromboembolic phenomena,SURFACE,1,0.025,KEPT
thrombolysis,SURFACE,1,0.025,KEPT
thrombophilia,SURFACE,1,0.025,KEPT
thrombophilia work-up,SURFACE,1,0.025,KEPT
thrombophilias,SURFACE,1,0.025,KEPT
thrombosis,SURFACE,1,0.025,KEPT
thrombotic events,SURFACE,1,0.025,KEPT
thrombotic risk,SURFACE,1,0.025,KEPT
thrombus extension,SURFACE,1,0.025,KEPT
thyroid function,SURFACE,1,0.025,KEPT
thyroid function assessments**,SURFACE,1,0.025,KEPT
thyroid levels,SURFACE,1,0.025,KEPT
thyroid panel,SURFACE,1,0.025,KEPT
tias,SURFACE,1,0.025,KEPT
tibial campomelia,SURFACE,1,0.025,KEPT
tick-borne encephalitis,SURFACE,1,0.025,KEPT
tick-borne encephalitis virus,SURFACE,1,0.025,KEPT
tied,SURFACE,1,0.025,KEPT
ties,SURFACE,1,0.025,KEPT
time of,SURFACE,1,0.025,KEPT
timeliness,SURFACE,1,0.025,KEPT
timetable,SURFACE,1,0.025,KEPT
timings,SURFACE,1,0.025,KEPT
tissue,SURFACE,1,0.025,KEPT
tissue analysis,SURFACE,1,0.025,KEPT
tissue samples,SURFACE,1,0.025,KEPT
titer,SURFACE,1,0.025,KEPT
tmq,SURFACE,1,0.025,KEPT
tnf,SURFACE,1,0.025,KEPT
to rule,SURFACE,1,0.025,KEPT
tone,SURFACE,1,0.025,KEPT
tongue,SURFACE,1,0.025,KEPT
tonic,SURFACE,1,0.025,KEPT
tonic seizures,SURFACE,1,0.025,KEPT
tonic-clonic seizures,SURFACE,1,0.025,KEPT
tool,SURFACE,1,0.025,KEPT
tophi,SURFACE,1,0.025,KEPT
torch,SURFACE,1,0.025,KEPT
torrent,SURFACE,1,0.025,KEPT
tortuous,SURFACE,1,0.025,KEPT
tortuous left ureter,SURFACE,1,0.025,KEPT
tortuous vessels,SURFACE,1,0.025,KEPT
total bile acid,SURFACE,1,0.025,KEPT
total body computed tomography,SURFACE,1,0.025,KEPT
total fluid,SURFACE,1,0.025,KEPT
total motor quotient,SURFACE,1,0.025,KEPT
touching,SURFACE,1,0.025,KEPT
toxic process,SURFACE,1,0.025,KEPT
toxicity,SURFACE,1,0.025,KEPT
toxicology,SURFACE,1,0.025,KEPT
toxicology studies,SURFACE,1,0.025,KEPT
toxicology testing,SURFACE,1,0.025,KEPT
toxicology tests,SURFACE,1,0.025,KEPT
toxins,SURFACE,1,0.025,KEPT
tp53,SURFACE,1,0.025,KEPT
trachea,SURFACE,1,0.025,KEPT
tracheoesophageal,SURFACE,1,0.025,KEPT
tracked,SURFACE,1,0.025,KEPT
tracking bodv-1,SURFACE,1,0.025,KEPT
tracking system,SURFACE,1,0.025,KEPT
traditional,SURFACE,1,0.025,KEPT
transabdominal,SURFACE,1,0.025,KEPT
transbronchial biopsy,SURFACE,1,0.025,KEPT
transesophageal echocardiogram,SURFACE,1,0.025,KEPT
transforming,SURFACE,1,0.025,KEPT
transfused,SURFACE,1,0.025,KEPT
transient ischemic attacks,SURFACE,1,0.025,KEPT
transient nodding,SURFACE,1,0.025,KEPT
transient ureteral obstruction**,SURFACE,1,0.025,KEPT
transitional,SURFACE,1,0.025,KEPT
transitions,SURFACE,1,0.025,KEPT
translocations,SURFACE,1,0.025,KEPT
transmittance,SURFACE,1,0.025,KEPT
transparent,SURFACE,1,0.025,KEPT
transposition,SURFACE,1,0.025,KEPT
transthoracic echocardiography,SURFACE,1,0.025,KEPT
transvaginal ultrasound,SURFACE,1,0.025,KEPT
transvaginal ultrasound**,SURFACE,1,0.025,KEPT
transverse,SURFACE,1,0.025,KEPT
transverse septum,SURFACE,1,0.025,KEPT
transverse vaginal septum,SURFACE,1,0.025,KEPT
traps,SURFACE,1,0.025,KEPT
traumatic fracture,SURFACE,1,0.025,KEPT
travel,SURFACE,1,0.025,KEPT
travels,SURFACE,1,0.025,KEPT
treat,SURFACE,1,0.025,KEPT
treatable conditions,SURFACE,1,0.025,KEPT
treatment approach,SURFACE,1,0.025,KEPT
treatment approaches,SURFACE,1,0.025,KEPT
treatment course,SURFACE,1,0.025,KEPT
treatment delays,SURFACE,1,0.025,KEPT
treatment development,SURFACE,1,0.025,KEPT
treatment failure,SURFACE,1,0.025,KEPT
treatment focus,SURFACE,1,0.025,KEPT
treatment planning,SURFACE,1,0.025,KEPT
treatment plans,SURFACE,1,0.025,KEPT
treatment regimen,SURFACE,1,0.025,KEPT
treatment responsiveness,SURFACE,1,0.025,KEPT
treatment strategies,SURFACE,1,0.025,KEPT
treatment strategy's focus,SURFACE,1,0.025,KEPT
treatment-related side,SURFACE,1,0.025,KEPT
"treatment.\"",\n\n",SURFACE,1,0.025,KEPT
tremors,SURFACE,1,0.025,KEPT
triangular,SURFACE,1,0.025,KEPT
triangular growth,SURFACE,1,0.025,KEPT
tricuspid valve,SURFACE,1,0.025,KEPT
tricuspid valve dysplasia,SURFACE,1,0.025,KEPT
tricuspid valve regurgitation,SURFACE,1,0.025,KEPT
trigger,SURFACE,1,0.025,KEPT
triggered by,SURFACE,1,0.025,KEPT
triggers,SURFACE,1,0.025,KEPT
trigonocephaly,SURFACE,1,0.025,KEPT
trimester pregnancy,SURFACE,1,0.025,KEPT
trimester screen,SURFACE,1,0.025,KEPT
trimester ultrasound,SURFACE,1,0.025,KEPT
trimethoprim,SURFACE,1,0.025,KEPT
trisomy 13)**,SURFACE,1,0.025,KEPT
trisomy 13)** -,SURFACE,1,0.025,KEPT
trisomy 18,SURFACE,1,0.025,KEPT
trisomy 21,SURFACE,1,0.025,KEPT
trisomy 21)** - while,SURFACE,1,0.025,KEPT
trisomy 21**: i,SURFACE,1,0.025,KEPT
tropical countries,SURFACE,1,0.025,KEPT
troponins,SURFACE,1,0.025,KEPT
trunk,SURFACE,1,0.025,KEPT
tth,SURFACE,1,0.025,KEPT
tubal occlusion,SURFACE,1,0.025,KEPT
tuberculin skin test**,SURFACE,1,0.025,KEPT
tubular bones,SURFACE,1,0.025,KEPT
tubular structure,SURFACE,1,0.025,KEPT
tumor characteristics,SURFACE,1,0.025,KEPT
tumor effects,SURFACE,1,0.025,KEPT
tumor markers,SURFACE,1,0.025,KEPT
tumor thickness,SURFACE,1,0.025,KEPT
tumor's,SURFACE,1,0.025,KEPT
tumor's size,SURFACE,1,0.025,KEPT
tumors**,SURFACE,1,0.025,KEPT
turnaround,SURFACE,1,0.025,KEPT
turner syndrome,SURFACE,1,0.025,KEPT
turnover,SURFACE,1,0.025,KEPT
turnover markers**,SURFACE,1,0.025,KEPT
tweaks,SURFACE,1,0.025,KEPT
twin died,SURFACE,1,0.025,KEPT
twin pregnancy,SURFACE,1,0.025,KEPT
twin sister,SURFACE,1,0.025,KEPT
twin sister's cancer,SURFACE,1,0.025,KEPT
two-pronged approach,SURFACE,1,0.025,KEPT
type i hae,SURFACE,1,0.025,KEPT
type i hereditary angioedema,SURFACE,1,0.025,KEPT
type ii,SURFACE,1,0.025,KEPT
type ii) 2,SURFACE,1,0.025,KEPT
type ii)**,SURFACE,1,0.025,KEPT
"type ii)**

2",SURFACE,1,0.025,KEPT
"type ii)**
   - **alagille syndrome**
   - **ehlers-danlos syndrome**
   - **metaphyseal dysplasia",SURFACE,1,0.025,KEPT
type ii)** remains,SURFACE,1,0.025,KEPT
typical,SURFACE,1,0.025,KEPT
typing,SURFACE,1,0.025,KEPT
tyrosine,SURFACE,1,0.025,KEPT
tyrosinemia,SURFACE,1,0.025,KEPT
tyrosinemia**,SURFACE,1,0.025,KEPT
ubm,SURFACE,1,0.025,KEPT
ulcerations,SURFACE,1,0.025,KEPT
ulna,SURFACE,1,0.025,KEPT
ultra-sound b-scan,SURFACE,1,0.025,KEPT
ultrasound assessment**,SURFACE,1,0.025,KEPT
ultrasound assessments,SURFACE,1,0.025,KEPT
ultrasound assessments**,SURFACE,1,0.025,KEPT
ultrasound biomicroscopy,SURFACE,1,0.025,KEPT
ultrasound examination,SURFACE,1,0.025,KEPT
ultrasound examinations,SURFACE,1,0.025,KEPT
ultrasound exams,SURFACE,1,0.025,KEPT
ultrasound focus**,SURFACE,1,0.025,KEPT
ultrasound follow-up,SURFACE,1,0.025,KEPT
ultrasound follow-up**,SURFACE,1,0.025,KEPT
ultrasound measurements,SURFACE,1,0.025,KEPT
ultrasound protocols,SURFACE,1,0.025,KEPT
ultrasound protocols**,SURFACE,1,0.025,KEPT
ultrasound scan,SURFACE,1,0.025,KEPT
ultrasound scans,SURFACE,1,0.025,KEPT
ultrasound technique,SURFACE,1,0.025,KEPT
ultrasound**,SURFACE,1,0.025,KEPT
ultrasound/mri,SURFACE,1,0.025,KEPT
umbilical cord,SURFACE,1,0.025,KEPT
umbrella,SURFACE,1,0.025,KEPT
unaddressed,SURFACE,1,0.025,KEPT
uncertainties,SURFACE,1,0.025,KEPT
unchanged,SURFACE,1,0.025,KEPT
uncommon,SURFACE,1,0.025,KEPT
uncommon bacteria,SURFACE,1,0.025,KEPT
uncommon infections,SURFACE,1,0.025,KEPT
unconditional,SURFACE,1,0.025,KEPT
unconscious,SURFACE,1,0.025,KEPT
undefined,SURFACE,1,0.025,KEPT
underdiagnosis,SURFACE,1,0.025,KEPT
underline,SURFACE,1,0.025,KEPT
underlying immunodeficiency,SURFACE,1,0.025,KEPT
understated,SURFACE,1,0.025,KEPT
unexplained abnormalities,SURFACE,1,0.025,KEPT
unexplained joint pain,SURFACE,1,0.025,KEPT
unexplained symptoms,SURFACE,1,0.025,KEPT
unexplained tachycardia,SURFACE,1,0.025,KEPT
unexplained weight loss,SURFACE,1,0.025,KEPT
unfold,SURFACE,1,0.025,KEPT
unification,SURFACE,1,0.025,KEPT
uniparental disomy,SURFACE,1,0.025,KEPT
united,SURFACE,1,0.025,KEPT
united states,SURFACE,1,0.025,KEPT
unknown etiology** - could,SURFACE,1,0.025,KEPT
unless anomalies,SURFACE,1,0.025,KEPT
unlikely,SURFACE,1,0.025,KEPT
unlock,SURFACE,1,0.025,KEPT
unprovoked,SURFACE,1,0.025,KEPT
unrecognized,SURFACE,1,0.025,KEPT
"unremarkable.\"",\n  \""past medical history\",SURFACE,1,0.025,KEPT
"unremarkable.\"",\n\n",SURFACE,1,0.025,KEPT
unreported,SURFACE,1,0.025,KEPT
unveil,SURFACE,1,0.025,KEPT
up-gaze,SURFACE,1,0.025,KEPT
upper arch,SURFACE,1,0.025,KEPT
upper body,SURFACE,1,0.025,KEPT
upper bulbar conjunctiva,SURFACE,1,0.025,KEPT
upper gastrointestinal endoscopy,SURFACE,1,0.025,KEPT
upper limb abnormality,SURFACE,1,0.025,KEPT
upper limbs:** such as x-rays,SURFACE,1,0.025,KEPT
upper segment lower segment ratio,SURFACE,1,0.025,KEPT
upper trunk,SURFACE,1,0.025,KEPT
upper/lower limb,SURFACE,1,0.025,KEPT
urban,SURFACE,1,0.025,KEPT
urban area,SURFACE,1,0.025,KEPT
urea,SURFACE,1,0.025,KEPT
ureter,SURFACE,1,0.025,KEPT
ureteral anatomy,SURFACE,1,0.025,KEPT
ureteral anomalies,SURFACE,1,0.025,KEPT
ureteral atresia,SURFACE,1,0.025,KEPT
ureteral duplication,SURFACE,1,0.025,KEPT
ureteral passage,SURFACE,1,0.025,KEPT
ureteropelvic junction obstruction,SURFACE,1,0.025,KEPT
urgent imaging,SURFACE,1,0.025,KEPT
uric acid production,SURFACE,1,0.025,KEPT
urinary c1 esterase inhibitor activity**,SURFACE,1,0.025,KEPT
urinary flow,SURFACE,1,0.025,KEPT
urinary symptoms,SURFACE,1,0.025,KEPT
urinary tract,SURFACE,1,0.025,KEPT
urinary tract afflictions,SURFACE,1,0.025,KEPT
urinary tract anomalies,SURFACE,1,0.025,KEPT
urinary tract tract pathologies,SURFACE,1,0.025,KEPT
urinary tracts,SURFACE,1,0.025,KEPT
urinary tracts**,SURFACE,1,0.025,KEPT
urine analysis,SURFACE,1,0.025,KEPT
urine culture,SURFACE,1,0.025,KEPT
urine dipstick,SURFACE,1,0.025,KEPT
urine flow,SURFACE,1,0.025,KEPT
urine microscopy,SURFACE,1,0.025,KEPT
urine output,SURFACE,1,0.025,KEPT
urine testing,SURFACE,1,0.025,KEPT
urine tests,SURFACE,1,0.025,KEPT
urine volume,SURFACE,1,0.025,KEPT
"urine.\""\n}",SURFACE,1,0.025,KEPT
urodynamics,SURFACE,1,0.025,KEPT
urokinase,SURFACE,1,0.025,KEPT
urologists,SURFACE,1,0.025,KEPT
urticarial-like rash,SURFACE,1,0.025,KEPT
us scan,SURFACE,1,0.025,KEPT
usa,SURFACE,1,0.025,KEPT
usual,SURFACE,1,0.025,KEPT
uterine,SURFACE,1,0.025,KEPT
uterine abnormalities,SURFACE,1,0.025,KEPT
uterine anomalies,SURFACE,1,0.025,KEPT
uterine anomalies**,SURFACE,1,0.025,KEPT
uterine cavity,SURFACE,1,0.025,KEPT
uterine structural,SURFACE,1,0.025,KEPT
"utero.\"",\n\n",SURFACE,1,0.025,KEPT
utilizing,SURFACE,1,0.025,KEPT
uv light exposure,SURFACE,1,0.025,KEPT
uveitis,SURFACE,1,0.025,KEPT
uveitis specialists,SURFACE,1,0.025,KEPT
v/q scans,SURFACE,1,0.025,KEPT
"vaccination.\"",\n\n",SURFACE,1,0.025,KEPT
vaccinations,SURFACE,1,0.025,KEPT
vaccine,SURFACE,1,0.025,KEPT
vaccines,SURFACE,1,0.025,KEPT
vacterl,SURFACE,1,0.025,KEPT
vagal nerve stimulation,SURFACE,1,0.025,KEPT
vagina,SURFACE,1,0.025,KEPT
"vagina.\"",\n\n  \""past medical history\",SURFACE,1,0.025,KEPT
vaginal anomalies,SURFACE,1,0.025,KEPT
vaginal obstruction,SURFACE,1,0.025,KEPT
vaginal septum,SURFACE,1,0.025,KEPT
valgus,SURFACE,1,0.025,KEPT
valgus knees,SURFACE,1,0.025,KEPT
validate,SURFACE,1,0.025,KEPT
validity,SURFACE,1,0.025,KEPT
valuable,SURFACE,1,0.025,KEPT
valuable thoughts,SURFACE,1,0.025,KEPT
valve morphology,SURFACE,1,0.025,KEPT
valve structure,SURFACE,1,0.025,KEPT
valvular,SURFACE,1,0.025,KEPT
valvular heart disease,SURFACE,1,0.025,KEPT
valvular pathology,SURFACE,1,0.025,KEPT
variable immunodeficiency,SURFACE,1,0.025,KEPT
variably,SURFACE,1,0.025,KEPT
variant's,SURFACE,1,0.025,KEPT
variation,SURFACE,1,0.025,KEPT
varicella-zoster virus,SURFACE,1,0.025,KEPT
varying,SURFACE,1,0.025,KEPT
vascular anomalies,SURFACE,1,0.025,KEPT
vascular bruits,SURFACE,1,0.025,KEPT
vascular diseases,SURFACE,1,0.025,KEPT
vascular events,SURFACE,1,0.025,KEPT
vascular health,SURFACE,1,0.025,KEPT
vascular integrity,SURFACE,1,0.025,KEPT
vascular interventionalist,SURFACE,1,0.025,KEPT
vascular ischemia,SURFACE,1,0.025,KEPT
vascular malformations,SURFACE,1,0.025,KEPT
vascular medicine,SURFACE,1,0.025,KEPT
vascular occlusions,SURFACE,1,0.025,KEPT
vascular pathologies,SURFACE,1,0.025,KEPT
vascular structures,SURFACE,1,0.025,KEPT
vascular surgeons,SURFACE,1,0.025,KEPT
vascular surgery,SURFACE,1,0.025,KEPT
vascular tumors,SURFACE,1,0.025,KEPT
vascularity,SURFACE,1,0.025,KEPT
vasculature,SURFACE,1,0.025,KEPT
vasculitic process,SURFACE,1,0.025,KEPT
vasculitides,SURFACE,1,0.025,KEPT
vasculitides**: consideration,SURFACE,1,0.025,KEPT
vasculopathic,SURFACE,1,0.025,KEPT
vasoconstriction,SURFACE,1,0.025,KEPT
vasoconstrictive agents,SURFACE,1,0.025,KEPT
vasospasm,SURFACE,1,0.025,KEPT
vcug,SURFACE,1,0.025,KEPT
vegetations,SURFACE,1,0.025,KEPT
veins,SURFACE,1,0.025,KEPT
vemp,SURFACE,1,0.025,KEPT
venous doppler ultrasound:**,SURFACE,1,0.025,KEPT
venous insufficiency,SURFACE,1,0.025,KEPT
venous insufficiency**,SURFACE,1,0.025,KEPT
venous insufficiency** and **lymphatic obstruction**,SURFACE,1,0.025,KEPT
venous status,SURFACE,1,0.025,KEPT
venous structures,SURFACE,1,0.025,KEPT
venous system,SURFACE,1,0.025,KEPT
venous thromboembolism,SURFACE,1,0.025,KEPT
venous thromboembolisms,SURFACE,1,0.025,KEPT
ventilation-perfusion,SURFACE,1,0.025,KEPT
ventilator,SURFACE,1,0.025,KEPT
ventilator-assisted ventilation,SURFACE,1,0.025,KEPT
ventilatory,SURFACE,1,0.025,KEPT
ventral septal defect,SURFACE,1,0.025,KEPT
"ventral septal defect (vsd).\""\n",SURFACE,1,0.025,KEPT
vera,SURFACE,1,0.025,KEPT
verbal iq,SURFACE,1,0.025,KEPT
vermilion,SURFACE,1,0.025,KEPT
vernal keratoconjunctivitis,SURFACE,1,0.025,KEPT
version,SURFACE,1,0.025,KEPT
vertebrae,SURFACE,1,0.025,KEPT
vertebral,SURFACE,1,0.025,KEPT
vertebral fusion,SURFACE,1,0.025,KEPT
vertical gaze palsy,SURFACE,1,0.025,KEPT
vesicoureteral junction obstruction,SURFACE,1,0.025,KEPT
vesicoureteral junction obstruction**,SURFACE,1,0.025,KEPT
vessel,SURFACE,1,0.025,KEPT
vessel rupture,SURFACE,1,0.025,KEPT
vestibular,SURFACE,1,0.025,KEPT
vestibular contributions,SURFACE,1,0.025,KEPT
vestibular disorders,SURFACE,1,0.025,KEPT
vestibular dysfunction,SURFACE,1,0.025,KEPT
vestibular examination,SURFACE,1,0.025,KEPT
vestibular function,SURFACE,1,0.025,KEPT
vestibular function tests,SURFACE,1,0.025,KEPT
vestibular function tests**,SURFACE,1,0.025,KEPT
vestibular neuritis,SURFACE,1,0.025,KEPT
vestibular status,SURFACE,1,0.025,KEPT
vestibular testing,SURFACE,1,0.025,KEPT
vetted,SURFACE,1,0.025,KEPT
vgkc-complex,SURFACE,1,0.025,KEPT
viability,SURFACE,1,0.025,KEPT
video,SURFACE,1,0.025,KEPT
video eeg,SURFACE,1,0.025,KEPT
video eeg**,SURFACE,1,0.025,KEPT
video electroencephalography,SURFACE,1,0.025,KEPT
video laryngoscope,SURFACE,1,0.025,KEPT
video laryngoscopy,SURFACE,1,0.025,KEPT
video telemetry,SURFACE,1,0.025,KEPT
vignette,SURFACE,1,0.025,KEPT
viral agent,SURFACE,1,0.025,KEPT
viral agents,SURFACE,1,0.025,KEPT
viral anterior uveitis,SURFACE,1,0.025,KEPT
viral arthritis,SURFACE,1,0.025,KEPT
viral clearance,SURFACE,1,0.025,KEPT
viral encephalitis,SURFACE,1,0.025,KEPT
viral etiologies,SURFACE,1,0.025,KEPT
viral hepatitis tests,SURFACE,1,0.025,KEPT
viral infections,SURFACE,1,0.025,KEPT
viral levels,SURFACE,1,0.025,KEPT
viral loads,SURFACE,1,0.025,KEPT
viral panels alongside,SURFACE,1,0.025,KEPT
viral pathogens like **borrelia** species,SURFACE,1,0.025,KEPT
viral symptoms,SURFACE,1,0.025,KEPT
viral syndromes,SURFACE,1,0.025,KEPT
viral syndromes)**,SURFACE,1,0.025,KEPT
visibility,SURFACE,1,0.025,KEPT
visible,SURFACE,1,0.025,KEPT
visible choriocapillaris,SURFACE,1,0.025,KEPT
visible tumor,SURFACE,1,0.025,KEPT
vision quality,SURFACE,1,0.025,KEPT
visit,SURFACE,1,0.025,KEPT
visits,SURFACE,1,0.025,KEPT
visual aids,SURFACE,1,0.025,KEPT
visual auras,SURFACE,1,0.025,KEPT
visual component,SURFACE,1,0.025,KEPT
visual decline,SURFACE,1,0.025,KEPT
visual dysfunction,SURFACE,1,0.025,KEPT
visual function,SURFACE,1,0.025,KEPT
visual loss,SURFACE,1,0.025,KEPT
visual quality questionnaire**,SURFACE,1,0.025,KEPT
visual signs,SURFACE,1,0.025,KEPT
visually,SURFACE,1,0.025,KEPT
vital avenues,SURFACE,1,0.025,KEPT
vital moving,SURFACE,1,0.025,KEPT
vital observations,SURFACE,1,0.025,KEPT
vitals,SURFACE,1,0.025,KEPT
vitamin,SURFACE,1,0.025,KEPT
vitamin b12,SURFACE,1,0.025,KEPT
vitamin e,SURFACE,1,0.025,KEPT
vitamin e deficiency,SURFACE,1,0.025,KEPT
vitamin e deficiency** –,SURFACE,1,0.025,KEPT
vitamin levels,SURFACE,1,0.025,KEPT
vitelliform lesion,SURFACE,1,0.025,KEPT
vitelliform stage,SURFACE,1,0.025,KEPT
vitiating conditions,SURFACE,1,0.025,KEPT
vitreous,SURFACE,1,0.025,KEPT
vkc,SURFACE,1,0.025,KEPT
vns,SURFACE,1,0.025,KEPT
vocal cord,SURFACE,1,0.025,KEPT
vocal cords,SURFACE,1,0.025,KEPT
vocalizations,SURFACE,1,0.025,KEPT
voice your thoughts,SURFACE,1,0.025,KEPT
voices,SURFACE,1,0.025,KEPT
voiding cystoureterography,SURFACE,1,0.025,KEPT
volar surface,SURFACE,1,0.025,KEPT
volumes,SURFACE,1,0.025,KEPT
vomiting,SURFACE,1,0.025,KEPT
vsd,SURFACE,1,0.025,KEPT
vulnerability,SURFACE,1,0.025,KEPT
vus,SURFACE,1,0.025,KEPT
vzv,SURFACE,1,0.025,KEPT
wais test,SURFACE,1,0.025,KEPT
waist,SURFACE,1,0.025,KEPT
wait,SURFACE,1,0.025,KEPT
wait post-biopsy,SURFACE,1,0.025,KEPT
wakefulness,SURFACE,1,0.025,KEPT
waking,SURFACE,1,0.025,KEPT
walker,SURFACE,1,0.025,KEPT
walking defects,SURFACE,1,0.025,KEPT
warrants,SURFACE,1,0.025,KEPT
wary,SURFACE,1,0.025,KEPT
watchful,SURFACE,1,0.025,KEPT
waves,SURFACE,1,0.025,KEPT
weather,SURFACE,1,0.025,KEPT
"week.\"",\n\n",SURFACE,1,0.025,KEPT
weekly,SURFACE,1,0.025,KEPT
wegener's granulomatosis)**,SURFACE,1,0.025,KEPT
weight management,SURFACE,1,0.025,KEPT
welcome,SURFACE,1,0.025,KEPT
well-articulated analyses,SURFACE,1,0.025,KEPT
well-articulated arguments,SURFACE,1,0.025,KEPT
well-articulated diagnostic,SURFACE,1,0.025,KEPT
well-rounded strategy,SURFACE,1,0.025,KEPT
well-taken,SURFACE,1,0.025,KEPT
west nile virus,SURFACE,1,0.025,KEPT
west syndrome,SURFACE,1,0.025,KEPT
west syndrome)** -,SURFACE,1,0.025,KEPT
wheezing,SURFACE,1,0.025,KEPT
whipple's disease,SURFACE,1,0.025,KEPT
white,SURFACE,1,0.025,KEPT
white blood cell,SURFACE,1,0.025,KEPT
white blood cells,SURFACE,1,0.025,KEPT
white british,SURFACE,1,0.025,KEPT
white conjunctiva,SURFACE,1,0.025,KEPT
white lung,SURFACE,1,0.025,KEPT
white lung' characteristic,SURFACE,1,0.025,KEPT
white matter,SURFACE,1,0.025,KEPT
white-yellow sputum,SURFACE,1,0.025,KEPT
who-fc,SURFACE,1,0.025,KEPT
whole genome sequencing,SURFACE,1,0.025,KEPT
wide-field autofluorescence imaging,SURFACE,1,0.025,KEPT
widespread,SURFACE,1,0.025,KEPT
wild type,SURFACE,1,0.025,KEPT
wild-type,SURFACE,1,0.025,KEPT
will prepare,SURFACE,1,0.025,KEPT
williams syndrome,SURFACE,1,0.025,KEPT
wilms tumor**,SURFACE,1,0.025,KEPT
window,SURFACE,1,0.025,KEPT
wishes,SURFACE,1,0.025,KEPT
withdraw,SURFACE,1,0.025,KEPT
work,SURFACE,1,0.025,KEPT
work-up,SURFACE,1,0.025,KEPT
worked,SURFACE,1,0.025,KEPT
working hypotheses,SURFACE,1,0.025,KEPT
world health organization functional class,SURFACE,1,0.025,KEPT
worsen,SURFACE,1,0.025,KEPT
wrap up,SURFACE,1,0.025,KEPT
written summaries,SURFACE,1,0.025,KEPT
x-linked agammaglobulinemia,SURFACE,1,0.025,KEPT
x-linked intellectual disability syndromes,SURFACE,1,0.025,KEPT
x-ray examination,SURFACE,1,0.025,KEPT
xerosis,SURFACE,1,0.025,KEPT
ya'an,SURFACE,1,0.025,KEPT
yellow lesions,SURFACE,1,0.025,KEPT
yellowish,SURFACE,1,0.025,KEPT
yersinia,SURFACE,1,0.025,KEPT
yield,SURFACE,1,0.025,KEPT
younger,SURFACE,1,0.025,KEPT
younger adults,SURFACE,1,0.025,KEPT
younger age,SURFACE,1,0.025,KEPT
younger demographic,SURFACE,1,0.025,KEPT
younger patient,SURFACE,1,0.025,KEPT
younger patients,SURFACE,1,0.025,KEPT
your,SURFACE,1,0.025,KEPT
your list,SURFACE,1,0.025,KEPT
your point,SURFACE,1,0.025,KEPT
z score,SURFACE,1,0.025,KEPT
z-score,SURFACE,1,0.025,KEPT
z-scores,SURFACE,1,0.025,KEPT
zap-x system,SURFACE,1,0.025,KEPT
zones,SURFACE,1,0.025,KEPT
β-galactosidase activity,SURFACE,1,0.025,KEPT
β-galactosidase deficiency,SURFACE,1,0.025,KEPT
’ thoughts,SURFACE,1,0.025,KEPT
’s analysis,SURFACE,1,0.025,KEPT
’s collaboration,SURFACE,1,0.025,KEPT
’s contributions,SURFACE,1,0.025,KEPT
’s progress,SURFACE,1,0.025,KEPT

# SUMMARY
# n_cases,40
# threshold,0.9
# cutoff_count,36
# stoplisted_cuis,0
# stoplisted_surfaces,25
# total_unique_cuis,0
# total_unique_surfaces,9179



